Protocol V59_77 
Page 1of86  GSK  
24 JUN 16 Final  Protocol  Versioo  1 Confidentia l 
PR0--01 TEMP  06 / Atlas  No. 293620  
VersionNo.4  / VersionDate:  Jan\131)'29  , 2015  
  
 
 
CLINI CAL STUD Y PROTOCOL VS9 77 Versio n 1 
 
 
 
A Phase 3b , Controlled, Open -Label , Multi-Center Study to Evaluate Safety and 
Inumnogenicit y of a Single  Dose of GlaxoSm iht Kline's Meningococca l ACWY 
Conjugate Vaccine  (Menveo ), Administered  to Healthy  Individuals 15 through 55 years 
of age, approximately 4-6 years  after primary ACWY vaccination.  
 
 
Safety  and Immunogenicity Study of a Single Dose of Menveo , Administered  to Subjects 
15 through 55 years  of age, approximately  4-6 years  after primary ACWY vaccination  
 
 
 
 
Proper ty of GlaxoSmithKline Biologicals S.A (hereafter refened to as GSK) 
Confidential  
May not be used, divulged , published or otherw ise  disclosed without  \ VIi tt .en 
co n se nt  of GSK  
Protocol V59_77 
Page 2of86  GSK  
24 JUN 16 Final  Protocol  Versioo  1 Confidentia l 
PR0-01 TEMP  06 / Atlas  No.293620  
VersionNo.4  / Version Date:  Jan\131)'29,  2015   
  
TABLE OF CONTE NTS 
TABLE  OF CONTENTS  ..................................................................................................... 2 
PROTOCOL SYNOPS IS VS9 77 ................................................................................... 7  
LIST OF ABBREVIATIONS  ............................................................................................. 20 
1. BACKGROUND AND RATIONALE  ..................................................................... 21  
1.1 Background .......................................................................................................... 21 
1.2 Rationale  .............................................................................................................. 22 
2. OBJECTIVES  ........................................................................................................... 23 
2.1 Primary  Object ive(s) ............................................................................................... 23  
2.2 Secondary  Objective(s)  ......................................................................................... 23 
2.3 Exploratory  Objective(s)  ...................................................................................... 24 
3. STUDYDESIGN ................................................................................................. 2S 
3.1 OverviewofStudyDesign. ..............................................................................        2S 
3.2 StudyPeriod ..................................................................................................... 27  
3.3 Blinding Procedures  ............................................................................................. 27 
3.4 Data  Collect ion ............................................................................................................. 27  
3.4.1 Data Collected  from Subjects  .................................................................... 27  
3.4.2 Tools Used  for Data  Collect ion ......................................................................... 28  
3.S Collection of Clinical  Specimens  .................................................................... 29  
3.6 Stopping/Pausing Guidelines  ........................................................................... 30  
3.7 Data  Monitoring Committee  ............................................................................ 30  
3.8 Premature Withdrawal  from Study  .................................................................. 30  
3.9 EndofStudy ............................................................................................... 33  
4. SELECTION  OFSTUDY  POPULATION  .......................................................... 34  
4.1 Inclusion Criteria  ............................................................................................. 34  
4.2 Exclusion Criteria  ............................................................................................ 3S 
4.3 Criteria  for Delay  of Vaccination  and/or Blood Sampling  ............................... 36  
S. STUDYPROCEDURES  ...................................................................................... 37  
S.1 Pre-vaccination  Clinic  Visit(s)  ......................................................................... 37  
Protocol V59_77 
Page 3of86  GSK  
24 JUN 16 Final  Protocol  Versioo  1 Confidentia l 
PR0-01 TEMP  06 / Atlas  No.293620  
VersionNo.4  / Version Date:  Jan\131)'29,  2015   
 5.1.1 Informed Consent/Assen t ............................................................................................ 37  
5.1.2 Screening  ....................................................................................................... 38 
5.1.3 Enrolment ..................................................................................................... 40 
5.1.4 Randomization .............................................................................................. 40 
5.1.4.1  Randomization of supplies  ....................................................................... 40 
5.1.4.2  Study group and treatment nwnber allocation  .................................... 40  
5.2 Vaccination  Clinic  Visit.  ................................................................................. 41  
5.2.1 Post-vaccina tion Procedures ...................................................................... 41  
5.2.2 Post-vaccina tion Reminders  .......................................................................... 42 
5.3 Post-vaccination  Visit(s)  .................................................................................. 43  
5.3.1 Follow -up Clinic  Visit(s)  .......................................................................... 43  
5.3.2 Safety Follow -up Calls  .................................................................................. 44 
5.4 Unscheduled Visits  .......................................................................................... 44  
5.5 Study Termination  Visit.  .................................................................................. 44  
5.5.1 Early  Termination  Visit.  ........................................................................... 45  
6. TREA1MENT  OFSUBJEC TS ..................................................................................... 46  
6.1 StudyVaccine(s)  ..................................................................................................... 46  
6.2 Non-Study Vaccines  ......................................................................................... 47  
6.3 Vaccine Preparation  and Administration  ......................................................... 47  
6.3.1 Replacement of unusable vaccines  .................................................................. 48 
6.4 Vaccine Administration  Error or Overdose ofVaccine .................................... 48  
6.5 Prior and Concomitant Medications  and Vaccines  .......................................... 49  
6.6 Vaccine Supply, Labeling , Storage and Tracking .................................................. 50  
7. ASSESSMENTS  ...................................................................................................... 51 
7.1 SafetyAssessment ............................................................................................ 51  
7.1.1 Solicited  Adverse Events  .......................................................................... 51  
7.1.2 Unsolicited  Adverse Events  ...................................................................... 53  
7.1.3 Evaluation of Adverse Events  ................................................................... 53  
7.1.4 Serious Adverse Events  ............................................................................. 55  
Protocol V59_77 
Page 4of86  GSK  
24 JUN 16 Final  Protocol  Versioo  1 Confidentia l 
PR0-01 TEMP  06 / Atlas  No.293620  
VersionNo.4  / Version Date:  Jan\131)'29,  2015   
  
7.1.4.1 Adverse Events of Special Interest ..................................................... S6 
7.1.S Methods for Recording Adverse Events  and Serious Adverse Events ........ S6 
7.1.S.1 Post-Study Events  .............................................................................. S8 
7.1.6 Pregnancies. .............................................................................................. S8 
7.1.7 Safety LaboratoryMeasurements .............................................................. S9 
7.2 Efficacy   Assessment ........................................................................................  S9 
7.3 Immunogenicity  Assessment ............ ................................................................  S9 
8. STATISTICAL CONSIDERATIONS  ..................................................................... 60 
8.1 Endpoints ......................................................................................................... 60  
8.1.1 Primary  Endpoint(s) ........................................................................................... 60  
8.1.1.1  Primary  SafetyEndpoint(s) ................................................................ 60  
8.1.1.2  Primary  EfficacyEndpoint(s) ............................................................. 60  
8.1.1.3  Primary  Immunogenicity Endpoint(s) ................................................ 60  
8.1.2 SecondaryEndpoint(s) .............................................................................. 60 
8.1.2.1  Seco ndary SafetyEndpoint(s) ........................................................ 60  
8.1.2.2  Seco ndary Efficacy Endpoint(s) .......................................................... 61  
8.1.2.3  Seco ndary Immunogenicity Endpoint(s)  ................................................. 61  
8.1.3 ExploratoryEndpoint(s) ............................................................................ 61  
8.1.3.1  Exploratory Safety Endpoint(s) .......................................................... 61  
8.1.3.2  Exploratory  Efficacy  Endpoint(s) .......................................................... 61 
8.1.3.3  Exploratory Immunogenicity  Endpoint(s) .......................................... 62  
8.2 Success  Criteria  ................................................................................................ 62  
8.2.1 Success Criteria for  Primary  Objective(s)  .................................................... 62 
8.2.1.1  Success  Criteria for Primary Safety  Objective(s)  ................................. 62  
8.2.1.2  Success  Criteria for Primary Efficacy Objective(s)  ................................ 62  
8.2.1.3  Success  Criteria for Primary Immunogenicity  Objective(s)  ................. 62  
8.2.2 Success  Criteria for Secondary  Objective(s)  ....................................... 62  
8.2.2.1  Success  Criteria  for Secondary Safety Object ive(s) ................................. 62  
8.2.2.2  Success Criteria for Secondary  Efficacy  Objective(s)  ........................... 62 
Protocol V59_77 
Page 5of86  GSK  
24 JUN 16 Final  Protocol  Versioo  1 Confidentia l 
PR0-01 TEMP  06 / Atlas  No.293620  
VersionNo.4  / Version Date:  Jan\131)'29,  2015   
  
8.2.2.3  Success  Criteria for Secondary Immunogenicity Object ive(s) ........... 62  
8.3 Analysis  Sets .................................................................................................... 63  
8.3.1 All Enrolled Set ......................................................................................... 63  
8.3.2 All Exposed Set ......................................................................................... 63  
8.3.3 Safety Set. ................................................................................................. 63  
8.3.4 Full Analysis Set (FAS)  Efficacy/Immunogenicity Set. ............................ 63  
8.3.5 Per Protocol (PP) Set Efficacy/Immunogenicity Set ................................. 64  
8.3.6 Other  Analysis  Sets ................................................................................... 64  
8.3.7 Subgroups ................................................................................................. 64  
8.3.8 Protocol Deviations  .................................................................................. 64  
8.4 Statistical  Analysis  Plan ................................................................................... 65  
8.4.1 Analysis  of Demographic and Baseline Characteristics  ............................ 65  
8.4.2 Analysis of Primary Objective(s)  .................................................................. 65 
8.4.2.1  Analysis of  Primary SafetyObjective(s) ........................................ 65  
8.4.2.2  Analysis  of Primary Efficacy  Object ive(s)  ........................................ 65  
8.4.2.3  Analysis of Primary Immunogenicity O bjective(s)  ................................ 65 
8.4.2.3.1  Statisti cal Hypotheses .................................................................. 65  
8.4.2.3.2  Analysis  Sets ............................................................................... 65  
8.4.2.3.3  Statisti cal Methods ....................................................................... 66  
8.4.3 Analysis of Secondary Objective(s)  ............................................................... 66 
8.4.3.1  Analysis  of Secondary Safety Objective(s)  ..................................... 66  
8.4.3.1.1  Analysis  of Extent  of Exposure ................................................... 66  
8.4.3.1.2  Analysis  of Solici ted Local , Systemic  and Other  Adverse Events  66 
8.4.3.1.3  Analysis of Unsolicited  Adverse Events  ..................................... 67  
8.4.3.1.4  Statisti cal Hypotheses ...................................................................... 68 
8.4.3.1.5  5 ................................................................................. Analysis  Sets
 68 
8.4.3.1.6  Statist ical Methods ...................................................................... 68  
8.4.3.2  Analysis  of Secondary Efficac y Objective(s)  .................................. 68  
8.4.3.3  Analysis of  Secondary ImmunogenicityObject ive(s) ........................ 69  
Protocol V59_77 
Page 6of86  GSK  
24 JUN 16 Final  Protocol  Versioo  1 Confidentia l 
PR0-01 TEMP  06 / Atlas  No.293620  
VersionNo.4  / Version Date:  Jan\131)'29,  2015   
 8.4.3.3.1  Statis itcal Hypotheses .............................................................. 69  
8.4.3.3.2  Analysis  Sets ............................................................................... 69  
8.4.3.3.3  Statist ical Meth ods ................................................................................ 69  
8.4.4 Analysis  of ExploratoryObject ives ............................................................... 71  
8.4.4.1  Analysis  of ExploratorySafety Objective(s)  .............................................. 71  
8.4.4.2  2  Analysis of Exploratory Efficacy  Object ive(s) ................................... 71  
8.4.4.3  Analysis  of ExploratoryimmunogenicityObjective(s)  .......................... 71  
8.5 Sample  Size and Power  Considerations of Primary  and Secondary  Objectives . 71 
8.6  Interim Analysis  ............................................................................................... 74  
9. SOURCE DOCUMENTATION, STUDY MONITORING AND AUDITING  ...... 75 
9.1 Source Documentation ..................................................................................... 75  
9.2 Study  Monitoring , Auditing  and Sourc e Data Verification   ................................ 76 
10. DATA MANAGEMENT  ......................................................................................... 77 
IO. I  Data Entry  and Management  ................................................................................ 77 
10.2 Data  Clarification  ............................................................................................. 77  
10.3 Data  Protection ................................................................................................ 77  
11. RECORD RETENTION  .......................................................................................... 78 
12. USE  OF INFORMATION  AND PUBLI CATION  ...................................................... 79  
13. ETHICAL  CONSIDERATIONS  ............................................................................. 80 
13.I   Regulatory and Ethical  Compliance  ..................................................................... 80 
13.2 Infonned Consent Procedures .......................................................................... 80  
13.3 Responsibilitiesof the  Investigator and!RB/EC ............................................... 8 1 
13.4 Protoco l Amendments ...................................................................................... 82  
14. REFERENCE  LIST  ...............................................................................................................  84 
APPENDIX I : INVESTIGAT OR AGREEMENT  ......................................................... 85  
Protocol V59_77 
Page 7of86  GSK  
24 JUN 16 Final  Protocol  Versioo  1 Confidentia l 
PR0-01 TEMP  06 / Atlas  No.293620  
VersionNo.4  / Version Date:  Jan\131)'29,  2015   
 PROTOC OL SYNOP SIS V59 77  
 
Name of Spo nsor: 
GlaxoSmithKline 
Biologicals S.A  Protoco  l number:  
 
V59 77  Gene1i c name of s tudy vaccine(s):  
 
Meningococcal  (groups A, C, W, and Y) 
oligosaccharide diphtheria CRM -197 
conjugate vaccine  
Titl e of Study: A Phase 3b, Controlled, Open -Label,Multi -Center Study to Evaluate 
Safet y and Immunogenicity  of a Single  Dose  of GlaxoSm iht Kline ' s Meningococcal 
ACWY Con jugate Vaccine (Menveo ,)Administered  to Healthy  Individuals 15 througll 
55 years  of age, approximately 4-6 years  after primary ACWY vaccination . 
Study Pe1i od : Approximately  180 days 
(six months ). Clinical Ph ase:3b 
Background and Rati onale: 
 
Neisseria meningitidis  is a leading  cause of bacterial meningitis  and sepsis worldwide, 
capable  of causing outbreaks and epidemics of invasive disease. Meningococcal disease 
is associated  with higll morbidity  and mortality  even among patients  who receive  early 
antibiotictreatment . Most casesof invasive disease  worldwide  are caused by serogroups 
A, B, C, W and Y. 
The quadrivalent meningococcal oligosaccharide diphtheria CRM -197 conjugate 
vaccine (MenACWY -CRM; Menveo, GSK Vaccines ) is approved for active 
inlmunization ofindividuals from 2 months througll 55 years of age in the United 
States , and in over 60 other countries . As of February 2015, more than 30,000of 
subjects have  been  exposed to MenACWY- CRM  vaccine  in completed  clinical  studies 
and more  than 24 million  doses of the vaccine have been  distributed globally . 
The US Advisory Committee  on Immunization  Practices  (ACIP)  recommends  routine 
vaccination with a quadrivalent conjugated meningococcal vaccine for adolescents at 
11-12 years of age with a booster dose administered 5 years later. While a substantial 
body of data exists showing a robust inlmune response and good antibody persi stence 
after a single dose ofMenACWY- CRM in adolescents , the response to a booster dose of 
MenACWY- CRM in this agegroup has only been evaluated in 2 clinical studies with 
limited  number of subjects . 
A robust anamnestic  inlmune response to a booster do se ofMenveo vaccine 
administered  at approximately  5 years  after previous vaccination with thesame  vaccine 
or a licensed  meningococcal oolysaccharide vaccine (Menomune®) was demonstrated in 
Protocol V59_77 
Page 8of86  GSK  
24 JUN 16 Final  Protocol  Versioo  1 Confidentia l 
::, z u 
8  
  
Name of Spo nsor: 
 
GlaxoSmithKline 
Biologicals S .A Protoco l number:  
V59 77  Gene1i c name of s tudy vaccine(s):  
 
Meningococcal (groups A, C, W, and Y) 
oligosaccharide diphtheria CRM -197 
conjugate vaccine  
the phase 2 clinical study V59P6El . High titers of bactericidal antibodies against the 
vaccine serogroups were achieved at 7 and 30 days after booster dose in MenACWY - 
pr
imed subjects. However , the number of subjects included in this studywas relatively 
small (N =l 0l , including 50 subjects who received a booster dose after the primary 
MenACWY -CRM vaccination) . 
 
In the phase 3b clinical study V59Pl3 El , a booster dose of MenACWY -CRM was 
given 3 years after primary vaccination with either MenACWY -CRM or Menactra®(a 
meningococcal diphtheria toxoid- conjugated MenACWY vaccine , MenACWY- D) in 
adolescents . A booster dose was able to substantially increase antibody titers against all 
4 serogroups irrespective of the priming vaccine . Again, only a small number of  
subjects (N=160) received the MenACWY -CRM booster , (83 who received primary  
MenACWY -CRM and 77 who received MenACWY -D). 
 
In the light of thecurrent ACIP recommendation for a booster dose of MenACWY - 
CRM ,
 there exists  a need to evaluate  the response  to a MenACWY- CRM  booster  given 
at -5  years  after primary  vaccination  in meningococca -lvaccin eprimed  adolescent s. 
Generation of this data would  also be of relevance in outbreak management  and 
vaccination  of travelers  to endemic areas . 
 
The purpose/aim of this study is to assess the safety and antibody response to 
vaccination with a booster  dose  of Menveo  given  4-6 years  after primary vaccination 
and the response  to a single  dose  given  to vaccine -naivesubjects, and to describe  the 
immune response  over time after a booster  dose  of Menveo, administered to subjects 
previously vaccinated  with Menveo or Menactra, and after a single  dose  ofMenveo to 
vaccine -naive subjects . The inclusion  of vaccine- naive  subjects  in a separate study  arm 
is to enable comparison of the rapidity  and magnitude  of an anamnestic response  to a 
booster  dose (in primed  individuals)  or the primary response  to a first dose  (in naive 
individuals) of  MenACWY- CRM . 
Study Objectives : 
 
P1i ma r y Objecti ve(s): Immun ogenicity objective:  
 
1. To demonstrate a sufficient immune response following a booster dose of 
MenACWY -CRM (Menveo) vaccine , !riven to subjects who oreviously  
 
PR0-01 TEMP 06 / Atlas No . 293620  
VersionNo.4 / Vers ion Date: Jan \131)'29 , 2015  
00 
Protocol V59_77 
Page 9of86  GSK  
24 JUN 16 Final  Protocol  Versioo  1 Confidentia l 
::, z u 
8  
  
Name of Sponsor: 
GlaxoSmithKline 
Biologicals S.A Protoco l number:  
V59 77  Gene1i c name of study vaccine(s):  
 
Meningococcal  (groups A, C, W, and Y) 
oligosaccharide diphtheria CRM- 197 
conjugate vaccine  
received Menveo , as measured bythe percentage of subjects with hSBA  
seroresponsel against N. meningitidis serogroups A, C, Wand Y at Day 29 
after vaccination  
2. To demonstrate a suffic ientimmune response following a booster dose of 
MenACWY -CRM (Menveo ) vaccine , given to subjects who previously 
received Menactra, as measured by the percentage of subjects with hSBA 
seroresponsel against  N . meningitidis  serogroups A, C, Wand  Y at Day 29 
after vaccination  
Criteria to demonstrate immune response sufficiency The immune response 
sufficiency  will be tested  sequentially ; first in the group of subjects who received 
primary  vaccination  with Menveo  and, if met, also in the group of subjects who 
received primary vaccinati on with Menactra . The immune response will be 
considered  as suffic ientif the lower limit of the one- sided  97.5% CI for percentage 
of subject s with hSBA seroresponse1 against  serogroups A, C, Wand  Y is greater 
than 75%. The study will beconsi dered successful if the immune response 
sufficiency  will be demonstrated  at least in the group of subjects who received 
primary  vaccination  with Menveo . 
Seco ndar y Objective(s): 
Immun ogenicity objectives:  
1. To compare the immune response s over time fo llowinga booster dose of 
MenACWY- CRM vaccine, between subjects who previously received Menveo , 
subjects who previously received Menactra, and subjects who previously 
received Menveo or Menactra (pooled vaccine group) and following a single 
dose in vaccine -naive individuals , as measured by the percentages of subjects 
with  hSBA s erorespons e1  hSBA t iters ,::8 and 2:16, and hSBA  GMT s agains t N. , menin<ritidis seroornuos A. C Wand Y at Dav1. Dav 4 Dav 6 and Dav 29  
 
 
 
1 Seroresponse is defined forthis study asfollows: For subjectswith pre-vaccination titers <4, pos-t 
vaccin
ation  titers  2: 16; forsubjects with pre-vaccination titers 2::4, post vaccination  titers  at least4 timesthe 
pre-vaccination  titers. 
 
 
PR0- 01 TEMP 06 / Atlas No. 293620  
VersionNo.4 / VersionDate: Jan \131)'29, 2015 
00 
Protocol V59_77 
Page 10of86  GSK  
24 JUN 16 Final  Protocol  Versioo  1 Confidentia l 
::, z u 
8  
  
Name of Spo nsor: 
GlaxoSmithKline 
Biologicals S.A Protoco l nu mber:  
V59 77 Gene1i c name of study vaccine(s):  
 
Meningococcal  (groups A, C, W, and Y) 
oligosaccharide  dipht heriaCRM-197 
conjugatevaccine  
after vaccination  
2. To assess  persistence of bactericidal antibodies  against  serogroups  A, C, Wand 
Y at approximately  4-6 years after  the primary  vaccination  with Menveo  and 
after the primary  vaccination  with Menactra  in comparison with naturally - 
acquire d levels in vaccine-naiveindividual s, as measured  by the percentages  of 
subjects  with hSBA titers  8 and hSBA GMTs at Day1 . 
Safety objec tives:  
1. To assess reactogenicity and safety of MenACWY -CRM vaccine when 
administered  to subjects who previously received  Menveo or Menactra  and 
vaccine -naive individuals . 
Study Design: 
This is a phase 3b, controlled , open-label, multi -center studyto evaluate safety and 
inlmunogenicity of MenACWY -CRM after a single vaccination in healthy individuals 
who were  vaccinated  with Menveo  or Menactra  4 to 6 years  before  and in vaccine- naive 
individuals . 
Study population Approximately 700 healthy subjects 15 througll 55 years of age will 
be enrolled in the study . 
Duration  of the study The duration of this study is approximately  6 months per subject.  
Writte n informe d consent and, as applicabl e accordin g to local  guidelin es, written 
assent will be obtained  before conducting  any study -specificprocedures . 
Vaccination  schedule: All subjects will receive  a single dose of MenACWY- CRM  at 
Day1 . 
Study groups:  
• Group Menveo- Menveo: approximately 300 subjects, who were  vaccinated  with a 
single dose ofMenveo 4 to 6 years before , will receive one doseof MenACWY - 
CRM.  
• Grouo  Menactra- Menveo:aooroximatelv 300 subiects, who were  vaccinated  with a 
 
PR0-01 TEMP 06 / Atlas No. 293620  
VersionNo.4 / Vers ion Date: Jan\131)' 29 , 2015 
00 
Protocol V59_77 
Page 11of86  GSK  
24 JUN 16 Final  Protocol  Versioo  1 Confidentia l 
::, z u 
8  
  
Name of Sponsor: 
 
GlaxoSmithKline 
Biologicals S.A Protoco l number:  
V59- 77 Gene1i c name of study vaccine(s):  
 
Meningococcal (groups A, C, W, and Y) 
oligosaccharide diphtheria CRM -197 
conjugate vaccine  
single dose ofMenactra 4 to 6 years before , will receive one dose ofMenACWY - 
CRM.  
• Group Naive: approximately 100 subjects , of similar age to subjects enrolled in 
other  primed groups , with enrolment distributed  across all clinical  sites, who have  
not received any meningococcal  vaccination,  will receive one dose ofMenACWY - 
CRM.  
 
Randomization / Stratification:  
Within eachstudy group , subjects will be randomized into one of two different blood 
draw schedules according to a 1:1 ratio, described as follows:  
• Subjects  getting  blood  draws  at Day 1 , Day4 and Day29. 
• Subjects  getting  blood draws  at Day 1, Day 6 and Day 29. 
For a schematic overview , see Table  1. 
Table I: Schema tic diagra m of the VS9_77 stu dy gro ups 
Vacc.ine History Vacc.ination in current 
study Blood draw schedule   
Menveo 
N=300 Menveo Blood draw Day I , 4, 29 (N =l50) 
Blood draw Day I , 6, 29 (N =150) 
Menactra 
N=300 Menveo Blood draw Day I , 4, 29 (N =l50) 
Blood draw Day I , 6, 29 (N=l50 ) 
Vaccine- Naive 
N=l OO Menveo Blooddraw Day I , 4, 29(N =50) 
Blooddraw Day I , 6, 29(N =50) 
 
Blinding  open- label study.  
 
Blood  samn!P.s : Three  (3) blood samples  of approximately  10 mL each  will be collected 
according  to the blood  draw  schedule  in Table  1. 
Data collection: Electronic Case Report Form (eCRF).  
 
Studv clinic visits : Three (3) clinic visi ts at Day 1, Day 4 or Day 6 and Day 29 are  
 
PRO- 01 TEMP 0 6 / Atlas No . 2936 20 
VersionNo.4 / Vers ion Date: January 29, 2015 
00 
Protocol V59_77 
Page 12of86  GSK  
24 JUN 16 Final  Protocol  Versioo  1 Confidentia l  
  
Name ofSponsor:  
 
GlaxoSmithKline 
Biologicals S.A Proto col number:  
V59 77  Gene1i c name of study vaccine(s):  
 
Meningococcal (groups A, C, W, and Y) 
oligosaccharide diphtheria CRM -197 
conjugate vaccine  
planned for each subject.  
 
Reminder  Phone  calls: Two  (2) reminder  phone  calls  will beconducted at Day 3 and 
Day 5 after the study  vaccination to remind the subject/  legal  guardian  to complete the 
diary  card.  
Safety phone  calls: Three (3) safety phone  calls  (at Day 15, Day91 and Day 181)  will 
be conducted to collect any medically -attended  AEs, AEs leading  to withdrawal,  SAEs , 
related medications  and any vaccinations.  In addition,  all unsolicited  AEs and related 
medications  occurring  after  the vaccination  will be collected  during  the safety  call at 
Day15.The  Day 181 Safety Phone  call will also serve as the termination  visit.  
 
Solicited  Adverse  Events  (injection  site pain,  erythema, induration,  fatigue , headache , 
myalgia,  arthralgia,  loss of appetite , nausea, chills  and fever) occurring  on the day of 
vaccination  and the following  six days (Day  I through  Day 7) will be recorded  daily 
using  a Diary  Card  for all subjects . 
 
Unsolicited AEs occurring within 28 days after studyvaccination will be collected . 
Qualified site staff will interview the subject by phone approximately 14 days after 
vaccination  and in person  at the study  site approximately 28 days after study  vaccination 
to assess  the occurrence of any unsolicited  AEs.  
 
Medically -attended  AEs,  AEs leading  to study withdrawal  and SAEs  will be collected  
during  the entire  study  period . These  data will be captured  by interviewing  the subject  
and/or  subjects ' parents / guardian  (as applicable ) during the site visits  and phone  calls 
and by review  of available  medical records.  Subjects  and/or  parents / guardian  will be 
encouraged to call the site in the event of any medically- attended AEs or any AEs which 
theyperceive  as being  of concern during the entire  study period.  
 
Table 2: Schematic diagram of the VS9_77 study desig n. 
Day l Day 4  Day 6  Day15  Day 29  Day 91  Day181 
Blood draw 
(all subjects) Blood draw 
(50% of Blood draw 
(50% of Safety 
Phone call Blood draw 
(all subjects ) Safety 
Phone  Safety 
Phone call 
Menveo  subj ects ) subjects )   call Study  
      tennination  
Number of Subjects planned: Aooroximatelv  700 subiects  are planned  for enrolment  
 
PR0-01 TEMP 06 / Atlas No. 293620  
VersionNo.4 / Vers ion Date: January 29, 201 5 

Protocol V59_77 
Page 13of86  GSK  
24 JUN 16 Final  Protocol  Versioo  1 Confidentia l 
::, z u 
8  
  
Name of Spo nsor:  
 
GlaxoSmithKline 
Biologicals S.A Protoco l number:  
V59- 77 Gene1i c name of study vaccine(s):  
 
Meningococcal (groups A, C, W, and Y) 
oligosaccharide diphtheria CRM -197 
conjugate vaccine  
into this study , approximately 300 subjects who previously received Menveo (Menveo - 
Menveo group) , 300 subjects who previously received Menactra (Menactra- Menveo 
group) and 100 meningococcal vaccine -naive subjects (Naive group) . Assuming a 10% 
drop- out rate that should provide approximately 630 evaluable subjects . 
Study Population and Subject C haracte1i stics: The list of inclusion and exclusion 
criteria is included in protocol section 4, Selection of Study Population.  
Stu dy Pro ced ures: The study  includes  three  clinic  visits , one vaccination , three  blood 
draws , and threesafety phone  calls  for each  subject.  All study procedures associated 
with the pre-vaccination , vaccination , post-vaccination and study termination  visit are 
described in section  5.0. 
Study Vacc ines: 
 
GlaxoS mithKline Menin gococca l MenAC \1VY- CRl "\1 vacc in e (M e n veo): 
Meningococcal (groups A, C, Wand Y)oligosaccharide diphtheria CRM- 197 con jugate 
vaccine is supplied as a vial that contains 10 µg of serogroup A oligosaccharides and 5 
µg of serogroups C, W and Y oligosaccharides , conjugated to Corynebacterium  
diphtheri.ae CRM 191protein. Overall injection volume of 0.5 mL. 
 
The vaccine  will be administered intramuscularly , preferably in the deltoid  area of the 
non-dominant  arm.  
P1i mary E ndpoint(s): 
Immun ogenicity E ndpoi nts: 
The following measures will be summarized for Menveo -Menveo and Menactra - 
 
 
  
 
  
 
PR0-01 TEMP 06 / Atlas No. 293620  
VersionNo.4 / Version Date: Jan\131)'29 , 2015  
00 
Protocol V59_77 
Page 14of86  GSK  
24 JUN 16 Final  Protocol  Versioo  1 Confidentia l 
::, z u 
8  
  
Name of Sponsor:  
 
GlaxoSmithKline 
Biologicals S.A Protoco l number:  
V59 77  Gene1i c name of study vaccine(s):  
 
Meningococcal (groups A, C, W, and Y) 
oligosaccharide diphtheria CRM -197 
conjugate vaccine  
Menveo groups:  
1. Percentage of subjects  with hSBA  seroresponse1 against  N. meningitidis  serogroups  
A, C, Wand Yat Day29.  
 
Secon dary Endpoints: 
Immun ogenicity endpoints: 
Thefollowing measures will be summarized for Menveo- Menveo, Menactra -Menveo , 
Naive and the pooled (Menveo -Menveo and Menactra -Menveo) groups:  
 
1. Percentage of subjects with hSBA titer 2:8 and 2:16 against N. meningitidis 
serogroups A, C, Wand Y at Day 1, Day 4, Day 6 and Day 29 and between- group 
differences ; 
2. Percentages  of subjects with hSBA  seroresponse2 against  N. meningitidis  serogroups  
A, C, Wand Y at Day4 , Day 6 and Day 29 and between -group differences ; 
3. hSBA  GMTs  against  N. meningitidis  serogroup  A, C, Wand Y at Day 1 , Day 4, Day 
6 andDay29;  
4. Ratios  ofhSBA  GMTs  at Day 1, Day 4, Day 6 and Day 29 (between  study  groups).  
5. hSBA Geometric  Mean  Ratios  (G:MRs)  at Day 4, Day 6, and Day 29 compared  to 
Day 1 (within study groups).  
 
Safety e ndpoi n ts: 
Safety of the study vaccine will be assessed in the Menveo -Menveo and Menactra - 
Menveo groups and the pooled vaccine group (Menveo- Menveo and Menactra - 
Menveo) and the vaccine -naive orou o in terms of the fr"'mencies (oercenta2es) of  
 
 
1-2 Seroresponse is defined forthisstudy as follows : Forsubjects with prevaccinationtiters <4, post - 
vaccin
ation  titers  2: 16; forsubjects  ,vitbprevaccinationtiters  2:4, post vaccination  titers 4 timestbe pre- 
vaccination  titers . 
 
  
PR0-01 TEMP 06 / Atlas No.293620  
VersionNo.4 / VersionDate: Jan \131)'29, 201 5 
00 
Protocol V59_77 
Page 15 of86  GSK  
24JUN 16Final  Protocol  Versioo  1 Confidentia l  
  
Name of Spo nsor:  
GlaxoSmithKline 
Biologicals S.A Protoco l nu mber:  
 
V59 77 Gene1i c name of study vaccine(s):  
 
Meningococcal  (groups A, C, W, and Y) 
oligosaccharide diphtheria CRM -197 
conjugate vaccine  
reported adverse events including  
1. Any unsolicited AEs reported  within  30minutes  after vaccination; 
2. Solicited  local  and systemic AEs reported  from  Day 1 (6 hours) through Day 7 after 
vaccination; 
3. Other indicators of reactogenicity (e.g. use of analgesics / antipyretics , body 
temperature) within  7 days after vaccination;  
4. All unsolicited AEs reported  from  Day 1 through Day 29 after vaccination;  
5. Medically -attended  AEs, AEs leading  to withdrawal  and SAEs reported  from  Day1 
through Day 181 (during the entire  study period) . 
Statistical Anal yses: 
P1i mary Immunoge nicity O bjective 
The primary  population  for the analysis  of sufficient  immune  response is the Per 
Protocol  Set (PPS) , and willconsist of the Menveo -Menveo  group (n=270 evaluable 
subjects)  and Menactra -Menveogroup (n=270 evaluable  subjects ).Todemonstrate 
immune  response sufficiency  after MenACWY -CRM booster vaccine administration, 
the lower  limit of the one- sided  97.5%  Confidence Interval  (CI) for percentage  of 
subjects  with hSBA  seroresponse against eacliof  serogroups A, C, Wand  Y must  be 
greater than 75%. This willbetested  sequentially  first in the group of subjects who 
received  primary  vaccination  with Menveo  and, if met, also in the group of subjects 
who received  primary  vaccination  with Menactra.  
Hypothesis:  
Null hypothesis Alternative  hypothesis  
pij 0.75 pij > 0.75 
Where: Pij is the population booster seroresponse rate; j = 1,2 refer to group Menveo - 
Menveo  (f
irst test) and Menactra -Menveo  (second test) respectively ; i = 1,2,3,4 refer to 
serogroup  A, C, Wand  Y respectively.  
 
 
 
PR0-01 TEMP 06 / Atlas No. 293620  
VersionNo.4 / Vers ion Date: Jan\131)'29 , 2015  

Protocol V59_77 
Page 16 of86  GSK  
24JUN 16Final  Protocol  Versioo  1 Confidentia l 
::, z u 
8  
  
Name of Sponsor:  
 
GlaxoSmithKline 
Biologicals S.A Protoco l number:  
V59 77  Gene1i c name of study vaccine(s):  
 
Meningococcal (groups A, C, W, and Y) 
oligosaccharide diphtheria CRM -197 
conjugate vaccine  
Sample Size: 
Statistical power was estimated based on observed data from study V59P13El.  
 
Assuming  the true booster  seroresponse  rates  in the Menveo- Menveo  group range  from 
90%  to 97%  (alterna tive hypothesis)  for each  serotype , a sample  size of n=270 will have 
at least 96% power to show sufficiency of immune response to a booster dose of 
MenACWY -CRM, compared with a pre -specified reference booster seroresponse of 
75%  (null  hypothesis)  using  an exact  test with 0.025 one-sided  significance  level.  
 
Assuming  the true booster  seroresponse  rates  in the Menactra-Menveo group  range  from 
91% to 100% (alternative hypothesis ) for eachserotype , a sample size of n=270 will 
have at least  96%  power to show  sufficiency of inlmune  response  to a booster dose  of 
MenACWY -CRM, compared with a pre -specified reference booster seroresponse of 
75%  (null  hypothesis)  using  an exact  test with 0.025 one-sided  significance  level.  
 
Overall  statistical  power to show  sufficiency  of inlmune response to a booster  dose  of 
MenACWY -CRM  for each serotype  in both the Menveo-Menveo and the Menactra - 
Men
veo group will be at least 92%. 
 
When taking  a 10%  dropout  rate into account , N=300 previously  vaccinated  subjects 
with Menveo  and N=300 previously  vaccinated  subjects  with Menactra  have  to be 
enrolled in the study . 
Calculations have been done with nQuery Advisor (Version 7.0).  
In terim Analysis: No interim analysis is planned for this study.  
Data Monito1i ng Co mmitt ee : No DMC will be utilized for the study.  
 
 
 
  
 
  
 
PR0- 01 TEMP 06 / Atlas No . 29362 0 
VersionNo.4 / Version Date: Jan\131)'29 , 2015 
00 
GSK  
24 JUN 16 Final Protocol  Version  1 Confidential  Protocol V59_77 
Page 17 of86  
::, z u 
8  
  
Table4  Time and E vents Table 
 
Visit Type 
Study period  
Study Day 
 
Visit Window (Days) 
 
 
Visit Number  Clinic Visit  Clinic Visit Phone Ca ll Clinic Visit  Phone Call Clinic Visit Phone Call Phone Ca ll 
Screening  Treatment  Tre.itment Treatment  Treatment  T reatment Follow - up Follow- up 
 1 3, 5 4/6• 15 29 91 181 
 
-5 
to 1  
0 2 days (- 
1/+l ), 4 
days (0/ +2) 
after vacc 3/5 days 
(-1/+l) 
after vacc  14 da ys 
(-2/+2) 
after vacc  28 d a ys 
(-7/+14) 
after vacc 90 da ys 
(-14/+14) 
aftel' vacc  180 da ys 
(-14/ +14) 
after vacc 
Pre- 
vacc.ina tion 1 N/A 2 3 4 5 6 
Stud y Event Referen ces  
Study Treatment    
Vaccina tion (vacc ) Section 5.2  X       
Screening and 
Safety    
Informed Consent"  Section 5.1.1  X        
Medical HistOJY  Section 5.1.2 X        
Physical Exam  Sections 5.1.2 
and 5.3.l X x<  X  X   
Pregnancy Test Sections 3 .5 and 
5 .1.2 X x<       
Exclusion/Inclusi on 
Criteriad Section4  X X       
Randomization  Section 5. 1.4  x<       
30 Minutes Post 
Injection Assessment  Section 5.2.1  X       
 
PR0--01 TEMP 06 / Atlas No. 293620  
Versi on No. 4 / Version D ate: January 29, 2015  
00 
GSK  
24 JUN 16 Final Protocol  Version  1 Confidential  Protocol V59_77 
Page 18 of86  
::, z u 
8  
  
Visit Type 
Study period  
Study Day 
 
Visit Window (Days) 
 
Visit Number  Clinic Visit Clini c Visit PhoneCa ll Clinic Vis it Phone Call Clinic Visit Phone Call Phone Call 
Screening  Treatmen t Tre.itment Treatm ent Treatmen t Treatment Follow-up Follow-up 
 1 3, 5 4/6• 15 29 91 181 
 
-5 
to 1  
0 2 days (- 
1/+l ), 4 
days(0/+2) 
after vacc 3/5 da)'S 
(-1/+l ) 
after vacc 14 da ys 
(-2/+2) 
after vacc  28da ys 
(-7/+14) 
after v acc 90da ys 
(-14/+14) 
aftel' vacc  180 da ys 
(-14/+14) 
after vacc 
Pre- 
vacc.ination 1 NIA 2 3 4 5 6 
Study Event References   
SubjectDiary 
Dispensed w ith 
Training   
Section 5.2.1   
X       
SubjectDiary  
Reminder Call Section 5.2.2   X' X'     
SubjectDiary 
Reviewed and 
Collected   
Section 5.3.1        
X   
Assess Unso licited  
AEs Section7 .1  X  X X X   
Assess SAEs  Section 7.1.4   X  X X X X X 
Assess fo r medically 
attended AEs an d 
AEs leading to 
withdrawal   
Sections 7. I.4.I 
and7.1.3   
X   
X  
X  
X  
X  
X 
Assess relevant 
medications/ 
vaccina tions Sections 5.1.2 
and 6.5  
X  
X   
X  
X  
X  
X  
X 
 
PR0 --01 TEMP 06 / Atlas No . 293620 
Versi on No. 4 / Versi on Date: January 29 , 2015  
00 
GSK  
24 JUN 16 Final Protocol  Version  1 Confidential  Protocol V59_77 
Page 19 of86  
::, z u 
8  
  
Visit Type 
Study period  
Study Da y 
 
Visit Window (Days)  
 
 
Visit Number  Clinic Visit  Clinic V isit PhoneCa ll Clinic Visit  Phone Call  Clinic Visit P hone Call  Phone Ca ll 
Screening  Treatment  Tre.itment Treatment  Treatment  Treatment Follow - up Follow- up 
 1 3, 5 4/6• 15 29 91 181 
 
-5 
to 1  
0 2 days (- 
1/+l ), 4 
da ys (0 /+2) 
after vacc  3/5 da)'S 
(-1/+l )  
after vacc  14 days  
(-2/+2)  
after vacc  28days 
(-7/+14) 
after vacc  90days 
(-14/+14) 
aftel' vacc  180 days 
(-14/+14)  
after vacc  
Pre- 
vacc.ina tion 1 NIA 2 3 4 5 6 
Study  Event I References   
Imm unogenicity    
Serology blood draw  I Section 3.5  X"  X  X   
Study C-0mp lerion 
Pt·ocedure  
Study Tenninatior n I Sec tion 5.5        X 
 Notes : 
• Subject  will be randomized  into a blooddraw  schedu le in a 1:1 ratio. The second  clinic  visit will occur  at Day 4 OR Day 6. 
b Confirm consent fonn( s) signed prior to any procedures.  
' Procedure to be performed prior to vaccination  
d Reminder for previously vaccinated sub jects, appropriate written documentation of the identity of the primary meningococcal vaccination 
(Menveo o r Menactra) and vaccination date must be provided prior to enrollment.  
• If the clinic  visit at Day4 is overlapping withthe specified  window  of the Day 3 reminder  call, the Day 3 reminder  call maybe  omitted . 
If the clinic visit at Day 6 is overlapping  with the specified  window  of the Day 5 reminder  call,the Day 5 reminder  call mayb e omitted . 
f    Subjects who  tenninate thestudy early are  recommended to   complete certainstudy -related procedures .   See section  5.5  for    further  details . 
 
  
 
 
PR0--01 TEMP 06 / Atlas No. 293620  
Vers ion No. 4 / Version Date : January 29, 2015  
00 
Protocol V59_77 
Page 20of86  GSK  
24JUN 16Final  Protocol  Versioo  1 Confidentia l 
PR0-01 TEMP  06 / Atlas  No. 293620  
VersionNo.4  / Version Date:  Jan\131)' 29 , 2015   
  
LIST OF ABBREV IATIONS  
 
ACIP 
AE 
CI 
CBER 
CRM 
CRO 
EC 
EoS 
eCRF 
EDC 
FAS 
FDA  
GCP 
GMR 
GMT 
GSK 
HIPAA 
hSBA 
IB 
ICF 
ICH  
 
IM 
IRB 
LSLV  
MedDRA  
pp 
Ref. 
SAE  
SDAF  
SBIR  
soc 
SOP  Advisory Committee on Imm1mization  Practices 
Adverse Event  
Confidence Inteival  
Center for Biologics Evalua tion and Research 
Cross Reactive material  
Contract Research Organization 
Ethics Committee  
End of Study  
Electronic  Case Report  Form 
Electronic  Data Capture  
Full Analysis Set  
Food  and Drug Administration 
Good Clinical Practices 
Geometric Mean Ratio 
Geometric Mean Titer 
GlaxoSmithKline  Biologicals  
Health Insurance Porta bility and AccountabilityAct 
Human Serum Bactericidal Assay  
Investigator ' s Brochure  
Informed Consent Form  
International Conference on Harmonisation of Technical 
Requirements for Registration of Pharmaceuticals for Human Use 
Intramuscular  
Institutional Review Board 
Last Subject Last Visit  
Medical Dictionary for Regulatory Act ivities 
Per Protocol  
Reference  
Serious Adverse Event  
Source Documentation Agreement Form 
Source  Data Base for Internet Randomiza tion 
System  Organ Class  
Standard Operating Procedure  
Protocol V59_77 
Page 21of86  GSK  
24JUN 16Final  Protocol  Versioo  1 Confidentia l 
PR0-01 TEMP  06 / Atlas  No. 293620  
VersionNo.4  / Version Date:  Jan\131)' 29 , 2015   
  
l. BACKG ROUl''-D M 'D RATIO NALE  
 
1.1 Backgro und 
 
Neisseria meningitidis is a leading cause of bacterial meningitis and sepsis worldwide , 
capable of causing outbreaks and epidemics of invasive disease. Meningococcal disease is 
associated with high morb idity and mortality even among patients who receive early 
antibiotic treatmen t. Most cases of invasive disease worldwide are caused by serogroups 
A, B , C, W and Y . 
 
The quadrivalent meningococcal oligosaccharide diphtheria CRM- 197 conjugate vaccine 
(MenACWY -CRM ; Menveo, GSK B iologicals)is  approved  for active irom1mizati.on  of 
individuals  from  2 months  through  55 years of age in the United  States . As of February 
2015, more than 30,000 of subjects  have  been exposed to MenACWY- CRMvaccine in 
completed clinical studies and more than 24 million doses of the vaccine have been 
distributed  globally . 
 
The US Advisory Committee on Immunizat ion Practices (ACIP) recommends routine 
vaccination  with a quadrivalent  conjugated meningococcal vaccine for adolescents  at 11- 
12 years of age with a booster  dose administered 5 years  later. While  a substantial  body  of 
data exists showing a robust immune response and good antibody persistence after a 
single dose of MenACWY- CRM in adolescents , the response to a booster dose of 
MenACWY -CRM in this age group has only been evaluated in 2 clinical studies with 
limited  number  of subjects. 
 
A robust  anamnest ic immune response  to a booster  dose  of Menveo vaccine  administered 
at approximately 5 years  after previous  vaccination with the same vaccine  or a licensed 
meningococcal polysaccharide  vaccine (Menomune®) was demonstrated  in the phase 2 
clinical study V59 P6El . High titers of bactericidal antibodies against the vaccine 
serogroups were achieved at 7 and 30 days after booster dose in MenACWY -CRM - 
prime
d subjects. However , the number of subjects included  in this study  was relatively 
small (N=101, including 50 subjects who received a booster dose after the primary 
MenACWY -CRM  vaccination).  
 
In the phase 3b clinical study V59 Pl3 El , a booster dose of MenACWY -CRM was given 
3 years after primary vaccinat ion with either MenACWY -CRM or Menactra®(a 
meningococcal diphtheria toxoid- conjugated MenACWY vaccine , MenACWY- D) in 
adolescents . A booster dose was able to substantially increase antibody titers against all 4 
serogroups irrespective of the priming vaccine . Again, only small numb er of subjects 
(N=160) received the MenACWY- CRM booster , (83 who received primary MenACWY - 
CRM 
and 77 who received MenACWY- D). 
Protocol V59_77 
Page 22of86  GSK  
24JUN 16Final  Protocol  Versioo  1 Confidentia l 
::, z u 
8  
  
In the light of the current  ACIP recommendation for a booster dose  of MenACWY -CRM, 
there exists a need to evaluate the response to a MenACWY -CRM booster given at - 5 
years  after primary  vaccination in meningococcal -vaccineprimed adolescents . Generation 
of this data would also be of relevance in outbreak management and vaccination of 
travelers  to endemic areas . 
 
1.2 Rational e 
 
The pwpose/aim  of this study  is to assess the safety  and antibody  response  to vaccination 
with a booster doseofMenveo  given  4-6 years after primary vaccination  and the response 
to a single dose given to vaccine -naive subjects , and to describe the inunune response 
over time after a booster  dose  of Menveo , administered to subjects  previously vaccinated 
with Menveo  or Menactra, and after a single  dose of Menveo to vaccine -naive  subjects . 
The inclusion  of vaccine- naive  subjects  in a separate study  arm is to enable comparison of 
the rapidity and magnitude of an anamnestic response to a booster dose (in primed 
individuals)  or the primary  response  to a first dose  (in naive individuals)  ofMenACWY - 
CRM.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PR0-01 TEMP 06 / Atlas No. 293620  
VersionNo.4 / Vers ion Date: Jan \131)'29 , 2015  
00 
Protocol V59_77 
Page 23of86  GSK  
24JUN 16Final  Protocol  Versioo  1 Confidentia l 
::, z u 
8  
  
2. OBJE CTIVES 
 
2.1 Plima ry Objective(s)  
Immunogenicity objective: 
1. To demonstrate a sufficient immune response foll owing a booster doseof 
MenACWY -CRM (Menveo) vaccine , given to subjects who previously received 
Menveo , as measured by the percentage  of subjects  with hSBA  seroresponse1 against  
N. m.eningitidis serogroups A, C, W and Y at Day 29 after vaccination  
2. To demonstrate a sufficient immune response following a booster doseof 
MenACWY -CRM  (Menveo) vaccine , given  to subjects  who previously  received  
Menactra , as measured by the percentage of subjects with hSBA seroresponse1 against  
N. m.eningitidis serogroups A, C, W and Y at Day 29 after vaccination  
Criteria to demonstrate immune response sufficiency The immune response 
sufficiency will be tested sequentially ; first in the group of subjects who received 
primary vaccination with Menveo and, if met, also in the group of subjects who 
received primary vaccination with Menactra . The immune response will be 
consi dered as sufficient if the lower limit of the one-sided  97.5% CI for percentage of 
subjects with hSBA seroresponse1 against serogroups A , C, Wand Y isgreater than 
75%. The study will be consi dered successful if the immune response  sufficiency  will 
be demonstrated at least  in the groupof subjects  who received primary vaccination 
with Menveo . 
 
 
2.2 Secondar y Objectiv e(s) 
 
Secondar y Immun ogenicity obje ctives:  
1. To compare the immune responses over tinie following a booster doseof 
MenACWY -CRM vaccine, between subjects who previous ly received Menveo , 
subjects  who previously  received  Menactra, and subjects  who previously  received 
Menveo or Menactra (poo led vaccine  group)  and following  a single  dose in vaccine - 
naiv
e individuals , as measured by the percentages of subjects  with hSBA  
 
 
 
1 Seroresponse is defined for thisstudy asfollows: For subjects with pre-vaccinationtiters <4, pos-t 
vaccin
ation  titers  2: 16; for subjects with pre-vaccinationtiters2::4, post vaccinat ion titers  at least4 times the 
pre-vaccina tion titers.  
 
 
PRO --01 TEMP 06 / Atlas No.293620  
VersionNo.4 / Vers ionDate: Jan\131)'29, 2015  
00 
Protocol V59_77 
Page 24of86  GSK  
24JUN 16Final  Protocol  Versioo  1 Confidentia l 
::, z u 
8  
  
seroresponse1, hSBA titers  8  and ;,:16 , and hSBA GMfs against N. meningitidis  
serogroups A , C, Wand Y at Day I , Day 4 , Day 6 , and Day 29 after vaccination . 
2. To assess  persistence  of bactericidal ant ibodies  against  serogroups  A, C, Wand Y at 
approximately 4-6 years after the primary vaccination  with Menveo and after the 
primary vaccination  with Menactra in comparison with naturally -acquired level in 
vaccine- naive individuals , as measured by the percentages of subjects with hSBA 
titers 8  and hSBA GMfs at Day 1. 
Secondar y Safety objec tives: 
To assess the reactogenici ty and safety  of MenACWY -CRM  vaccine when  administered 
to subjects  who previously received  Menveo or Menactra  and vaccine -naive  individuals.  
 
2.3 Expl or atory Objective(s) 
There are no exploratory  objec tives. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PR0-01 TEMP 06 / Atlas No . 29362 0 
VersionNo.4 / Vers ion Date: Jan \131)'29 , 2015 
00 
Protocol V59_77 
Page 25of86  GSK  
24JUN 16Final  Protocol  Versioo  1 Confidentia l 
PR0-01 TEMP  06 / Atlas  No. 293620 
VersionNo.4  / Version Date:  Jan\131)'29  , 2015   
  
3. STUD Y DESIGN 
 
3.1 Overview o f Study Design 
This is a phase 3b, controlled, open -labe multi- center studyto evaluate safety and 
immunogenicityof  MenACWY -CRM  after a single  vaccination in healthy  individuals 
who were vaccinated with Menveo or Menactra 4 to 6 years before  and in vaccine- naive 
individuals . 
Study  populat ion: Approximately  700 healthy  subjects 15 through  55 years of age will be 
enrolled in the  study . 
Duration of the study  The duration of this study is approximately 6 months per subject.  
 
Written informed consent  and, as applicable according to local guidelines, written assent  
willbeobtained  before  conductin g anystudy-specifi cprocedur es. 
 
Vaccination  schedule: All subjects  will receive a single  dose  of MenACWY- CRM  at Day 
1. 
 
Study groups : 
 
Group  Menveo -Menveo : approximately  300 subjects , who were vaccinated with a single 
dose  ofMenveo  4 to 6 years before , willreceive  one dose  of MenACWY -CRM . 
 
Group Menactra- Menveo  approximately 300 subjects , who were vaccinated with a single 
dose  of Menactra 4 to 6 years  before , will receive one dose  of MenACWY- CRM.  
 
Group Naive: approximately 100 sub jects equally enrolled across all clinical sites, who 
have not received any meningococcal vaccination, willreceive one dose of MenACWY - 
CRM.  
 
Randomization / Stratification : 
Within each study group , subjects will berandomized into one of two different blood 
draw schedules according to a 1:1 ratio, described as follows:  
• Subjects  getting blood  draws  at Day 1, Day 4 and Day 29. 
• Subjects  getting blood  draws  at Day 1, Day 6 and Day 29. 
 
For a schematic overview , see Table 1  
Protocol V59_77 
Page 26of86  GSK  
24JUN 16Final  Protocol  Versioo  1 Confidentia l 
PR0-01 TEMP  06 / Atlas  No. 293620 
VersionNo.4  / Version Date:  Jan\131)'29  , 2015   
  
Table 3.1-1: Schematic diagr am of the VS9_ 77 study group s 
 
Vacd ne History  Vaccination in cwTent 
study  Blood draw sched ule 
Menveo  
N=300 Menveo  Blood draw Day 1, 4, 29 (N=l 50)  
Blood draw Day 1 , 6, 29 (N = l 50)  
Menactra  
N=300 Menveo  Blood draw Day 1 , 4, 29 (N =150) 
Blood draw Day 1 , 6, 29 (N = l 50) 
Vaccine -Naive  
N=IOO Menveo  Blood draw Day I, 4, 29 (N =50) 
Blood draw Day I, 6, 29 (N =50) 
 
Blinding· open- label study . 
 
Blood sanmles: Three (3) blood samples of approximately 10 mL each will be collected 
according to the blood draw schedule in Table 3.1.1. 
Data collection: Electronic Case Report Form (eCRF).  
 
Study  clinic  visits:  Three (3) clinic  visits  at Day I , Day 4 or Day 6 and Day 29 are 
planned for eachsubject.  
Reminder  Phone  calls : Two  (2) reminder  phone  calls  willbe conducted at Day 3 and Day 
S after the study  vaccination  to remind  the subject/legalguardian to complete  the diary 
card.  
 
Safety phone  calls : Three (3) safety phone  calls  (at Day IS, Day 91 and Day 181)  will be 
conducted to collect any medically -attendedAEs , AEs leading to withdrawal , SAEs , 
related medications and any vaccinations . In addition, all unsolicited AEs and related 
medications  occurring  after the vaccination  will be collected  during  the safety  call at Day 
IS. The Day 181 Safety Phonecall  will also serve as the termination  visit.  
 
Solicited  Adverse  Events (injection  site pain,  erythema , induration, fatigue , headache, 
myalgia, arthralgia , loss of appetite, nausea , chills  and fever) occurring on the day of 
vaccination  and the following  six days (Day  1 through  Day 7) willbe recorded daily 
using  a Diary  Card  for all subjects. 
 
Unsolicited AEs occurring within 28 days after studyvaccination will be collected . 
Qualified site staff willinterview the subject by phone approximately 14 days after 
vaccination  and in person at the studysite  approximately  28 days after studyvaccination 
to assess the occUITence of any unsolicited  AEs.  
Protocol V59_77 
Page 27of86  GSK  
24JUN 16Final  Protocol  Versioo  1 Confidentia l 
PR0-01 TEMP  06 / Atlas  No. 293620  
VersionNo.4  / Vers ion Date:  January  29, 2015   
  
Medically -attended AEs AEs leading  to stuqy  withdrawal  and SAEs will be collected 
during  the entire  study  period . These data will be captured by interviewing  the subject 
and/or  subjects ' parents  / guardian (as applicable)  during the sitevisits  and phone  calls 
and by review  of available  medical records.  Subjects  and/or  parents / guardian will be 
encouraged to call the site in the event of any medically -attended AEs or any AEs which 
theyperceive  as being  of concern during  the entire  study  period.  
 
Table 3.1-2: Schematic diagram  of the V59_77 study design  
 
Day l Da y 4  Da y 6 Da y 15 Da y 29  Da y 91 Da y 181 
Blood draw 
(allsubjec ts) Blood draw 
(50¾of  Blood draw 
(50% of Safety 
Phone call  Blood draw 
(all subjects ) Safety 
Phone  Safety Phone  
call 
Menveo  subjects ) subjects)   call Study  
      termina tion 
 
3.2 Study Period  
 
Each subject  should  expect  to participate  in the study  for 6 months , from  the time of 
enrohnent  through  the last study  visit.  
 
3.3 Blindin g Prnced ures 
 
The trial is designed as an open -label study . 
 
3.4 Data Collection  
3.4.l D ata Collected from Subject s 
 
The following  data will be collected from each subject over the duration of their  study 
participation:  
• Demographic  Information  
• Adverse  Events  
• Medical  History  
• Concomitant  Medications/Vaccinations  
• Information on the blood  samples  
 
All data collected must only be identified using the Subject ID , as described in section  
S.1.4, Randomization.  
Protocol V59_77 
Page 28of86  GSK  
24JUN 16Final  Protocol  Versioo  1 Confidentia l 
PR0-01 TEMP  06 / Atlas  No.293620  
VersionNo.4  / Version Date:  Jan\131)'29,  2015   
  
3.4.2 Tools Used for Data Collection 
 
Data willbe recorded  in the Subject Diary  and collected on electronic Case Report  Forms 
(eCRFs) . 
 
Subject Diar y 
 
Paper Diaries (pDiaries) , hereafter  referred  to as Subject Diaries  will be the onlysource 
document allowed for solicited local and systemic adverse events (including body 
temperature measurements) , starting  after  the initial,  30minute  post-vaccination period at 
the clinic.  The following  additional rules  apply  to documentation of safety  information 
collected  in the Subject Diary . 
 
The Investigator or delegated  staff should  monitor the Subject's  Diary  status  throughout 
the study  for compliance and any solicited  local and systemic  adverse events  that were of 
concern to the subject.  
 
• No corrections or additions to the information recorded by the subject or 
parent(s)/legal  guardian(s)  within  the Subject  Diary  willbe allowed  after it is 
delivered to the site. 
• Any blank  or illegible  fields  on the Subject  Diary  must  be described as missing  in the 
eCRF . 
 
Case Rep01t F or ms 
This study utilizes electronic Case Report Fonns (eCRFs) to collect study -related data 
from each subject. A qualified site staff member(s) is required to enter subject data in the 
eCRFs in English based on the medical information available in each subject ' s source 
record . 
 
Data should  be entered into the eCRF  in a timely  fashion following  each subject ' s clinic 
visit, study  procedure , or phone  call. Each subject 's eCRF casebook will be compared 
withthe  subject's  source  records  by a GSK -approved  study  monitor  (or designee) over 
the duration  of the study  in order to ensure data collection  accuracy.  
 
The following additional rules apply to documentation of Subject Diary information 
collected in the eCRFs:  
• The site must enter all readable  entries  in the Subject Diary  into the eCRF , including 
those  values that may be biologically  implausible (e.g. bodytemperature:  400°C).  
• Any illegible or implausible data should be reviewed with the subject and/or 
parent(s)/legal  guardian(s). If an underlying  solicited  or unsolicited  adverse  event is 
Protocol V59_77 
Page 29of86  GSK  
24JUN 16Final  Protocol  Versioo  1 Confidentia l 
PR0-01 TEMP  06 / Atlas  No.293620  
VersionNo.4  / Version Date:  Jan\131)'29,  2015   
  
described on review  with the subject , this should  be described in the source  document 
and reported as an unsolicited  adverse event in the Adverse  Event  eCRF  (e.g., if the 
subject above confinns body temperature of 40°C on the day in which body 
temperature: 400°C  was written  into his/her  Subject Diary , this fever  of 40°C  should 
be recorded in the Adverse Event eCRF).  
• Any newly described safety infonnation (including a solicited adverse event) nrust not 
be written into the Subject Diary and nrust be described in the study file as a verbally  
reported adverse event. Any adverse event reported in this fashion must be described 
as an unsolicited  adverse  event  and therefore  entered on the Adverse  Event eCRF . 
 
3.5 Collectio n of Clinic al Specimens 
 
• Collected  samples will beused for protocol  mandated research and purposes  related 
to the improvement , development and quality assurance of the laboratory tests 
described  in this protocol.  This may include  the management of the quality  of these 
tests, the maintenance or improvement  of these  tests, the development  of new test 
metho ds, as well as making  sure that new tests  are comparable  to previous  methods 
and work  reliably . 
• It is also possible that future findings may make it desirable to use the samples 
acquired in this study for future  research,  not described  in this protocol.  Therefore , all 
subjects in countries where this is allowedwill be asked to give a specific consent to 
allow GSK or a contracted partner to use the samples for future research . Future 
research willbesubject to the laws and regulations in the USAand willonly be 
performed once an independent Ethics Committee or Review Board has approved 
this research.  
Information on further invest igations and their rationale can be obtained from GSK.  
Any sample testing  willbedone  in line with the consent  of the individual 
subject/subject 's parent(s) . 
 
Refer also to the : Investigator  Agreement , where it is noted that the investigator  cannot 
perform any other biological assays except those described in the protocol or its 
amendment(s).  
 
If additional  testing  is performed, the marker  priority ranking given in the table  below 
may be changed.  
The following  clinical specimens are required  to be collected from  each subject  in this 
study:  
• Blood.  
Protocol V59_77 
Page 30of86  GSK  
24JUN 16Final  Protocol  Versioo  1 Confidentia l 
PR0-01 TEMP  06 / Atlas  No.293620  
VersionNo.4  / Version Date:  Jan\131)'29,  2015   
  
• Urine for  pregnancy  testing  (As per routine practice, specimens willbetested  at each 
site). 
 
Processing of a specimen should be completed bya qualified site member and in 
accordance with the study -specificLaboratory Manua .l Testing of serum specimens will 
be performed bya GSK or a designated laboratory . Refer to the study- specific Clinical 
Specimen Laboratory Manual for additional details . 
Blood S pecimens 
 
Approximately  10 mL sample of blood willbedrawn  from  all subjects at visit Day 1 
before vaccination,  and at visit Day 4 or Day 6 and visit Day29. The blood volume  will 
not exceed  10 mL at each  time point in order to provide  the necessary  serum  volume 
(approximate ly half of the blood  draw  volume)  for the serology assays.  
The blood will be used  for immunological assays. See section  7, Assessments for 
additional  details . 
The total amount of blood collected  over the study period  per subject will be 
approximately  30mL. 
 
U1in e S p eci m e ns 
 
Urine  willbe collected  for pregnancy testing  in females  of child  bearing  potential . Urine 
will be collected  at visit Day 1 before  vaccination  and the results  recorded  in the source 
document and eCRF . 
3.6 Stopping/P ausing Guideline s 
There are no predetermined  stopping rules  in this study. Subjects  may be withdrawn  from 
the study according to investigator discret ion as described in section 3. 8, Premature  
Withdrawal from  Study.  
 
3.7 Data Monitoting Co mmittee  
No DMC  willbeutilized  for the study . 
3.8 Prema tur e \Vithdrawal from Study 
Subjects may withdraw  at any time, or be dropped from  the study  at the discretion  of the 
investigator  should any untoward effects occur  and/or forsafety  reasons. In addition,  a 
subject  may be withdrawn  by theinvestigator  or the Sponsor  if he/sheviolates the study  
Protocol V59_77 
Page 31of86  GSK  
24JUN 16Final  Protocol  Versioo  1 Confidentia l 
PR0-01 TEMP  06 / Atlas  No.293620  
VersionNo.4  / Version Date:  Jan\131)'29,  2015   
  
plan or for dministrative reasons . The investigato r or study  coordinator  nrust  notify  the 
Sponsor immediately when a subject  has been withdrawn  due to an adverse  event.  
The circumstances  above  are referred to as premature  withdrawal  from  the study , and the 
reason for premature  withdrawal should  be clearly  documented and detailed  in the source 
documentation. The invest igator should make every attempt to evaluate the subject 's 
safety , including resolution of ongoing AEs, at the time of premature withdrawal . If a 
subject  wants  to withdraw  from  the study  before  or prior  to the last planned  study  visit, 
the subject  will be asked to be followed  for safety  for the duration  of the study. When a 
subject  withdraws , or is withdrawn,  from the study , the procedures  described in section  
S.5.1, Early  Termina tion Visit  should be completed if possibl e. 
The reasons for premature withdrawal from the study include: Adverse event , death, 
withdrawal of consent, lost to fo llow-up, administrative reason, and protocol deviation . 
These reasons are described in greater detail below . 
AdverseE vent 
 
For any subject withdrawn from study participation prior to the planned Study 
Termination  Visit,  it is important to determine  if an AE was associated  with the reason for 
discontinuing  the study. This AE must  be identified  on the AE eCRF page  by indicating 
"Withdrawn from study due to AE". Any ongoing AEs at the time of studywithdrawal 
must be followed  until resol ution or stabilization  
 
Death 
 
For anysub ject withdrawn  from  study  participation  due to death,  this should  be noted  on 
the StudyTermination  eCRF  page and the associated SAE  that led to the death  must be 
reported.  
, v ithdrawal of consent 
 
The subject and/or  parent(s)/legal  guardian(s) can withdraw  consent  for participation  in 
the study  at any time without  penalty  or loss of benefit to which  the subject  is otherwise 
entitled . Reason  for early termination  should  be deemed as " withdrawal of consent'' if the 
subject  withdraws  from  participation  due to a non- medical reason (i.e., reason other  than 
AE). If the subject  and/or  parent(s)/legal  guardian(s)  intends  to withdraw  consent  from 
the study , the invest igator  should  clarify if the subject  will withdraw  comp letely from the 
study or if the subject willcontinue study participation for safety, or a subset of other 
study  procedures . If the subject requests  comp lete withdrawal from  the study , no further 
study  interventions  will be performed  with the subjec t. 
Protocol V59_77 
Page 32of86  GSK  
24JUN 16Final  Protocol  Versioo  1 Confidentia l 
PR0-01 TEMP  06 / Atlas  No.293620  
VersionNo.4  / Version Date:  Jan\131)'29,  2015   
  
If a subject and/or parent(s )/legal  guardian(s) withdraws  consent but does not revoke  the 
HIPAA authorization, the Sponsor will have fullaccess to the subject's medical records , 
including termination visit information. If a subject and/or parent(s)/legal guardian(s) 
revokes only the HIP AA authorization, the Sponsor will have fullaccess to all of the 
subject's medical  records  prior to the date and time of written  revocation.  
 
Lost to Follow -Up 
 
For subjects who fail to show up for finalvisits  (clinic  or telephone contacts), or  for three 
consecutive visits, study staff are encouraged  to make  at least three documented  attempts 
to contact  the subjec t by telephone and at least one documented written  attempt  to contact 
the subject and/or parent(s)/legal guardian(s) to encourage the completion of study 
teimination procedures . These efforts to contact the subject should be recorded in the 
source document. The termination date for the subject to be captured on the Study 
Termination  eCRF  page  is the date of the last successful contact  (clinic  visit or telephone ) 
withthe  subjec t. 
Administrative Reason  
 
Examples forsubjects withdrawn  from  the study due to administrativereason  can include: 
Sponsor decision to terminate the study, subject discontinuation for insurance issues , 
moving, no time , etc. This reason should be noted in the StudyTermination eCRF page 
and any ongoing AEs at the time of studywithdrawal should be followed until 
resolution/stabilization, if possible.  
If the clinical study is prematurely terminated bythe Sponsor , the investigator is to 
promptly  inform the study  subjects and local EC/IRB  and should assure appropriate 
therapy  and follow up for the subjects. All procedures and requirements pertaining  to the 
archiving of study documents should be followed. All other study materials ( study 
medication/vaccine ,setc.) must  be returned  to the Sponsor . 
For subjects who are withdrawn from the study due to receipt of an excluded 
medication/vaccination  or due to significant  protocol non-compliance , this reason  should 
be noted in the StudyTermination eCRF  page.  
 
Protoco l D evia ti on 
A protocol  deviation  is any change, divergenc e, or departure  from  the study design  or 
procedures of a study protocol. In general, subjects associated  with protocol deviations 
may remain  in the study unless continuation in the study jeopardizes  thesubjec t's health, 
safety , or rights . 
Protocol V59_77 
Page 33of86  GSK  
24JUN 16Final  Protocol  Versioo  1 Confidentia l 
PR0-01 TEMP  06 / Atlas  No.293620  
VersionNo.4  / Version Date:  Jan\131)'29,  2015   
  
Investigators will apply due diligence to avoid protocol deviation. sUnder no 
circumstances should  the investigator  contact GSK or its agents , if any, monitoring  the 
study to request approval of a protocol deviation, as no authorized deviations are 
pennitted . If the investigator  feels  a change to the protocol would  improve  theconduct  of 
the studythis must  be considered  a protocol  amendmen ,tand unless such  an amendment 
is agreed  upon by GSK  and approved  by the IRB/EC and health  authorities  it cannot  be 
implemented . 
Anysubject who becomes  pregnant during the study, despite the protocol requirement for 
adequate contraception should be encouraged to continue participating in the study for 
safety  follow- up only. The site must complete  a Pregnancy  Report  CRF  (initial report) as 
soon as possible after learning of pregnancy occurrence (see section 7.1.6, Pregnancies  
for further details) . If the subject withdraws fromthe study for any of the above 
categories except death, the site will obtain permission from the subject to continue to 
remain in contact with heruntil the outcome of the pregnancy is known, even if the 
outcome is not known until a fter thesubj ect reaches  theend of follow -up period . 
 
3.9 End of St udy 
Most clinica l trials intende d to suppor t theefficac y/immuno genicit yand safety  of an 
InvestigationalProduct  proceed  to full comp letionof  planned  sample size accrual. For the 
pwpose of this protocol , End of Study (EoS) is defined as the date of the last 
testing/reading  released  of human  biologicals samples , related  to primary and secondary 
end points , to be achieved  no later than 8 months after  Last Subject  Last Visit (LSLY .) 
 
If the comp letion of testing  occurs prior  the completion  of the Last Subject Last Visit 
(LSL V) the latter  date defines the end of study  visit.  
Protocol V59_77 
Page 34of86  GSK  
24JUN 16Final  Protocol  Versioo  1 Confidentia l 
::, z u 
8  
  
4. SELECTIO N OF STUDYPOP ULA TION 
 
4.1 Inclusion C1i teria  
 
In order to participate  in this study , all subjects must  meet  ALL of the inclusion  criteria 
described . 
 
I. Individuals of IS through SS years of age on the day of informed consent or assent.  
2. Individuals who received Menveo 4 to 6 years prior to enrolment at an age of 11 years 
or older  (Menveo -Menveo group)  
OR 
Individuals who received Menactra 4 to 6 years prior to enrolment at an age of 11 
years or older (Menactra -Menveo group)  
OR 
Individuals  who have  not received any previous  meningococcal vaccine  (Naive 
group) . 
3. Individuals who have vo luntarilygiven written informed consent (and/or assent , if 
applicab le) after the nature of the studyhas been explained according to local 
regulatory  requirements , prior to study entry . If the subject  is under age 18 at the time 
of enrolment, the parent(sJ/legal guardian(s)  of the subject should  have  voluntarily 
given  written  informed  consent.  
4. Individuals  who can comply  with study procedures  including  follow -up1 
S. Males 
Or 
Females of non- childbearing potential2 
Or 
 
 
 
1 A subjectand/or  paren t(s)/Jegal guardian(s ) is/are cons ideredto  be compliant  if the Investigator  judges 
thatthesub ject will comp letetheSubject  Diary and return  for all thefollow- up visitsscheduled in the 
study.  
2 A female is considered to be of non-childbearingpotential  prior  to menarche and after natural or induced 
menopause . Natural  menopause  is recognized to have  occurred after 12 consecutive  months  of amenorrhea 
for which thereis  nootherobvious  pathological or physiol ogical cause.  Induced menopause  is recognized 
to have occurred after hysterectomy, after bilateral oophorecotmy , or iatrogenic ablation of ovarian 
ftmction.  
 
 
PR0-01 TEMP 06 / Atlas No . 293620  
VersionNo.4 / Vers ion Date: January 29 , 2015 
00 . 
Protocol V59_77 
Page 35of86  GSK  
24JUN 16Final  Protocol  Versioo  1 Confidentia l 
::, z u 
8  
  
Females  of childbearing potential who are using aneffective  birth  control method1 
which  they intend to use for at least 30 days after the study vaccination  
4.2 Exclusion Crite1i a 
 
Each sub ject must not have:  
1. History of any meningococcal vaccine administrationother than the single 
vaccination given 4 to 6 years before (Menveo -Menveoand Menactra -Menveo 
groups)  
OR 
History of any meningococcal vaccine administration (Naive group).  
2. Current  or previous, confirmed  or suspected disease caused  by N. meningitidis . 
3. Household  contact  with and/or intimate  exposure to an individual with any laboratory 
confirmed  N. meningitidis  infection  within  60 days prior to study vaccination  
4. Progressive , unstable or \ lllcontrolled  clinical  conditions. 
S. Hypersensitivity, including allergy , to any component of vaccines, medicinal products 
or medical equipment whose use is foreseen in this study . 
6. Clinical conditions representing a contraindication  to intramiscular vaccination  (IM) 
and blood draws.  
7. Abnormal function of the immlllle  system resulting from:  
a. Clinical  conditions . 
b. Systemic administration  of corticosteroids (PO/IV/IM) for more  than 14 
consecutive days within  90 days prior  to study vaccination  
c. Administration  of antineoplastic  and immllllomodulating  agents  or radiotherapy 
within  90 days prior to study vaccination 
 
 
 
1 The fo llowing birth control methods areconsidered effective: 
Abstinence  
Hormonal contracept ive(such asoral,injection, transdennal patch, implant) if used for at least 30  
days prior to informed consent  
Diaphragm preferably with spermicide, tubal occlusion device 
Intrauterine device (IUD)  
Tubal ligation 
Male par1ner using condom preferab ly with spermicide  
Male par1ner having been vasectomized at least six months p riorto informed consent  
 
 
PR0--01 TEMP 06 / Atlas No . 293620  
VersionNo.4 / Vers ion Date: January 29 , 2015 
00 
Protocol V59_77 
Page 36of86  GSK  
24JUN 16Final  Protocol  Versioo  1 Confidentia l 
::, z u 
8  
  
8. Received immunoglobulins  or any blood  products  within  180 days  prior  to informed 
consent.  
9. Received syste mic antibiotic  treatment  (PO/IV/IM) within  3 days prior  to study  
vaccination or blood draw . 
10. Received an investigational or non- registered  medicinal product  within  30 days prior  
to study  vaccination.  
11. Study  personnel  as an immediate  family  or household  member . 
12. Individuals who have received any other vaccines within 7 days (for inactivated  
vaccines) or 14 days  (for live vaccines) prior  to vaccination  in this study  or who are 
planning to receive any vaccine within  28 days from  the study vaccination.  
13. Individuals who have experienced a moderate or severe acute infection and/or fever 
defined as a temperature 38°C (100.4°F) within 3 days prior to study vaccination.  
14. Any other clinical  condition  that, in the opinion of the investigator, might  pose 
additional  risk to the subject  due to participation  in the study . 
4.3 C1ite1ia for De.lay of Vaccinatio n and/or Blood Sampling  
 
There may be instances  when individuals  meet all eligibili ty criteria  for vaccination  yet 
have a transient clinical circumstance which  may warrant  delay  of vaccination : body 
temperature elevation [ 38.0° C 100 .4° F) within 3 days prior to intended study 
vaccinatio n], systemic  antibiotic treatment within  3 days prior to study vaccina tion or 
blood draw . Unde r such  circumstanc es, a subject may be considere d eligible  for study 
enrolment after  the appropriate  window for delay has passed and inclusion/exclusion 
criteria have  been rechecked, and if the subject  is confirmed to be eligible . 
 
There is a clinical circumstance that warrants delay of blood collection for 
immunogenicityassessments in this study subject has received a dose of systemic 
antibiotics less than 3 days before the intended blood collection. In the event that a 
subject  meets  this criterion for delay of blood  collection , blood  collection  may proceed 
once  the window  for delay  has passed.  
 
 
 
 
 
 
 
 
 
 
 
 
 
PR0-01 TEMP 06 / Atlas No. 293620  
VersionNo.4 / Vers ion Date: Jan\131)'29 , 2015  
00 
Protocol V59_77 
Page 37of86  GSK  
24JUN 16Final  Protocol  Versioo  1 Confidentia l 
::, z u 
8  
  
5. STUDY PROCEDURE S 
 
The sections  that follow  provide an overview  of the procedures  that are to be followed  in 
enrolling,  evaluating , and following  subjects  who participate  in this clinical  study . Visits 
can be either  clinic  visits  or safety follow- up telephone  calls, as specified in the Table 
below  and in the T ime and Events Table4. 
 
Tabl e 5-1 Study Procedur es 
 
Visit Category  Procedu res 
Pre-vaccinationClinic Visit(s)  Section 5.1 describes procedures to be followed 
priorto study vaccinati on: informed consent/assent,  
screening , enrolment , andrandomizat ion 
Vaccinat iooClinic Visit(s)  Section 5.2 describes procedures  to be followed 
during  each clinic  visit involving vaccination: 
vaccinati on, post-vaccination procedures,  and post- 
vaccination reminders  
Post-vaccinat ion Visit(s)  Section 5.3 describes follow -up clinic  visits  and 
safety  follow-up calls  
Unschedu led Visit(s)  Section 5.4  
Unschedu led visits are not expected within this 
protoco l. 
Study Termination Visit  Section  5.5 describes  procedures  to be followed  at 
the last study  visit for a subject (may  include  early 
termination  visit)  
 
 
5.1 Pre-vacc inati on Clinic Visit.(s) 
 
This section  describes the procedures  that must be performed  for each potential subject 
prior  to vaccination,  including  obtaining informed  consent/assent,  screening , enrolment 
and randomization.  
5.1. l Informed Consent/Assent 
 
"Informed consent" is the voluntary agreement of an individual or his/her legal 
guardian(s) to participate in research. Consent must be given with free will of choi ce, and 
without undue inducement. The individual must have sufficient knowledge and 
understanding of the nature of the pro posed research, the anticipated risks and potential 
benefits , and the requirements of the research to be able to make an informed decision . 
 
"Assent"  is a term used to express  willingness  to participate  in research by persons  who 
are by definition too young to give informed  consent  but who are old enough  to 
 
 
PR0--01 TEMP 06 / Atlas No.293620 
VersionNo.4 / Vetsion Date:January 29,2015 
00 
Protocol V59_77 
Page 38of86  GSK  
24JUN 16Final  Protocol  Versioo  1 Confidentia l 
PR0-01 TEMP  06 / Atlas  No.293620  
VersionNo.4  / Version Date:  Jan\131)'29,  2015   
  
understand  the proposed  research in general , its expected risks and possible  benefits,  and 
the activities expected of them as subjects . Assent by itself is not sufficient , however. If 
assent is given, informed consent must still be obtained from the subject's parent(s) or 
legal guardian(s). Local laws  define  who constitutes  a "child,"  and such definitions  dictate 
whether  or not a person  can legally consent to participate  in a protocol  (Levine  1988) . 
 
Info11lled consent of the parent(s)/legal guardian(s) and assent of subject following local 
IRB/EC guidance must be obtained before conducting any study -specific procedures (i .e., 
all of the procedures described in the protocol) . The process of obtaining informed 
consent and assent should be documented in the subject source document in addition to 
maintaining a co py of the signed and dated informed consent. Additional specifics 
regarding  the informed  consent  and assent processes are located in section 13.2, Info11lled  
Consent  Procedures . 
If a subject and/or parent(s)/legalguardian(s) is unable to read, an impartial witness 
should be present during the entire informed consent and assent discussion . An impartial 
witness is defined as a person who is independent from study conduct, who cannot be  
unfairly influenced by those involved with the study, who attends the informed consent 
process if the subject or the subject's legally acceptable representative cannot read, and 
who reads the informed consent form and any other written information supplie d to the 
subject. After the written informed consent form and any other written informati on to be 
provided to subjects , is read and explained to the subject and/or parent(s)/legal 
guardian(s) and after the subject and/or parent(s)/legal guardian(s) has verbally consented 
to the subject's participation in the study and, if capable of doing so , has signed and 
personally dated the informed consent fo11ll, the witness should sign and personally date 
the consent form. By signing the consent fo11ll, the witness attests that the information in 
the consent form and any other written information was accurately explained to, and 
apparently understood by, the subject and/or parent(s)/legal guardian(s) and that informed 
consent  was freely  given by the subject  and/or  parent(s) /legal guardian(s) . 
5.1.2 Screening  
Subject  identification  numbers will be assigned  sequentially  to the subjects  who have 
consented to participate in the study , according to the range of subject identification 
numbers allocated to each  study  center . The eligibility  of the subject  will be determined 
based on the inclusion and exclusion criteria listed in section 4, Selection of Study 
Population  and evaluated during this screening procedure . 
 
Prior  to study enrolment , demographic  data will be collected from  the subject,  including: 
date of birth, gender , race, ethnicity , prior vaccination against meningitis . Note: 
Appropriate written documentation of the brand of primary vaccination (Menveo or 
Menactra) and vaccination date must be provided prior  to enrollment.  
Protocol V59_77 
Page 39of86  GSK  
24JUN 16Final  Protocol  Versioo  1 Confidentia l 
PR0-01 TEMP  06 / Atlas  No.293620  
VersionNo.4  / Version Date:  Jan\131)'29,  2015   
  
Medical history willalso be collected, including but not limited to any medical history 
that may be relevant to subject eligibility for study participation such as prior 
vaccinations , concomitant medications , and previous and ongoing illnesses or injurie s. 
Relevant medical history can also include any medical history that contributes to the 
understanding of an adverse event that occurs during study participation, if it represents 
an exacerba tion of an underlying disease /pre-existing problem.  
 
Review of systems is a structured interview that queries the subject and/or parent(s)/legal 
guardian(s) as to any complaints the subject has experienced across each organ system 
This will beperformed before enrolment and used to guide physical examination . 
 
If applicable, prior and concomitant  medications  or vaccinations taken  prior  to start of 
study  should  be collected (refer to section  6.5, Prior  and Concomitant  Medications  and 
Vaccines for further  details) . 
 
Collect vital signs  (heart  rate, blood pressure , and temperature (preferably taken  orally) . 
Measure height  and weight.  
Perform pregnancy testing in women of childbearing potential (refer to section 3.5, 
Collection of Clinical Specimens for additional information ) 
A general physical examination is to be performed by a qualified health care practitioner. 
"Qualified health care practitioner" refers to any licensed heal th care pro fessional who is 
permitted by institutional policy to perform physical examinations and who is identified 
within the Study Staff Signature Log . 
 
The data collected through study  assessments listed  above  willbewritten  in the source 
document  (see section  9.1, Source  Documentation ). Should the physical  assessment 
reveal any abnormal  values  or events , these  must be documented in the CRF  Adverse 
Events  Form  
 
Prior to vaccination, approximately 10 mL of b lood will bedrawn from all subjects for 
the immunological testing see section 3.5, Collection of Clinical Specimens . 
In the even t that the individua l is determined  ineligibl e for studyparticipation , he/she  is 
considered a screen failure . The reason for screen failure must be documented in the 
Screening and Enrolment  log. If the individual  is determined to be eligible for the study, 
he/she  willbeenrolled into the study . 
Protocol V59_77 
Page 40of86  GSK  
24JUN 16Final  Protocol  Versioo  1 Confidentia l 
PR0--01 TEMP  06 / Atlas  No. 293620  
VersionNo.4  / Version Date:  Jan\131)'29  , 2015   
  
5.1.3 Em·olment 
 
After signing the informed consent , if an individual i s determined to be eligib le for study 
participation, the invest igator will enroll the subject and enter the subject information into 
randomization system, Source Data Base for Internet Randomization (SBIR) . 
5.1.4 Randomiza tion 
 
5.1.4.1  Rando mizati on of supplies  
The randomizat ion of suppli es within  blocks  will be performed  at GSK,  using  MATerial 
EXcellence (MATEX) , a program developed for use in Statistical Analysis System 
(SAS®)  (Cary, NC, USA)  by GSK.  Entire  blocks  will be shipped  to the study  centre . 
 
5.1.4.2  Study group and tJ·ea tm e n t numb e r all oc a tio n 
Enrolled subjects willbe randomized in the SBIR system to one of two different blood 
draw schedules according to a 1:1 ratio , described as follows:  
• Subjects  getting blood  draws  at Day 1, Day 4 and Day 29. 
• Subjects  getting blood  draws  at Day 1, Day 6 and Day 29. 
Allocation of the subject to a blood draw schedules at the investigator site will be 
performed using a central randomization system on internet (SBIR).  
The randomizat ion algorithm will use 3 minim ization procedure  accounting  for the 
previous  vaccinat ion status  (Menveo , Menactra  or Vaccine -Nai've  study  group) . 
 
For each dose, the study staff in charge of vaccine administration will access SBIR, 
provide  the subject  ID, and the system  will provide a treatment  number consistent  with 
the allocated treatment  arms . 
 
SBIR will also be used to ensure adequate and appropriate  distribution  of enrolment  of 
naivesubjects  across  all sites. 
 
For any question  regarding  SBIR,  please refer to the SBIR  user guide  and SBIR Manual 
for specific  instructions . If for any reason,  after signing  the informed consent form  (ICF), 
the subject who is eligible and enrolled fails to be randomized, this is called a 
randomization failure  and the early termination  study procedures  must  be applied. The 
reason for all randomizat ion failures should  be recorded in the Screening and Enrolment 
Log and in the source  document  as specified  in the Source  Documentation  Agreement 
Form  (SDAF) . The information on subjects  who are randomization failures  should  be 
Protocol V59_77 
Page 41of86  GSK  
24JUN 16Final  Protocol  Versioo  1 Confidentia l  
  
kept distinct  from  subjects  who are screen failures , as described in section  S.1.2, 
Screening.  
If for any reason , after enrolment the subject fails to undergo treatment/study procedures 
this is an Early Termination and the reason should be recorded in source document as 
specified in the Source Documentation Ag reement (SD.AF) . The information on these 
Early Termination subjectsshould be kept distinct in the source documentation from 
subjects who are screen failures , as described in section 5.1.2 , Screening . 
5.2 Vaccination Clinic Visit 
 
The first vaccination will be performed on Day 1 . 
 
For studies  which  have  visits  for concomitant  vaccinations  or treatments , see section  6.5, 
Prior  and Concomitant  Medications  and Vaccines for those  visit procedures.  
 
Ensure all blood samples are taken p 1i or to the vaccination . 
 
After completing the pre -vaccination procedures on day 1, administer the vaccine to the 
subject according to the procedures described in section 6.3, Vaccine Preparation and  
Administration. Observe the blinding procedures described in section 3.3, Blinding  
Procedures . 
Prior to administrationof  study  vaccinat ion, confirm  that the subject does not meet any 
criteria for delaying additional  study  vaccinat ions as described in section  4, Selection of 
Study  Populat ion. 
5.2.1 Post-vaccinatio n Proced ures 
 
The fo llowing post -vaccination procedures will be performed on day 1.  
 
• After vaccination, the subject willbe observed for at least 30 minutes including 
observation for unsolicited adverse events , solicited adverse events, and body 
temperature measurement. Record all safetydata collected during this time in the 
subject 's source  document.  
• A Subject Diary will be used in this studyto document solicited adverse events . The 
Subject Diary is the only source for collection of these data ; therefore , it is criti cal that 
the su bject comp letes the Subject Diary correctly . The subject should be trained on how 
and when to complete  eac!J field  of the Subject  Diary . 
• The subject and/or parent(s )/legal guardian(s) should be trained on how to self- 
measu
re localsolicited  adverse  events . The measurement of solicited  local  adverse 
events is to be performed  using  the ruler provided  by the site. 
 
 
 
00 
 
::, z 
u 
8 PR0-01 TEMP 06 / Atlas No. 293620  
VersionNo.4 / Vers ion Date: Jan \131)'29 , 2015  
Protocol V59_77 
Page 42of86  GSK  
24JUN 16Final  Protocol  Versioo  1 Confidentia l 
PR0--01 TEMP  06 / Atlas  No.293620  
VersionNo.4  / Version Date:  Jan\131)'29,  2015   
  
• The subject and/or  parent(s)/legal  guardian(s) should be instructed  how to perform 
bodytemperature measurement using the thermometer provided by the site.If the 
subject  feels unusually hot or cold during  the day, the subject and/or  parent(s)/legal 
guardian(s) should  check body  temperature. If the subject has fever , the highest  body  
temperature observed  that dayshould  be recorded in the Subject  Diary . 
 
Subject Diary training should be directed at the individual(s) who will perform the 
measurements of adverse events and who will enter the information into the Subject 
Diary. This individual may not be the subj ect and/or parent(s)/legal guardian(s) , but if a 
person other than the sub ject and/or parent(s)/legal guardian(s) enter s information into the 
Subject Diary , this person 's identity must be documented in the Subject Diary or subject ' s 
source record . Any individual that makes entries into the Subject Diary must receive 
training on completion of the Sub ject Diary at the time of the visit. This training must be 
documented in the subject 's source record . 
 
The same individual should complete the Sub ject Diary throughout the course of the  
study.  
 
• The site should schedule the next study activity clinic visit on Day 4 or Day 6 
depen ding to which blood draw schedule subject was randomized to with the subject  
and/or  parent(s)/legalguardian(s).  
 
The subject  and/or  parent(s)/legal  guardian(s) will be reminded  to complete the Subject 
Diary  and to contact the site if there  are any questions , and to contact the siteimmediately 
(or as soon  as the subject  is medically stable)  if the subject  has a medical  condition  that 
leads  to a hospitalization  or an emergency roomvisit  or to a visit to/by  a doctor  or is of 
concern.  
5.2.2 Post-vaccination Reminde rs 
 
Reminder  calls  or alerts are not intended  to be an interview  for collection  of safety data. If 
the subject and/or parent(s)/legal  guardian(s) wishes  to describe  safety  information,  this 
information should only be collected by a healthcare professional at the site , and the 
safety  data described must be written  down in the subject 's medical chart.  
 
Subject Diary Reminder Calls 
 
Subject Diary reminder calls will be performed on day 3 and day S. The purpose of this 
callis to remind the subject and/or parent(s)/legal guardian(s) about completion of the 
Subject Diary. The call follows the Subject Diary Reminder Telephone Call Script 
provided to the site . The subj ect and/or parent(s)/legal guardian(s) should be reminded to 
contact the site via the telephone number provided in the informed consent to discuss  
Protocol V59_77 
Page 43of86  GSK  
24JUN 16Final  Protocol  Versioo  1 Confidentia l 
PR0-01 TEMP  06 / Atlas  No.293620  
VersionNo.4  / Version Date:  Jan\131)'29,  2015  
  
medical questions . If the clinic visit at Day 4 or Day 6 overlaps  with the specified  window 
of the Day 3 or Day 5 reminder  call, the Day 3/Day  5 reminder call may be omitted . 
 
5.3 Post-vaccination Visit(s)  
 
Post-vaccinationvisits  will be performed on Day 4 or Day 6 according  to the blood  draw 
schedule to which  subject  was randomized and Day 29. 
 
5.3.l Follow -up Clinic Visit(s)  
 
Follow -up clinic  visits  willbe performed on Day 4 or Day 6 according  to the blood draw 
schedule to which  subject  was randomized  and on Day 29. During the follow -up clinic 
visit:  
 
• Subject  Diary  willbe reviewed  at Day 29. No changes to the information  recorded 
within  the Subject  Diary  are permissible . For details  on the Subject Diary  see sections  
3.4.2, Tools Used for Data Collection and 5.2.1, Post -vaccinationProcedures . The 
subject and/or parent(s)/legal guardian(s) will be interviewed to determine if any 
unsolicited  adverse events  occurred and if any concomitant  medications  or vaccines  
were taken/rece ived in the time since  the last clinic  visit. This interview  will follow  a 
script which will facilitate the collection of relevant safety information. The 
healthcare profess ional reviewing these data will discuss the symptoms (if any) 
reported  by the subject  and will determine  if any additional  diagnoses  and/or  adverse 
events are present. Adverse events reported by the subject and/or parent(s)/legal 
guardian(s) at this follow -up clinic visit must be recorded in the subject's source 
document and on an Adverse Events CRF , as specified in section 7 .1, Safety  
Assessment, and not written  on the script  used for the interview . 
• Perform a brief symptom -directed physical examination if necessary according to 
symptoms  the subject has reported . This is a physical  examinat ion that will include  an 
examinat ion of organ  systems  that are relevant to the investigator  based on review  of 
the subject's reported adverse events and concomitant medication use. This 
assessment may include : measurement of vital signs , bodytemperature  and a check  of 
general appearance . The physical  assessment must be performed by the investigator  or 
designee of the investigator , who is qualified to perform a phys ical assessment in 
accordance  with their  institutional  policy.  Corresponding  information  is documented 
in the subject 's source document  and CRF(s).  
• Collect a blood sample (see section 3.5, Collection of Clinical Specimens for 
additional information).  
 
The site should schedule the next study activity  safety  call withthe subject and/or 
parent(s)/legal  guardian(s).  
Protocol V59_77 
Page 44of86  GSK  
24JUN 16Final  Protocol  Versioo  1 Confidentia l 
PR0-01 TEMP  06 / Atlas  No.293620  
VersionNo.4  / Version Date:  Jan\131)'29,  2015  
  
Thesubject and/or  parent(s)/legal  guardian(s)  will receive a written  reminder  of the next 
planned study  activity.  The subject and/or  parent(s)/legal  guardian(s) will be reminded  to 
contact the site if there  are any questions  and to contact  the site immediately  (or as soon 
as the subject is medically stable)  if the subject has a medical condition  that leads to a 
hospitalizationor an emergency  roomvisit.  
5.3.2 S afety Follow-upCalls 
 
Safety follow -up call will be performed on Day 15, Day 91 and Day 181.  
 
Safety follow -up calls are calls made to the sub ject by a healthcare professional 
designated on the site log. These calls will follow a script which will facilitate the 
collection of re levant safety information . The subject and/or pare nt(s)/legalguardian(s) 
will be interviewed  according  to the script, and information  related  to unsolicited  adverse 
events (only at Day 15), serious adverse events (SAEs), medically attended adverse 
events , AEs leading to withdrawal and concomitant medications or vaccinations  
associated with those events will be reviewed . All safety information described by the 
subject must be written down in a designated location within the source document and not 
written on the script used for the telephone call. 
 
Thesite  should schedule the next study  activity  with the subject and/or  parent(s)/legal 
guardian(s).  
 
The subject and/or  parent(s)/legal  guardian(s) will be reminded  to contact the site if there 
are any questions and to contact the site immediately (or as soon as the subject is 
medically  stable) if the subject has a medical condition that leads to a hospitalizationor 
an emergency room  visit.  
5.4 Unsch eduled Visits 
 
Unscheduled visits are not expected within this protocol.  
 
5.5 Study Terminati on Visit 
 
The study termination visit willoccur on Day 181. The termination visit will be a 
telephone call . The date of terminat ion is the date of the last contact ( clinic visit or 
telephonecall) in which the subject 's health status was assessed or, in cases where the 
subject  does not agree to any further  safety  follow- up, it is the date consent  is withdrawn. 
This date should  be recorded on the termination  CRF  page . For visit procedures  to be 
performed  for a subject whose planned study  participation  ends  prematurely , please  see 
section 5.5.1 , Early Termination Visit.  
Protocol V59_77 
Page 45of86  GSK  
24JUN 16Final  Protocol  Versioo  1 Confidentia l 
PR0-01 TEMP  06 / Atlas  No.293620  
VersionNo.4  / Version Date:  Jan\131)'29,  2015  
  
During the telephone call , the following procedures will be performed: interview of 
subject and/or parent(s )/legal guardian(s) to collect medically attended adverse events, 
AEs leading to withdrawal , SAEs , as well as interview of subject and/or parent(s)/legal 
guardian(s) to co llect concomitant medications/ vaccinations associated with those events. 
All safety infollillltiondescribed by the subject must be written down in a designated 
location within the source document and not written on the script used for the telephone 
call. 
 
The site will review with the subject and/or parent(s)/legal guardian(s) the plan of when 
infonnation relating to the subject's participation in the study may be available  (e.g., 
study results , treatment assignmen ts). It will also be discussed how information relating to 
the subject ' s participation in the study will be shared with the subject's healthcare 
provider , if the subject and/or parent(s)/legalguardian(s)  chooses to  share this 
infonnation.  
 
The site willcomplete the termination  CRF  page , and this will mark the completion of the 
subject 's participation in the study.  
5.5.1 Early Termination Visit  
 
When a subject is withdrawn  from  treatment or withdraws  from  the study , the investigator 
will notifythe  Sponsor  and, when  possible, will perform  the procedures listed  below.  The 
reason(s)  for the early  termination  will be included  in the subject's  source  documentation. 
If the EarlyTermination  Visit  is a telephone call, collect as muclt  information  as possible. 
Early Termination Visits  include  subjects  who were randomized but not treated.  
 
At the clinic visit or during the telephone call, the following procedures will be 
performed: interview of subject and/or parent(s)/legal guardian(s) to collect adverse 
events , medically attended adverse events, AEs leading to withdrawal , SAEs , interview of 
subject and/or parent(s)/legalguardian(s) to collect concomitant  medications/ 
vaccinations . 
 
The site will review with the subject and/or parent(s)/legal guardian(s) the plan of when 
infonnation relating to the subject's participation in the study may be available  (e.g., 
study results , treatment assignments). It will also be discussed how information rela ting to 
the subject's participation in the study will be shared with the subject's healthcare 
provider , if the subject and/or parent(s)/legalguardian(s)  chooses to  share this 
infonnation.  
 
The sitewillcomplete  the termination  CRF  page  and this will mark the completion of the 
subject 's participation in the  study.  
Protocol V59_77 
Page 46of86  GSK  
24JUN 16Final  Protocol  Versioo  1 Confidentia l 
::, z u 
8  
  
6. TREATME1''T OF SUBJECTS  
 
All vaccines assoc iated with this study  are to be stored  separately  from  other  vaccines and 
medicat ions in a secure  location  under appropriate  storage  conditions  with temperature 
monitoring . All vaccines associa ted w ith this study must be checked for  expir ation 
date p1i or to use. Expired vaccines must not be admini stered to subjects. 
6.1 Study Vaccine(s) 
 
The term 'study  vaccine ' refers  to those  vaccines provided  by the Sponsor , which  will be 
evaluated as part of the study  objectives . The study  vaccines specific  to this study  are 
described below. The study vaccines specific to this study is the MenACWY- CRM 
vaccine (Menveo®  , GSK  Biologicals) . 
 
The Meningococcal ACWY conjugate vaccine is obtained by extemporaneous mixing 
just before in jection of the lyophilized MenA -CRM component with the MenCWY -CRM 
fullliquid vaccine . The pharmaceutical form is Powder and solution for solution for 
inject ion. Men veo® is provided as vial/vial presentation . MenA lyophilised conj ugate 
component (glass vial) and MenCWY liquid conjugate component (glass vial). After 
reconstitution, MenACWY -CRM will have the following composit ion per O.S mL of 
injectable solut ion (SeeTable  6.1-1): 
Table 6.1-1: MenAC\VY-CR"l\1 Com  position 
 
Name of Ingredient  Unit and/ol' Percentage Fol'mula 
(Dose 0.5 mL) 
D1111gSubstances  
CRM 191-MenA conjug;ite  10 µg MenA, 16.7- 33.3µg CRM 191 
CRM 191-MenC conjug;ite  5 µgMenC, 7.1 - 12.5 µg CRM197  
CRM 191-MenWconjugate  5 µg MenW, 3.3-  8.3µgCRM191 
CRM 191-MenYconjug;ite  5 µg MenY , 5.6- 10µgCRM197  
Sodium chloride  4.5mg  
Excipients 
Sucrose  12.5 mg 
Sodium phosphate buffer 
Sodium dihydrogen phosphate  
Disodium hydrogen phosphate dehydrate  l0mM 
2.5mM  
7.5mM  
Potassium dihydrogen phosphate  5mM  
Water fo r Injection  q.s 0.5 mL 
VolumeofFormulation  0.6mL  
 
 
PRO --01 TEMP 06 / Atlas No.293620  
VersionNo.4 / Versi onDate: January29,2015  
00 
Protocol V59_77 
Page 47of86  GSK  
24JUN 16Final  Protocol  Versioo  1 Confidentia l 
::, z u 
8  
  
Name of Ingredient  Unit and/ol' Percen tage Fol'mula 
(Dose 0.5 mL) 
Appearance  Colorlessto light yel low 
Vaccine Presentation  Asingle do se of two vials  
One 0.5 mL dose ofMenACWY will be administered by intranruscular (IM) injection  in 
the deltoid  area of non-dominant arm (preferably .) 
 
For more  detailed  information,  refer  to the latest  version  of Investigator Brochure  and 
SPC for Menveo ® , which  are included  in the investigator site file. 
6.2 Non-Study Vaccines 
Not applicable.  
6.3 Vaccine Preparati on and Admini stra tion 
The investigator or designee will beresponsible for oversight of the administration of 
vaccine to subjects enrolled in the study according to the procedures stipulated in this 
study protocol All vaccines  will be administered  onlyby personnel who are qualified  to 
perform  that function under applicable  local  laws and regulations for the specific  study 
site. 
All studyvaccines to be administered  to the subjects must be stored in a safe and locked 
place  with no access  by unauthorized  personnel.  
The study vaccines will be stored  at the defined  temperature range (i.e. +2 to +8 C). The 
storage  temperature  of the vaccines  will be monitored daily  withtemperature  monitoring 
devices and  willberecorded . 
Any temperature deviation, i .e. temperature outside the range (+2 to +8 °C), must be 
reported  to thesponsor as soon as detected . Following  the exposure to such a temperature 
deviation, vaccines  will not be used until written  approval has been  given  by the sponsor . 
The study vaccine  should be allowed  to reach room temperature  before  administration, 
according  to local  vaccination  practice.  
MenACWY -CRM (Menveo) vaccine is prepared  by aseptically  withdrawing all fluid 
fromthe  vial containing the MenCWY -CRM  liquid  conjugate component and injecting 
the liquid  into the vial containing the MenA- CRM lyophilized portion. Invert  and shake 
the vial well until the vaccine is dissolved. The finalmixed vaccine is then ready for 
administrationof the MenACWY  formulation  (0.5 mLJdose of injectable  solution) . 
 
 
 
PR0-01 TEMP 06 / Atlas No . 29362 0 
VersionNo.4 / Vers ion Date: Jan \131)'29 , 2015  
00 
Protocol V59_77 
Page 48of86  GSK  
24JUN 16Final  Protocol  Versioo  1 Confidentia l 
::, z u 
8  
  
Detailed  vaccine preparation and administration  instructions  willbe provided  to 
investigators  in the Clinical  Trials  Supply  Manual prior  to study  start.  
 
PRE CAUTIONS TO B E OB SERVED IN ADMINIS TERING STUDY VACCI NE:  
 
Prior  to vaccination, subjects  must  be determined to be eligible for studyvaccina tion and 
it must  be clinically  appropriate  in the judgment  of the investigator  to vaccinate . 
Eligibilityfor vaccination prior to first study vaccine dministration  is detennined by 
evaluating the entry  criteria  outlined  in protocol  sections  4.1, Inclusion  Criteria  and 4.2, 
Exclusion Criteria . 
 
Eligibility  for non-study vaccines should  be determined by the investigator, pending  the 
review  of the package  insert of the relevant vaccine.  
 
Study vaccines sho uld not be administered to individuals with known hypersensitivity to 
any component of the vaccines . 
 
Anxiety -related reactions, including vasovagal reactions (syncope ), hyperventilation or 
stress -related reactions may occur in association with vaccinat ion as a psychogenic 
response to the needle injection. It is important that procedures are in place to avoid 
injury from fainting . 
Standard immunization practices are to be observed and care should be taken to 
administer the injection  intramuscularly.  Before  dminist"'1'ing  vaccine , the vaccinat ion 
site is to be disinfected with a skin disinfectant  (e.g., 70%  alcohol). Allow  the skin to dry. 
DO NOT inject intravascularl y. 
 
As with all injectable vaccines , trained medical personnel and appropriate medical 
treatment  should  be readily  available in case of anaphylactic reactions following  vaccine 
administration . For example, epinephrine 1:1000, diphenhydramine , and/or other 
medications  for treating  anaphylaxis should be available . 
6.3.1 Replacement of unusabl e vaccines 
 
In addition to the vaccine doses provided for the planned number of subjects (including 
extra doses to allow flexibility in enrolment at the different sites) , at least 15% additional 
vaccine doses willbe supplied to replace those that are unusable.  
6.4 Vaccine Adminish ·ation Erro r or Overdose  of Vaccine 
 
Vaccine  administration  error  is defined  as receiving a dose  of studyvaccine  that was not 
reconstituted  as instructed  or administered by a different  route  from  the intended  route  of 
administration.  An overdose  of studyvaccine  (whether accidental  or intentional)  is 
 
PR0-01 TEMP 06 / Atlas No. 293620  
VersionNo.4 / Vers ion Date: Jan\131)'29 , 2015  
00 
Protocol V59_77 
Page 49of86  GSK  
24JUN 16Final  Protocol  Versioo  1 Confidentia l 
::, z u 
8  
  
defined  when a dosage higher than the recommended  dosage is administered  in one dose 
of study vaccine.  
6.5 Plior and Co ncomitant Medications and Vaccines 
All medications , vaccines and blood  products taken  or received  by the subject within  30 
days prior  to the start of the study are to berecorded  on the Prior and Concomitant 
Medicat ions CRF. 
In addition , the following are considered prior medications for this protocol: all 
medicati on/vaccinesdescribed  in theinclusion and exclusion  criteria  of this protocol 
including:  
 
• Systemic  administration  of corticostero ids (PO/IV/IM) for more  than 14 consecutive 
days within  90 days  prior to study vaccination ; 
• Administration of antineoplastic and imm1momodulating  agents or radiotherapy 
within  90 days prior to study vaccination;  
• Tmmnnnglobulins or anyblood products within  180 days prior to informed consent ; 
• Systemic antibiotic  treatment  within  3 days prior to study vaccination or blooddraw;  
• Any investigationalor non-registered  medicinal  product within  30 days prior to study 
vaccination ; 
• Administration  of vaccines  within  7 days (for inactivated  vaccines)  or 14 days (for 
live vaccines) prior  to vaccination  in this study  or who are planning to receive any 
vaccine  within  28 days from the studyvaccination . 
Use of analgesics/antipyreticsto prevent or treat so licitedAEs will be captured in the 
Subject Diary from day 1-7 following each vaccination . Medications taken for 
prophylaxis are those intended to prevent the onset of symptoms . Medications taken for 
treatment  are intended to reduce  or eliminate  the presence  of symptoms that are present. 
Concomitant medicat ions include  all prescription  and non-prescription  medications 
(including  vaccines)  taken  by/administeredto  the subject  during the 30 days  after study 
vaccination  andmust  be documented on the Concomitant  Medications CRF. Mineral 
supplements  and vitamins  are not considered  concomitant  medications.  
When recording concomitant medications/vaccine, sthey should be clJecked against the 
study entry  and continuat ion criteria  in section  4, Selection  of Study Population to ensure 
that the subject  should be enrolled/continue in the study.  
 
 
 
 
PR0-01 TEMP 06 / Atlas No.293620  
VersionNo.4 / Vers ion Date: Jan \131)'29, 2015  
00 
Protocol V59_77 
Page 50of86  GSK  
24JUN 16Final  Protocol  Versioo  1 Confidentia l 
::, z u 
8  
  
Concomitant medicat ion dministered  for treatment of AEs with medically -attended 
visits, AEs leadingto study withdrawal  andSAEs  must be documented  during the entire 
study period.  
Any vaccine  not foreseen  in the studyprotocol in the period  starting  at Day1 and ending 
at Day 181 must be recorded  in the eCRF. 
6.6 Vaccine Suppl y, Labe ling, Storage and Tracking 
Detailed  vaccine  supply, labeling, storage  and tracking  instructions will be provided to 
investigators in the Clinical Trials  Supply Manual  prior to study start. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PR0-01 TEMP 06 / Atlas No. 293620  
VersionNo.4 / Vers ion Date: Jan\131)'29 , 2015 
00 
Protocol V59_77 
Page 51of86  GSK  
24JUN 16Final  Protocol  Versioo  1 Confidentia l 
::, z u 
8  
  
7. ASSESSMENTS 
 
7.1 Safety Assess ment 
The measures  of safety  used in this study areroutine  clinical procedures. They include a 
close vigilance for, and stringent reporting of, selected local  and systemic adverse  events 
routinely monitored in vaccine  clinical  studies as indicators of reactogenicity.  
An adverse event (AE) is defined as anyuntoward medical occurrence in a subject or 
clinical  investigation subject administered  a pharmaceutical  product at any dose that does 
not necessarily have to have a causal relationship withthis treatment. Therefore, an AE 
can be any unfavorable and unintended s ign (including an abnonnal laboratory finding, 
for example), symptom, or disease temporally associated with the use of an 
investigational product, whether or not considered related  to the investigational product. 
This defin tiion includes  intercurrent  illnesses or injuries  and exacerbation  of pre-existing 
conditions . 
The period  of observation  for AEs extends  fromthe  time the subject signs informed 
consent  until  he or she completes  the specified  safety  follow -up period  of 180 days  or 
terminates  the study early  (whichever  comes first). AEs occurring after  the informed 
consen t form  is signe d but prior  to receiving  studyvaccin ep/roduct will be documented  as 
an adverse event and recorded  within  source  document.  However, any AEs occurring  
prior to receipt of anystudyvaccine  will be analyzed separately from " treatment 
emergent' ' AEs (AEs occurring after administration of the first study vaccine) . 
Adverse events are collected  as either  solicited or unsolicited adverse events. Solicited 
events  arederived from  organized  data collection  systems, such as Subject  Diaries . 
7.1.1 Solicited Advers e Events 
 
The term"reactogenicity " refers to solicited signs and symptoms ("solicited adverse 
events ") occurring in the hours and days following a vaccinat ion, to be collected by the 
subject and/or paren t(s)/legal guardian(s) for 7 consecutive days, using a pre- defmed 
Subject Diary.  
The following  solicited  adverse events are included  in the Subjec t Diary . Each  adverse 
event  is to be assessed using the scoring system reported  in parentheses  below:  
 
 
 
 
 
 
 
 
PR0--01 TEMP 06 / Atlas No. 293620  
VersionNo.4 / Vers ion Date: Jan\131)' 29 , 2015  
00 
Protocol V59_77 
Page 52of86  GSK  
24JUN 16Final  Protocol  Versioo  1 Confidentia l 
::, z u 
8  
  
Solicited  Local   Adverse Events 
Injection  site pain, erythema, induration 
Solicited Systemi c Adve rse Events 
Fatigue , headache , myalgia, arthralgia , loss of appetite , nausea , chills , and fever. 
Tabl e 7.1.1-1 Severi ty grading for solicited local and syste mic AEs  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Feve r is defined  and measure d by a body  temperatur e 38.0°C(100.4°F). Route  of 
temperature measurement is preferably oral.  
 
Other Indicators of R eactoge nicity: 
• Use of analgesics / antipyretics  for prophylaxis  (Days  1-7) 
• Use of analgesics / antipyretics  for treatment  (Days 1 -7) 
• Body temperature , described in degrees Celsius and summarized by route of 
measurement and in 05°C increments from 36.·o c . 
 
 
 
PR0-01 TEMP 06 / Atlas No. 293620  
VersionNo.4 / Vers ion Date: Jan \131)'29, 2015  
00  ]',fil d Moderate  Se.vel'e 
Pain  No inteiference with 
daily activity  Inteiferes with daily 
activity  Prevents daily activity  
Erythema  25-50mm  51- lOOmm  > l OOmm  
lnduration  25-50 mm  51- lOOmm  > l OOmm  
Fatigue  No inteiference with 
daily activity  Inteiferes with daily 
activity  Prevents daily activity  
Headache  No inteiference with 
activity  Inteiferes with daily 
activity  Prevents daily a act ivity 
Myalgia  No inteiference with 
activity  Inteiferes with daily 
activity  Prevents  daily  activities  
Arthralgja  No inteiference with 
activity  Inteiferes with daily 
activity  Prevents daily act ivity 
Loss ofappetite  Eating less than usual 
with no effect  on normal  
activity  Eating less than usua l / 
inteifered with normal 
activity  Not eating at all  
Nausea  No inteiference with 
dailyactivity  Inteiferes with daily  
activity  Prevents daily activity  
Chills  No inteiference with 
activity  Inteiferes with daily 
activity  prevents dai ly activity  
 
Protocol V59_77 
Page 53of86  GSK  
24JUN 16Final  Protocol  Versioo  1 Confidentia l  
  
The study staff must review the data entered  into the Subject Diary  as described  in section 
3.4.2, Tools Used  for Data  Collection  and section  S.3.1, Follow-up Clinic  Visit(s) . 
Note:  Anysolicited  adverse  event  that meets  any of the following  criteria  must be entered 
into subjects' source document (see sectio n 9.1, Source Documenta tion) and also as an 
adverse event  on the Adverse Event  CRF: 
 
• Solicited  local  or systemic adverse event  that continues beyond day7 after 
vaccination.  
• Solicited  local  or systemic adverse  event  that leads  to a visit to a healthcare  provider  
(medically  attended  adverse  event, see sectio n 7.1.3, Evaluation of Adverse Events ). 
• Solicited  local or systemic  adverse event  leading  to thesubject withdrawing  fromthe 
study  or the subject  being  withdrawn  from the studyby  the invest igator (adverse  event 
leading  to withdrawal,  see section  7.1.3, Evaluation  of Adverse Events ). 
• Solicited  local  or systemic adverse event  that otherwise meets  the definition  of a 
serious adverse  event  (see section  7.1.4, Serious  Adverse Events ). 
7.1.2 Unsolicited Adve rse Events 
An unsolicited adverse event is an adverse  event that was not solicited  using a Subject 
Diary and that was spontaneously commtmicated bya subject and/or parent(s)/legal 
guardian(s) who has signed the informed consent. 
 
Potential unsolicited  AEs may be medically  attended  (defined  as symptoms  or illnesses 
requiring hospitalization,  or emergency room  visit, or visit to/by a health  care provider ,) 
or were of concern to the subject and/or parent(s)/legal guardian(s) . In case of such 
events , subjects and/or parent(s)/legal  guardian(s) will be instructed  to contact  the site as 
soon as possible to report the event(s). The detailed information about the reported 
unsolic ited AEs willbe collected  by the qualified  site personnel during the interview  and 
will be documented  in the subject's records . 
 
Unsolicited  AEs that arenot  medically  attended  nor perceived  as a concern  by subjects 
and/or parent(s )/legalguardian(s) will be collected during interview with the subject 
[and/or parent(s)/legalguardian(s ) and by review of available  medical  records  at the next 
visit (see section 5.3, Post -vaccinatio n Visit(s )). 
7.1.3 Evaluation of Adverse  Events 
Adverse events , reported  at a clinic  visit or at a scheduled safety  call, should be recorded 
in the eCRF  verbatim,  as reported  by the subject.  
 
PR0-01 TEMP 06 / Atlas No. 293620  
VersionNo.4 / Vers ion Date: Jan \131)'29 , 2015  

Protocol V59_77 
Page 54of86  GSK  
24JUN 16Final  Protocol  Versioo  1 Confidentia l 
::, z u 
8  
  
Theseverity of events  reported  on the Adverse Events  CRF  willbe determined  by the 
investigator  as: 
 
Mild: 
Moderate: 
Severe:  transient with no limitation in normal daily activity. 
some limitation in normal daily activity.  
unable to perform normal daily activity.  
 
The relationship of the studytreatment to an AE will be determined by the investigator 
based on the followin g definitions:  
 
1. Not Related  
The AE is not related to an investigational vaccine if there is evidence that clearly 
indicates an alternat ive explanation. If the subject has not received the vaccine , the timing 
of the exposure to the vaccine and the onset of the AE are not reasonably related in time, 
or other facts , evidenc e or arguments exist that reasonably suggest an alternative 
explanation, then the AE is not related . 
2. Possibly  Related  
 
The administrationof the investigational vaccine and A E are considered reasonably 
related in time and the AE could be explained by exposure  to the investigational  vaccine 
or by other causes.  
3. Probably  Related  
 
Exposure  to the investigational vaccine  and AE are reasonably related in time and no 
alternat ive explanation has been identified . 
 
The relationship of the studytreatment to an unsolicited AE will be determined by the 
investigator . 
 
Note : solicited  AEs will not be evaluated for relati onship to study treatment.  Grading for 
severity of solicited local and systemic AEs is described in section 7.1.1, Solicited  
Adverse  Events . 
 
Adverse events will also be evaluated by the investigator for the co -existence of any of 
the other following conditions:  
 
• "Medically  attended adverse  event ": an adverse event that leads  to a visit to a 
healthcare provider.  
• AEs leading  to withdrawal:  adverse  events  leadin g to study or vaccine  withdrawal.  
 
PR0-01 TEMP 06 / Atlas No. 293620  
VersionNo.4 / Vers ion Date: Jan \131)'29 , 2015 
00 
Protocol V59_77 
Page 55of86  GSK  
24JUN 16Final  Protocol  Versioo  1 Confidentia l 
::, z u 
8  
  
If solicited or unsolicited adverse events have been reported and the subject and/or 
parent(s)/legal  guardian(s)]  indicated that the symptoms  required  medical  attendance or 
were of concern, the subject and/or parent(s)/legalguardian(s) must be contacted for 
further information.  
When  the subject and/or parent(s)/legal  guardian(s) is contacted  for any of these reasons , 
the contact  must be documented in thesubject's source documentation.  
All AEs, regardless  of severity , will be monitored until resolution or until the investigator 
assesses them as chronic or stable . All subjects experiencing AEs - whether considered 
associated with the use of the study vaccine or not - must bemonitored until symptoms 
subside and any abnormal  laborator y values  have  returned  to baselin e, or until there  is a 
satisfactory explanation for the changes observed, or until death, in which case a full 
pathol ogist's report  shoul d be supplied,  if possibl e. The investigator' sassessmen t of 
ongoing Adverse Events at the time of each subject' s last visit should be documented  in 
the subject ' s medical  chart. 
7.1.4 Serious Adverse Events 
A serious adverse event  (SAE)  is defined  as any untoward medical  occurrence  that at any 
dose results  in one or more  of the following:  
• Death.  
• Is life-threatening (i.e ., the subject was , in theopinion of the investigator , at 
immediate  risk of death  from  the event as it occurred); it does not refer  to anevent 
which  hypothetically might have  caused  death  if it were  more  severe.  
• Required or prolonged hospitalization. 
• Persisten tor significan t disability /incapacity(i .e., the even t causes a substantial 
disruption of a person 's ability  to conduct normal life functions. ) 
• Congenital anomaly /or birth  defect.  
• An important and significant medical event that may not be immediately life 
threatening or resulting in death or hospitalization but, based upon appropriate 
medical  judgment, may jeopardize  the subject or may require  intervention  to prevent 
one of the other outcomes listed  above . 
Adverse events which do not fall into these categories are defined as non -serious.  
It should be noted that a severe  adverse  event  need  not be serious in nature  and that a 
serious adverse  event  need  not, bydefinition, be severe.  
 
 
PR0-01 TEMP 06 / Atlas No . 293620  
VersionNo.4 / Vers ion Date: Jan \131)'29 , 2015  
00 
Protocol V59_77 
Page 56of86  GSK  
24JUN 16Final  Protocol  Versioo  1 Confidentia l 
::, z u 
8  
  
Serious  adverse  events will be captured  both on the Vaccines  Serious  Adverse  Event 
(VSAE)  form  as well as on the AE CRF . All SAEs will be evaluated by the investigator 
for relationship of the event to studyvaccine . SAEs that are judged to be possib ly or 
probably  related to the study vaccine shoul d be reported  to the Sponsor  as related  events . 
 
The relationship of the study treatment  to an SAE  will be determined by the investigator 
based on the following  definitions:  
 
1. Related  
 
The SAE is judged by the investigator to be poss ibly or probably related to the study 
vaccine on the AE CRF page (see section 7.1.3, Evaluation of Adverse Events ). 
 
2. Not Related  
The SAE is not related if exposure to the study vaccine has not occurred , or the 
occurrence of the SAE is not reasonabl y related in time, or the SAE is considered 
unlikely  to be related  to use of the study vaccine , i.e., there  are no facts  (evidence ) or 
arguments to suggest  a causal  relationship . 
 
The relationship of the studyvaccine to an SAE will be determined by the investigator . 
 
In addition , SAEs willbe evaluated by the Sponsor or designee for " expectedness. " An 
unexpected  AE is one that is not listed  in the ct11Tent  Summary  of Product  Characteristics 
or the Investigator's Brochure or an event that is by nature more specific or more severe 
than a listed  event  
 
In addition , a pre -existing event or condition that results in hospitalization should be 
recorded  on the Medical  History  CRF. If the onset  of an event  occt11Ted before  the subject 
entered the study (e.g., any pre -planned hospitalization for condit ions like cosmet ic 
treatments or for non -emergency routine visits for a pre -existing condition ), the 
hospitalizationwould not lead to an AE being classified as serious unless , in the view of 
the investigator , hospitalization was prolonged as a result of participation in the clinical 
study  or was necessary  due to a worsening  of the pre-existing  condition . 
 
7.1.4.1 Adverse Events of Special Interest 
Adverse Events of Special Interest (AESis ) will not be assessed during the study.  
 
7.1.S Methods for R ecording Adverse Events and Se1ious Adverse Events 
 
Findings regarding Adverse Events must be reported on an Adverse Events CRF , as 
specified in section  7.1.1, Solicited  Adverse  Events , and on the VSAE  form,  if applicab le, 
 
PR0-01 TEMP 06 / Atlas No. 293620  
VersionNo.4 / Vers ion Date: Jan\131)'29 , 2015  
00 
Protocol V59_77 
Page 57of86  GSK  
24JUN 16Final  Protocol  Versioo  1 Confidentia l 
PR0-01 TEMP  06 / Atlas  No.293620  
VersionNo.4  / Version Date:  Jan\131)'29,  2015   
  
which  is part of the Investigator  Site File. All findings  in subjects  experiencing AEs must  
be reported also in the subject's source document.  
All SAEs which  occur during  the course  of the study, whether  considered to be associated 
withthe  study  vaccination or not, must  be reported w i thin 24 hours of the site becomi ng 
aware of the event to GSK or its designee . Specific instructions and contact details for 
collecting  and reporting SAEs  to GSK will be provided to the investigator . Specifically , 
once an investigator becomes aware that a SAE has occurred in a study subject , the 
investigator  (or designate) must  complete a paper expedited Adverse  Events report  and 
forward it to GSK WITHIN 24 HOURS. The report will always be completed as 
thoroughly  as possible  with all available  details  of the event and then dated and signed  by 
the investigator (or designate) . Even if the investigator does not have all information 
regarding a SAE , the report  should still be completed  and forwarded to GSK  within  24 
hours . Once  additional  relevant information is received, the report  should  be updated and 
forwarded to GSK WITHIN 24 HOURS. The investigator will always provide an 
assessment of causality at the time of the initial report . All SAEs are also to be 
documented on the Adverse  Events  CRF.  Any medication  or other  therapeutic  measures 
used to treat the AE will be recorded on the appropriate CRF(s) in addition to the 
outcome of the AE. 
After receipt of the initial report, representatives of GSK or its designee will contact the 
investigator if it is necessary to obtain further information for assessment of the event. Of 
note, after the initial AE/SAE report, the investigator is required to proactively follow 
each subject and provide additional relevant information on the subject's condition to  
GSK Biologicals (within 24 hours for SAEs , and within 2 weeks for pregnancies).  
 
All SAEs must be reported by the investigator to his/her corresponding EC/ IRB 
applicable regulatory authorities in accordance with institutional policy /regulatory 
requirements and adequate documentation of this notification must be provided to the 
Sponsor . 
 
GSK or its designee must also comply with the applicable regulatory requirement(s) 
related to the reporting  of suspected  unexpected  serious  adverse vaccine reactions (also 
known  as SUSARs)  to the regulatory authority(ies)  and the IRB/EC . If a SUSAR or other 
safety signal relating to use of one of the study vaccines is reported to GSK or its 
designee , the Sponsor will communicate the information to the investigator and the 
investigator  will be responsible  for submitting  this information  to the EC/IRB  and other 
relevant  authorities . 
Protocol V59_77 
Page 58of86  GSK  
24JUN 16Final  Protocol  Versioo  1 Confidentia l 
PR0-01 TEMP  06 / Atlas  No.293620  
VersionNo.4  / Version Date:  Jan\131)'29,  2015   
  
7.1.5.1 P ost-Study Events 
 
AnySAEthat  occurs  outside  of the protocol -specifiedfoll ow-up period and considered  to 
be caused by the study vaccine nrust  be reported to GSK or its designee . These SAEs will 
be processed by GSK  or its designee as during the course  of the study, until  I month after 
Last Subject Last Visit (LSLV). Instructions and contact details for collecting and 
reporting these  suspected  SAEs will be provided  to the investigato .r 
 
7.1.6 Pregnan cies 
 
To ensuresubj ects' safety , each  pregnancy in a subject after study  vaccination must be 
reported to GSK or delegate in due time of the site learning of its occurrence . If the 
subject  agrees  to submit  this information,  the pregnancy must  be followed  to determine 
outcome , including  spontaneous  or voluntary  termination,  details of the birth,  and the 
presence or absence of any birth  defects , congenital  abnormalities , or maternal and/or 
newborn  complications . This follow -up should  occur even  if intended duration  of safety 
follow -up for the study has ended . 
 
Pregnancy data must be recorded on a Pregnancy Report CRF (initial report) and 
Pregnancy Follow -Up CRF (outcome report) and reported to GSK or de legate.  
Instructions and contact details for submitting the Pregnancy CRFs will be provided to the 
investigator . 
 
Any pregnancy outcome mee ting the definition of a SAE (see section 7 .1.4, Serious  
Adverse Events ) must also be reported on the VSAE Report Form The following should 
always be considered as SA E. 
• Spontaneous pregnancy loss, including  
spontaneous  abortion,  (spontaneous  pregnancy  loss before /at 22 weeks of 
gestation)  
ectopic and molar pregnancy  
still birth (intrauterine death of foetus after 22 weeks of gestation).  
Note : the 22 weeks cut-off in gestational age is based on WHO -ICD 10 noted in the 
EMA Guideline  on pregnancy exposure . It is recognized  that national  regulations 
might be  different.  
• Any early neonatal  death (i.e. death  of a live born  infant  occurring  within  the first 7 
days of  life). 
• Any congenital anomaly or birth defect (as per the Metropolitan Atlanta Congenital  
Defects  Program  (E rro r! Refer ence sour ce not foun d.) guidelines) identified  in the 
offspring of a study subject (either during pregnancy, at birth or later) regardless of  
Protocol V59_77 
Page 59of86  GSK  
24JUN 16Final  Protocol  Versioo  1 Confidentia l 
00 
::, z u 
8  
 ,  
whether the foetus is delivered dead or alive . Thi s includes anomalies identified by 
prenatal ultrasound , amniocentesis or examination of the products of conception after 
elective or spontaneous abortion . 
 
7.1.7 Safety  La bora tor y l\lll eas ur em e n ts 
 
No safety laboratory measurements will be done in this study . 
 
7.2 Efficacy  Asse ssment  
This section is not applicable . This study has no efficacy measurements . 
 
7.3 Immunoge nicity A55ess m en t 
 
The functional  measure of inununogenic ity used in this study , Serum Bacteric idal Assay 
(SBA) , is a measure of the ability  of antibodies , in concert with human complement, to 
kill meningococci, and is widely used and generally recognized as the serological 
correlate  of protection.  The key measures of inununogenicitywill be the percentages of 
subjects with seroresponse 1 percentages of subjects who achieve hSBA titers 8 and, and  
the hS BA GMTs against serogroups A, C , W and Y reference strains  
 
These measurements willbe assessed  in serology samp les collected at Visit Day 1, 4 or 6 
and Day 29. The measures of inununogenicity used in this study  are standard, i.e., wide ly 
used and generally recognized as reliable , accurate , and relevant (able to describe the 
quality  and extent  of the inunune  response).  
 
All subjects  will have  a blood  draw  at Day1 , before  vaccination. Subsequent  blood draws 
willbe at either Day 4 or Day6  post vaccination,  and at Day 29 post vaccination.  
 
Testing will be conducted by qualified and certified laboratories . All assays will be 
performed in GSK Clinical Laboratory Sciences or delegate laboratory , as provided in the 
protoco l ancillary document.  
 
 
 
 
 
 
 
 
1 Seroresponse is defined forthisstudy asfollows: Seroresponse to N. meningitidis serogroups A, C, Wand 
Y is defined as: For subjects with pre-vaccination titers <4, post-vaccinatioo titers 2: 16; for subjects with 
pre-vaccinat ion titers2:4, post vaccinati on titersat least 4 times the pre-vaccination titers . 
 
 
PR0--01 TEMP 06 / Atlas No. 293620  
VersionNo.4 / Vers ion Date: January 29, 2015 
Protocol V59_77 
Page 60of86  GSK  
24JUN 16Final  Protocol  Versioo  1 Confidentia l 
00 
::, z u 
8  
  
8. STATISTICAL CONSIDERATIO  NS 
 
8.1 E ndpoints 
8.1.1 Plim  a i-y En d p oin t(s) 
 
8.1.1.1  P1im  a r y Saf ety En d p oin t (s) 
 
There are no primary safety endpoints in this study.  
 
8.1.1.2  P1imar y Efficacy En dpoint (s) 
 
There are no primary efficacy endpoints in this study.  
 
8.1.1.3  P1imar y I mmun ogenicity E ndpoin  t(s) 
The following  measure willbe summarized  for the Menveo -Menveo  and Menactra - 
Men
veo groups:  
1. Percentage of subjects  with hSBA  seroresponse1 against  N. meningitidis  
serogroups A, C , W and Y at Day 29.  
8.1.2 Secondary Endpoin t(s) 
 
8.1.2.1  Secondar y Safety Endpoint(s)  
 
Safety of the study vaccine will be assessed in the Menveo -Menveo , Menactra -Menveo , 
Naive and the poo led (Menveo -Menveo and Menactra -Menveo) groups in temlS of the 
frequencies (percentages) of reported adverse events including : 
 
1. Any unsolicited  AEs reported  within  30 minutes  after vaccination;  
2. Solicited  local and systemic  AEs reported from  Day 1 (6 hours)  through  Day 7 
after vaccination;  
3. Other  indicators  of reactogenicity  (e.g. use of analgesics / antipyret ics, body 
temperature)  within  7 days after vaccinat ion; 
4. All unsolicited  AEs reported  from  Day 1 through  Day 29 after vaccination;  
 
 
1 Seroresponse is defined forthis study asfollows: For subjectswi th pre-vaccinationtiters <4, pos-t 
vaccination ti ters 2: 16; for subjects with pre-vaccination titers2::4 , post vaccinat ion titers at least4 times the 
pre-vaccination titers.titers.  
 
 
PR0--0 1 TEMP 06 / Atlas No.293620  
VersionNo.4 / Vers ionDate: Jan \131)'29, 2015  
Protocol V59_77 
Page 61of86  GSK  
24JUN 16Final  Protocol  Versioo  1 Confidentia l  
  
5. Medically -attended AEs, AEs leading to withdrawa l and SAEs reported from Day 
1 through Day 181 (entire  study period).  
Adverse events will be coded using MedDRA preferred terms as applicable.  
 
8.1.2.2  Seco ndary Efficacy E ndpoint(s) 
There are no secondary efficacy endpoints in this study.  
 
8.1.2.3  Secondary Immunoge nicity Endpoint(s) 
The following measures will be summarized for Menveo -Menve ,oMenactra -Menveo, 
Naive and the pooled (Menveo- Menveoand Menactra- Menveo)groups:  
 
1. Percentage of subjects with hSBA titer 8 and 16 against N. meningitidis 
serogroups A, C, Wand  Y at Day 1, Day 4, Day 6 and Day 29 and between -group 
differences ; 
2. Percentagesof subjects with hSBA seroresponse1 against N. meningitidis  
serogroups A, C, Wand  Y at Day 4, Day 6 and Day 29 and between -group 
differences ; 
3. hSBA GMfs  againstN.  meningitidis  serogroup A , C, Wand Y at Day 1, Day 4, 
Day 6 and Day 29; 
4. Ratios ofhSBA  GMfs atDay  1, Day 4, Day 6 and Day 29 (between  study  
groups).  
5. hSBA Geometric  Mean  Ratios  (GMRs) at Day 4, Day6 , and Day 29 compared to 
Day 1 (within  study groups) . 
8.1.3 Expl ora tory Endpoin t(s) 
 
8.1.3.1  Expl oratory Safety Endpoi nt(s) 
There are no exploratory safety endpoints in this study.  
 
8.1.3.2  Expl or atory Efficacy Endpoin t(s) 
There are no exploratory efficacy endpoints in this study.  
 
 
1 Seroresponse is defined forthis study asfollows: For subjectswi th pre-vaccinationtiters <4, pos-t 
vaccination  titers 2: 16; forsubjects  with pre-vaccination titers2::4 , post vaccina tiontiters  at least4 times the 
pre-vaccination  titers.  
 
 
PR0- 01 TEMP 06 / Atlas No. 293620  
VersionNo.4 / Vers ionDate: Jan \131)'29, 2015  

Protocol V59_77 
Page 62of86  GSK  
24JUN 16Final  Protocol  Versioo  1 Confidentia l 
::, z u 
8  
  
8.1.3.3  Explorat ory Immunogenicity  Endp oin t(s) 
 
There are no exploratory imm unogenic ity endpoints in this study . 
 
8.2 Success C1iteria  
 
8.2.1 Success C1iteria for P1imary Objective(s) 
 
8.2.1.1 Success C1ite1ia for P1imary S afety Obje ctive(s) 
There are no primary  safety objectives in this study . 
8.2.1.2 Success C1iteria for Primar y Efficacy Objective(s) 
There are no primary  efficacy objectives  in this study . 
8.2.1.3 Success C1ite1ia for P1imary Immun ogenicity  Obje ctive(s)  
 
To demonstrate immune  response  sufficiency  after MenACWY- CRM booster  vaccine 
administrati on, the lower limit o f the one-sided 97.5% Confidence Interval(CI) for 
percentage of subjects  with hSBA booster  seroresponse against each  of serogroups  A, C, 
Wand Ymust  be greater than 75% . This will be tested sequentially  first in the group of 
subjects  who received primary  vaccinat ion with Menveo and, if met, also in the group of 
subjects  who received primary  vaccinat ion with Menactra.  
 
8.2.2 Success C1iteria for Secon dar y Objec tive(s)  
 
8.2.2.l Success C1ite1ia for Secondar y Safety Obje ctive (s) 
 
There are no success crit eria assoc iated with the secondary safety objectives . 
 
8.2.2.2  Success C1ite1ia for Secondary Efficacy Obje ctive(s) 
There  are no secondary efficacy object ives in this study.  
8.2.2.3  Success C1ite1ia  for Secondar y Immunogenic ity Obje ctive(s) 
There areno  success criteria assoc iated with the secondary immunog enicity object ives in 
this study . 
 
 
 
 
 
 
PR0  -01 TEM P 06 / Atlas No. 293620  
Vers ion No.4 / Vers ion Date: Jan \131)'29 , 2015 
00 
Protocol V59_77 
Page 63of86  GSK  
24JUN 16Final  Protocol  Versioo  1 Confidentia l 
::, z u 
8  
  
8.3 Anal ysis Sets  
 
8.3.l All Enrolled Set 
 
All screened subjects  who provide  informed  consent and provide  demographic  and/or 
baseline  screening assessments , regardless of the subject's  randomiza tion and treatment 
status  in the study , and received a Subject  ID. 
 
8.3.2 All Exposed  Set 
 
All subjects in the enrolled set who receive a study vaccination.  
 
8.3.3 Safety Set 
 
Solicite d Safety Set (so licited local and systemic adverse events a nd ot her solicite d 
adverse events)  
 
All subjects in the Exposed Set with any solicited adverse event data. 
 
Unsolicited Safety Set (unso licited adve rse events) 
 
All subjects in the Exposed Set with unsolicited adverse event data.  
 
Overa ll Safety Set 
 
All subjects who are in the Solicited Safety Set and/o r Unsolicited SafetySet.  
 
8.3.4 Full Anal ysis Set (FAS)  Efficacy/I mmunoge nicity Set 
Full An alysis Set Immun ogenicity 
FAS <Day 1) 
All subjects in the All Enrolled Set who:  
• are randomized;  
• provide evaluable serum samples at Day 1 whose resul t is available for at least one 
serogroup . 
FAS <Day29)  
All subjects in the All Enrolled Set who:  
• are randomized;  
• receive  the study  vaccination;  
 
PR0--01 TEMP 06 / Atlas No.293620 
VersionNo.4 / VersionDate: Jan\ 131)'29, 201 5 
00 
Protocol V59_77 
Page 64of86  GSK  
24JUN 16Final  Protocol  Versioo  1 Confidentia l 
PR0-01 TEMP  06 / Atlas  No. 293620  
VersionNo.4  / Version Date:  Jan\131)'29  , 2015   
  
• provide evalua bleserum  samples at Day1  whose  result is available  for at least  one 
serogroup  (excep t for hSBA  titer 8 and 16, GMTs and GMRs  calculated  at specific 
timepoints);  
• provide evalua bleserum  samples at Day 29 whose  result  is available  for at least one 
serogroup.  
8.3.S Per Prot ocol (PP) Set Efficacy/l mmunoge nicity Set 
A PPSwill be defined  for each FAS described  in the previous  Section  with additional 
criteria specified below . 
All subj ects in the FAS Immunogenicitywho  
• Have no protocol  deviat ionsleadingto exclusion (see section 8.3.8 , Protocol  
Deviation )s as defined  prior  to unblinding / analysis.  
• Are not excluded  due to other reasons  defmed  prior to unblinding or analysis  (see 
section 8.3.8, Protocol Deviat ions) 
Examples for subjects excluded due to other reasons than protocol deviations are: 
Subjects who withdre w informed consen t. 
8.3.6 Other Anal ysis Sets 
 
There are no other analysis sets used in this study. 
8.3.7 Subgroups 
 
Using the PPS (Day  29), the analyses  of the  primaryobjectives  will be replicated  bysex 
and race. 
8.3.8 Protocol D eviations 
 
A protocol  deviation  is any change, divergenc e, or departure  from  the study design or 
procedures of a study protocol.  A protocol  deviation  may be a reason  to remove  data from 
an analysis set at the time of analysis . CSR -reportable protocol  deviations  will be defined 
as exclusionary  fromthe  analysis  according to protocol objectives and endpoint ,swhich 
will be specified  in the statistical analysis  plan. In some  cases exclusion  of data may be 
due to a reason  other  than a protocol  deviation,  e.g. early termina tion. 
Protocol V59_77 
Page 65of86  GSK  
24JUN 16Final  Protocol  Versioo  1 Confidentia l 
PR0-01 TEMP  06 / Atlas  No. 293620  
VersionNo.4  / Version Date:  Jan\131)'29  , 2015   
  
8.4 Statistical Anal ysis Plan  
 
8.4.1 Anal ysis of Demographic and Baseline Characteristics 
 
Descriptive statistics  (mean,  standard  deviation,  median , minimwn  and maximwn)  for 
age, height  and weight  at enrolment will be calculated overall  and by study group . 
Distributions  of subjects  by sex, race and ethnic  origin  will be summarized  overall  and by 
study  group . 
 
8.4.2 Anal ysis of Primary  Objective(s)  
 
8.4.2.l Anal ysis of Primary Safety Objective(s) 
There are no primary  safety objectives in this study.  
8.4.2.2  Anal ysis of Primar y Efficacy Objective(s)  
There are no primary efficacy objectives in this study.  
 
8.4.2.3  Anal ysis of Primary Immun ogenicity Objective(s)  
 
8.4.2.3.1  Statistical H ypotheses 
Null hypothesis : P,j 0.75 
Alternative  hypothesis : Pij > 0.7 5 
Where: P,j is the population  booster  seroresponse  rate; j = 1,2 refer  to group  Menveo - 
Men
veo (first  test) and Menactra -Menveo (second  test) respecti vely; i = 1,2,3,4  refer  to 
serogroup  A, C, Wand  Y respectivel .yThelevel  of significance  is fixed at one-sided 
0.025.  
8.4.2.3.2  Anal ysis Sets 
 
The analysis population to be used for the primary o bjectives is the PPS (Day 29). 
Analyses  of primary objectives willbe repeated on the FAS  (Day 29) to assess robustness 
of results . 

Protocol V59_77 
Page 66of86  GSK  
24JUN 16Final  Protocol  Versioo  1 Confidentia l 
PR0--01 TEMP  06 / Atlas  No. 293620  
VersionNo.4  / Version Date:  Jan\131)' 29 , 2015   
  
8.4.2.3.3  Statistical Methods 
General 
Missing immunogenicityvalues are assumed MCAR (Missing Completely At Random ) 
and therefore may not contain information that impact the result of the analysis (i.e., not 
informative). Imputation methods will therefore not be used.  
 
Overall  significance  level  for all hypothesis  tests is one-sided  a = 2.5%. 
Sero response (Day 29) 
Seroresponse for this booster study is defined  as: a) post-vaccination  hSBA  titer ,::16 for 
subjects with a pre-vaccination hSBA titer <4; b) forsubjects with a pre -vaccination 
hSBA  titer ,::4, an increase of at least four times the pre-vaccinationhSBA  titer. 
For each  individual  vaccine  group (Menveo- Menveo and Menactra- Menveo)  and each 
ACWY  serogroup, the percentage of subjects  with seroresponse will be computed,  along 
with associated two-sided 95%  Clopper -Pearson Cis. 
 
Further details of the statistical methods will be provided in the SAP . 
 
8.4.3 Anal ysis of Seco nda ry O bjective(s)  
 
8.4.3.1  Anal ysis of Seco nda ry Safety O bjective(s) 
 
8.4.3.1.1  Anal ysis of Ext ent of Exposur e 
 
Subjects will be analyzed to the extent that they were exposed to study vaccines and 
according to the availab le safety data for the subject during any study period . Subjects 
who withdraw  early or who are lost to follow -up will be removed  from  the summary table 
denominator  for the time period  in which  they have no available  safety data collected . 
 
8.4.3.1.2  Analys is of Solicited  Local,Sys temic  and Other  Adve rse Events 
 
All solicited  adverse events  will be summarized according  to defined  severity  grading 
scales . 
 
Frequencies and percentages of sub jects experiencing each adverse event will be 
presented for each symptom severity . Summary  tables  showing  the occurrence of any 
localor  systemic  adverse event overall and at each  time point  will also be presented . 
Protocol V59_77 
Page 67of86  GSK  
24JUN 16Final  Protocol  Versioo  1 Confidentia l 
PR0-01 TEMP 06 / Atlas No.293620  
VersionNo.4  / Version Date:  Jan\131)' 29, 2015   
  
Post- vaccination solicited adverse events reported from Day 1 to Day 7 will be 
summarized  for the intervals  Day 1 (6 hours) - Day 3, Days  4-7, Day 1 (6 hours)  - Day 7 
by maximal severity and by study group. Separate analyses will be performed for 
solicited AEs reported 30 minutes after vaccination. Theseverity of solicited local 
adverse events , including injection-site erythema  and induration, will be categorized 
based on linear measurement: None  (0-24 mm), Mild  (2S-SOmm) , Moderate  (S1-100 
mm), Severe (> 100mm) . 
 
Injection site pain and systemic reactions, including fatigue , headache , myalgia , 
arthralgia,  chills, nausea, loss of appetite , occurring  up to 7 days after  each  vaccination 
will be nmmari7ed  according to"mild ", "moderate " or"severe" . 
Each solicited local and systemic adverse event will also be further summarized as"none " 
versus ''anY '. 
Use of antipyret ics and analges ics will be summarized  by frequency, by type of use 
(prophylactic  versus  treatment)  and percentage  of subjects reporting  use. 
Body tefl1lElrature will be summarized separately according  to the 3 schemes  described 
below and will be broken down according to route of measurement:  
• by O.S °C increments from 36.0°C upto ,::40°C;  
• by 1°C increments:  <36.0, 36 .0-36 .9, 37.0-37 .9, 38.0-38 .9, 39.0-39 .9, ,::40°C; 
• According  to different  cut-offs (< versus ,::): 38 .0, 38 .S, 39 .0, 39 .S, 40 .0 °C . 
8. 4.3 .1. 3 Anal y sis of U n so licited Advene Events 
 
This analysis applies to all adverse events occurring during the study, judged either as 
probably related , possibly related, or not related to vaccination bythe investigato ,r 
recorded in AE CRF, with a start date on or after the dateof  first vaccination. AE starting 
prior to the first vaccinat ion willonly be listed . The original verbatim terms used by 
investigators to i dentify adverse events in the CRFs will be mapped to preferred terms 
using the MedDRA dictionary. The adverse events will then be grouped by MedDRA 
preferred terms into frequency ta bles according to system organ class (SOC).  
 
All reported adverse events , as well as adverse events j udged by theinvestigator as at 
least possibly related to study vaccine, will be summarized according to SOC and 
preferred term within SOC. These summaries will be presented by study group and b y 
interval of study observation . When an adverse even t occurs more than once for a 
subject, the maximal severity and strongest relationship to the vaccine will be counted.  
Separate summaries  will be produced for the following categories:  
Protocol V59_77 
Page 68of86  GSK  
24JUN 16Final  Protocol  Versioo  1 Confidentia l 
PR0-01 TEMP 06 / Atlas No.293620  
VersionNo.4  / Version Date:  Jan\131)' 29, 2015   
  
• Adverse  events  that are possibly or probably  related to vaccine  
• Unsolicited  AEs reported within  30 minutes  after  vaccination  
• Unsolicited  AEs reported within  29 days  after vaccinat ion 
• Adverse  events  leading  to withdrawal  
• Adverse  events  leading  to a medically attended  visit  
• Serious adverse events  
• 
Data listings  of all adverse events will be provided  by subject. In addition , adverse events 
in the categories above  will be provided  as listed  data.  
 
8.4.3.1.4 Statistical H ypothe ses 
 
There are no statistical hypotheses associated withthe secondary safety objectives . 
 
8.4.3.LS Anal ysis Sets  
 
Analyses  of solicited  adverse events - and other  solicited  reactions  - and unsolicited 
adverse events  will be performed  on the relevant safety  sets. 
 
8.4.3.1.6 StatisticalMethods 
 
For unsolicited  adverse  events , the entirestudy  period  will be divided  into the following 
intervals : onset within 30 minutes after vaccination , onset within 28 days after 
vaccination;  and from  Day 1 through  Day 181. For solicited  adverse  events , the solicited 
study period will be divided into intervals: from 6 hours through day 3; from day 4 
through day 7 ; and from  6 hours  through day 7. 
No imputation methods will be used to address missing safety data . 
 
SnmmariP.s of safety  will be presented  using  frequencies  and percentages within  each 
study  group . No statist ical comparisons  among  the studygroups  with respect to any of the 
safety  parameters will be performed.  
8.4.3.2  Anal ysis of Seco nda ry Efficacy Objective(s)  
There are no secondary efficacy objectives associated with this study.  
Protocol V59_77 
Page 69of86  GSK  
24JUN 16Final  Protocol  Versioo  1 Confidentia l 
PR0--01 TEMP  06 / Atlas  No. 293620 
VersionNo.4  / Version Date:  Jan\131)'29  , 2015   
  
8.4.3.3  Anal ysis of Seco ndary Immunoge nicity Objective(s)  
 
8.4.3.3.1  Statistical Hypoth eses 
Analyses related to the secondary immunogenicityobjectives willbedescriptiv ;eno 
formal statistical tests will be performed.  
 
8.4.3.3.2  Anal ysis Sets  
 
Analyses of secondary imm1mogenicity  will be based on the P PS and repeated on the 
FAS.  
8.4.3.3.3  Statistical Methods 
General 
The hSBA  titers  at each  visit will belogarithmicallytransformed  (basel  0) to obtain 
approximately normally distributed  data. 
 
For comparison of percentages and GMT ratios , unadjusted estimates will beobtained 
along with adjusted estimates from regression models to account for potential baseline 
imbalance between study groups . 
For eachN. m.eningitidis  serogroup A, C, Wand Y , unad justedGMTs  will becalculate, d 
withtheir associated two -sided 95% Cls, by exponentiating the corresponding log - 
tra
nsformed  means  and their  95%  Cls. Adjusted  GMTs  willbeobtained from  Analysis  of 
Covariance (ANCOVA)  models . 
 
See section 8.4 .2.3.3 for other relevant details . 
 
Sero response (Day 4, Day 6, and Da y 29) 
 
The percentage of sub jects withseroresponse and associated two- sided 95% Clopper - 
Pe
arson Cls willbecomputed by group (Menveo -Menveo , Menactra- Menveo , the Nai've 
and the pooled  [Menveo -Menveo  and Menactra- Menveo]groups)  andN. m.eningitidis 
serogroups  A, C, W and Y test strains . Differences  in percentages and associated 95%  Cls 
between  study  groups  willbecalculated using  the Miettinen  & Nurminen  score method . 
 
In a descriptive  fashion  - using  the difference in percentages and 95%  Cls - each  of the 
previously vaccinated groups  (individually  and pooled  [Menveo-Menveoand Menactra - 
Me
nveo]) will becompared to the nai've  group . Also  the two previously  vaccinated study 
groups  willbecompared to each other . 
Protocol V59_77 
Page 70of86  GSK  
24JUN 16Final  Protocol  Versioo  1 Confidentia l 
PR0-01 TEMP  06 / Atlas  No. 293620  
VersionNo.4 / Version Date: Jan\131)'29 , 2015   
  
As sensitivity  analyses , the difference  in percentages willalso be obtained  from  a log- 
line
ar model  adjusting for pre-vaccinationt iter. Please see SAP  for technical details.  
 
Percenta ge of Subjects \Vith  hSBA titer <'.'.8  (Da   y  I ,  Da   y  4 ,  Da   y  6,   and Da   y  29) 
F or each study group and in the pool ed group (Menveo- Menveo and Menactra -Menveo) , 
the percentage of subjects with hSBA titer 8 and 16 and associated two -sided 95% 
Clopper -Pearson Cls willbecomputed by the N. meningitidis serogroups A, C, W and Y 
teststrains on Day 1 , Day 4 , Day 6 and Day 29 (as applicable , depending on blood draw 
schedule ). 
 
Differences in percentages and associated 95% Cis between study groups will be 
calculated using the Miettinen & Nurminen score method . 
 
In a descriptive fushion  - using  the difference in percentages  and 95%  Cis - the previously 
vaccinated groups (individually and pooled [Menveo -Menveo and Menactra- Menveo ]) 
will becompared to the nai've  group  . Also  the two previously  vaccinated  groups  will be 
compared to each  other . 
 
As sensitivity  analyses , the difference  in percentages willalso be obtained  from  a log- 
line
ar model  adjusting  for pre-vaccinationt iter. Please see SAP  for technical details.  
 
Between-gr oup Rati os of Gl\lll T s (A d jus te d a n d Un ad ju sted)  
 
The between  -group ratio  ofhSBA  GMTs  and corresponding 95%  CI, at each of Visit Day 
1 (Persistence) , Day 4, Day 6 and Day 29 against  each N. meningitidis  serogroups  A, C, 
W and Y test strains willbeobtained by exponentiatingthe mean between -group 
differences in log -transformed titers and the corresponding 95% Cls at each of the 
timepoints  specified.  
Additionally , adjusted  ratio  of GMTs  willbeobtained  fromANCOVA models  including 
pre-vaccination  titer as fuctors  in the model.  
 
The previous ly vaccinated groups (individually and pooled [Menveo- Menveoand 
Menactra- Menveo]) willbecompared to the nai've  group  at each  timepoint - descriptively  
- using the ratios of GMTs . 
The two previously vaccinated  groups  willbecompared at each timepoint  using  GMT 
ratios.  
\Vit hin -gro up G MRs (Adjusted and Unadjusted)  
 
Within  each  study  group  and for each serogroup , GMRs  will be calculated, as applicab le, 
at: 
Protocol V59_77 
Page 71of86  GSK  
24JUN 16Final  Protocol  Versioo  1 Confidentia l 
PR0-01 TEMP  06 / Atlas  No. 293620  
VersionNo.4 / Version Date: Jan\131)'29 , 2015   
  
• Visit Day4 versus  at Visit  Day 1 ; 
• Visit Day 6 versus  at Visit Day 1 ; and 
• Visit Day 29 versus  at Visit  Day 1. 
 
The unadj usted  GMR.s  and 95%  Cis willbeconstructed  by exponentiating  the mean 
within -groupdifferences  in log-transformed titers  and the corresponding  95%  Cis. 
Further details  of the statistical methods  willbeprovided in the Statistical Analysis  Plan 
(SAP) . 
 
8.4.4 Anal ysis of E xplora tory O bjectives 
 
8.4.4.1  Anal ysis of E xplora tory Safety O bjective(s) 
There are no exploratory safety objectives in this  study.  
8.4.4.2  Anal ysis of Explora tory Efficacy  Objective(s)  
There are no exploratory efficacy  objectives  in this study.  
8.4.4.3  Anal ysis of Explora tory Immunoge oicity Objective(s)  
There are no exploratory  immunogenicityobjectives  in this study.  
8.5 Sample Size and Power Considera tions of Primary  and Seco ndary  Objectives  
 
Statist ical power was estimated based on observed data from a previous study  
(V59Pl3 El) assessing the immunogenicityof  a booster dose ofMenveo among subjects 
who had previously been vaccinated with either Menveo or Menactra 3 years prior in 
another study  (V59P13)  whilesub jects were 11-18 years old. Data  from study V59Pl3  El , 
were used to compute booster seroresponse rates at one- monthpost booster dose of 
MenACWY -CRM using the following definition of booster seroresponse: a) post - 
va
ccination hSBA titer,:: 16 for subjects with a pre-vaccinationhSBA titer <4; b) for 
subjects  with a pre-vaccination  hSBA  titer ,::4, an increase of at least four times the pre- 
vac
cination  hSBA  titer (cf. table  8.5-1). 
Protocol V59_77 
Page 72of86  GSK  
24JUN 16Final  Protocol  Versioo  1 Confidentia l 
::, z u 
8  
  
Table 8.5-1: hSBASeroresponse at One Mo nth Following the Booster at 3 
Years Aft er Vaccinatio n, bySerogroup - Boos ter- PP Population 
 
 
 
 Vaccination ACW Y/A 
 
Group IV Y l\fenactr a/ACW Y 
 
Gt·onp V 
 <I'. 
.Q.. :, e .e. 
"'  
 
Overall  
Seroresponse   
68(97%)  
(90-100) 
N=70   
70 (100%)  
(95-100) 
N=70 
u 
.Q.. :, e .e. "'  
 
Overall  
Seroresponse   
66(93%)  
(84-98) 
N=71   
65 (93%) 
(84-98) 
N=70 
.Q.. :, e  
e  
 
Overall  
Seroresponse   
63 (91%)  
(82-97) 
N=69    
64 (93%)  
(84-98) 
N=69  
> 
.Q.. :, e .e. "'  
 
Overall  
Seroresponse   
63 (90%)  
(80-96) 
N=70   
64 (91%)  
(82-97) 
N=70 
 
 
Assuming  the true booster  seroresponse  rates in the Menveo -Menveogroup range  from 
90%  to 97%  (alternative  hypothesis)  for each serotype , a sample  sizeof n=270will have 
at least 96% power to show sufficiency of immune response to a booster dose of 
MenACWY -CRM , compared with a pre-specifiedreference booster  seroresponse  of7S% 
(null  hypothesis)  using  an exact test with 0.02Sone- sidedsignificance  level (cf table 8.S- 
2a). 
 
Assuming  the true booster  seroresponse  rates  in the Menactra- Menveogroup  range  from 
91% to 100%  (alternat ive hypothes is) for each  serotype, a sample  sizeof  n=270will  have 
at least 96%  power to show  sufficiency of immune response  to a booster  dose  of 
 
 
PR0--01 TEMP 06 / Atlas No. 293620  
VersionNo.4 / Vers ion Date: January 29, 20 15 
00 
Protocol V59_77 
Page 73of86  GSK  
24JUN 16Final  Protocol  Versioo  1 Confidentia l 
::, z u 
8  
  
MenACWY -CRM,  compared with a pre-specified  reference booster seroresponse  of 75% 
(null  hypothesis) using  an exact test with 0.02Sone- sided  significance  level  (cf table  8.S- 
2b). 
 
Table 8.S-2a: Statistical  Power to Test for Sufficien cy of Immun e Respo nse 
Give n a Range of True Booster  Seror  espo nse Ra tes for 
Evaluable Sample Size of 270 subjects in the Me nveo-Menveo 
grou p 
Serot}11e  T111e  Seroresponse  Rate Power  
A 0.97 0.99 
C 0.93 0.99 
w 0.91 0.99 
y 0.90 0.99 
Total  Power  0.96 
 
Calculations have been done with nQuety Advisor (Version 7. 0). 
 
Table 8.S-2b: Statistical Power to Test for Sufficie ncy of Immun e Response 
Give n a Range of True Booster Serorespo nse Rates for 
Evaluable Sample Size of 270 s ubjects in the Me nactra -1\lle n veo 
gro u p 
 
 Se.-0!}11e  T111e Seroresponse Rate Power  
 A >0.99  0.99 
 C 0.93 0.99 
 w 0.93 0.99 
y  0.91 0.99 
 Total Power   0.96 
Calculations have been done with nQuety Advisor (Version 7. 0). 
 
Overall  statistical  power to show  sufficiency  of immune response  to a booster dose of 
MenACWY -CRM  for each serotype in both the Menveo-Menveo and the Menactra - 
Menv
eo group will be at least 92%.  
 
When taking a 10% dropout rate into account, N=300 previously vaccinated subjects with 
Menveo and N=300 previously vaccinated subjects with Menactra have to be enrolled in 
the study.  
 
A total of 100 meningococcal vaccine- naive subjects are planned to be enrolled in the 
study for co mparisonof immune responses after a sing le dose in unprimed subjects with 
the booste r response in primed subjects. The sample size of 100 naive subjects is based on  
 
PR0-01 TEMP 06 / Atlas No . 293620  
VersionNo.4 / VersionDate: Jan\ 131)'29 , 2015  
00 
Protocol V59_77 
Page 74of86  GSK  
24JUN 16Final  Protocol  Versioo  1 Confidentia l 
::, z u 
8  
  
previous  MenACWY studies  Pxamining  the response  to a booster  and to ensure a 
rniuirnnm  sample  sizeof  sosubjects in each  blood draw schedule  for adequate  
compansons . 
 
8.6 Interim Anal ysis 
No interim analysis of data from this study is planned.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PR0- 01 TEMP 06 / Atlas No.293620  
VersionNo.4 / Vers ion Date: Jan\131)'29, 2015 
00 
Protocol V59_77 
Page 75of86  GSK  
24JUN 16Final  Protocol  Versioo  1 Confidentia l 
PR0--01 TEMP  06 / Atlas  No.293620  
VersionNo.4  / Version Date:  Jan\131)'29,  2015   
  
9. SOUR CE DOCUMENT ATION, STUDY MONITORING  AND A UDITING  
In order to ensure consistency across sites, study monitoring and auditing willbe 
standardized and performed in accordance with the Sponsor's or delegated contract 
research organization ' s (CRO) standard operating procedures and applicable regulatory 
requirements (e.g., FDA, EMA, and ICH guidelines).  
Prior to enrolment of the first s tudy subject, GSK or delegate willtrain invest igators 
and/or their study staff on the study protoco allapplicable studyprocedures, 
documentation  practices and all electronic  systems . CRFs  supplied  by the Sponsor  must 
be comp leted for each randomized sub ject (see section 8.3.1, All Enrolled Set for 
definition  of enrolled  subject).  Documentation  of screened but not enrolled subjects  must 
be maintained at the site and made available for review by the site monitor . Data and 
documents  willbechecked by the Sponsor and/or  monitor . 
9.1 Source Documenta toi n 
 
Prior to the start of the study , the site staff participating in the study conduct will be 
instructed  on what  documents  willberequired  for review  as source documents . The kinds 
of documents that willserve as source documents willbe agreed between Sponsor or 
delegate and investigator and designees and specified in the SDAF prior to subjec t 
enrolment.  
 
In addition , source documentation must include all of the following: subject identification 
(on each page) , eligibility and participation, proper informed consent procedures, dates of 
visits , adherence to protocol procedures , adequate reporting and follow -up of adverse 
events ,: documentation of prior /concomitant medication/ vaccines , study vaccine 
receipt/dispensing/return records , study vaccine administration information, any data 
collected by a telephone conversation with the subject and/or parent(s)/legal guardian(s) 
and date of complet ion and reason.  
 
The subjec t and/or parent(s)/legal guardian(s) must also allow access to the subjec t's 
medical records . Each sub ject and/or the parent(s)/legal guardian(s) must be informed of 
this prior to the start of the study and consent for access to medical records may be 
requir ed in accordance with local regulations . 
All safetydata reported by subjects  must  be written  down in source documents  prior  to 
entry  of the data into CRFs.  If there  are multiple  sources of information  (e.g., Subject 
Diary , verbal  report  of the subject,  telephone contact details , medical chart)  supporting 
the diagnosis of an adverse event , thesesources must be identified in the source 
documents , discrepancies between sources clarified, the ultimate diagnosis must be 
justified  and written  in the source  documents , and this diagnosis  must be captured  in the 
Protocol V59_77 GSK  Confidentia l 
PR0-01 TEMP  06 / Atlas  No.293620  
VersionNo.4 / Vers ion Date: Jan\131)'29, 2015   
 24JUN 16Final  Protocol  Versioo 1 Page  76of86  
 
 
Adverse Event CRF (AE CRF) . The AE CRF must also capture which source(s) of 
infonnation were  used to detennine the adverse event (e.g., subject  recall , medical  chart, 
Subject  Diary) . 
9.2 Study Monitoring, Auditin g and Sow·ce Data Verification 
Prior to enrolment of the first study subject, GSK or its designee (e.g., a CRO) will 
develop a Clinical Monitoring Plan to specify  how centralized and/or on- site monitoring , 
including clinical specimens reconciliation, will be performed for the study. Study 
progress will be monitored byGSK or its designee as frequently as necessary to ensure:  
• that the rights and well-beingof human  subjects are protected,  
• the reported  study data are  accurate , complete , and verifiable  from  the source 
documents and 
• the conduct of the study is in compliance with the cUITent  approved 
protocol/am ednment(s ), GCP and applicabl e regulatory  requirements. 
Contact  details  for the GSK teamor its designee involved in study monitoring w ill be 
provided to the investigator . Study data recorded  on CRFs will be verified  by checking 
the CRFentries against source documents in order to ensure data completeness and 
accuracy  as required  by study protocol . . 
Data verification may also be performed through a centralized review of data (e. g., 
checking for outliers  or other anomalies) . Additional documents such as the investigator 
site file, pharmacy records , and infonned consent documentation must also be availab le 
for review  if requested. Arrangements  for monitoring visits  will be made  in advance  in 
accordanc e with the monitorin g plan, excep t in case of emergency . 
The investigator and/or site s taff must  make  source documents of subjects enrolled  in this 
study  available  for inspection  by GSK or its representative at the time of each  monitoring 
visit and Sponsor  audits , when  applicable. These documents  must  also be available  for 
inspection, verification and copying, as required by regulation, sbyofficials of the 
regulatory health authorities (e.g., FDA, EMA and others) and/or ECs/IRBs . The 
investigator and study  site staff must  comp ly with applicable  privacy, data protection  and 
medical  confidentialitylaws  for use and disclosure of infonnation related  to the study and 
enrolled  subjects.  
Protocol V59_77 GSK  Confidentia l 
PR0-01 TEMP  06 / Atlas  No.293620  
VersionNo.4 / Vers ion Date: Jan\131)'29, 2015   
 24JUN 16Final Protocol Versioo 1 
 
10. DATA MANAGEME1''T  
10.1 Data Enh·y and Man agement  Page n of86  
 
In this study , all clinical data (including , but not limited to , AEISAEs , concomitant 
medications , medical history, and physical  assessments), safety  data, and immllllogenicity 
data will be entered onto case report fonns  (CRFs)  in a timely  fashion by the investigator 
and/or the investigator 's dedicated site staff. Data entered onto CRFs are stored on a 
secure website. The data collected on this secure website are assimilated into an 
electronic data capture  (EDC)  system,  which  is compliant with Title  21 Part 11 policies  of 
the Code of Federal Regulations (FDA 1997). The data system includes password 
protection  and internal  quality  checks. The EDC  system  will be designed and validated  by 
the Sponsor prior to activation for data entry by sites. The investigator or designated 
delegate nrust review data entered and e lectronicallysign the CRFs to verify their 
accuracy.  
 
Access to the EDC system for data entryor review will require training and  distinct 
individual  access code assignments  to those site staff members who willbe entering  study 
data and those  involved  in study  oversight  who may review  study  data. Data  are collected 
within  the EDC  system,  to which  the Sponsor  and site monitors  have  exclusively  "read 
only" access.  
 
10.2 Data Cla1ifi cati on 
 
As part of the conduct  of the trial, the Sponsor may have quest ions about  the data entered 
by the site, referred  to as queries . The monitors  and the Sponsor are the only parties  that 
can generate a query . All corrections and clarifications will be entered into the EDC 
system  and will be identified  by the person entering the information,  tlJe reason for the 
change, as well as the time of tlJe changes made. If changes are made to a previously  and 
electronically signed  CRF , the investigator  must  confirm  and endorse  the changes . 
 
10.3 Data Protectio n 
 
GSK  respects  the subjects ' rights  to privacy and willensure the confidentiality  of their 
medical information  in accordance  with all applicablelaws  and regulations.  
PR0-01 TEMP  06 / Atlas  No.293620  
VersionNo.4 / Vers ion Date: Jan\131)'29, 2015  Protocol V59_77 
Page 78of86  GSK  
24JUN 16Final  Protocol  Versioo  1 Confidential   
  
11. RECORD  RETEN TION  
Following closure of the study, the investigator must maintain all site study records 
(except  for those required by local regulations to be maintained  elsewhere) in a safe and 
secure location . The records nrust be easily accessible , when needed (e.g. audit or 
inspection, )and must be available for review in conjunction with assessment of the 
facility , supporting systems , and staff. Where permitted by applicable laws/regulations or 
institutional policy , some  or all of these records  can be maintained  in a validated  format 
other than hard copy ( e.g. microfiche, scanned, electronic); howeve ,rcaution needs to be 
exercised  before  such action  is taken . The investigator  nrust ensure  that all reproductions 
are legible and are a true and accurate copy of the original and meet accessibility and 
retrieval standards , including re- generatinga hard copy, if required . Furthermore , the 
investigator must ensure  that an acceptable  back-up of the reproductions exists and that 
there  is an acceptab le quality  control procedure  in place for making these  reproduction. s 
GSK will inform theinvestigato /rinstitutionof  the time period  fur retaining  these records 
to comply  with all applicable regulatory requirements. Thi,, minimmn  retention  time will 
meet the strictest  standard  applicable  to a particular site, as dictated  by ICH GCP, any 
institutional  requirements , applicable  laws or regulations , or GSK  standards /procedures , 
otherwise, the minimum retention  period  will default to 25 years  after comp letion  of the 
study report . 
The investigator /institutionnrust notify  GSK  of any changes  in the archival  arrangements, 
including, but not limited  to archival  at an off-site facility , transfer  of ownership of the 
records  in the event  the investigator leavesthe  site. 
 
The principles for the storage of laboratory samples are provided below: 
Collected  samples will be stored  for a maximum of20 years (countingfrom when  the last 
subject  performed  the last study visit), unless local  rules, regulations  or guidelines  require 
different  timeframes  or different procedures , which  will then be in line with the subject 
consent.  These extra  requirements  need  to be communicated  formally  to and discussed 
and agreed  with GSK.  
PR0-01 TEMP  06 / Atlas  No.293620  
VersionNo.4 / Vers ion Date: Jan\131)'29, 2015  Protocol V59_77 
Page 79of86  GSK  
24JUN 16Final  Protocol  Versioo  1 Confidential   
  
12. USE OF Jll,'F O RMATIO N AND P UBLICATION  
 
GSK  assures  that the key design elements of this protocol  will be posted  in a publicly 
accessible database such as clinicaltrials .gov, and in compliance with cUITent  re gulations . 
 
GSK  also assures that key results  of this clinical  study  will be posted  in a publicly 
accessible database within  the required time-frame from  theend  of study  as defined in 
section  3.9, End of Study.  
In accordance withstandard  editorial , ethical  practices and cUITent  guidelines  of Good 
Publication  Practice ( Graf 2009) , GSK  will generally support  publication  ofmulticenter 
studies  only in their  entirety  and not as individual  center data. In this case, a coordinating 
investigator  will be designated by mutual  agreement  prior  to the start of the study . The 
coordinating investigator  will also sign the clinical study report  on behalf of the principal 
investigators  (CPMP/EWP /2747 /00). Authorship  will be determined by mutual agreement 
and in line with International Committee of Medical Journal Editors authorship 
requirements . Any fonnal publication of the studyin which contribution ofGSK 
personnel exceeded that of conventional monitoring will be considered as a joint 
publication  by the investigator  and the appropriate  GSK  personnel.  
 
GSK must be notified  of any intent to publish  data collected  from  the study  and prior 
approval  from  GSK must be obtained prior  to submission  for publication . 
PR0-01 TEMP  06 / Atlas  No.293620  
VersionNo.4 / Vers ion Date: Jan\131)'29, 2015  Protocol V59_77 
Page 80of86  GSK  
24JUN 16Final  Protocol  Versioo  1 Confidential   
  
13. ETID CAL C ONSIDERATIO NS 
 
13.1 Regulatory and Ethical Compliance 
The study will beconducted in compliance  with the protocol, GCP  and applicable 
regulatory  requirement(s) . 
This clinical study was designed and shall be implemented and reported in accordance 
withthe ICH Harmonized Tripartite Guidelines for Good Clinical Practice, with 
applicable local regulations including European Directive 2001 /20/EC , US Code of 
Federal Regulations Title 21, and Japanese Ministry ofHealth, Labor , and Welfare , GSK 
codes on protection of human rights , and with the ethical principles laid down in the 
Declaration of Helsinki ( European Council 2001, US Code of Federal Regulations , ICH 
1997) . 
 
13.2 Informed Conse nt Proced  ures 
 
Eligible subjects may be included in the study only after providing written informed 
consent or assent , as described in section 5.1.1, Informed Consent/ Assent.  Before  the start 
of the study , the invest igator will have the informed consent and any other materials that 
will be provided to the subjects reviewed and approved bythe IRB/EC . This review and 
approval will be documented and stored with other studydocuments. The investigator or 
designee must fully inform thesubjec t or legal guardian of all pertinent aspects of the 
study . A copy  of the written  informed  consent will be given to the subject or the designee . 
The subject/designee must  be allowed  ample  time to ask about thedetails  of the study and 
to make a decision as to whether or not to participate in the study. The subject and/or 
legal  guardian(s)  must sign the consent form  indicating  their agreement  to participate  in 
the studybefore anystudy- related procedures are conducted . The informed consent 
process may be conducted up to 5 days prior to vaccination on Day 1 . If the subject  
and/or legal  guardian(s) is unable to read and write , a witness  must be present  during the 
informed consent discussion and at the time of informed  consent signature . 
Prior to the start of the study, GSK will provide to investigators a proposed informed 
consent form  that complies  with the ICH GCP  guideline and regulatory requirements and 
is considered appropriate for this study . Any changes to the proposed consent form 
suggested by the investigator nrust be agreed to byGSK  before  submission to the IRB/EC 
and a copy of the approved version  must be provided to the GSK monitor after IRB/EC 
approval  
Women  of childbearing potential should be informed  that taking the study medication 
may involve unknown risks to the fetus  if pregnancy were  to occur during the study and 
agree  that in order to participate  in the study they must adhere  to the contraception  
PR0-01 TEMP  06 / Atlas  No.293620  
VersionNo.4 / Vers ion Date: Jan\131)'29, 2015  Protocol V59_77 
Page 81of86  GSK  
24JUN 16Final  Protocol  Versioo  1 Confidential   
  
requirements  indicated in the protocol  for the duration  of the study. In case of doubts  on 
the ability  of a subject to adhere to these requirements , that subject  should not be allowed 
in the  study  
 
Before the start of the study, the investigator will have the informed assent, the informed 
consent, and any other materials that will be provided to the subject and/or parent(s)/legal 
guardian(s) reviewed and approved by the IRB/EC. This review and approval will be 
documented and store d with other study documents. The investigator or designee must 
fully inform the subject and/or parent(s)/legalguardian(s) of all pertinent aspects of the 
study. A copy of the written informed consent and informed assent will be given to the 
subject and/or  parent(s)/legal guardian(s).  
In addition , the investigator  or designee  should explain pertinent  aspects of the study  in an 
age appropriate manner to pediatric subjects who are eligible for informed assent in 
accordance with local policies. The subject and parent(s)/legal guardian(s) must be 
allowed ample time to ask about the details of the study and to make a decision as to 
whether  or not to participate in the study. The subject and parent(s)/legal  guardian(s) must 
sign the consent/assent forms  indicating  their  agreement to participate  in the study  before 
any study- related procedures are conducted. If the subject and/or parent(s)/legal 
guardian(s)  are unable  to read and write , a witness  must  be present  during the informed 
consent/assent discussion  and at the time of informed  consent/assentsignature.  
13.3 Respo nsibilities of the Investigator a nd IRB/EC 
 
The protocol  and the proposed  informed  consent  form  must  be reviewed  and approved by 
a properly  constituted  IRB/EC before  study start.  Properly  constituted  IRB/EC  is defined 
in ICH Guideline  for Good  Clinical  Practice E6 (RI), Section  3 (ICH 1997 ). A signed and 
dated statement that the protocol and informed consent have been approved by the 
IRB/EC  must be given to GSK before  study  initiation.  Prior  to study start and at any time 
the protocol is amended during studyconduct , the investigator is required to sign a 
protocol  signature  page  confirming  his/her  agreement  to conduct the study  in accordance 
withthese documents  and all of the instructions  and procedures  found in this protocol  and 
to give access to all relevant data and records to GSK monitors , auditors , GSK Clinical 
Quality  Assurance  representatives , designated agents  of GSK,  IRBs/ECs , and regulatory 
authorities as required. If an inspection of the clinical site is requested by a regulatory 
authority, the investigator  must inform  GSK immediately that this request  has been made . 
The investigator also responsible for the following:  
• Maintaining  a list of appropriately  qualified  persons  to whom  the investigator  has 
delegated significant study- related  duties . 
PR0-01 TEMP  06 / Atlas  No.293620  
VersionNo.4 / Vers ion Date: Jan\131)'29, 2015  Protocol V59_77 
Page 82of86  GSK  
24JUN 16Final  Protocol  Versioo  1 Confidential   
  
• Demonstrating the capability  of recruiting  the required  number of suitable  subjects 
within  the recruitment  period.  
• Demonstrating sufficient  time and staffing  to properly conduct and complete  the study 
within  the agreed study period.  
• Ensuring that all persons  assisting with the study are adequately  informed about the 
protoco  the investigationa lproduct( )s, and their study- related  duties  and functions.  
• Ensuring that appropriately trained  health  care professionals  are responsible for all 
study- related  medical  decisions and for ensuring appropriate  medical  care of subjects  
experiencing  any adverse  event related  to the study.  
• If permission  to do so is given  by the subjec t and/o r parent( s)/lega lguardian(s) , 
ensuring that the subject' s primary healthcare  provider is informed of the subject' s 
participation  in the study.  
The investigator should not implement any deviation from, or changes  of the protocol 
without agreement  by the Sponsor and prior review and documented approval/favourable 
opinion from  theIRB/IEC of an amendment,  except  where  necessary  to eliminate  an 
immediate  hazard(s) to study  subjects, or when  thechange(s)  involves only logistical  or 
administrative aspects of the study (e.g., change in monitor(s ,)change of telephone 
nwnber(s)) . In addition, the investigato ,ror person  designated  by the investigato ,rshould 
document and explain  any deviation  from  the approved protocol.  
 
The investigator may implement a deviation from, or a change of, the protocol to 
eliminate an immediate hazard(s) to study subjects without prior IRB/IEC 
approval/favourable opinion . As soon as possible , the implemented deviation or change , 
the reasons for i t, and, if appropriate, the proposed protocol amendment(s) should be 
submitted:  
(a) to theIRB/IEC for review and approval/favourable opinion,  
(b) to the Sponsor for agreement  and, if required,  
(c) to the regulatory authority(ies).  
13.4 Protocol Ame ndments 
An amendment  is a written  description  of change(s) to or formal  clarification of a study 
protocolwhich may impact on the conduct of the clinical study, potential benefit of the 
clinical study, or may affect subject safety, including changes of study objectives , study 
design, subject population, sample sizes , studyprocedures, or significant administrative 
aspects. An administrative change of a study protocol is a minor correction or 
clarification  that has no significant  impact  on the waythe  clinical  study is to be conducted  
PR0-01 TEMP  06 / Atlas  No.293620  
VersionNo.4 / Vers ion Date: Jan\131)'29, 2015  Protocol V59_77 
Page 83of86  GSK  
24JUN 16Final  Protocol  Versioo  1 Confidential   
  
and no effect on subject safety  (e.g., change of telephone number(s) , logistical changes). 
Protocol amendments  nrust be approved  by GSK,  health  authorities  where  required,  and 
the IRB/EC.  In cases when the amendment is required  in order  to protect  the subject 
safety , the amendment can be implemented  prior  to IRB/EC  approval.  Notwithstanding , 
the need  for formal approval  of a protocol  amendmen ,tthe investigator is expected  to take 
any inunediate  action  required  for the safety  of anysubject  included  in this study , evenif 
this action  represents  a deviation from the protocol. In such cases, GSK should be notified 
of this ac tion, the IRB/EC at the study site, and, if required bylocal regulations, the 
relevant  health  authority)  should be informed  within  10 working days.  
Protoco l V59_77 
Page 84of86  GSK  
24 JUN 16 Final Protoco l Version 1 Confidential  
PR0- 01 TEMP  06 / Atlas No. 293620  
VersionNo.4  / VersionDate:  January29 , 2015  
  
14. REFERENCE LIST 
Code  of Federal  Regulations  (1997):  Food and Drug  Administration,  U.S. Depar1ment  of 
Health and Human Services: Title 21, Part 11: Electronic Records Electronic Signatures . 
Federal Register 62: 13464  
European Medicines Agency (2005): EMEA/CHMP /313666/2 005 Guideline on the 
exposure to medicinal products during pregnancy: need for post -authorisation data, 
London, 14 November 2005  
European Parliament (1995):  Directive  95/46/EC  of the European  Parliament and of the 
Council  of 4 April  2001.  Official  Journal  of the European  Communities . L 281/31-39 
European Parliament (2001):  Directive  2001/ 20/EC  of the European  Parliament and of 
the Council  of 4 April  2001.  Official Journal  of the European Communities . L 121/34-44 
Graf C, Battisti WP , Bridges D (2009) . Good publication practice for communicating 
company Sponsored medical research: the GPP2 guidelines . BMJ ; 339: b4330  
ICH (1997)  ICH Harmonised Tripartite  ICH Guideline  for Good  Clinical Practices E6 
(RI). Federal Register , 62 (90):  25691 -25709  
 
ICH (1998)  ICH Harmonised Tripartite  ICH Guideline for Statistical  Principles  for 
Clinical  Trials E9. Federal Register , 63 (179): 49583  
Levine  RJ. (1988) Ethics  and Regulations  of Clinical  Research . New  Haven : Yale 
University  Press . 
Metropolitan Atlanta Congenital Defects Program (MACDP) 
http://www.cdc.gov /ncbddd/birthdefects/documents/macdpcode0807.pdf  
 
U.S. Depar1ment of Health and Human Services , Food and Drug Administration, CBER 
(2009 ): Guidance for Industry Patient- Reported Outcome Measures: Use in Medical 
Product Development to Support Labeling Claims  
59th World Medical Association General Assembly (October 2008) Declaration of 
Helsinki - Ethic al Principles for Medical Research Involving Human Subjects . Seoul , 
Korea  
Protoco l V59_77 
Page 85of86  GSK  
24 JUN 16 Final Protoco l Version 1 Confidential  
PR0- 01 TEMP  06 / Atlas No. 293620  
VersionNo.4  / VersionDate:  January29 , 2015  
  
Appe ndix 1: In vestig a tor Agree ment 
I agree:  
 
• To conduct the study in compliance with this protocol, any future protocol 
amendments  or protocol  administrativechanges , with the terms of the clinical  trial 
agreement and with any other study conduct procedures and/or study conduct 
documents  provided  by GlaxoSmithKline  (GSK)  Biologicals . 
• To assume  responsibilityfor the proper  conduct  of the study  at this site. 
• That I am aware of, and willcomply with,  'Good  Clinical  Practice ' (GCP) and all 
applicable regulatory requirements . 
• To ensure  that all persons  assisting  me with the study are adequately  informed about 
the GSK Biologicals ' study  vaccine(s) /product(s)  and other study- related  duties  and 
functions  as described in the protocol . 
• To acquire the reference ranges for laboratory tests perfonned locally and, if required 
by local regulations , obtain the laboratory's cUITent certification or Quality  Assurance 
procedure  manual . 
• To ensure  that no clinical  samples (including serum samples)  are retained onsite  or 
elsewhere  without  the approval  of GSK Biologicals  and the express  written  informed 
consent of the subject  and/or  the subject's legally  acceptable representative . 
• To perform no other biological assays on the clinical samples except those described 
in the protocol or its  amendment(s) . 
• To co- operate  with a representative of GSK  Biologicals  in the monitoring  process of 
the study  and in resolution  of queries  about  the data. 
• That I have  been informed that certain regulatory authorities  require  the sponsor  to 
obtain and supply, as necessary , details about  the investigator ' s ownership  interest  in 
the sponsor or the invest igationalvaccine(s)/ product(s), and more generally about 
his/her financial tieswith the sponsor. GSK Biologicals will use and disclose the 
information  solely  for the purpose  of complying with regulatory  requirements.  
 
Hence I:  
 
• Agree to supply GSK Biologicals with any necessary information regarding 
ownership interest and financial ties (including those of my spouse and dependent 
children).  
• Agree  to promptly update  this information  if any relevant changes  occur during  the 
course  of the study  and for one year following  completion of the study.  
Protoco l V59_77 
Page 86of86  GSK  
24 JUN 16 Final Protoco l Version 1 Confidential  
PR0- 01 TEMP  06 / Atlas No. 293620  
VersionNo.4  / VersionDate:  January29 , 2015  
  
• Agree  that GSK Biologicals  may disclo se any infonnation it has about such 
ownership interests  and financial  ties to regulatory authoritie .s 
• Agree  to provide GSK Biologicals  with an updated Curriculum  Vitae  and other 
documents required  by regulatory agencies  for this study . 
 
eTrack  study number and 
Abbreviated  Title  
IND number: 
Date of protoco :l 
Detailed Title: 
 
 
 
 
 
Investigator name:  
 
 
Signature : 
 
 
Date:  205352 (MENACWY CONJ -038 (V59 _77)) 
 
 
IND11278  
 
 
A Phase 3b, Controlled, Open -Label , Multi -Center 
Study to Evalua te Safety and Immunogenicity of a 
Single Dose of GlaxoSmithKline's Meningococcal 
ACWY Conjugate Vaccine (Menveo), Administered to 
Heal thy Individuals 15 through 55 years of age , 
approximately 4-6 years after primary ACWY 
vacc ination . 
 
 
 
 
 
 
 
 
 
 
 ---- I Novarti s 
 
 
 
PPo• -    - -' Document A !J!ro val Ce rtificate / 
PPD /    
1.,;..  _  
 
 
 
Theindivi:lual s listed have appl'()ved this docume nt for ii!Jplementatio n using an electronic signature in the 
Atlas EDMS . tFPO  
I S 
U serName: pp-o• -   -   - .. PP D 
Ti tl e: C l u ster  Phys ician -Meningi  t is an d Sepsis Franch ise 
Date: Friday, 12 August 20 16 , 12 :44 GMT  
Meani ng: As an approver, I agree with the content and format of this document  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ai 
 
::, z 
u 
8 

Protocol V59_77 
Page 1of86  GSK 
03FEB16  Confidentia l 
Regulatory Review Protoco l Version 2 
PR0--01 TEMP  06 / Atlas  No. 293620  
VersionNo.4  /  VersionDate: January 29,2015   
  
 
 
CLINI CAL STUD Y PROTOCOL VS9 77 Versio n 2 
 
 
 
A Phase 3b , Controlled, Open -Label , Multi-Center Study to Evaluate Safety and 
Inumnogenicit y of a Single  Dose of GlaxoSm iht Kline's Meningococca l ACWY 
Conjugate Vaccine  (Menveo), Administered  to Health y Individuals 15 through 55 years 
of age, approximate ly 4-6 years  after primary ACWY  vaccinat ion. 
 
 
Safety  and Immunogenicity Study of a Single Dose of Menveo, Administered  to Subjects 
15 through 55 years  of age, approximately  4-6 years  after primary ACWY vaccina tion 
 
 
 
 
Property o f GlaxoSmithKline Vaccines (hereafter referred to as GSK) 
Confidential 
May not be used, divul ged, published or otherw ise disclosed wit hout  \VIi tt .en 
co n se nt  of GSK  
Protocol V59_77 
Page 2of86  GSK 
03FEB16  Confidentia l 
Regulatory Review Protoco l Version 2 
PR0-01 TEMP  06 / Atlas  No. 293620  
VersionNo.4  / VersionDate: January 29,2015   
  
TABLE OF CONTENTS 
TABLE  OF CONTENTS  ..................................................................................................... 2 
PROTOCOL SYNOPS IS VS9 77 ................................................................................... 7  
LIST OF ABBREVIATIONS  ............................................................................................. 20 
1. BACKGROUND AND RATIONALE  ..................................................................... 21  
1.1 Background .......................................................................................................... 21 
1.2 Rationale  .............................................................................................................. 22 
2. OBJECTIVES  ........................................................................................................... 23 
2.1 Primary  Objective(s)  ........................................................................................... 23 
2.2 Secondary Objective(s)  ........................................................................................ 23 
2.3 Exploratory  Objective(s)  ...................................................................................... 24 
3. STUDYDESIGN ................................................................................................. 2S 
3.1 OverviewofStudyDesign. ..............................................................................        2S 
3.2 StudyPeriod ..................................................................................................... 27  
3.3 Blinding Procedures  ............................................................................................. 27 
3.4 Data  Collection  ................................................................................................ 28  
3.4.1 Data Collected  from Subjects  .................................................................... 28  
3.4.2 Tools Used  for Data  Collection  ................................................................. 28  
3.S Collection of Clinical Specimens ......................................................................... 29 
3.6 Stopping/Pausing  Guidelines  ........................................................................... 30  
3.7 Data  Monitoring Committee  ............................................................................ 30  
3.8 Premature Withdrawal  from Study  .................................................................. 30  
3.9 EndofStudy ............................................................................................... 33  
4. SELECTION  OFSTUDY  POPULATION  .......................................................... 34  
4.1 Inclusion Criteria  ............................................................................................. 34  
4.2 Exclusion Criteria  ............................................................................................ 3S 
4.3 Criteria  for Delay  of Vaccination  and/or Blood Sampling  ............................... 36  
S. STUDYPROCEDURES  ...................................................................................... 37  
S.1 Pre-vaccination  Clinic  Visit(s)  ......................................................................... 37  
Protocol V59_77 
Page 3of86  GSK 
03FEB16  Confidentia l 
Regulatory Review Protoco l Version 2 
PR0-01 TEMP  06 / Atlas  No. 293620  
VersionNo.4  / VersionDate: January 29,2015   
 5.1.1 Informed Consent/Assent ......................................................................... 37  
5.1.2 Screening  ....................................................................................................... 38 
5.1.3 Enrolment ................................................................................................. 39  
5.1.4 Randomization .............................................................................................. 40 
5.2 Vaccination  Clinic  Visit.  ................................................................................. 41  
5.2.1 Post-vaccinationProcedures  ........................................................................... 41  
5.2.2 Post-vaccination Reminders  ......................................................................... 42 
5.3 Post-vaccination Visit(s) ........................................................................................ 43  
5.3.1 Follow -up Clinic  Visit(s)  ........................................................................... 43  
5.3.2 Safety Follow-up Calls  .................................................................................. 44 
5.4 Unscheduled Visits .............................................................................................. 44 
5.5 Study Terminati on Visit. ........................................................................................ 44  
5.5.1 Early  Termination  Visit.  ........................................................................... 45  
6. TREATMENT  OF SUBJECTS ................................................................................ 47 
6.1 StudyVaccine(s)  ..................................................................................................... 47  
6.2 Non-Study Vaccines  ......................................................................................... 48  
6.3 Vaccine Preparationand Administration  .......................................................... 48  
6.4 Vaccine Administration  Error or Overdose ofVaccine .................................... 50  
6.5 Prior and Concomitant Medications  and Vaccines  .......................................... 50  
6.6 Vaccine Supply , Labeling, Storage and Tracking  ................................................. 51  
7. ASSESSMENTS  .................................................................................................. 53  
7.1 SafetyAssessment ............................................................................................ 53  
7.1.1 Solicited  Adverse Events  .......................................................................... 53  
7.1.2 Unsolic ited Adverse Events  ....................................................................... 55  
7.1.3 Evaluation of Adverse Events  ................................................................... 55  
7.1.4 Serious Adverse Events ............................................................................. 57  
7.1.4.1  AdverseEvents of Special  Interest  ...................................................... 58  
7.1.5 Methods for Recording Adverse Events  and Serious Adverse Events  ....... 59  
7.1.5.1  Post-Study Events  ............................................................................... 59  
Protocol V59_77 
Page 4of86  GSK 
03FEB16  Confidentia l 
Regulatory Review Protoco l Version 2 
PR0-01 TEMP  06 / Atlas  No. 293620  
VersionNo.4  / VersionDate: January 29,2015   
 7.1.6 Pregnancies  ................................................................................................... 60 
7.1.7 Safety Laboratory Measurements  .............................................................. 60 
7.2 Efficacy  Assessment  ............................................................................................. 60 
7.3 ImmunogenicityAssessment  ................................................................................ 60 
8. STATISTICAL  CONSID ERATIONS ..................................................................... 62 
8.1 Endpoints  .............................................................................................................. 62 
8.1.1 Primary  Endpoint(s) ....................................................................................... 62 
8.1.1.1  Primary  SafetyEndpoint(s)  ................................................................ 62 
8.1.1.2  Primary  Efficacy  Endpoint(s)  ................................................................. 62 
8.1.1.3  Primary  ImmunogenicityEndpoint(s)  ..................................................... 62 
8.1.2 SecondaryEndpoint(s)  .............................................................................. 62 
8.1.2.1  Secondary SafetyEndpoint(s)  ............................................................ 62 
Adverse  events  will be coded using  MedDRA preferred teims  as applicable  .... 63 
8.1.2.2  Secondary Efficacy  Endpoint(s)  ............................................................. 63 
8.1.2.3  Secondary ImmunogenicityEndpoint(s)  ............................................ 63 
8.1.3 ExploratoryEndpoint(s) ............................................................................ 63 
8.1.3.1  Exploratory  Safety  Endpoint(s)  ............................................................... 63 
8.1.3.2  Exploratory Efficacy  Endpoint(s)  ........................................................... 63 
8.1.3.3  Exploratory ImmunogenicityEndpoint(s)  ............................................... 63 
8.2 Success  Criteria  ................................................................................................ ..... 64 
8.2.1 Success Criteria for  Primary  Objective(s)  ......................................................64  
8.2.1.1  Success  Criteria  for Primary  Safety  Objective(s)  ....................................64  
8.2.1.2  Success Criteria for Primary  Efficacy  Objective(s)  ................................ 64 
8.2.1.3  Success Criteria for Primary ImmunogenicityOb jective(s) ............... 64 
8.2.1.3.l Rationale for Combining the Menveo- Menveo and Menactra- Menveo  
groups ............................................................................................. 64 
8.2.2 Success Criteria  for Secondary  Objective(s)  ............................................. 65 
8.2.2.1  Success Criteria  for Secondary  Safety  Objective(s)  ........................... 65 
8.2.2.2  Success Criteria for Secondary  Efficacy Objective(s)  ........................ 65 
Protocol V59_77 
Page 5of86  GSK 
03FEB16  Confidentia l 
Regulatory Review Protoco l Version 2 
PR0-01 TEMP  06 / Atlas  No. 293620  
VersionNo.4  / VersionDate: January 29,2015   
 8.2.2.3  Success  Criteria for Secondary Imm unogenicityObject ive(s) ...............  66 
8.3 Analysis  Sets .................................................................................................... 66  
8.3.1 All Enro lled Set .................................................................................... 66  
8.3.2 All Exposed Set ......................................................................................... 66  
8.3.3 Safety  Set. ........................................................................................... 66  
8.3.4 Full Analysis Set (FAS) Efficacy/Immunogenic ity Set. .............................. 66  
8.3.5 Per Protoco l (PP) Set Efficacy/Immunogenicity Set ................................... 68  
8.3.6 Other  Analysis  Sets ................................................................................... 68  
8.3.7 Subgroups ...................................................................................................... 68 
8.3.8 Protocol Deviations ....................................................................................... 68 
8.4 Statistical Analys is Plan ................................................................................... 68  
8.4.1 Analysis of Demographic  and BaselineCharacteristics  ............................ 68  
8.4.2 Analysis of Primary  Objective(s)  .............................................................. 69  
8.4.2.1  Analys is of Primary  SafetyObjective(s)  ............................................. 69  
8.4.2.2  Analys is of Primary  Efficacy Object ive(s)  ............................................... 69  
8.4.2.3  Analys is of Primary  Immunogenicity O bjecti ve(s) ............................. 69  
8.4.2.3.1  Statist ical Hypotheses ............................................................. 69  
8.4.2.3.2  Analysis  Sets ............................................................................... 69  
8.4.2.3.3  Statist ical Methods  .................................................................. 69  
8.4.3 Analysis of  Secondary Objective(s) ......................................................... 70  
8.4.3.1  Analys is of Secondary Safety Objective(s)  ................................................ 70  
8.4.3.1.1  Analysis of  Extent  ofExposure .................................................... 70  
8.4.3.1.2  Analysis  of Solicited Local , Systemic  and Other  Adverse Events  70 
8.4.3.1.3  Analysis of Unso licited Adverse Events  ...................................... 71  
8.4.3.1.4  Statisti cal Hypotheses  ................................................................. 72  
8.4.3.1.5  Analysis  Sets ............................................................................... 72  
8.4.3.1.6  Statisti cal Methods  ....................................................................... 72  
8.4.3.2  Analys is of Secondary Efficacy  Objective(s)  ..................................... 72  
8.4.3.3  Analysis of Secondary Immunogenicity Object ive(s) ........................ 72  
Protocol V59_77 
Page 6of86  GSK 
03FEB16  Confidentia l 
Regulatory Review Protoco l Version 2 
PR0-01 TEMP  06 / Atlas  No. 293620  
VersionNo.4  / VersionDate: January 29,2015   
 8.4.3.3.1  Statis itcal Hypotheses  .............................................................. 72  
8.4.3.3.2  Analysis  Sets ............................................................................... 72  
8.4.3.3.3  Statisti cal Methods  ....................................................................... 73  
8.4.4 Analysis of  Exploratory Object ives .............................................................. 75  
8.4.4.1  Analysis  of Exploratory Safety  Objective(s) ............................................. 75  
8.4.4.2  Analysis of Exploratory Efficacy  Objecti ve(s) ........................................ 75  
8.4.4.3  Analysis of Exploratory Immunogenicity Objective(s)  .......................... 75 
8.5 Sample  Size and Power  Considerations of Primary  Object ives ....................... 75  
8.6 Interim Analysis  ............................................................................................... 76  
9. SOURCE DOCUMENTATION, STUDY MONITORING  AND AUDITING  ........ 77 
9.1 Source Documentation .................................................................................... 77  
9.2 Study  Monitoring , Auditing  and Sourc e Data Verification   .................................. 78 
10. DATA  MANAGEMENT  .......................................................................................... 79 
IO. I Data Entry and Management  ................................................................................. 79 
10.2 Data  Clarification  ............................................................................................ 79  
10.3 Data  Protection  ................................................................................................ 79  
11. RECORD RETENTION ........................................................................................... 80 
12. USE OF INFORMATION AND PUBLICATION  ................................................... 81 
13. ETHICAL  CONSIDERATIONS  ............................................................................. 82 
13.I  Regulatory and Ethical  Compliance  ...................................................................... 82 
13.2 Infonned Consent Procedures .......................................................................... 82  
13.3 Responsibilitiesof the  Investigator and!RB/EC ............................................... 83  
13.4 Protocol Amendments .......................................................................................... 84 
14. REFERENCE  LIST  ...............................................................................................................  86 
Protocol V59_77 
Page 7of86  GSK 
03FEB16  Confidentia l 
Regulatory Review Protoco l Version 2 
PR0-01 TEMP  06 / Atlas  No. 293620  
VersionNo.4  / VersionDate: January 29,2015   
 PR OTO COL SYNOP SIS V59 77 
 
Name of Sponsor: 
GlaxoSmithKline 
Vaccines  Proto col numb er: 
 
V59 77 Gene1ic nam e of study vaccine(s): 
 
Meningococcal (groups A, C, W, and Y) 
oligosaccharide diphtheria CRM -197 
conjugate vaccine  
Titl e of Study: A Phase3b , Controlled, Open -Label,Multi -Center Study to Evaluate 
Safet y and Immunogenicity  of a Single  Dose  of GlaxoSmi ht Kline ' s Meningococcal 
ACWY Con jugate Vaccine (Menveo ,)Administered  to HealthyIndividuals 15 througll 
55 years  of age, approximate ly 4-6 years  after primary  ACWY vaccination . 
Study Pe1i od : Approximately  180 days 
(six months) . Clinical Pha se: 3b 
Background and Rati onale: 
 
Neisseria meningitidis is a leadingcause of bacterial meningitis and sepsis worldwide , 
capab le of causing outbreaks and epidemics  of invasive disease . Meningococcal disease 
is associated  with higll morbidity  and mortality  even  among patients  who receive  early 
antib iotictreatment.  Most  cases  of invasive disease worldwide are caused  byserogroups 
A, B, C, W and  Y. 
The quadrivalent meningococcal oligosaccharidediphtheria CRM -197 conjugate 
vaccine (MenACWY -CRM; Menveo, GSK Vaccines) is approved for active 
immunization of individuals from 2 months througll 55 years of age in the United 
States . As of February 2015 , more than 30,000of subjects have been exposed to 
MenACWY- CRM vaccine in completed clinical studies and more than 24million doses 
of the vaccine  have  been distributed  globally . 
The US Advisory Committee  on Immunization  Practices  (ACIP)  recommends  routine 
vaccination with a quadriva lentconjugated meningococcal vaccine for adolescents at 
11-12 years  of age with a booster dose administered 5 years  later. While  a substantia l 
body of data exists showing a robust immune  response and good antibody persistence  
after a singl e dose of MenACWY-CRM in adolescents , the response  to a booster  dose of 
MenACWY -CRM  in this agegroup  has only been  evaluated  in 2 clinical  studies  with 
limited  number  of subjects.  
A robust anamoestic  immune response to a booster doseofMenveo vaccine 
administered  at approximately  5 years  after previous vaccination  with the same  vaccine 
or a licensed  meningococcal oolysaccharide vaccine (Menomune®) was demonstrated in 
Protocol V59_77 
Page 8of86  GSK 
03FEB16  Confidentia l 
Regulatory Review Protoco l Version 2 
PR0-01 TEMP 06 / Atlas No. 293620  
VersionNo.4  / Version Date:  January  29, 2015  00 
" 
::, z u 
8  
  
Name of Spo nsor: 
 
GlaxoSmithKline 
Vaccines  Protoco l number:  
V59 77  Gene1i c name of s tudy vaccine(s): 
 
Meningococcal (groups A, C, W, and Y) 
oligosaccharide diphtheria CRM -197 
conjugate vaccine  
the phase 2 clinical study V59P6El . High titers of bactericidal antibodies against the 
vaccine serogroups were achieved at 7 and 30 days after booster dose in MenACWY - 
pri
med subjects. However , the number of subjects included in this studywas relatively 
small (N =l 0l , including 50 subjects who received a booster dose after the primary  
MenACWY -CRM vaccination).  
 
In the phase 3b clinical study V59Pl3 El , a booster dose of MenACWY- CRM was 
given 3 years after primary vaccination with either MenACWY -CRM or Menactra®(a 
meningococcal diphtheria toxoid- conjugated MenACWY vaccine , MenACWY- D) in 
adolescents . A booster dose was able to substantially increase antibody titers against all 
4 serogroups irrespective of the priming vaccine. Again, only a small number of  
subjects (N=160) received the MenACWY -CRM booster , (83 who received primary  
MenACWY -CRM and 77 who received MenACWY -D). 
 
In the light of the current ACIP recommendation for a booster dose of MenACWY - 
CRM ,
 there  exists  a need  to evaluate the response  to a MenACWY- CRM  booster  given 
at -5  years  after primary  vaccination  in meningococca -lvaccin eprimed  adolescent s. 
Generation of this data would also be of relevance in outbreak management and 
vaccination of travelers to endemic areas . 
 
The purpose/aim of this study is to assess the safety and ant ibodyresponse to 
vaccination with a booster  dose  of Menveo  given  4-6 years  after primary vaccination 
and the response  to a single  dose  given to vaccine -naive subjects , and to describe  the 
inlmune response over time after a single dose of Menveo , administered to subjects 
previous ly vaccinated with Menveo or Menactra or to vaccine -naive subjects. The 
inclusion of vaccine -naive subjects in a separate study arm is to enable comparison of 
the rapidity and magnitude of an aoarooestic  response to a booster dose (in primed 
individuals) or the primary response to a first dose (in naive individuals) of 
MenACWY -CRM . 
Study O bjectives : 
 
P1i ma ry Objective(s) : Immun ogenicity ob jective:  
 
L To demonstrate a sufficient inlmune response following a single dose of 
MenACWY -CRM  (Menveo)  vaccine,  !riven  to sub jects who previously  received  
Protocol V59_77 
Page 9of86  GSK 
03FEB16  Confidentia l 
Regulatory Review Protoco l Version 2 
PR0-01 TEMP 06 / Atlas No. 293620  
VersionNo.4  / Version Date:  January  29, 2015  00 
" 
::, z u 
8  
  
Name of Spo nsor:  
 
GlaxoSmithKline 
Vaccines  Protoco l number : 
V59 77  Gene1i c name of s tudy vaccine(s):  
 
Meningococcal (groups A, C, W, and Y) 
oligosaccharide diphtheria CRM -197 
conjugate vaccine  
Menveo or Menactra, as measured by the percentage of subjects with hSBA 
seroresponse against N. meningitidis serogroups  A, C, W and  Y at Day 29 after 
vaccination  
Criteria to demonstrate  immune  response  sufficiency:  The immune  response  will be 
considered  as sufficient  if the lower limit of the one-sided  97.5%  CI for percentage 
of subjects with hSBA  seroresponse  against  serogroups A, C, Wand  Y is greater 
than 80% (in pooled group of subjects who received primary vaccination with 
Menveo  or Menactra).  
Seco ndary O bjec tive(s) : 
Immun ogenicity objectives:  
1. To compare the immunogenicityofa s ingle dose ofMenACWY -CRM vaccine , 
between subjects who previously recei ved Menveo, subjects who previously 
received  Menactra  and vaccine -naive  individuals , as measured  by the percentage  of 
subjects with hSBA titer 8, with hSBA seroresponse, and hSBA GMTs against N. 
meningitidis serogroups  A, C, W and Y at Day 29 after  vaccination  
2. To compare the immune responses  following  a single  dose  ofMenACWY -CRM  
vaccine , between subjects who previously received Menveo , subjects who 
previous ly received Menactra and vaccine -naiv e individuals, as measured by the 
percentage  of subjects with hSBA titer ,::8 and hSBA GMTs  against N. meningitidis  
serogroups  A, C, Wand Y at Day I, Day 4 , Day 6, and Day 29 after vaccination  
3. To assess persistence of bacteric idal antibodies against serogroups A , C, Wand Y at 
approximate ly 4-6 years after the primary vaccination with Menveo and after the 
primary vaccination with Menactra in comparison with naturally -acquired level in 
vaccine -naive individuals , as measured by the percentage of subjects with hSBA 
titer ,::8 and hSBA  GMTs  at Day 1. 
4. To compare the immune response  to a single dose ofMenACWY -CRM  vaccine , 
between subjects who previously received Menveo , subjects who previously 
received  Menactra and vaccine- naive  individuals , by age grou p (15-25 and 26 
years  of age), as measured by percentages of subjects  with hSBA  titer ,::8, hSBA 
seroresponse and hSBA  GMTs  at Day 29. 
Protocol V59_77 
Page 10of86  GSK 
03FEB16  Confidentia l 
Regulatory Review Protoco l Version 2 
PRO -01 TEMP  06 / Atlas  No. 293620  
VersionNo.4  / Version Date:  January  29, 2015  00 
" 
::, z u 
8  
  
Name of Spo nsor: 
 
GlaxoSmithKline 
Vaccines  Protoco l nu mber:  
V59 77 Gene1i c name of s tudy vaccine(s):  
 
Meningococcal  (groups A, C, W, and Y) 
oligosaccharide diphtheria CRM- 197 
conjugate vaccine  
Safety objec tives: 
1. To assess  reactogenicity  and safety of MenACWY- CRM  vaccine when  administered 
to subjects who previously received Menveo or Menactra and vaccine -naive 
individuals  
Stud y Design: 
This is a phase 3b, controlled , open-label, multi -center studyto evaluate safety and 
inlmunogenicity of MenACWY -CRM  after a single vaccinat ion in healthy  individuals 
who were  vaccinated  with Menveo  or Menactra  4 to 6 years  ago and in vaccine-naive 
individuals . 
Study population: AJ>proximately  700 healthy  subjects  15 throug!I 55 years  of age will 
be enrolled in the study. 
Duration  of the study The duration of this study is approximately 6 months per subject. 
Writte n informe d consen t and, as applicabl e accordin g to local  guidelin es, written 
assent will be obtained  before conducting any study -specificprocedures . 
Vaccination  schedule: All subjects will receive  a single dose ofMenACWY -CRM at 
Day I. 
Study groups:  
• Group  Menveo -Menveo: approximately  300 subjects , who were  vaccinated  with a 
single dose of Menveo 4 to 6 years  ago, will receive  one dose of MenACWY-CRM.  
• Group Menactra- Menveo:approximately 300 subjects, who were  vaccinated  with a 
single dose ofMenactra 4 to 6 years ago, will receive onedose of MenACWY - 
CRM.  
• Group Naive: approximately 100 subjects, of similar age to subjects enrolled in 
other primed  groups, equally  enrolled  across  allclinical sites, who have not received 
any meningococcal vaccination,  will receive  one dose of MenACWY- CRM.  
Randomization/ Stratification:  
Protocol V59_77 
Page 11of86  GSK 
03FEB16  Confidentia l 
Regulatory Review Protoco l Version 2 
PRO -01 TEMP  06 / Atlas  No. 293620  
VersionNo.4  / Version Date:  January  29, 2015  
  
Name of Sponsor: 
 
GlaxoSmithKline 
Vaccines  Protoco l number : 
V59 77  Gene1i c name of study vaccine(s): 
 
Meningococcal (groups A, C, W, and Y) 
oligosaccharide diphtheria CRM -197 
conjugate vaccine  
Within  eachstudy  group , subjects  will be enrolled  across  age range  of 15 to 55 years  of 
age as  follows:  
• Menveo -Menveo and Menactra -Menveo groups : approximately 80% of subjects  will 
be enrolled  in age group  of 15 to 25 years  and 20%  of subjects  willbe enrolled in 
26-55 years age group;  
• Naive group  approximately 50% of subjects will be enrolled in age group of 15 to 
25 years  and 50%  of subjects willbe enrolled  in age group  of26- 55 years . 
 
Within each  age category in each  studygroup , subjects  willbe randomized into one of 
two different  blood  draw  schedules according  to a 1:1 ratio, described as follows:  
• Subjects  getting  blood draws  at Day 1, Day 4 and Day 29. 
• Subjects  getting b lood draws  at Day 1, Day 6 and Day 29. 
For a schematic overview , see Table  1. 
Ta ble I: Schema tic diagra m of the VS9_77 stu dy gro ups 
Vacdne 
History Vacdnation in 
c.un  ent study Age Catego ry Blood drawsched nle 
Menveo  
N=300 Menveo  15-25 years  
(N=240)  Blood draw Day I, 4, 29 (N =l 20)  
Blood draw Day I, 6, 29 (N = l20) 
26-55 years  
(N=60)  Blood draw Day 1, 4, 29 (N=30) 
Blood draw Day I , 6, 29 (N=30) 
Menactra  
N=300 Menveo  15-25 years  
(N=240)  Blood draw Day I, 4, 29 (N =l 20)  
Blood draw Day I, 6, 29 (N = l20) 
26-55 years 
(N=60)  Blood draw Day 1, 4, 29 (N=30) 
Blood draw Day I , 6, 29 (N=30) 
Vaccine- 
Naive 
N= l OO Menveo  15-25 years 
(N=50) Blood draw Day 1, 4, 29 (N =25) 
Blood draw Day I, 6, 29 (N =25) 
26-55 years 
(N=50) Blood draw Day 1, 4, 29 (N =25) 
Blood draw Day I, 6, 29 (N =25) 
 
Blinding: open- label study . 
Protocol V59_77 
Page 12of86  GSK 
03FEB16  Confidentia l 
Regulatory Review Protoco l Version 2 
PR0-01 TEMP  06 / Atlas  No. 293620  
VersionNo.4  / Version Date:  January  29, 2015   
  
Name of Spo nsor: 
 
GlaxoSmithKline 
Vaccines  Protoco l number:  
 
V59 77 Gene1i c name of s tudy vaccine(s):  
 
Meningococcal (groups A, C, W, and Y) 
oligosaccharide diphtheria CRM -197 
conjugate vaccine  
Blood  samn!P.s : Three  (3) blood  samples  of approximately  10 mL each  will be collected 
according  to the blood  draw  schedule  in Table  I. 
Data collection:  Electronic Case Reporting Form (eCRF) . 
 
Study  clinic  visits: Three  (3) clinic  visits  at Day 1 , Day 4 or Day 6 and Day 29 are 
planned for each subject.  
Reminder  Phone calls: Two  (2) reminder  phone  calls  will beconducted at Day 3 and 
Day 5 after the study  vaccination to remind the subject/  legal guardian  to complete the 
diary  card.  
Safety phone  calls : Three  (3) safety phone  calls  (at Day 15, Day91 and Day181)  will 
be conducted to collect  any medically -attended  AEs, AEs leading  to withdrawal , SAEs, 
related medications  and any vaccinations . In addition , all unsolicited  AEs and related 
medications  occurring  after  the vaccination  will be collected  during  the safety  call at 
Day15. The Day 181 Safety Phone  call will also serve as the termination  visit.  
 
Solicited  Adverse  Events  (injection  site pain,  erythema, induration,  fatigue , headache , 
myalgia,  arthralgia,  loss of appetite , nausea, chills and fever) occurring  on the day of 
vaccination  and the following  six days  (Day I through  Day 7) will be recorded  daily 
using  a Diary  Card  for all subjects . 
 
Unsolicited AEs  occurring within 28 days after study vaccination will be collected . 
Qualified site staff will interview the subject by phone approximately 14 days after 
vaccination  and in person at the studysite  approximately  28 days after study vaccination 
to assess the occurrence of any unsolicited  AEs . 
 
Medically -attended AEs AEs leading  to studywithdrawal  and SAEs will be collected 
during  the entire  study  period. These data will be captured by interviewing  the subject 
and/or  subjects ' parents  / guardian  (as applicable)  during  the site visits  and phone  calls 
and by review  of available medical records . Subjects  and/or  parents  / guardian will be 
encouraged to call the site in theevent of any medically -attendedAEs  or any AEs which 
theyperceive  as being  of concern during the entire  studyperiod.  
Protocol V59_77 
Page 13of86  GSK 
03FEB16  Confidentia l 
Regulatory Review Protoco l Version 2 
::, z u 
8  
 ....  
Name ofSpo nsor: 
 
GlaxoSmithKline 
Vaccines  Proto col number: 
V59- 77 Gene1i c name of s tudy vaccine(s): 
 
Meningococcal (groups A, C, W, and Y) 
oligosaccharide diphtheria CRM -197 
conjugate vaccine  
Table 2: Schematic diagram of the VS9_77 study desig n. 
Day l Day 4  Day 6  Day 15 Day 29  Day 91  Day181 
Blood draw 
(all subjects ) 
Menveo Blood draw 
(50%)  Blood draw 
(50% ) Safety 
Phone call Blood draw 
(all subjects ) Safety 
Phone 
call Safety 
Phone call 
Study  
tennination  
Number of Subjects planned: Approximately 700 sub jects are planned for enrollment 
into this study , approximately 300 subjects who previously received Menveo (Menveo- 
Menveo group), 300 subjects who previously received Menactra (Menactra- Menveo 
group) and 100 meningococcal vaccine -naive subjects (Naive group) . Assuming a 10% 
drop- out rate that should pro vide approximately 630 evaluable subjects.  
Study Po pulation and Subject C haracte1i stics : The list of inclusion and exclusion  
criteria is included in protocol section 4, Selection of Study Population.  
Stu dy Pro ced ures: The study  includes  three  clinic  visits , one vaccination , three  blood  
draws , and threesafety  phone  calls  for each  subject. All studyprocedures  associated 
with the pre-vaccination , vaccination, post -vaccination, unscheduled and study 
temiination  visit are described in section  5.0. 
Study Vaccines : 
 
GlaxoSmit hKline Menin gococca l MenAC \VY-CR.1!"1 vacc in e (M e n veo) : 
Meningococcal (groups A, C, Wand Y)oligosaccharide diphtheria CRM- 197 con jugate 
vaccine is supplied as a vialcontain 10 µg of serogroup A oligosaccharides and 5 µg of 
serogroups C, W and Y oligosaccharides, conjugated to Corynebacterium diph theriae 
CRM 191 protein. Overall injection volume of 0 .5 mL. 
 
The vaccine will be administered intramuscularly, preferably in the deltoid area of the 
non-dominant arm  
P1i mary Endpoint(s): 
 
 
 
00 
....  
PR0-01 TEMP 06 / Atlas No. 2 9362 0 
VersionNo.4 / Vers ion Date: January 29, 2015 
Protocol V59_77 
Page 14of86  GSK 
03FEB16  Confidentia l 
Regulatory Review Protoco l Version 2 
::, z u 
8  
  
Name of Spo nsor:  
 
GlaxoSmithKline 
Vaccines  Protoco l number : 
V59 77  Gene1i c name of s tudy vaccine(s): 
 
Meningococcal (groups A, C, W, and Y) 
oligosaccharide diphtheria CRM -197 
conjugate vaccine  
Immun ogenicity E ndpoints: 
The following  measures will be summarized for the pooled (Menveo -Menveo and 
Menactra- Menveo)  group.  
2. Percentage of subjects  with hSBA  seroresponse1 against  N. meningitidis  serogroups 
A, C, Wand Y at Day29. 
 
Seco ndaryE ndpoints: 
Immun ogenicity  e ndpo ints:  
The following measures will be summarized for Menveo- Menveo, Menactra -Menveo , 
Naive and the pooled (Menveo -Menveo and Menactra -Menveo) groups unless 
otherwise noted:  
1. Percentage  of subjects  with hSBA  titer 8 against  N. meningitidis  serogroups  A, C, 
Wand Y at Day 1 , Day 4 , Day 6 and Day 29; 
2. Percentage s of subjects  with hSBA seroresponse against  N. meningitidis  serogroups 
A, C, Wand Y at Day4 , Day 6 and Day 29 (Day  29: Except the pooled  group);  
3. hSBA  GMfs  against  N. meningitidis  serogroup A, C, Wand  Y at Day 1, Day 4 , Day 
6 andDay29;  
4. Ratios  ofhSBA  GMTs  at Day 1 , Day 4, Day 6 and Day29 (between study  groups).  
5. Ratios  ofhSBA  GMfs  at Day 4 , Day 6, and Day 29 compared to Day 1 (within  
study  groups).  
Safety endpoi nts: 
 
Safety of the study vaccine will be assessed in the pooled vaccine group (Menveo - 
Men
veo and Menactra -Menveo)  and the vaccine- naive  group in terms of the frem1encv  
 
 
1 Seroresponse is defined as: a) post -vaccination hSBA 8 for subjectswith a pre -vaccination hSBA <4; b) 
for subjects with a pre -vaccinationhSBA - an increase of at least four times the pre-vaccinationhSBA.  
 
 
PR0-01 TEMP 06 / Atlas No. 293620 
00 VersionNo.4 / VersionDate: January 29, 2015 
" 
Protocol V59_77 
Page 15 of86  GSK 
03FEB16  Confidentia l 
Regulatory Review Protoco l Version 2  
  
Name of Sponsor: 
 
GlaxoSmithKline 
Vaccines  Protoco l number : 
 
V59 77 Gene1i c name of s tudy vaccine(s): 
 
Meningococcal (groups A, C, W, and Y) 
oligosaccharide diphtheria CRM -197 
conjugate vaccine  
(percentage) of reported adverse events including:  
1. Any unsolicited  AEs reported within 30 minutes  after vaccination;  
2. Solicited  local and systemic  AEs reported from  Day 1 (6 hours) through  Day 7 after  
vaccination;  
3. Other  indicators  of reactogenicity (e.g. use of analgesics / antipyret ics, body 
temperature) within  7 days  after  vaccination;  
4. All unsolicited  AEs reported from  Day 1 through Day 29 after  vaccination;  
5. Medically -attended AEs, AEs leading  to withdrawal and SAEs reported from  Day 1 
through Day 181 (during  the entire  studyperiod).  
Statistical Anal yses: 
P1i mary Immun ogenicity O bjective  
The primary  population  for the analysis of sufficient  immune response  is the Full 
Analysis  Set (FAS) , and will consist  of pooled  data from  the Menveo -Menveoand 
Menactra- Menveo  group  (n=540 evaluable).  
 
To demonstrate immune response  sufficiency  after  MenACWY -CRM  booster  vaccine 
administration, the lower limit of the one -sided 97. 5% Confidence Interval (CI) for 
percentage of subjects  with hSBA  seroresponse  against each  of serogroups  A, C, W and 
Y must be greater than 80% (in the pooled group of subjects who received primary 
vaccination  with Menveo or Menactra)  
 
Hypothe sis: 
Null hypothesis  Alternative  hypothesis  
P, s 0.80 P, > 0.80  
Where: P., is the population seroresponse  rate for the pooled  Menveo-Menveo and 
Menactra- Menveo  group; i = 1,2,3,4 refer to serotypes  A, C, Wand Y respectively.  
 
Sample Size: 
Statistical nower was estimated based on observed data from studv V59Pl3El, where  
 
PR0-01 TEMP 06 / Atlas No. 293620 
VersionNo.4 / Vers ionDate: January 29, 2015 

Protocol V59_77 
Page 16 of86  GSK 
03FEB16  Confidentia l 
Regulatory Review Protoco l Version 2 
::, z u 
8  
  
Name of Sponsor: 
 
GlaxoSmithKline 
Vaccines  Proto col numb er: 
V59- 77 Gene1ic nam e of study vaccine(s): 
 
Meningococcal  (groups A, C, W, and Y) 
oligosaccharide diphtheria CRM -197 
conjugate vaccine  
seroresponse  rates  at one-month  post booster  dose of MenACWY -CRM  ranged  from: 
97% (90% -100%) to 100% (95%- 100%)  for serogroupA; 93% (85%- 98%)for 
serogroup C; 91% (82% -97%)to 93% (84%- 98%) forserogroup W; and 90% (80% - 
96%) to 93% (84%- 98%) forserogroup Y among  subjects primed  with MenACWY - 
CRM or Menactra  in the three  years  preceding the study.  
Assuming the true seroresponse rates in the pooled group range from 90% to 97% 
(alternative  hypothesis) for each serotype , a sample  size of n=540 will have at least 96% 
power to show  sufficiency of immune  response to a booster dose of MenACWY -CRM 
in the pooled group , compared with a pre-specified reference seroresponse of 80% (null 
hypothesis) using an exact test with 0.025 one-sidedsignificance level When taking a 
10% dropout rate into account , N=600 previously vaccinated subjects have to be 
enrolled  in the study. Calculations  have  been  done  with nQuery  Advisor (Version  7.0). 
 
Tabl e 3:  Stati stic al Po wer to Tes t for S uffi ciency of Immun  e Res ponse 
Give n a Ran ge of  True  Seroreponse  Rate s  for E valuabl e 
Sampl e Size of 540 subjects 
Se.-oty pe T111e Serores  po nse Rate Powel'  
A 0.97 0.99 
C 0.93 0.99 
w 0.91 0.99 
y 0.90 0.99 
Total Power   0.96 
In terim Anal ysis: No interinI analysis is planned for this study . 
Data Monito1ing Co mmitt ee: No DMC will be utilized for the study . 
 
 
 
 
 
 
 
 
 
PR0-01 TEMP 06 / Atlas No. 293620  
00 VersionNo.4 / Version Date: January  29,201 5 
" 
GSK  
03 FEB 16 Confidential  
Regulatory Review Protoco l Version 2  Protocol  V59_77 
Page 17 of86  
::, z u 
8  
 ....  
Table 4 Time and Events  Table  
 
Visit Type 
Study period  
Study Day 
 
Visit Window (Days)  
 
 
Visit Number  Clinic Visit  Clinic Visit  Phone Call  Clinic Visit  Phone Call Clinic Visit Phone Call Phone Call  
Screening  Treatment  Tre.itment  Treatment  Treatment  Treatment  Follow -up Follo w-up 
 1 3, 5 4/6• 15 29 91 181 
 
-5 
to 1  
0 2 days (- 
1/+l ), 4 
da ys (0/ +2) 
after vacc  3/5 days 
(-1/+l)  
after vacc  14 days  
(-2/+2)  
after vacc  28days 
(-7/+14) 
after Yacc  90days 
(-14/+14) 
aftel' vacc  180 days 
(-14/+14)  
after vacc  
Pre- 
vacc.ina tion 1 N/A 2 3 4 5 6 
Study Event  References   
Study Treatment    
Vaccination (vacc) Section 5.2  X       
Screening and 
Safety    
Informed Consent"  Section 5.1.1  X        
Medical History  Section 5.1.2 X        
Physical Exam  Sections 5.1.2 
and 5 .3.1 X x<  
X  
X   
Pregnancy Test Sections 3 .5 and 
5 .1.2 X x<       
Exclusion/Inclusion 
Criteria  Section4  X        
Randomization  Section 5. 1.4  x<       
30 Minutes Post 
Injection Assessment  Section 5.2.1  X       
 
 
00 
.... PR0--01 TEMP 06 / Atlas No. 293620  
Versi on No.4 / VersionDate : January29, 2015  
GSK  
03 FEB 16 Confidential  
Regulatory Review Protoco l Version 2  Protocol  V59_77 
Page 18 of86  
::, z u 
8  
 ....  
Visit Type 
Study period  
Study Da y 
 
Visit Window (Days)  
 
 
Visit Number  Clinic Visit  Clinic Visit  PhoneCall  Clinic Visit  Phone Call Clinic Visit Phone Call Phone Call 
Screening  Treatment  Tre.itment  Treatment  Treatment  Treatment  Follo w-up Follo w-up 
 1 3, 5 4/6• 15 29 91 181 
 
-5 
to 1  
0 2 days (- 
1/+l ), 4 
days(0/+2) 
after vacc  3/5 da)'S 
(-1/+l ) 
after vacc  14 days  
(-2/+2) 
after vacc  28days  
(-7/+14) 
after Yacc  90days 
(-14/+14) 
aftel' vacc  180 days  
(-14/+14)  
after vacc  
Pre- 
vacc.ina tion 1 NIA 2 3 4 5 6 
Study Event References   
Subject Diary 
Dispensed w ith 
Training   
Section 5.2.1   
X       
Subject Diary  
Reminder Call Section 5.2.2   xi xi     
Subject Diary 
Reviewed  and 
Collected   
Section 5.3.1        
X   
Assess Unso licited  
AEs Secti on 7. 1  X  X X X   
Assess SAEs  Section 7. 1.4  X  X X X X X 
Assess fo r medically 
attended AEs and 
AEs leading to 
withdrawal   
Sections 7. I.4.I 
and7.1.3   
X   
X  
X  
X  
X  
X 
Assess relevant 
medications/ 
vaccina tions Secti ons5.1.2 
and 6.5  
X  
X   
X  
X  
X  
X  
X 
 
 
00 
.... PR0--01 TEMP 06/ Atlas No. 293620  
Versi on No.4 / Version Date: January29 , 2015  
GSK  
03 FEB 16 Confidential  
Regulatory Review Protoco l Version 2  Protocol  V59_77 
Page 19 of86  
::, z u 
8  
 ....  
Visit Type 
Study period  
Stud y Da y 
 
Visit Window (Days)  
 
 
Visit Num ber Clinic Visit  Clinic Visit Phone Ca ll Clinic Visit  Phone Call  Clinic Visit Phone Call  Phone Ca ll 
Screening  Treatment Tre.itment Treatment Treatment Treatment Follow - up Follow- up 
 1 3, 5 4/6• 15 29 91 181 
 
-5 
to 1  
0 2 da ys ( - 
1/+l ), 4 
days (0/+2) 
after vacc  3/5 da)'S 
(-1/+l ) 
after vacc  14 days  
(-2/+2) 
after vacc  28days 
(-7/+14) 
after Yacc  90 days 
(-14/+14) 
aftel' vacc  180 days 
(-14/+14)  
after vacc  
Pre- 
vacc.ina tion 1 NIA 2 3 4 5 6 
Study  Event I References   
Imm unogenicity    
Serology blood draw  I Section 3.5  X"  X  X   
S tu dy C-0mp le rio n 
Pt·oced ure 
StudyTennination' I Section 5.5        X 
 Notes : 
• Subject  will berandomized  into a blooddraw  schedule  in a I: I ratio. Toe second  clinic  visit will occur  at Day 4 OR Day 6. 
b Confirm consent fonn( s) signed prior to any procedures . 
' Procedure to be performed prior to vaccination  
d If the clinicvisit at Day 4 is overlapping w ith the specified window of theDay 3 reminder c.ill, the Day 3 reminder call may be omitted.  
If the clinic visit at Day 6 is overlapping w ith the specified window of the Day 5 reminder call, the Day 5 reminder call may beomitted.  
• Subjects  who tenninate  the study early  are recommended  to complete certainstudy -related  procedures . See section 5.5 for further details . 
 
 
 
 
 
 
 
00 
....  
PR0--01 TEMP 06 / Atlas No. 293620  
Vers ion No. 4 / Version Date : January 29, 2015  
Protocol V59_77 
Page 20of86  GSK 
03FEB16  Confidential  
Regulatory  Review  Protoco l Version  2 
PR0-01 TEMP  06 / Atlas  No. 293620  
VersionNo.4  / Version Date:  January  29, 2015   
  
LIST OF ABBREVIATIONS  
 
ACIP 
AE 
CI 
CBER 
CRM 
CRO 
EC 
eCRF 
EDC 
FAS 
FDA 
GCP 
GMR  
GMT 
GSK 
hSBA 1B 
ICF 
ICH
 
 
IM 
IRB 
LSLV  
MedDRA  
pp 
Ref. 
SAE  
soc 
SOP  Advisory  Committee  on Tmm1mization  Practices 
Adverse  Event  
Confidence Inteival  
Center for Biologics E valuation and Research 
Cross Reactive material  
Contract Research Organization 
Ethics Committee  
Electronic  Case Report  Form 
Electronic  Data Capture  
Full Analysis Se t 
Food and Drug Administration 
Good Clinical Practices 
Geometric Mean Ratio 
Geometric Mean Titer GlaxoSmithKline Vaccines 
Human Serum Bactericidal Assay 
Investigator ' s Brochure
 
Informed Consent Form  
International Conference on Harmonisation of Technical 
Requirements for Registration of Pharmac euticals for Human Use 
Intramuscular  
Institutional Review Board  
Last Subject Last Visit  
Medical Dictionary for Regulatory Act ivities 
Per Protocol  
Reference  
Serious Adverse Event 
System Organ Class  
Standard Operating Procedure  
Protocol V59_77 
Page 21of86  GSK 
03FEB16  Confidential  
Regulatory  Review  Protoco l Version  2 
PR0-01 TEMP  06 / Atlas  No. 293620  
VersionNo.4  / Version Date:  January  29, 2015   
  
l. BACKGR OlU''-D  M'D   RATIONALE  
 
1.1 Background 
 
Neisseria meningitidis is a leading cause of bacterial meningitis and sepsis worldwide , 
capable of causing outbreaks and epidemics of invasive disease. Meningococcal disease is 
associated with high morbi dity and mortality even among patients who receive early 
antibiotic treatment. Most cases of invasive disease worldwide are caused by serogro ups 
A, B, C, W and  Y. 
 
The quadrivalent meningococcal oligosaccharide diphtheria CRM- 197 conjugate vaccine 
(MenACWY -CRM; Menveo , GSK Vaccines) is approved for active immunization of 
individuals  from  2 months  through  55 years of age in the United  States . As of February 
2015, more than 30,000 of subjects  have  been exposed to MenACWY- CRM vaccine in 
completed clinical studies and more than 24 million doses of the vaccine have been 
distributed  globally . 
 
The US Advisory Committee on Immunizat ion Practices (ACIP) recommends routine 
vaccination with a quadrivalent conjugated meningococcal vaccine for adolescents at 11- 
12 years of age with a booster dose administered 5 years later. While a substantial body of 
data exists showing a robust immune response and good anti body persistence after a 
single dose of MenACWY -CRM in ado lescents, the response to a booster dose of 
MenACWY -CRM in this age group has only been evaluated in 2 clinical studies with 
limited number of  subjects . 
 
A robust anamnest ic immune response to a booster dose of Menve o vaccine administered 
at approximately 5 years after previous vaccination withthe same vaccine or a licensed 
meningococcal polysaccharide vaccine (Menomune®) was demonstrated in the phase 2 
clinical study V59P6E l . High titers of bactericidal antibodies against the vaccine 
serogroups were achieved at 7 and 30 days after booster dosein MenACWY- CRM - 
pr
imed subjects. However, the number of subjects included in this study was relatively 
small (N=101, including 50 subj ects who received a booster dose after the primary 
MenACWY -CRM vaccination) . 
 
In the phase 3b clinical study V59Pl3El  , a booster  dose  of MenACWY -CRM  was given 
3 years after primary vaccinat ion with either MenA CWY -CRM or Menactra® (a 
meningococcal diphtheria toxoid -conjugated MenA CWY vaccine , MenACWY -D) in 
adolescents . A booster  dose  was able to substantially increase antibody  titers  against all 4 
serogroups irrespective of the priming vaccine . Again , only small number of subjects 
(N=160)  received the MenACWY -CRM  booster, (83 who received primary  MenACWY - 
CRM  a
nd 77 who received MenACWY -D). 
Protocol V59_77 
Page 22of86  GSK 
03FEB16  Confidential  
Regulatory  Review  Protoco l Version  2 
PR0-01 TEMP  06 / Atlas  No. 293620  
VersionNo.4 / VersionDate: January 29, 2015  00 
" 
::, z u 
8  
  
In the light  of the current ACIP  recommendation for a booster dose ofMenACWY -CRM, 
there  exists  a need to evaluate the response  to a MenACWY -CRM  booster given  at - 5 
years after primary vaccination in meningococcal -vaccineprimed adolescents. Generation 
of this data would also be of relevance in outbreak management and vaccination of 
travelers  to endemic areas . 
 
1.2 Rationale  
 
The pwpose/aim of this study is to assess the safety and anti body response to vaccination 
with a booster doseofMenveo given 4 -6 years after primary vaccination and the response 
to a single dosegiven to vaccine -naive subjects , and to describe the immune response 
over time after a single dose of Menveo , dministi>red  to subjects previously vaccinated 
with Menveo or Menactra  or to vaccine -naive  subjects.  The inclusion  of vaccine -naive 
subjects  in a separate study  arm is to enable comparison of the rapidity  and magnitude  of 
an anamnestic response to a booster  dose  (in primed individuals)  or the primary  response 
to a first dose (in naive  individuals)  of MenACWY -CRM.  
Protocol V59_77 
Page 23of86  GSK 
03FEB16  Confidential  
Regulatory  Review  Protoco l Version  2 
PR0--01 TEMP  06 / Atlas  No. 293620  
VersionNo.4  / Version Date:  January  29, 2015  00 
" 
::, z u 
8  
  
2. OBJE CTIVES 
 
2.1 Plimary Objectiv e(s) 
 
Plimary Immunog eoicity Obj ective(s)  
 
1. To demonstrate a sufficient immune response following a single dose of MenACWY - 
CRM (
Menveo) vaccine , given to subjects who previously received Menveo or 
Menactra , as measured by the percentage of subjects with hS BA seroresponse against  
N. m.eningitidis serogroups A , C, W and Y at Day 29 after vaccination  
Criteria  to demonstrate immune  response sufficiency: The immune  response will be 
considered  as sufficient if the lower  limit of the one-sided  97.5%CI  for percentage  of 
subjects with hSBA  seroresponse against serogroups  A, C, Wand  Y is greater  than 
80% (in pooled  group  of subjects who received  primary vaccination  with Menveo  or 
Menactra).  
 
2.2 Second ar y O bjecti ve(s) 
 
Second ar y I mm un og eni city O b je cti ve(s) 
 
1. To compare the immunogenicityof a single dose of MenACWY -CRM vaccine , 
between  subjects  who previous ly received Menveo, subjects who previously  received 
Menactra and vaccine- naive  individuals , as measured by the percentage of subjects  
withhS BA titer ;,:8, with hSBA seroresponse , and hSBA GMTs against N. 
meningitidis  serogroups  A, C, W and Y at Day 29 after  vaccination  
2. To compare the immune responses fo llowing a single dose of MenACWY -CRM 
vaccine, between  subjects  who previous ly received Menveo , subjects who previously 
received  Menactra and vaccine- naive  individuals , as measured by the percen tage o f 
subjects  with hSBA titer 8 and hSBA GMTs  against N. m.eningitidis  serogroups  A, 
C, Wand  Y at Day1 , Day 4, Day 6, and Day 29 after  vaccination  
3. To assess  persistence of bacteric idal antibodies  against  serogroups  A, C, Wand Y at 
approximately 4-6 years after  the primary vaccination  with Menveo and after the 
primary vaccination  with Menactra  in comparison with naturally -acquired level in 
vaccine- naive  individuals , as measured by the percentage of subjects with hSBAtiter 
8 and hSBA GMTs at Day  1. 
4. To compare the immune response to a single dose of MenACWY -CRM vaccine , 
between  subjects  who previous ly received Menveo, subjects who previously  received 
Menactra and vaccine- naive individuals, by age group  (15-25 and ;,:26  years of age), 
as measured by percentages of subjects with hSBA titer 8, hSBA  seroresponse and 
hSBA GMTs  at Day 29. 
Protocol V59_77 
Page 24of86  GSK 
03FEB16  Confidential  
Regulatory  Review  Protoco l Version  2 
PR0-01 TEMP  06 / Atlas  No. 293620  
VersionNo.4  / Version Date:  January  29, 2015  00 
" 
::, z u 
8  
  
Secondar y Safe ty Obje ctive(s)  
1. To assess reactogenicity andsafety of MenACWY -CRMvaccine when administered 
to subjects who previously received Menveo or Menactra and vaccine -naive  
individuals.  
2.3 Explor atory Objecti ve(s) 
There are no  exploratoryobject ives. 
Protocol V59_77 
Page 25of86  GSK 
03FEB16  Confidential  
Regulatory  Review  Protoco l Version  2 
PR0-01 TEMP  06 / Atlas  No. 293620  
VersionNo.4 / VersionDate: January 29 , 2015  
  
3. STUD Y DESIGN 
 
3.1 Overview of Study Design 
 
This is a phase 3b, controlled, open -labe multi- center studyto evaluate safety and 
immunogenicityof  MenACWY -CRM  after a single  vaccination in healthy  individuals 
who were vaccinated with Menveo or Menactra 4 to 6 years  ago and in vaccine- naive 
individuals  
Study population:  Approximately 700 healthy subjects 15 through 55 years of age will be 
enrolled in the study.  
Duration of the study: The duration of this study is approximately 6 months per subject.  
 
Written  informed  consent  and, as applicable  according  to local  guidelines, written  assent 
willbe obtained  before  conducting anystudy- specificprocedures.  
 
Vaccination  schedule:  All subjects  will receive a single  dose  of MenACWY- CRM  at Day 
1. 
 
Study groups : 
 
Group  Menveo -Menveo : approximately  300 subjects , who were vaccinated with a single 
dose  ofMenveo  4 to 6 years ago, will receive  one dose  of MenACWY -CRM.  
 
Group  Menactra- Menveo approximately 300 subjects,  who were vaccinated with a single 
dose  of Menactra  4 to 6 years  ago, will receive  one doseof  MenACWY -CRM.  
 
Group Naive : approximately 100 subjects equally enrolled across all clinical sites, who 
have not received any meningococcal vaccination, will receive one dose of MenACWY - 
CRM.  
Randomization / Stratification : 
Within  each study  group , subjects  will be enrolled  across age range  of 15 to 55 years  of 
age as  follows:  
• Menveo -Menveo and Menactra -Menveo groups : approximately 80% of subjects will 
be enrolled in age groupof 15 to 25 years  and 20%  of subjects  will be enrolled  in 26- 
55 years age  group.  
• Naive group: approximately 50% of subjects will be enrolled in age groupof 15 to 25 
years  and 50%  of subjects  will be enrolled  in age group of26- 55 years.  
Protocol V59_77 
Page 26of86  GSK 
03FEB16  Confidential  
Regulatory  Review  Protoco l Version  2 
PR0-01 TEMP  06 / Atlas  No. 293620  
VersionNo.4 / VersionDate: January 29 , 2015  
  
Within  each  age category in each study  group , subjects  willberandomized into one of 
two different  blood  draw  schedules according  to a 1:1 ratio , described  as follows:  
• Subjects  getting  blood draws  at Day 1, Day 4 and Day 29. 
• Subjects  getting  blood draws  at Day 1, Day 6 and Day 29. 
 
For a schematic overview , see Table 1  
 
Table 3.1-1: Schematic diag r am of the VS9_77 study group s 
 
Vacc.ine 
History V ac c.inatio  n in 
cun ent study  Age Category  Blood dra w sched ule 
Menveo 
N=300 Menveo  15-25 years  
(N=240)  Blood draw Day 1 , 4, 29 (N =l20) 
Blood draw Day I, 6, 29 (N =l20) 
26-55 years  
(N=60 ) Blood draw Day I, 4, 29 (N =30) 
Blood draw Day I, 6, 29 (N =30) 
Menactra 
N=300 Menveo  15-25 years  
(N=240)  Blood draw Day 1 , 4, 29 (N =120) 
Blood draw Day I, 6, 29 (N =l20) 
26-55 years  
(N=60 ) Blood draw Day I, 4, 29 (N =30) 
Blood draw Day I, 6, 29 (N =30) 
Vaccine -Naive 
N=IOO Menveo  15-25 years  
(N=50) Blood draw Day I, 4, 29 (N =25) 
Blood draw Day I, 6, 29 (N =25) 
26-55 years 
(N=50) Blood draw Day I, 4, 29 (N =25) 
Blood draw Day I, 6, 29 (N =25) 
 
Blinding - open- label study.  
 
Blood sanmles: Three (3) blood samples of approximately 10 mL each will becollected 
according to the blood draw schedule in Table 3.1.1. 
 
Data collection: Electronic Case Reporting Form (eCRF) . 
 
Study  clinic  visits:  Three (3) clinic  visits  at Day 1 , Day 4 or Day 6 and Day 29 are 
planned for eachsubject.  
 
Reminder  Phone calls : Two  (2) reminder  phone  calls  willbeconducted at Day 3 and Day 
S after the study  vaccination  to remind  the subject/ legal  guardian  to complete the diary 
car d . 
 
Safety phone calls : Three (3) safety  phone  calls  (at Day 1S, Day 91 and Day 181)  willbe 
conducted to collect  any medically -attendedAEs , AEs leading  to withdrawal, SAEs,  
Protocol V59_77 
Page 27of86  GSK 
03FEB16  Confidential  
Regulatory  Review  Protoco l Version  2 
PR0-01 TEMP  06 / Atlas  No. 293620  
VersionNo.4 / VersionDate: January 29 , 2015  
  
related medications and any vaccinations . In addition, all unsolicited AEs and related 
medications  occurring  after the vaccination  will be collected during the safety call at Day  
15. The Day 181 Safety Phone call will also serve as the termination visit  
 
SolicitedAdverse Events  (injection  site pain, erythema, induration,  fatigue , headache, 
myalgia, arthralgia , loss of appetite, nausea , chills  and fever) occurring on the day of 
vaccination  and the following  six days (Day  1 through  Day 7) will be recorded  daily 
using  a Diary  Card  for all subjects. 
 
Unsolicited AEs occurring within 28 days after studyvaccination will be collected . 
Qualified site staff will interview the subject by phone approximately 14 days after 
vaccination  and in person at the studysite  approximately  28 days after  studyvaccination 
to assess  the occurrence  of any unsolicited  AEs.  
 
Medicall y-attended  AEs AEs leadin g to study  withdrawal  and SAEs will be collected 
during  the entire  study period.  These data will be captured by interviewing  the subject 
and/or  subjects ' parents  / guardian (as applicable)  during the sitevisits  and phone  calls 
and by review  of available  medical records . Subjects and/or  parents / guardian  will be 
encouraged to call the site in the event of any medically -attended AEs or any AEs which 
theyperceive  as being  of concern during  the entire  study  period.  
 
Table 3.1-2: Schematic diagram of the V59_77 study design 
 
Day l Day 4 Day 6 Day 15 Day 29  Day 91 Day 181 
Blooddraw 
(allsubjects) 
Menveo  Blood draw 
(50%)  Blood draw 
(50°/c,)  Safety 
Phone call  Blood draw 
(all subjects)  Safety 
Phone 
call Safety  Phone 
call 
Study  
termination  
 
 
3.2 St u dy Pe riod 
 
Each subject should  expect  to participate in the study  for 6 months,  from  the time of 
enrolment through  the last study  visit. 
 
3.3 Blinding Procedur es 
The trialis designed as an open -label study.  
Protocol V59_77 
Page 28of86  GSK 
03FEB16  Confidential  
Regulatory  Review  Protoco l Version  2 
PR0-01 TEMP  06 / Atlas  No. 293620  
VersionNo.4 / VersionDate: January 29 , 2015  
  
3.4 Data Collec tion 
 
3.4.1 Data Collected from Subjects 
Thefollowing  data will becollected  from each  subject  over the duration  of their  study 
participation:  
• Demographic  Information.  
• Adverse  Events . 
• Medical  History . 
• Concomitant  Medications/Vaccination. s 
• Information on the blood samples . 
 
All data collected  must only be identified  using  the Subject  ID, as described in section  
S.1.4, Randomization.  
3.4.2 Tools Used for Data Collectio n 
 
Data willberecorded in the Sub ject Diary and collected on electronic Case Report Fo11l1S 
(eCRFs)  . 
 
S ubj ect Diar y 
Paper  Diaries (pDiaries) , hereafter referred to as Subject Diaries  will betheonlysource 
document allowed for solicited local and systemic adverse events (including body 
temperature measurements) , starting  after the initial,  30minute  post-vaccination period  at 
the clinic . The following  additional  rules  apply to documentation of safety  information 
collected  in the Subject Diary.  
 
The Investigator  or delegated  staff should  monitor  the Subject's  Diary  status  throughout 
the study  for compliance and anysolic ited local and systemic  adverse events  that were of 
concern to the sub ject 
 
• No corrections or additions to the information recorded by the subject or 
parent(s)/legal guardian(s) within the Subj ect Diary willbeallowed after it is 
delivered to the  site. 
• Any blank  or illegible  fields  on the Subject  Diary  must  be described as missing  in the 
eCRF.  
Protocol V59_77 
Page 29 of86  GSK 
03FEB 16 Confidential  
Regulatory Review Protoco l Version 2  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
"6'; 
00 
" 
::, z 
u 
8 Case Rep01t Forms  
This study utilizes electronic Case Report Forms (eCRFs) to collect study -related data 
from  each subject.  A qualified  site staffmember(s)  is required  to enter subject  data in the 
eCRFs in English based on the medical information available in each subject' s source 
record . 
Data should be entered into the eCRF  in a timely  fashion  following each subject's clinic 
visit,study procedure, or phone call. Each subject' s eCRF casebook will be compared 
withthe  subject's source records  by a GSK- approved  study monitor (or designee) over 
the duration of the study in order to ensure data collection accuracy . 
The following  additional rules  apply to documentation of Subject  Diary  information 
collected  in the eCRFs:  
• The site must  enter all readable  entries  in the Subject  Diary  into the eCRF , including 
those values  that may be biologically  implausible (e.g. bodytemperature: 400°C) . 
• Any illegible or implausible data should be reviewed with thesubject and/or 
parent(s)/legal guardian(s) . If an underlying solicited or unsolicited adverse event is 
described  on review with the subject, this should be described in the source document 
and reported  as an unsolicited adverse  event  in the Adverse Event eCRF  (e.g., if the 
subject above confinns body temperature of 40°C on the day in which body 
temperature: 400°C was written  into his/her Subject  Diary , this fever of 40°C  should 
be recorded  in the Adverse Event eCRF) . 
• Any newly  described  safety  information  (including a solicited  adverse event) nrust not 
be written  into the Subject Diary  andnrust  be described  in the study file as a verbally 
reported  adverse  event.  Any adverse  event  reported  in this fashion  must be described 
as an unsolicited adverse  event  and therefore  entered  on the Adverse  EventeCRF . 
 
3.5 Collection of Clinical Specimens  
The following  clinical specimens  are required  to be collected  from  each subject in this 
study:  
• Blood. 
• Urine  for pregnancy  testing  (As per routine practice, specimens will betested  at each 
site). 
 
Processing of a specimen should be completed bya qualified site member and in 
accordance with the study -specificClinical Specimen Laboratory Manual. Testing of 
serum specimens will be performed by a GSK or a designated laboratory. Refer to the 
study- specif ic Clinical Specimen Laboratory Manual for additional details . 
PR0-01 TEMP 06 / Atlas No. 293620  
VersionNo.4 / Vers ion Date: January 29, 2015 
Protocol V59_77 
Page 30 of86  GSK 
03FEB 16 Confidential  
Regulatory Review Protoco l Version 2 
PR0-01 TEMP  06 / Atlas  No.293620  
VersionNo.4 / Version Date: January 29,2015   
  
Blood Specimens 
Approximately  10 mL sample of blood willbedrawn  from all subjects at visit Day 1 
before vaccination,  and at visit Day 4 or Day 6 and Day 29. The blood volume willnot 
exceed 10mL at each time point in order to provide the necessary serum volume 
(approximately  half of the blood draw  volume)  for the serology assays . 
The blood will be used for inummologi cal assay s. See sectio n 7, Assessment s for 
additional  details . 
The total ammmt of blood collected  over the study  period  per subject  will be 
approximately  30mL. 
U1in e S p eci m e ns 
Urine  willbe collected  for pregnancy  testing  in females of child  bearing  potential. Urine 
will becollected  at visit Day 1 before  vaccination  and the results  recorded  in the source 
document and  eCRF . 
3.6 Stopping/P ausing Guideline s 
 
There are no predetermined  stopping rules  in this study. Subjects  may be withdrawn  from 
the study according to investigator discret ion as described in section 3.8, Premature 
Withdrawal from  Study.  
3.7 Data Monitming Co mmittee  
No DMC  willbeutilized  for the study . 
3.8 Premature \Vithdrawal from  Study 
 
Subjects  may withdraw at any time, or be dropped from  the study at the discretion  of the 
investigator should any untoward effects occur and/or forsafety reasons . In addition, a 
subject may be withdrawn by theinvestigator or the Sponsor if he/she violates  the study 
plan or for administrative  reasons. The investigator or study coordinator nrust notify the 
Sponsor immediately  when  a subject has been  withdrawn  due to an adverse  event.  
The circumstances  above are referred  to as premature  withdrawal  from  the study, and the 
reason  for premature withdrawal  should be clearly  documented and detailed  in the source 
documentation. The investigator should make every attempt to evaluate thesubject 's 
safety , including resolution of ongoing AEs, at the time of premature withdrawal . If a 
subject wants  to withdraw from  the study before  or prior to the last planned study visit, 
the subject will be asked to be followed  for safety  for the duration of the study. When  a 
Protocol V59_77 
Page 31 of86  GSK 
03FEB 16 Confidential  
Regulatory Review Protoco l Version 2 
PR0-01 TEMP  06 / Atlas  No.293620  
VersionNo.4 / Version Date: January 29,2015   
  
subject  withdraws , or is withdrawn,  from  the study , the procedures  described in section  
S.5.1,  Early Termina tion Visit  should be comp leted if possible . 
 
The reasons for premature  withdrawal  from  the study  include:  Adverse event , death, 
withdrawal of consent,  lost to follow-up, administrative  reason,  and protocol deviation . 
These reasons  are described in greater detail  below . 
Adverse Event  
 
For any subject withdrawn from study participation prior to the planned Study 
Termination  Visit,  it is important to determine  if an AE was associated  with the reason for 
discontinuing  the study.  This AE nrust  be identified  on the AE eCRF  page  by indicating 
"Withdrawn from study due to AE". Any ongoing AEs at the time of studywithdrawal 
must be followed  until resol ution or stabilization  
 
Death 
 
For anysubject withdrawn  from  study  participation  due to death , this should be noted on 
the StudyTermination  eCRF  page  and the associated  SAE  that led to the death  must be 
reported.  
, v ithdraw al of conse nt 
 
The subject and/or  parent(s)/legal  guardian(s) can withdraw  consent  for participation  in 
the study  at any time without  penalty or loss of benefit to which  the subjec t is otherwise 
entitl ed. Reason  for early termination  should  be deemed as " withdrawal of consent'' if the 
subject  withdraws  from  participation  due to a non- medical reason (i.e., reason other  than 
AE). If the subject  and/or  parent(s)/legal  guardian(s)  intends  to withdraw  consent  from 
the study , the invest igator should clarify if the subject  will withdraw  completely  from  the 
study or if the subject willcontinue study participation for safety, or a subset of other 
study  procedures.  If the subject  requests complete  withdrawal from  the study , no further 
study  interventions  will be performed  with the subjec t. 
If a subject  and/or parent(s)/legalguardian(s) withdraws  consent but does not revoke  the 
HIPAA authorization,  the Sponsor will have fullaccess to the subject ' s medical records , 
including  termination  visit information. If a subject  and/or  parent(s)/legal  guardian(s) 
revokes only the HIPAA authorization, the Sponsor will have fullaccess to all of the 
subject 's medical  records  prior to the date and time of written  revocation.  
 
Lost to Follow -Up 
For subjects  who fail to show  up for final visits  (clinic  or telephone contacts) , or for three 
consecutive  visits , study  staff are encouraged  to make at least three  documented attempts  
Protocol V59_77 
Page 32 of86  GSK 
03FEB 16 Confidential  
Regulatory Review Protoco l Version 2 
PR0-01 TEMP  06 / Atlas  No.293620  
VersionNo.4 / Version Date: January 29,2015   
  
to contact the subject by telephone and at least one documented written attempt to contact 
the subject and/or parent (s)/legal guardian(s) to encourage the completion of study 
termination procedures. These efforts to contact the subject should be recorded in the 
source document. The termination date for the subject to be captured on the Study 
Termination eCRF page is the date of the last successful contact (clinic visit or telephone ) 
withthe subject.  
 
Administrative Reason  
 
Exampl es for subjects withdrawn from the study due to administrative reason can include: 
Sponsor decision to terminate the study , subject discontinuation for insurance issues , 
moving , no time, etc. This reason should be noted in the StudyTermination  eCRF page 
and any ongoing AEs at the time of studywithdrawal should be followed until 
resolution/stabilization, if possible.  
If the clinical study is prematurely terminated by the Sponsor, the investigator is to 
promptly inform the study subjects and local EC/IRB and should assure appropriate 
therapy  and follow  up for the subjects . All procedures  and requirements  pertaining  to the 
archiving of study documents should be followed. All other study materials (study 
medication/vaccines , etc.) must be returned to the Sponsor . 
For subjects who are withdrawn from the study due to receipt of an excluded 
medication/vaccination or due to significant protocol non- compliance , this reason should 
be noted in the StudyTermination eCRF page.  
Protocol D eviation 
 
A protocol deviation is any change , divergence, or departure from the study design or 
procedures of a study  protocol.  In general, subjects  associated with protocol  deviations 
may remain  in the study  unless  continuation  in the study  jeopardizes  the subject's  health, 
safety , or rights . 
 
Investigators will apply due diligence to avoid protocol deviations. Under no 
circumstances should the investigator contact GSK or its agents , if any, monitoring the 
study to request approval of a protocol deviation, as no authorized deviations are 
permitted . If the investigator feels  a change  to the protocol  would  improve  the conduct  of 
the study this must be considered a protocol amendment , and unless such an amendment 
is agreed upon by GSK and approved by the IRB/E C and health authorities it cannot be 
implemented.  
 
Any subject who becomes  pregnant  during the study , despite  the protocol  requirement  for 
adequate contraception should  be encouraged to continue  participating  in the study  for 
Protocol V59_77 
Page 33 of86  GSK 
03FEB 16 Confidential  
Regulatory Review Protoco l Version 2 
::, z u 
8  
  
safety  follow -up only. The site nrust  complete a Pregnancy  Report  CRF  (initial report) as 
soon  as possible  after  learning of pregnancy  occurrence  (see section  7.1.6, Pregnancies  
for further details ). If the subject withdraws fromthe study for any of the above 
categories  except  death, the sitewill obtain  permission  from  the subject  to continue  to 
remain in contact with her until the outcome of the pregnancy is known, even if the 
outcome  is not known  until  after  the subject reaches the end of follow -up period.  
 
3.9 End of Study  
 
Most  clinical  trials  intended  to support  the efficacy /immunogenicityand safety of an 
Investigational  Product  proceed to fullcomple tion of planned  sample  size accrual.  
 
Evaluation  of the primary and/or  secondary immunogenicity/ efficacyobjectives  requires 
the testing  of biological  samples from  the study  subjects , which  can only be completed 
after all samp les are collected . The last samples for the analysis of the primary and/or 
secondary objectives will be taken at the last clinic  visit, Day 29. For the purpose  of this 
protocol, end of study is define d as the completion of the testing of such biological 
samples , to be achieved no later than 8 months after collection of the last biological 
sample  at Day 29 visit  
 
If thecomp letionof testin g occurs  prior  the completion  of the Last Subjec t Last Visit 
(LSLV) the latter date defines the end of study visit  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
"6;' 
00 
"  
PR0-01 TEMP 06 / Atlas No. 293620  
VersionNo.4 / Vers ionDate: January 29, 2015 
Protocol V59_77 
Page 34 of86  GSK 
03FEB 16 Confidential  
Regulatory Review Protoco l Version 2 
::, z u 
8  
 ....  
4. SELECTION  OF STUDY POPULA TION 
 
4.1 Inclusion C1iteria  
 
In order  to participate in this study, all subjects must  meet  ALL  of the inclusion criteria 
described . 
 
1. Individuals  of IS through SS years of age on the day of informed  consent  or assent.  
2. Individuals  who received Menveo  4 to 6 years prior  to enrollment  at an age  of 11 
years  or older  (Menveo -Menveo group) 
OR 
Individuals who received Menactra 4 to 6 years prior to enrollment at an age of 11 
years  or older  (Menactra -Menveo group) 
OR 
Individuals who have not received any previous meningococcal vaccine (Naive 
group) . 
3. Individuals who have  voluntarily given written  informed  consent  or assent after the 
nature  of the study has been  explained according  to local  regulatory  requirements , 
prior  to study entry . If the subject is under  age 18 at the tinie  of enrollment , the 
parent (s)l1egal  guardian( s) of the subject  should  have  voluntarily  given  written  
informed consent.  
 
4. Individuals who can comp ly with  study procedures  including follow -up2 
S. Males  
Or 
Fema les of non- childbearingpotential3 
Or 
 
 
2 A subject and/or  parent(s )/Jegal guardian(s)  is/are considered to be compliant if the Investigator  judges 
thatthe subjectwill comp letethe Subject  Diary  and return  for all thefollow -up visitsscheduled in the 
study.  
3 A female is considered to be of non-childbearingpotential prior  to menarcheand  after natural or induced 
menopause.  Natural  menopause  is recognized to have  occuned  after 12 consecutive  months  of amenorrhea 
for which thereis  nootherobvious  pathological or physiol ogicalcause.  Induced menopause  is recognized 
to have occurred after hysterectomy, after bilateral oophorectomy, or iatrogenic ablation of ovarian 
ftmction.  
 
 
 
00 
.... PR0-01 TEMP 06 / Atlas No.293620  
VersionNo.4  / Vers ionDate: January 29,2015 . 
Protocol V59_77 
Page 35 of86  GSK 
03FEB 16 Confidential  
Regulatory Review Protoco l Version 2 
VersionNo.4 / VersionDate: January 29, 2015  00 
" 
::, z u 
8  
  
Female s of childbearing potential who are using aneffective birth control method4 
which they intend to use for at least 30 days after the last study vaccination. 
4.2 Exclusion Crite1i a 
 
Each subject must not have:  
1. History of any meningococcal vaccine administrationother than the single 
vaccination  given at 4 to 6 years  ago (Menveo- Menveo  and Menactra -Menveo 
groups)  
OR 
History of any meningococcal vaccine administration (Naive group)  
2. Curren t or previous , confirme d or suspecte d disease caused  by N. meni ngitidi s. 
3. Household contact  with and/or intimate  exposure to an individual with any laboratory 
confirmed  N. meningitidis  infection  within  60 days prior to study vaccination. 
4. Progressive , unstable or uncontrolled clinical  conditions. 
S. Hypers ensitivity , including allergy , to any component of vaccines, medicinal products 
or medical equipment whose use is foreseen in this study . 
6. Clinical conditions representing a contraindication  to intramiscular vaccination  (IM) 
and blood draws.  
7. Abnormal function of the iimnune system resulting from:  
a. Clinical  conditions . 
b. Systemic administration  of corticosteroids (PO/IV/IM) for more  than 14 
consecutive days within  90 days prior to study vaccination.  
c. Administration  of antineoplastic and iimnunomodulating agents or radiotherapy 
within  90 days prior to study vaccination. 
 
 
 
4 The following  birth  control  methods  areconsidered  effective: 
Abstinence  
Hormonal  contraceptive (such asoral,injection,  transdennal  patch,  implant) if used for at least 30 
days prior to informed consent  
Diaphragm preferably with spermicide, tubal occlusiondevice 
Intrauterine device (IUD)  
Tubal ligation 
Male par1ner using condom preferably with spermicide  
Male par1ner having been vasectomized at least six months prior toinformed consent  
 
 
PR0--01 TEMP 06 / Atlas No. 293620  
Protocol V59_77 
Page 36 of86  GSK 
03FEB 16 Confidential  
Regulatory Review Protoco l Version 2 
VersionNo.4 / VersionDate: January 29, 2015  00 
" 
::, z u 
8  
  
8. Received immunoglobulins  or any blood  products  within  180 days  prior  to informed 
consent.  
9. Received systemic antibiotic  treatment within  3 days  prior  to study vaccination  or 
blood  draw . 
10. Received an investigational  or non- registered  medicinal  product  within  30 days prior 
to study  vaccination  . 
11. Study  personnel  as an  immediate  family  or household  member . 
12. Individuals who have received any other vaccines within 7 days (for inactivated 
vaccines) or 14 days (for live vaccines)  prior to vaccination in this study or who are 
planning  to receive  any vaccine  within  28 days from the study vaccination.  
13. Individuals who have experienced a moderate or severe acute infection and/or fever 
defined as a temperature 38°C (100.4°F) within 3 days prior to study vaccination.  
14. Any other clinical  condition  that, in the opinion of the investigator, might  pose 
additional  risk to the subject  due to participation  in the study . 
 
 
4.3 C1ite1i a for Delay of Vaccina tion and/or BloodS ampling 
 
There may be instances when  individuals  meet all eligibility  criteria for vaccination yet 
have a transient  clinical circumstance which  may warrant  delay of vaccination: body 
temperature elevation [ 38.0° C 100 .4° F) within 3 days prior to intended study 
vaccination ], systemic antibiotic treatment within  3 days prior to study  vaccination or 
blood  draw . Unde r such  circumstanc es, a subjec t may be considere d eligible  for study 
enrolment after  the appropriate  window for delay  has passed and inclusion/exclusion 
criteria have  been rechecked, and if the subject  is confirmed to be eligible.  
 
There is a clinical circumstance that warrants delay of blood collection for 
immunogenicityassessments in this study.  This situation  is listed  below.  In the event  that 
a subject meets this criterion  for delay  of blood collection,  blood  collection  may proceed 
once  the window  for delay  has passed.  
 
Subject  has received  a dose  of systemic  antibiotics  lessthan  3 days before the intended 
blood  collection.  
 
 
 
 
 
 
 
 
PR0- 01 TEMP 06 / Atlas No. 293620  
Protocol V59_77 
Page 37 of86  GSK 
03FEB 16 Confidential  
Regulatory Review Protoco l Version 2 
VersionNo.4 / VersionDate: January 29, 2015  00 
" 
::, z u 
8  
  
5. STUDY PROCE DURE S 
 
The sections  that follow  provide an overview  of the procedures  that are to be followed  in 
enrolling,  evaluating , and following  subjects  who participate  in this clinical  study. Visits 
can be either  clinic  visits  or safety  follow -up telephone calls, as specified  in the Table 
below  and in the Time and Events  Table4 . 
 
Tabl e 5-1 Study Procedu r es 
 
Visit Category  Procedu res 
Pre-vaccinationClinic Visit(s)  Section 5.1 describes procedures to befollowed 
prior  to study  vaccinat ion: informed  coosent/assent,  
screening , enrolment , andrandomization  
Vaccinat iooClinic Visit(s)  Section 5.2 describes procedures to befollowed 
during each clinic visit involving vaccination: 
vaccination,  post-vaccination procedure ,sand post- 
vaccina tion reminders  
Post-vaccination Visit(s)  Section 5.3 describes follow -up clinic  visits  and 
safety  follow-up calls  
Unschedu led Visit(s)  Section  5.4 describes  possib le procedures  to be 
followed  at unscheduled clinic visit 
Study Termination Visit  Section 5.5 describes  procedures  to befollowed  at 
the last study visit for a subject (mayinclude early  
termination visit)  
 
5.1 Pre-vacci nation Clinic Visit(s) 
 
This section  describes the procedures  that must be performed  for each potential subject 
prior  to vaccination,  including  obtaining informed  consent/assent,  screening , enrolment 
and randomization.  
5.1.l Infor med Consent/Assent 
 
"Informed consent" is the voluntary agreement of an individual or his/her legal 
guardian(s) to participate in research. Consent must be given with free will of choice, and 
without undue inducement. The individual must have sufficient knowledge and 
understanding of the nature of the proposed research, the anticipated risks and potential 
benefits , and the requirements of the research to be able to make an informed decision.  
 
"Assent"  is a term  used to express willingness  to participate  in research by persons  who 
are by definition too young to give informed consent but who are old enough to 
understand  the proposed  research in general , its expected risks and possible  benefits , and 
 
 
PR0--01 TEMP 06 / Atlas No. 293620  
Protocol V59_77 
Page 38 of86  GSK 
03FEB 16 Confidentia l 
Regulatory Review Protoco l Version 2  
  
the activities  expected  of them  as subjects . Assent  by itself is not sufficient,  however.  If 
assent is given, informed consent must still be obtained from the subject's parent(s) or 
legal guardian(s). Local laws  define  who constitutes  a "child,"and such  definitions  dictate 
whether  or not a person can legally consent to participate  in a protocol  (Levine  1988) . 
 
Infonned consent of the parent(s)/legal guardian(s) and assent of subject fo llowing local  
!RB/EC guidance must be obtained before conducting any study -specific procedures (i.e., 
all of the procedures described in the protocol) . The process of obtaining informed 
consent and assent should be documented in the subject source document in addition to 
maintaining a copy of the signed and dated informed consent . Additional specifics 
regarding the informed consent and assent processes are located in section 13.2, Infonned 
Consent Procedures . 
If a subject and/or parent(s)/legalguardian(s) is unable to read, an impartial witness 
should  be present  during  the entire  informed consent and assent  discussion.  An impartial 
witness is defined as a person who is independent from study conduct, who cannot be 
unfairly  influenced by those  involved  with the study , who attends  the informed consent 
process if the subject  or the subject's  legally  acceptable representative  cannot  read, and 
who reads the informed  consent  form  and any other  written  information  supplied  to the 
subject.  After the written  informed  consent form  and any other  written  information to be 
provided to subjects , is read and explained to the subject and/or parent(s)/legal 
guardian(s)  and after the subject  and/or parent(s)/legal  guardian(s)  has verbally  consented  
to the subject's participation in the study and, if capable of doing so, has signed and 
personally  dated the infonned  consent  fonn,  the witness  should sign and personally date 
the consent  form. By signing  the consent  fonn,  the witness  attests that the information  in 
the consent form and any other written information was accurately explained to, and 
apparently understood  by, the subject  and/or  parent(s)/legal  guardian(s) and that informed 
consent was freely  given  by the subject and/or  parent(s)/ legal  guardian(s) . 
 
5.1.2 Screening  
 
After  an individual  has consented  to participate  in the study  and infonned  consent/assent 
is signed,  that individual  will begiven  a unique  Screening Number manually created by 
the investigator. The subject ' s unique Screening Number will bedocumented in the 
Screening and Enrolment log. The eligibility  of the subject will bedetermined based on 
the inclusion  and exclusion  criteria  listed  in section  4, Selection of Study  Population  and 
evaluated during  this screening  procedure.  
Prior  to study enrolment , demographic  data willbecollected from  the subject,  including: 
date of birth,  gender, race, ethnicity , prior  vaccination against meningitis.  
 
 
 
PR0-01 TEMP 06 / Atlas No.293620  
VersionNo.4 / Vers ion Date: January 29,2015 

Protocol V59_77 
Page 39 of86  GSK 
03FEB 16 Confidentia l 
Regulatory Review Protoco l Version 2 
VersionNo.4  / Version Date:  January  29, 2015  00 
" 
::, z u 
8  
  
Medical history will also be collected, including but not limited to any medical history 
that may be relevant to subject eligibility for study participation such as prior 
vaccinations , concomitant medications , and previous and ongoing illnesses or injuries . 
Relevant medical history can also include any medical history that contributes to the 
understanding  of an adverse event that occurs during study participation, if it represents 
an exacerbation of an underlying disease /pre-existing problem.  
Review of systems is a structured interview that queries the subject and/or parent(s)/legal 
guardian(s) as to any c omplaints the subject has experienced across each organ system 
This will be performed before enrolment and used to guide physical examination . 
 
If applicable, prior and concomitant  medications  or vaccinations taken  prior  to start of 
study  should be collected (refer to section  6.5, Prior  and Concomitant  Medicat ions and 
Vaccines for further  details) . 
 
Collect  vital signs  (heart rate , blood  pressure , and temperature (preferably  taken  orally) . 
Measure height  and weight.  
Perform pregnancy testing in women of childbearing potential (refer to section 3.5 , 
Collection of Clinical Specimens for additional information ) 
A general physical examination is to be performed by a qualified health care practitioner. 
"Qualified health care practitioner" refers to any licensed health care professional who is 
permitted by institutional policy to perform physical examinations and wh o is identified 
within the Study Staff Signature Log . 
 
The data collected through study  assessments listed  above  will be written  in the source 
document  (see section  9.1, Source  Documentation ). Should the physical  assessment 
reveal any abnormal  values or events,  these  must  be documented in the CRF  Adverse 
Events  Form  
 
Prior to vaccination, approximately 10 mL of blood will be drawn from all subjects for 
the immunological testing see section 3.5, Collection of Clinical Specimens . 
In the even t that the individua l is determined  ineligibl e for studyparticipation , he/she  is 
considered a screen failure . The reason for screen failure must be documented in the 
Screening and Enrolment  log. If the individual  is determined to be eligible for the study, 
he/she  will be enrolled  into the study . 
5.1.3 Em·olment 
 
 
 
"6'; After  signing  the informed  consent/assent fonn,  if an individual  is determined to be 
eligible  for study  participation,  the investigator  will emoll the subject.  
PR0-01 TEMP 06 / Atlas No. 293620  
Protocol V59_77 
Page 40 of86  GSK 
03FEB 16 Confidentia l 
Regulatory Review Protoco l Version 2 
VersionNo.4 / Version Date: January 29, 2015 00 
" 
::, z u 
8  
  
5.1.4 Randomization  
 
Upon  entering  subject demographic  data in IRT, the system willassign  a 7 digit  subject 
ID number consisting  of the 3 digit  site number  and 4 digit  order  of randomization  at the 
site. Access to IRT can be obtained  by the site staff either  via web or telephone  (as back 
up). The Subject ID willbethesubjec' ts unique identification number for all CRFs and 
associated study documentation that will beused for duration of the study. After 
randomization,  the Screening Number  ceases to be used and remains  in the Screening and 
Enrolment Log only .: During the randomization transaction in IRT Subjects will be 
assigned a kit number for Menveo vaccination and will berandomized  to a blood  draw  
schedule (1:1 according to age group and previous vaccination status).The list of 
randomization assignments  is produced  by the IRT service provider and approved  by 
GSK Randomizat ion Office  according to applicable  GSK  Standard Operating  Procedure 
(SOP) . 
 
IRT will also be used to ensure adequate and appropriate distribution of enrolment of 
naivesubjects  across all sites. Further details may be found  in study -specific  plans , for eg, 
the IRT User  Manual and the Randomization  Configuration Document.  
 
If for any reason, after signing the info11lled consent form (ICF) , the subject who is 
eligible  and enrolled  fails to be randomized, this is called  a randomization  failure  and the 
early terminat ion studyprocedures must be applied . The reason for all randomization 
failures should be recorded in the Screening and Enrolment Log and in the source 
document  as specified  in the Source  Data Agreement  (SDA) . The information on subjects 
who are randomization failures should be kept distinct from subjects who are screen 
failures , as described in section  5.1.2, Screening.  
If for any reason , after randomization the subject fails to undergo treatment, this is an 
Early Termination and the reason should be recorded in source document as specified in 
the SDA. The information on these Early Termination subjects should be kept distinct in 
the source  documentation from randomizat ion failures.  
 
Within each  study group, subjects willbeenrolled  across  age rangeof 15 to 55 years  of 
age as  follows:  
• Menveo -Menveo and Menactra -Menveo groups : approximately 80% of subjects will 
beenrolled in age groupof 15 to 25 years and 20% of subjects willbeenrolled in 26- 
55 years age group ; 
• Naive group:  approximately 50%  of subjects  willbeenrolled in age groupof 15 to 25 
years  and 50%  of subjects  will beenrolled  in age group  of26 -55 years . 
 
 
"6';  
PR0--01 TEMP 06 / Atlas No. 293620  
Protocol V59_77 
Page 41 of86  GSK 
03FEB 16 Confidentia l 
Regulatory Review Protoco l Version 2 
VersionNo.4 / Version Date: January 29, 2015 00 
" 
::, z u 
8  
  
Within  each age category in each study  group , subjects  will be randomized  into one of 
two different  blood  draw  schedules according  to a 1:1 ratio , described as follows:  
• Subjects  getting blood  draws  at Day 1, Day 4 and Day 29. 
• Subjects  getting blood  draws  at Day 1, Day 6 and Day 29. 
 
If for any reason, after enrolment the subject  fails to undergo  treatment/study  procedures 
this is an Early  Tennination  and the reason should  be recorded in source  document  as 
specified in the Source Data Agreement (SDA) . The information on these Early 
Termination  subjects  should  be kept distinct  in the source  documentation  from subjects 
who are screen failures , as described in section  S.1.2 , Screening . 
5.2 Vaccination Clinic Visit  
 
The first vaccination will be performed on Day 1.  
 
For studies  which  have  visits  for concomitant  vaccinations  or treatments , see section  6.5, 
Prior  and Concomitant  Medications  and Vaccines for those  visit procedures.  
 
Ensure all blood samples are taken p1i or to the vaccination. 
 
After completing the pre -vaccination procedures on day 1, administer the vaccine to the 
subject according to the procedures described in section 6.3, Vaccine Preparation and  
Administration. Observe the blinding procedures described in section 3.3, Blinding  
Procedures . 
Prior  to administrationof  study  vaccination,  confirm that the subject does  not meet any 
criteria for delaying additional study vaccinations  as described in section  4, Selection  of 
Study  Populat ion. 
5.2.1 Post-vaccination Proced ures 
 
The following post -vaccination procedures will be performed on day 1. 
 
• After vaccination, the subject will be observed for at least 30 minutes including 
observation for unsolicited adverse events , solicited adverse events , and body 
temperature measurement. Record all safetydata collected during this time in the 
subject 's source  document.  
• A Subject Diary  will be used in this studyto document  solicited  adverse events . The 
Subject  Diary  is the only source  for collection  of these data; therefore , it is critical  that 
the subject completes the Subject Diary correctly . The subject should be trained on 
how and when to complete each field  of the Subject  Diary.  
 
 
PR0-01 TEMP 06 / Atlas No . 293620  
Protocol V59_77 
Page 42 of86  GSK 
03FEB 16 Confidentia l 
Regulatory Review Protoco l Version 2 
VersionNo.4 / Version Date: January 29, 2015 00 
" 
::, z u 
8  
  
• The subject and/or parent(s)/legal guardian(s) should be trained on how to self- 
measu
re localsolici ted adverse  events. The measurement of solicited  local adverse 
events is to be performed using  the ruler provided  by the site. 
• The subject and/or  parent(s)/legal  guardian(s)  should  be instructed  how to perform 
bodytemperature measurement using the thermometer provided by the site. If the 
subject  feels unusually hot or cold during  the day, the subject and/or  parent(s)/legal 
guardian(s) should  check  body  temperature.  If the subject  has fever , the highest  body  
temperature observed  that day shoul d be recorded in the Subject Diary.  
 
Subject Diary training should be directed at the individual(s) who will perform the 
measurements of adverse events and who will enter the information into the Subject 
Diary.  This individual  may not be the subject and/or parent(s)/legalguardian(s), but if a 
person  other than the subject and/or  parent(s)/legal  guardian(s)  enters information into the 
Subject  Diary , this person 's identity  must be documented in the Subject Diary  or subject ' s 
source record. Any individual that makes entries into the Subject Diary must receive 
training  on completion  of the Subject Diary  at the time of the visit.  This training  must be 
documented in the subject 's source record . 
 
The same individual should complete the Subject Diary throughout the course of the 
study.  
 
• The site should schedule the next study activity clinic visit on Day 4 or Day 6  
depending  to which  blood  draw  schedule subject was randomized  to with the subject  
and/or  parent(s)/legalguardian(s).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
"6'; The subject  and/or  parent(s)/legal  guardian(s)  will be reminded  to comp lete the Subject 
Diary  and to contact  the site if there  are any questions , and to contact the siteinunediately 
(or as soon  as the subject  is medically  stable) if the subject has a medical  condition  that 
leads to a hospitalization  or an emergency roomvisit  or to a visit to/by  a doctor  or is of 
concern.  
5.2.2 Post-vaccinati on Reminde rs 
 
Reminder  calls  or alerts are not intended to be an interview  for collection of safety data. If 
the subject and/or  parent(s)/legal  guardian(s) wishes  to describe safety information,  this 
information should only be collected by a healthcare professional at the site , and the 
safety  data described must be written  down  in the subject 's medical chart.  
 
Subject Diar y Reminder Calls 
Subject Diary reminder calls will be performed on day 3 and day S. The purpose of this 
callis to remind the subject and/or parent(s)/legal guardian(s) about completion of the  
 
PR0-01 TEMP 06 / Atlas No.293620  
Protocol V59_77 
Page 43 of86  GSK 
03FEB 16 Confidentia l 
Regulatory Review Protoco l Version 2 
VersionNo.4 / Version Date: January 29, 2015 00 
" 
::, z u 
8  
  
Subject Diary . The ca ll follows the Subject Diary Reminder Telephone Call Script 
provided to the site . The subj ect and/or parent(s)/legalguardian(s) should be reminded to 
contact the site via the telephone number provided in the informed consent to discuss 
medical questions. If the clinic visit at Day 4 or Day 6 overlaps with the specified window 
of the Day 3 or Day 5 reminder call , the Day 3/Day 5 reminder call may be omitted . 
5.3 Post-vaccinati on Visit(s) 
 
Post-vaccinationvisits  will be performed  on Day 4 or Day 6according  to the blood  draw 
schedule to which  subject was randomized and Day 29. 
 
5.3.l  Follow -up Clinic Visit(s) 
 
Follo w-upclinic visits  will be performed  on Day 4 or Day 6 accordin g to the blood  draw 
schedule to which  subject was randomized and on Day 29.During  the follow -up clinic 
visit:  
 
• Subject  Diary  will be reviewed  at Day 29. No changes to the information  recorded 
within  the Subject  Diary  are permissible . For details  on the Subject Diary  see sections  
3.4.2, Tools Used for Data Collection and 5.2.1, Post -vaccinationProcedures . The 
subject and/or parent(s)/legal guardian(s) will be interviewed to determine if any 
unsolicited  adverse events  occurred and if any concomitant  medications  or vaccines  
were taken/received in the time since  the last clinic visit.  This interview  will follow  a 
script which will facilitate the collection of relevant safety information. The 
healthcare professional reviewing these data will discuss the symptoms (if any) 
reported  by the subject  and will determine  if any additional diagnoses  and/or  adverse 
events are present. Adverse events reported by the subject and/or parent(s)/legal 
guardian(s) at this follow -up clinic visit must be recorded in the subject's source 
document and on an Adverse Events CRF , as specified in section 7.1 , Safety  
Assessment, and not written  on the script  used for the interview . 
• Performa brief symptom -directed physical examination if necessary according to 
symptoms  the subject  has reported. This is a physical  examination  that will include  an 
examination  of organ  systems that are relevantto the investigator  based on review  of 
the subject's reported adverse events , concomitant medication use. This assessment 
may include: measurement of vital signs , body temperature and a check of general 
appearance . The physical assessment must be performed by the investigator or 
designee of the investigator , who is qualified to perform a physical assessment in 
accordance  with their  institutional  policy . Corresponding information  is documented 
in the subject ' s source  document  and CRF(s).  
• Collect a blood sample (see section 3.5, Collection of Clinical Specimens for 
additional information).  
 
PR0--0 1 TEMP 06 / Atlas No.293620 
Protocol V59_77 
Page 44 of86  GSK 
03FEB 16 Confidentia l 
Regulatory Review Protoco l Version 2 
PR0-01 TEMP  06 / Atlas  No.293620  
VersionNo.4 / Version Date: January 29,20 15  
  
Thesite should  schedule the next study  activity  safety  call withthe  subject and/or 
parent(s)/legal  guardian(s).  
 
The subject and/or  parent(s)/legal  guardian(s)] will receive  a written  reminder  of the next 
planned study  activity . The subject and/or  parent(s)/legal  guardian(s) will be reminded  to 
contact the site if there  are any questions  and to contact  the site immediately (or as soon 
as the subject is medically stable)  if the subject  has a medical condition that leads to a 
hospitalizationor an emergency  roomvisit.  
 
5.3.2 S afety Follow-up Calls 
 
Safety follow -up call will be performed on Day 1S, Day 91 and Day 181.  
 
Safety follow -up calls are calls made to the sub ject by a healthcare professional 
designated on the site log. These calls will follow a script which will facilitate the 
collection of relevant safety information . The subject and/or parent(s)/legalguardian(s) 
will be interviewed according to the script, and information related to unsolicited adverse 
events (only at Day 1S), serious adverse events (SAEs),  medically attended adverse 
events , AEs leading to withdrawal and concomitant medications or vaccinations 
associated with those events will be reviewed . All safety information described by the 
subject must bewritten down in a designated locatio n within the source document and not 
written  on the script  used for the telephone  call. 
 
The site should schedule  the next study  activity  with the subject and/or  parent(s)/legal 
guardian(s) . 
 
The subject and/or  parent(s)/legal  guardian(s) will be reminded  to contact  the site if there 
are any questions and to contact the site immediately (or as soon as the subject is 
medically  stable) if the subject  has a medical condition  that leads to a hospitalizationor 
an emergency room  visit.  
5.4 Unsch eduled Visits 
 
Unscheduled visits are not expected within this protocol.  
 
5.5 Study Terminati on Visit 
 
The study termination visit willoccur on Day 181. The termination visit will be a 
telephone call . The date of termination is the date of the last contact ( clinic visit or 
telephonecall) in which  the subject 's health  status  was assessed or, in cases where  the 
subject  does not agree to any further  safety  follow- up, it is the date consent  is withdrawn. 
This date should  be recorded  on the termination  CRF page . For visit procedures  to be 
Protocol V59_77 
Page 45 of86  GSK 
03FEB 16 Confidentia l 
Regulatory Review Protoco l Version 2 
PR0-01 TEMP  06 / Atlas  No.293620  
VersionNo.4 / Version Date: January 29,20 15  
  
performed for a subject whose planned study participation ends prematurely , please see 
section 5.5.1 , Early Termination Visit.  
During the telephone call , the following procedures will be performed: interview of 
subject and/or parent(s)/legal guardian(s) to collect medically attended adverse events , 
AEs leading  to withdrawal , SAEs , as well as interview  of subject and/or  parent(s )/legal 
guardian(s) to collect concomitant  medications/  vaccinations  associated with those  events. 
All safety information described by the subject nrust be written down in a designated 
location  within  the source  document  and not written  on the script  used for the telephone 
call. 
The site will review with the subject and/or parent(s)/legal guardian(s) the plan of when 
infonnation relating to the subject's participation in the study may be available  (e.g., 
study results, treatment assignments). It will also be discussed how information relating to 
the subject ' s participation in the study will be shared with the subject's healthcare 
provider , if the subject and/or parent(s)/legalguardian(s)  chooses to  share this 
infonnation.  
 
The sitewillcomplete  the terminati on CRF  page  and this will mark the completion of the 
subject 's participation in the  study.  
5.5.1 Early Termination Visit  
When a subject is withdrawn  from  treatment or withdraws  from  the study , the investigator 
will notifythe  Sponsor  and, when  possible, will perform  the procedures listed  below.  The 
reason(s)  for the early termination  will be included  in the subject ' s source  documentation. 
If the EarlyTermination  Visit  is a telephone call, collect as much infonnation  as possible . 
Early Termination Visits  include  subjects  who were randomized but not treated.  
 
At the clinic visit or during the telephone call, the following procedures will be 
performed: interview of subject and/or parent(s )/legal guardian(s) to collect adverse 
events , medically attended adverse events, AEs leading to withdrawal, SAEs, interview of 
subject and/or parent(s)/legalguardian(s) to collect concomitant medications/ 
vaccinations.  
 
The site will review with the subject and/or parent(s)/legal guardian(s) the plan of when 
infonnation relating to the subject's participation in the study may be available  (e.g., 
study results , treatment assignments). It will also be discussed how information relating to 
the subject ' s participation in the study will be shared with the  subject 's healthcare 
provider , if the subject and/or parent(s)/legalguardian(s)  chooses to  share this 
infonnation.  
Protocol V59_77 
Page 46 of86  GSK 
03FEB 16 Confidentia l 
Regulatory Review Protoco l Version 2 
PR0-01 TEMP  06 / Atlas  No. 293620  
VersionNo.4 / Version Date: January 29 , 2015 00 
" 
::, z u 
8  
  
Thesitewillcomplete the terminat ion CRF  page  and this willmark the comple tion of the 
subject 's participat ion in the study . 
Protocol V59_77 
Page 47 of86  GSK 
03FEB 16 Confidentia l 
Regulatory Review Protoco l Version 2 
PR0--01 TEMP  06 / Atlas  No. 293620  
VersionNo.4  / Version Date:  January  29, 2015  00 
" 
::, z u 
8  
  
6. TREATMENT OF  SUBJECTS  
 
All vaccines  associated  with this study  are to be stored  separately from  other  vaccines  and 
medications in a secure location under appropriate storage conditions with temperature 
monitoring . All vaccines associated with  this study  must  be  checked  for  expiration 
date p1i or to use . Expired  vacc ines must  not be administered to subjects.  
6.1 Study Vaccine(s)  
 
The term  'study  vaccine ' refers  to those  vaccines  provided by the Sponsor , which  will be 
evaluated as part of the study objectives. The study vaccines specific to this study are 
described below . The study vaccines specific to this study is the MenACWY -CRM 
vaccine  (Menve o® , GSK)  . 
 
The Meningococcal ACWY conjugate vaccine is obtained by extemporaneous mixing 
just before  injection  of the lyophilized  MenA -CRM  component  with the MenCWY -CRM 
fullliquid vaccine . The pharmaceutical form is Powder and solution for solution for 
injection. Menveo® is provided as vial/vial presentation . MenA lyophilised conjugate 
component (glass vial) and MenCWY liquid conjugate component (glass vial). After 
reconstitution, MenACWY -CRM will have the following c omposition per O.S mL of 
injectable  solution  (See Table  6.1-1): 
Protocol V59_77 
Page 48 of86  GSK 
03FEB 16 Confidentia l 
Regulatory Review Protoco l Version 2 
PRO -01 TEMP  06 / Atlas  No.293620  
VersionNo.4  / VersionDate:  January 29,2015  00 
" 
::, z u 
8  
  
Table 6.1-1: MenAC\VY -CR"l\1 Com  position 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
One 0.5 mL dose  ofMenACWY  willbe . . . . 
administered by mtranruscular (IM) tnJection m 
the deltoid area of non- dominant ann (preferably).  
 
For more detailed  infonnation,  refer to the latest  version of Investigator  Brochure and 
SPC for Menveo ® , which  are included  in the investigator site file. 
 
6.2 Non-Study Vaccines  
Not applicable.  
6.3 Vaccine Pr epa ratio n a nd Admi nistra tion 
 
The investigator  or designee  will be responsible  for oversight  of the administration  of 
vaccine  to subjects  enrolled  in the study  according to the procedures  stipulated  in this 
study  protocol  All vaccines will be administered  onlyby  personnel  who are qualified  to 
perform  that function  under applicable  local  laws  and regulations  for the specific  study 
site. 
All study vaccines to be administered to the subjects must be stored in a safe and locked 
place with no access by unauthorized personnel.  Name of Ingredient  Unit an d/orPercentage Fo rmula  
(Dose 0.5 mL) 
D111g S ubstances 
CRM1 91-MenA conjug;ite  10 µgMenA , 16.7-33.3µgCRM1 91 
CRM1 91-MenC conjug;ite  5 µgMenC, 7.1-12.5 µgCRM197  
CRM1 91-MenWconjugate  5 µg MenW, 3.3-  8.3µgCRM1 91 
CRM1 91-MenYconjug;ite  5 µgMenY , 5.6- 10µgCRM197  
Sodium chloride  4.5mg  
Excipients  
Sucrose  12.5 mg 
Sodium phosphate buffer 
Sodium dihydrogen phosphate  
Disodium hydrogen phosphate dehydrate  !0mM 
2.SmM  
7.SmM  
Potassium dihydrogen phosphate  5mM  
Water for Injection  q.s 0.5 mL 
VolumeofFormulation  0.6mL  
Appearance  Colorless tolight yellow 
Vaccine Presentation  Asingle dose of two v ials 
 
Protocol V59_77 
Page 49 of86  GSK 
03FEB 16 Confidentia l 
Regulatory Review Protoco l Version 2  
  
The study  vaccines will be stored  at the defined  temperature range  (i.e. +2 to +8C).  The 
storage  temperature  of the vaccines  will bemonitored daily  with temperature  monitoring 
devices and willberecorded . 
Any temperature deviation, i .e. temperature outside the range (+2 to +8 °C), must be 
reported  to thesponsor as soon as detected.  Following  the exposure to such a temperature 
deviation, vaccines  will not be used until written  approval has been  given  by the sponsor . 
The study vaccine  should be allowed  to reach room temperature  before  administration, 
according  to local  vaccination  practice.  
MenACWY- CRM (Menveo) vaccine is prepared by aseptically withdrawing all fluid 
fromthe  vial containing the MenCWY -CRM  liquid  conjugate component and injecting 
the liquid  into the vial containing the MenA -CRM lyophilizedportion. Invert  and shake 
the vial well until the vaccine is dissolved. The finalmixed vaccine is then ready for 
administrationof the MenACWY fornrulation  (0.5 mLJdose of injectable  solution) . 
 
Detailed vaccine preparation and administrationinstructions willbe provided to 
investigators in the Protocol Ancillary Document prior to study start.  
 
PRE CAU TIONS TO BE OB SERVE D IN ADMINIS TERING STUDY VAC CINE: 
 
Prior to vaccination, subjects must be determined  to be eligible  forstudyvaccination and 
it must  be clinically  appropriate  in the judgment of the investigator to vaccinate . 
Eligibilityfor  vaccination  prior to first study vaccine arlroini slTation is determined  by 
evaluating  the entry  criteria  outlined  in protocol  sections 4.1, Inclusion Criteria  and 4.2, 
Exclusion Criteria . 
Eligibilityfor non-studyvaccines should be determined by the investigator , pending the 
review of the package insert of the relevant vaccine . 
 
Study vaccines  should not be administered  to individuals with known hypersensitivity to 
any component of the vaccines . 
Standard immunization practices are to be observed and care should be taken to 
administer the injection : intramuscularly. Before administering vaccine , the vaccination 
site is to be disinfected with  a skin disinfectant  (e.g., 70% alcohol .)Allow  the skin to dry. 
DO NOT inject in travascularly . 
 
As with all injectable vaccines, trained medical personnel and appropriate medical 
treatment  should be readily  available  in case of anaphylactic reactions  following vaccine 
administration . For example , epinephrine 1:1000 , diphenhydramine , and/or other 
medications for treating  anaphylaxis should  be available . 
PR0-01 TEMP 06 / Atlas No. 293620  
VersionNo.4 / Vers ion Date: January 29, 2015 

Protocol V59_77 
Page 50 of86  GSK 
03FEB 16 Confidentia l 
Regulatory Review Protoco l Version 2 
::, z u 
8  
 ....  
6.4 Vaccine Adminish· ation En or or Overdose of Vaccine 
Vaccine  administration  error  is defined  as receiving  a dose of studyvaccine that was not 
reconstituted  as instructed or administered bya different  route  from  theintended route  of 
administration. An overdose of studyvaccine (whether accidental or intentional) is 
defined  when  a dosage higher than the recommended  dosage is administered  in one dose 
of study vaccine.  
Any vaccine administrationerror  or overdose of study vaccine  detailed  in this protocol 
must be reported  as an adverse  event,  and if the vaccine  administrationerror or overdose 
is associated  with a serious adverse  event, it must  be reported as such within  24hours to 
the Sponsor.  
6.5 Plior  and Concomitant  Medications and Vaccines 
 
All medicatoi ns, vaccines  and blood  products  taken or received  by the subject within  30 
days prior to the start of the study are to be recorded on the Prior and Concomitant 
Medications CRF.  
In addition , the following are considered prior medications for this protocol: all 
medication/vaccines  described in theinclusion and exclusion criteria of  this protocol 
including:  
 
• Systemic administration  of corticosteroids  (PO/IV/IM) for more  than 14 consecutive  
days within  90 days prior to study vaccination ; 
• Administration of antineoplastic anrl imm1momodulating  agents or radiotherapy 
within  90 days prior to study vaccination;  
• Tmmnonglobulins or anyblood products  within 180 days prior to informed consent ; 
• Systemic antibiotic  treatment  within  3 days prior to study vaccination or blood draw; 
• Any investigationalor non-registered  medicinal  product within  30 days prior to study 
vaccination ; 
• Administration  of vaccines  within  7 days (for inactivated  vaccines)  or 14 days (for 
live vaccines)  prior  to vaccination  in this study or who are planning to receive any 
vaccine  within  28 days from the studyvaccination . 
Use of analgesics/antipyreticsto prevent or treat solicitedAE s will be captured in the 
Subject Diary from day 1-7 following each vaccination. Medications taken for 
prophylaxis arethose intended to prevent the onse t of symptoms. Medicationstaken for 
treatment  are intended to reduce  or eliminate  the presence  of symptoms that are present.  
 
 
 
00 
.... PR0-01 TEMP 06 / Atlas No. 293620  
VersionNo.4 / Vers ion Date: January 29, 2015 
Protocol V59_77 
Page 51 of86  GSK 
03FEB 16 Confidentia l 
Regulatory Review Protoco l Version 2 
PR0-01 TEMP  06 / Atlas  No. 293620  
VersionNo.4 / Version Date: January 29, 2015 00 
" 
::, z u 
8  
  
Concomitant medications include all prescription and non- prescriptionmedications 
(including vaccines) taken by /administeredto the subject during the 30 days after study 
vaccination and nrust be documented on the Concomitant Medications CRF . Mineral 
supplements and vitamins are not considered concomitant medications . 
 
When recording con comitant medications/vaccines, they should be checked against the 
study entry and continuation criteria in section 4, Selection of Study Population to ensure 
that the subject should be enrolled/continue in the study . 
Concomitant medication dministered for treatment of AEs with medically -attended 
visits , AEs leading  to study  withdrawal  and SAEs must  be documented  during  the entire 
study  period.  
 
Any vaccine  not foreseen  in the studyprotocol  in the period  starting  at Day 1 and ending 
at Day 181 must be recorded  in the eCRF . 
 
6.6 Vaccine Suppl y, Labe ling, Storage and Tracking  
 
The Sponsor will ensure the following  
 
• Supply  the study  vaccine(s) . 
• Appropriate  labeling of all studyvaccines provided  that corq>lies  with the legal  
requirements  of each country where  the study is to be performed.  
The investigator must ensure the following:  
 
• Acknowledge  receipt  of the study  vaccines by a designated staff member at the site, 
including  
Confirmation that the vaccines were received in good condition  
Confirmation to the Sponsor of the temperature range during shipment from the 
Sponsor to the investigator ' s designated storage location  
Confirmation by the Sponsor that the vaccines are authorized for use . 
• Proper storage  of the studyvaccines , including:  
Storage in a secure, locked, temperature- controlled location . 
Proper storage according to the instructions specified on the labels . 
Appropriate record keeping and inventory of the study vaccines , including regular 
documentation of adequate storage temperat ure. 
• Appropriate  use of the study  vaccines , including : 
Protocol V59_77 
Page 52 of86  GSK 
03FEB 16 Confidentia l 
Regulatory Review Protoco l Version 2 
PR0-01 TEMP  06 / Atlas  No. 293620  
VersionNo.4 / Version Date: January 29, 2015 00 
" 
::, z u 
8  
  
Not use of vaccines prior to receipt of authorization  for use fromthe  Sponsor. 
Use only in accordance  with the approved protocol  
Proper  han dling , including  confirmation  that the vaccine  has not expired  prior  to 
administration.  
• Appropriate documentation of administrationof vaccines to study subjects  including:  
- Date , dosage, batch/lot numbers, expiration  dates , unique  identifying numbers 
assigned to subjects  and study  vaccines , and time of vaccine administration. 1bis 
information  will bemaintained in an accountability log that will bereviewed by 
the site monitor.  
- Reconciliation of all vaccines received from the Sponsor . Reconciliation is 
defined as maintaining records of which and how many vaccines were received, 
which vaccines were administered to subjects , which vaccines were destroyed at 
the site, and which  vaccines  were returned  to the Sponsor , as applicable.  
- Proper  adherence  to the local  institutional policy  with respect  to destruction  of 
study vaccines.  
• Complete record keeping of vaccine use, wastage , return or destruction , including 
documentation  of 
Copy of the site's procedure for destruction of hazardous material.  
Number of doses  destroyed,  date of destruction,  destruction  code (if available) , 
method  of destruction,  and name of individual  performing destruction.  
Vaccines that have  been stored  differently from  the manufacturer's  indications  must not 
be used unless  the Sponsor provides  written  authorization  for use. In the event that the use 
cannot  be authorized,  the Sponsor willmake every effort  to replace the vaccine supply.  
All vaccines  used in conjunction  with this protocol  must be stored  separatel y from  normal  
hospital/practice stocks to prevent  unintentional  use of study  vaccines outside  of the 
clinical  study setting . 
 
Monitoring  of vaccine accountability will be performed by the study  monitor  during site 
visits  and at the completion  of the study.  
 
At the conclusion of the study , and as appropriate during the course of the study , the 
investigator must ensure that all unused studyvaccines , packaging and supplementary 
label s are destroyed locally  (upon  approval  fromSponsor)  or returned  to the Sponsor  or to 
the Depot for  destruction.  
Protocol V59_77 
Page 53 of86  GSK 
03FEB 16 Confidentia l 
Regulatory Review Protoco l Version 2 
VersionNo.4  / Version Date:  January  29, 2015  00 
" 
::, z u 
8  
  
7. ASSESSMENTS  
 
7.1 Safety Assess ment 
The measures of safety  used  in this study areroutine  clinical procedures . They  include  a 
close vigilance for, and stringent reporting of, selected  local and systemic adverse  events 
routinely  monitored in vaccine clinical  studies  as indicators  of reactogenicity . 
An adverse event  (AE) is defined  as anyuntoward medical  occurrence in a subject or 
clinical  investigat ionsubject administered  a pharmaceutical  product at any dose that does 
not necessarily  have  to have a causal  relati onshipwiththis  treatment. Therefore , an AE 
can be any unfavorable  and unintended  sign (including  an abnormal laboratoryfinding , 
for example) , symptom, or disease temporally associated with the use of an 
investigational product,  whether  or not considered  related  to the investiga itonalproduct. 
This definition includes  intercurrent  illnesses or injuries  and exacerbation of pre-existing 
condit ions. 
The period of observation for AEs extends fromthe time the subject signs informed 
consent until he or she completes the specified safety follow- up period of 180 days or 
terminates the study early (whichever comes first). AEs occurring after the informed 
consent form  is signed but prior to receiving  studyvaccine/product will be documented as 
an adverse  event and recorded  within  source  document. However , any AEs occurring 
prior to receipt of anystudyvaccine  will be analyzed separately from " treatment 
emergent' ' AEs (AEs occurring after administration of the first study vaccine) . 
Adverse events  are collected  as either  solicited  or unsolic ited adverse events . Solicited 
events arederived from organized data collection systems, such as Subject Diaries or 
interview.  
7.1.1 Solicited Advers e Events 
 
The term"reactogenicity'' refers to solicited signs and symptoms ("solicited adverse 
events ") occurring in the hours and days following a vaccination , to be collected by the 
subject and/or parent(s)/legalguardian(s) for 7 consecut ive days, using a pre -defmed 
Subject Diary . 
The following solicited  adverse events are included  in the Subject  Diary . Each  adverse 
event  is to be assessed  using the scoring system reported  in parentheses  below : 
 
 
 
 
 
 
PR0--0 1 TEMP 06 / Atlas No. 293620  
Protocol V59_77 
Page 54 of86  GSK 
03FEB 16 Confidentia l 
Regulatory Review Protoco l Version 2 
VersionNo.4  / Version Date:  January  29, 2015  00 
" 
::, z u 
8  
  
Solicited Local AdverseEvents 
Injectionsite  pain, erythema,  induration , Solicited Systemic  Adverse Events 
Fatigue, headache, myalgia, arthralgia , loss of appetite, nausea , chills  and fever . 
Tabl e 7.1.1-1 Severity gradin g for solicited local and systemic AEs 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fever  is defined  and measured  by a body temperature  38.0°C(100.4F) . Route  of 
temperature measurement is preferably  oral.  
 
Othe r Indicat ors o f Rea ctogenicity: 
• Use of analgesics  / antipyretics  for prophylaxis (Days  1-7) 
• Use of analgesics  / antipyretics  for treatment  (Days  1-7) 
• Body temperature , described  in degrees  Celsius  and summarized  by route  of 
measurement and in 05°C increments from 36.·o c . 
The study staff must review the data entered  into the Subject Diary  as described  in section 
3.4.2, Tools Used  for Data  Collection  and section  S.3.1 , Follow-up Clinic  Visit( s). 
 
 
PR0-0 1 TEMP 06 / Atlas No. 293620   ]',fil d Moder ate Se.vel'e 
Pain  No interference with 
dailyactivity  Interferes with daily 
activity  Prevents daily activity  
Erythema  25-50mm  51- IOOmm  > l OOmm  
lnduration  25-50 mm  51- IOOmm  > l OOmm  
Fa ti gue No interference with 
dailyactivity  Interferes with daily 
activity  Prevents da ily activity 
Headache  No interference with 
activity  Interferes with daily 
activity  Prevents  daily  activities  
Myalgia  No interference with 
activity  Interferes with daily 
activity  Prevents  daily  activities  
Arthralgja  No interference with 
activity  Interferes with da ily 
activity  Prevents  daily  activities  
Loss ofa ppeti te Eating less than usual 
with no effect  on normal  
activity  Eating less than usua l / 
interfered with normal  
activity  Not eating at all  
Nausea  No interference with 
dailyactivity  Interferes with daily 
activity  Prevents daily activity  
Chills  No interference with 
activity  Interferes with daily  
activity  prevents dai ly activit ies 
 
VersionNo.4 / VersionDate: January 29, 2015  00 
" 
::, z u 
8  
 GSK  
03FEB16  Confidentia l 
Regulatory  Review  Protoco l Version  2 Protocol V59_77 
Page 55 of86 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
"6'; Note:  Anysolicited  adverse  event  that meets  any of the following  criteria  must be entered 
into subjects' source document (see section 9. 1, Source Documentation) and also as an 
adverse event  on the Adverse Event  CRF: 
 
• Solicited  local  or systemic adverse  event  that continues beyond day 7 after 
vaccination.  
• Solicited  local  or systemic adverse  event  that leads  to a visit to a healthcare  provider  
(medically  attended  adverse  event,  see section 7.1.3, Evaluation of Adverse Events ). 
• Solicited  local  or systemic adverse event  leading  to thesubject withdrawing  fromthe 
study or the subject being  withdrawn  from  the study by the investigator  (adverse event  
leadingto withdrawal,  see section  7.1.3, Evaluation of Adverse Events) . 
• Solicited  local or systemic adverse event  that otherwise meets  the definition  of a 
serious adverse  event  (see section 7.1.4, Serious Adverse Events ). 
7.1.2 Unso licited Adve rse Events 
An unsolicited adverse event is an adverse  event that was not solicited  using a Subject 
Diary and that was spontaneously communicated bya subject and/or parent(s)/legal 
guardian(s) who has signed the informed consent. 
Potential unsolicited  AEs may be medically  attended  (defined  as symptoms  or illnesses 
requiring hospitalization, or emerg ency room visit, or visit to/by a health care provider ,) 
or were of concern to the subject and/or parent(s)/legal guardian(s) . In case of such 
events , subjects and/or parent(s)/legal  guardian(s) will be instructed  to contact  the site as 
soon as possibl e to report the event(s) . The detailed information about the reported 
unsolicited AEs willbe collected  by the qualified  site personnel  during the interview  and 
will be documented  in the subject's records . 
 
Unsolicited  AEs that arenot  medically  attended  nor perceived  as a concern  by subjects 
and/or parent(s)/legal guardian(s) will be collected during interview with the subject 
[and/or parent(s)/legalguardian(s)  and by review of available  medical  records  at the next 
visit (see section  5.3, Post- vaccination  Visit(s )). 
7.1.3 Evalu ation of Adverse  Events 
Every effort  should be made  by the investigator  to evaluate  safety information reported  by 
a subject  for an underlying diagnosis  and to capture  this diagnosis  as the event  in the AE 
page. In other words , the practice of reporting only symptoms (e .g., "cough" or "ear 
pain") are better reported  according to the underlying  cause (e.g., "asthma exacerbation " 
or "otitismedia "). 
 
PR0-01 TEMP 06 / Atlas No.293620  
Protocol V59_77 
Page 56of86  GSK 
03FEB 16 Confident ial 
Regula tory Review Protoco l Version 2 
PR0-01 TEMP  06 / Atlas  No. 293620  
VersionNo.4 / Version Date: January 29, 2015 00 
" 
::, z u 
8  
  
Theseverity of events reported  on the Adverse  Events  CRF  willbe determined  by the 
investigator  as: 
 
Mild: 
Moderate: 
Severe:  transient  with no limitation  in normal  daily  activity. 
some limitation  in normal  daily  activity.  
unable to perform normal daily activity.  
 
The relationship of the studytreatment to an AE will be determined by the investigator 
based  on the following definitions:  
 
1. Not Related  
The AE is not related to an investigational vaccine if there is evidence that clearly 
indicates  an alternat ive explanation . If the subject  has not received the vaccine , the timing 
of the exposure  to the vaccine  and the onset  of the AE are not reasonably related in time, 
or other facts, evidence or arguments exist that reasonably suggest an alternative 
explanation,  then the AE is not related . 
2. Possibly  Related  
 
The administrationof the investigational vaccine and AE are considered reasonably 
related  in time and the AE could  be explained  by exposure to the investigational  vaccine 
or by other  causes.  
 
3. Probably  Related  
 
Exposure to the investigational vaccine and AE are reasonably related in time and no 
alternati ve explanation has been identified . 
 
The relationship of the studytreatment to an unsolicited AE will be determined by the 
investigator . 
 
Note : solicited  AEs will not be evaluated for relati onship to study treatment.  Grading for 
severity of solicited local and systemic AEs is described in section 7.1.1, Solicited  
Adverse  Events . 
 
Adverse events will also be evaluated by the investigator for the co -existence of any of 
the other following conditions :  
 
• "Medically  attended adverse event ": an adverse event that leads  to a visit to a 
healthcare provider.  
• AEs leading  to withdrawal:  adverse  events  leadin g to study or vaccine withdrawal . 
Protocol V59_77 
Page 57of86  GSK 
03FEB 16 Confident ial 
Regula tory Review Protoco l Version 2 
PR0-01 TEMP  06 / Atlas  No. 293620  
VersionNo.4 / Version Date: January 29, 2015 00 
" 
::, z u 
8  
  
If solicited or unsolicited adverse events have been reported and the subject and/or 
parent(s)/legalguardian(s)]  indicated that the symptoms  required  medical  attendance or 
were of concern, the subject and/or parent(s)/legalguardian(s ) must be contacted for 
further information.  
When  the subject and/or parent(s)/legal  guardian(s) is contacted  for any of these reasons , 
the contact  must be documented in thesubject's source documentation.  
All AEs, regardless  of severity , willbe monitored until resolution or until the investigator 
assesses them as chronic or stable . All subjects experiencing AEs - whether considered 
associated with the use of the study vaccine or not - must bemonitored until symptoms 
subside and any abnormal  laborator y values  have  returned  to baselin e, or until there  is a 
satisfactory explanation for the changes observed, or until death, in which case a full 
pathol ogist's report  shoul d be supplie d, if possibl e. The investigator' sassessmen t of 
ongoing Adverse Events at the time of each subject's  last visit should be documented  in 
the subject ' s medical  chart.  
7.1.4 Serious Adverse  Events 
A serious adverse event  (SAE) is defined  as any untoward medical  occurrence  that at any 
dose results  in one or more  of the following:  
• Death.  
• Is life-threatening (i.e ., the subject was , in theopinion of the investigator , at 
immediate  risk of death  from  the event  as it occUITed); it does not refer to anevent 
which  hypothetically tnight have  caused  death  if it were  more  severe.  
• Required or prolonged hospitalization. 
• Persisten tor significan t disability /incapacity (i.e., the even t causes a substantial 
disruption of a person 's ability  to conduct normal life functions).  
• Congenital anomaly /or birth  defect.  
• An important and significant medical event that may not be immediately life 
threatening or resulting in death or hospitalization but, based upon appropriate 
medical  judgment, may jeopardize  the subject or may require  intervention  to prevent 
one of the other outcomes listed  above . 
Adverse events which do not fall into these categories are defined as non -serious.  
It should be noted that a severe  adverse  event  need  not be serious in nature  and that a 
serious adverse  event need  not, bydefinition,  be severe.  
Protocol V59_77 
Page 58of86  GSK 
03FEB 16 Confident ial 
Regula tory Review Protoco l Version 2 
PR0-01 TEMP  06 / Atlas  No. 293620  
VersionNo.4 / Version Date: January 29, 2015 00 
" 
::, z u 
8  
  
Serious  adverse events  will be captured both on the Vaccines  Serious  Adverse  Event 
(VSAE)  form  as well as on the AE CRF.  All SAEs will be evaluated by the investigator 
for relationship of the event to studyvaccine. SAEs that are judged to be possibly or 
probably related to the study vaccine should be reported to the Sponsor as 
related/suspected  events.  
 
The relationship of the studytreatment to an SAE will be determined by the investigator 
based on the following definitions:  
 
1. Related/suspect ed 
 
The SAE  is judged  by the investigator  to be possibly  or probably related to the study 
vaccine on the AE CRF  page (see section7.1.3, Evaluation of Adverse Events). 
 
2. Not Related  
 
The SAE is not related if exposure to the study vaccine has not occurred, or the 
occurrence of the SAE  is not reasonably related in time, or the SAE  is considered 
unlikely to be related to use of the study  vaccine, i.e., there  are no facts  (evidence)  or 
arguments to suggest  a causal  relationship . 
 
The relationship of the studyvaccine to an SAE will be determined by the investigator.  
 
In addition , SAEs  will be evaluated by the Sponsor or designee  for "expectedness. " An 
unexpected  AE is one that is not listed  in the cUITent  Summary  of Product  Characteristics 
or the Investigator's  Brochure  or an event that is by nature  more  specific  or more severe 
than a listed  event  
 
In addition , a pre -existing event or condition that results in hospitalization should be 
recorded  on the Medical  History  CRF. If the onset  of an event  occUITed  before  the subject 
entered the study (e.g., any pre -planned hospitalization for conditions like cosmet ic 
treatments or for non -emergency routine visits for a pre -existing condition) , the 
hospitalizationwould not lead to an AE being classified as serious unless , in the view of 
the investigator , hospitalization was prolonged as a result of participation in the clinical 
study or was necessary  due to a worsening  of the pre-existing  condition . 
7.1.4.1 Adverse Events of Spec ial Interest 
Adverse Events of Special Interest (AESis) will not be assessed during the study . 
Protocol V59_77 
Page  59 of86  GSK 
03FEB 16 Confident ial 
Regula tory Review Protoco l Version 2  
  
7.1.S Methods for R ecording Adverse Events and Se1ious Adverse Events 
 
Findings regarding Adverse Events must be reported on an Adverse Events CRF , as 
specified in section  7.1.1, Solicited  Adverse  Events , and on the VSAE  form,  if applicab le, 
which  is part of the Investigator  Site File. All findings  in subjects experiencing AEs nrust 
be reported also in the subject's  source  document.  
 
All SAEs which  occur during  the course  of the study, whether  considered to be associated 
withthe  study  vaccination or not, must  be reported w i thin 24 hours o f the site becomin g 
awar e of the event to GSK  or its designee . Specific  instructions  and contact details  for 
collecting  and reporting  SAEs to GSK  willbeprovided  to the investigator . 
 
All SAEs are also to be documented on the Adverse Events CRF. Any medication or 
other therapeutic measures used to treat the AE will berecorded on the appropriate 
CRF(s) in addition to the outcome of the AE.  
 
After receipt of the init ial report, representatives of GSK or its designee willcontact the 
investigator if it is necessary to obtain further information for assessment of the event.  
 
All SAEs must be reported by the invest igator to his/her corresponding EC / IRB 
applicab le regulatory authoriti es in accordance with inst itutional policy /regulatory 
requirements and adequate documentation of this notification must be provided to the 
Sponsor . 
 
GSK or its designee must also comply with the applicable regulatory requirement(s) 
related to the reporting  of suspected  unexpected  serious  adverse vaccine  reactions (also 
known  as SUSARs) to the regulatory  authority(ies)  and the IRB/EC . If a SUSAR or other 
safety signal relating to use of one of the study vaccines is reported to GS K or its 
designee, the Sponsor willcommunicate the information to the investigator and the 
investigato r will beresponsi lb e forsubmittin g this infonnation  to the EC/IR B and other 
relevant authorities . 
 
7.1.S. l Post-S tudy Even ts 
 
Any SAE  that occurs  outside  of the protocol -specifiedfo llow-up period  and considered to 
be caused by the study vaccine  nrust  be reported  to GSK or its designee . These SAEs will 
be processed by GSK or its designee  as during  the course  of the study, until  1 month  after 
Last Subject Last Visit (LSLV) . Instructions and contact details for collecting and 
reporting these  suspected  SAEs will beprovided  to the investigato .r 
 
 
 
 
 
PR0--0 1 TEMP 06 / Atlas No. 293620  
VersionNo.4 / Vers ion Date: January 29, 2015 

Protocol V59_77 
Page  60 of86  GSK 
03FEB 16 Confident ial 
Regula tory Review Protoco l Version 2 
::, z u 
8  
 ....  
7.1.6 Pregnan cies 
 
To ensuresub jects' safety , each  pregnancy in a subject after study  vaccination must be 
reported  to GSK or delegate within  72 hours  of the site learning  of its occurrence . If the 
subject  agrees to submit  this information,  the pregnancy must be followed  to determine 
outcome , including  spontaneous  or voluntary  termination,  details of the birth,  and the 
presence or absence of any birth  defects , congenital  abnormalit ies, or maternal and/or 
newborn  complications . This follow -up should occur even  if intended duration  of safety 
follow -up for the study  has ended . 
 
Pregnancy data must be recorded on a Pregnancy Report CRF (initial report) and 
Pregnancy Follow- Up CRF (outcome report) and reported to GSK or de legate.  
Instructions and contact details for submitting the Pregnancy CRFs will be provided to the 
investigator . 
Any pregnancy outcome mee ting the definition of a SAE (see section 7.1.4, Serious  
Adverse Events ) must also be reported on the VSAE Report Form.  
 
7.1.7 Safety  La bora tory l\lll eas ur em e n ts 
No safety laboratorymeasurements will be done in this study.  
 
7.2 Effica cy Assessment  
This section is not applicable . This study has no efficacy measurements.  
 
7.3 Immun ogenicity Assessm ent 
 
The functional measure of immunogenicity used in this study, Serum Bactericidal Assay 
(SBA) , is a measure of the ability of antibodies , in concert with human complement, to 
kill meningococci, and is widely used and generally recognized as the serological 
correlate of protection The key measures of irom1mogenicity willbe the percentages of 
subject s with  serorespon se[I J  , percentages  of subjects who achiev e hSBA  titers  8  and, 
and the hSBA GMfs against serogroups A, C , W and Y reference strains  
 
These measurements  willbe assessed  in serology samples collected at Visit Day 1 , 4 or 8 
and Day 29. The measures of immunogenicity  used in this study  are standard,  i.e., widely  
 
 
[I J Seroresponse to N. mening itidis serogrou ps A, C, W and Y is defined as: for subjects with a pre - 
vaccinat
ion hSBA  titer < 4, a post-vaccination hSBA  titer 2:8; for subjectswith  a pre-vaccinati on hSBA titer 
2:4, an increase in hSBA  titer of at least four times  the pre -vaccinationtiter.  
 
 
 
00 
.... PR0-0 1 TEMP 06 / Atlas No. 293620  
VersionNo.4 / Vers ion Date: January 29, 2015  
Protocol V59_77 
Page  61 of86  GSK 
03FEB 16 Confident ial 
Regula tory Review Protoco l Version 2 
VersionNo.4  / Version Date:  January  29, 2015  00 
" 
::, z u 
8  
  
used and generally recognized as reliable , accurate , and relevant (able to describe the  
quality and extent of the immune response).  
All subjects  will have  a blood draw  at Day I , before  vaccination.  Subsequent  blood  draws  
willbe at either Day 4 or Day 6 post vaccination, and at Day 29 post vaccination.  
Primary:  
Collected  samples may be used  in other assays , for test improvement  or development of 
analytical methods  related to the study  vaccines or the disease under evaluation  to allow a 
more reliable measurement of the vaccine response . Under these circumstances , 
additional testing on the samples may be performed by GSK outside the scope of the 
protocol Any sample testing willbe done in line with the consent of the individual 
subject's parent/  guardian.  
 
Testing willbe conducted by qualified and certified laboratories. All assays will be 
performed in GSK, Clinical Laboratory Sciences , or a delegate laboratory.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PR0-01 TEMP 06 / Atlas No. 293620  
Protocol V59_77 
Page  62 of86  GSK 
03FEB 16 Confident ial 
Regula tory Review Protoco l Version 2 
VersionNo.4  / Version Date:  January  29, 2015  00 
" 
::, z u 
8  
  
8. STATISTICAL CON SIDERATI ONS 
 
8.1 Endpoints 
8.1.1 Plim ai-y En dpoint(s) 
 
8.1.1.1  P1im ary Safety Endpoint(s) 
 
There are no primary safety endpoints in this study . 
8.1.1.2  P1im ar y Efficacy Endpoint(s) 
 
There are no primary efficacy endpoint s in this study.  
 
8.1.1.3  P1ima ry Immunogenicity Endpoin t(s) 
 
Thefollowing measure will be summarized for the pooled (Menveo -Menveo and 
Menactra- Menveo) group  
 
1. Percentage of subjects  with hSBA  seroresponse5 against N. meningitidis  
serogroups A, C, W and Y at Day 29. 
8.1.2 Seco ndary Endpoin t(s) 
 
8.1.2.1  Secon dary Safety Endpoint(s) 
 
Safety of the study vaccine willbe assessed in the pooled vaccine group (Menveo - 
Me
nveo and Menactra -Menveo) and the vaccine- naive group in terms of the frequency 
(percentage) of reported adverse events including  
 
1. Any unsolicited  AEs reported  within  30 minutes  after vaccination;  
2. Solicited  local and systemic  AEs reported from  Day 1 (6 hours)  through  Day 7 
after vaccination;  
3. Other  indicators  of reactogenicity  (e.g. use of analgesics / antipyretics , body 
temperature)  within  7 days after vaccination;  
4. All unsolicited  AEs reported  from  Day 1 through  Day 29 after vaccination;  
 
 
 
 
5 Seroresponse is defined as: a) post-vaccination hSBA?: 8 for subjectswith a pre-vaccinati on hSBA <4; b) 
for subjects with a pre -vaccinationhSBA ?:4, an increase of at least four times the pre-vaccination hSBA.  
 
 
PR0--01 TEMP 06 / Atlas No.293620 
Protocol V59_77 
Page 63 of86  GSK 
03FEB16  Confident ial 
Regula tory Review Protoco l Version 2  
  
5. Medically -attended AEs, AEs leading  to withdrawal and SAEs  reported from Day 
1 through Day 181 (entire  study period) . 
Adverse events will be coded using MedDRA preferred terms as applicabl e. 
 
8.1.2.2  Secondar y Effica cy Endp oint(s)  
There are no secondary efficacy endpoints in this study.  
 
8.1.2.3  Secondar y Immun ogenicity Endp oint(s) 
The following measures will be  nmmari:i:ed  for Menveo -Menveo , Menactra -Menveo, 
Naive and the pooled (Menveo-M enveoand Menactra-M enveo)groups unless otherwise 
noted:  
 
1. Percentage  of subjects  with hSBA titer 8 against  N. meningitidis  serogroups A , C, 
Wand  Y at Day 1, Day 4, Day6  and Day 29; 
2. Percentagesof  subjectswith  hSBA  seroresponse against  N. meningitidis  
serogroups A, C, Wand  Y at Day 4, Day6  and Day 29 (Day  29: Except  the 
pooled group);  
3. hSBA GMfs  againstN.  meningitidis serogroup A , C, Wand  Y at Day 1, Day 4, 
Day 6 and Day 29; 
4. Ratios  of hSBA GMfs  atDay 1 , Day 4, Day 6 and Day 29 (between  study  
groups).  
5. Ratios of hS BA GMfs  atDay  4, Day6, and Day 29 compared  to Day 1 (within 
study groups).  
8.1.3 Explora  tory En dpoin t(s) 
 
8.1.3.1  Explorat ory Safety Endpoint(s)  
There are no exploratory safety endpoints in this study.  
 
8.1.3.2  Explorat ory Effica cy Endpoint(s)  
There are no exploratory efficacy endpoints in this study . 
 
8.1.3.3  Explora tory Immun ogenicity Endpoint(s) 
 
There are no exploratory immunogenicity endpoints in this study.  
 
 
 
PR0-0 1 TEMP 06 / Atlas No. 293620  
VersionNo.4 / Vers ion Date: January 29, 20 15 

Protocol V59_77 
Page 64 of86  GSK 
03FEB16  Confident ial 
Regula tory Review Protoco l Version 2 
::, z u 
8  
 ....  
8.2 Success C1iteria  
 
8.2.1 Success C1iteria for P1imary Objective(s) 
 
8.2.1.1 Success C1ite1ia for P1imary S afety Obje ctive(s) 
There are no primary safety  objectives in this study . 
8.2.1.2 S uccess C1ite1ia for P1ima r y Effica cy O bjective(s)  
There  are no primary  efficacy  objectives  in this study.  
8.2.1.3 Success C1ite1ia for P1imary Immun ogenicity Objective(s)  
To demonstrate  immune response  sufficiency  after  MenACWY -CRM  booster  vaccine 
administration, the lower limit of the one -sided 97.S% Confidence Interval (CI) for 
percentage of subjects with hSBA  seroresponse  against each  of serogroups  A, C, Wand  
Y must be greater than 80% (in the poo led group of subjects who received primary  
vaccination with Menveo or Menactra) . The thresho ld of80% was previously agreed for 
demonstration of immune response adequacy in other age groups (e.g. in infants , study 
VS9_36). 
 
8.2.1.3.1  Rationale for C ombining the Menveo-Menveo and Menach ·a-Menveo 
groups 
Table 8 .2.1.3.1-1 shows  excerpt of data from  a previous  study  (VS9P l3El) assessing the 
immunogenicityof  a booster dose of Menveo among  subjects  who had previously been 
vaccinated with either Menveo or Menactra 3 years  prior  in another study  (VS9P13)  while 
subjects were 11- 18 years old. The table shows almost identical seroreponse rates and 
95%  Cls at one-month post-booster dose  of Menveo  for subjects  previous  vaccinated with 
Menveo and Menactra. This suggests that data from the two groups can be pooled or 
combined for analysis  of seroresponse  following  a booster  doseof Menveo as planned in 
the current  studyVS9_ 77. 
 
 
 
 
 
 
 
 
 
 
 
 
 
00 
.... PR0--0 1 TEMP 06 / Atlas No. 293620  
VersionNo.4 / Vers ion Date: January 29, 2015 
Protocol V59_77 
Page 65 of86  GSK 
03FEB16  Confident ial 
Regula tory Review Protoco l Version 2 
::, z u 
8  
 ....  
Table8.2.l.3.l -1:  hSBASerores ponse at One Month Follow ing the Booster at 3 
Year s After  Vaccination,  by Serogroup - Booster- PP Population  
 
Vacc ination  ACWY /ACW Y 
Gt·o up IV  Mena ctJ"a/A 
GroupV  Y Differ ence'  
G1·onp IV - G 1·onp V 
<I'. 
Q. :, eco   Overal l Seroresponse  
e  
 
68 (97%)  
(90-100)  
 
70(100°/o)  
(95 -100)   
 
(-3%) 
(-10-2) 
N=70 N=70  
u 
Q. :, eco   Overal l Seroresponse  
e  
 
66 (93%)   
 
65 (93%)    
 
(0%)  
(84-98) (84-98) (-9-10) 
N=71 N=70  
 
 
 
Q. :, 
ee  Overal l Seroresponse   
 
63 (91%) 
(82-97)  
 
64 (93%)  
(84-98)   
 
(-! %) 
(-11-8) 
N=69  N=69   
> 
Q. :, 
.ec.o   Overal l Seroresponse  e "'  
 
63 (90%)  
(80-96)  
 
65 (93%)  
(84-98)   
 
(-3%) 
(-13-7) 
N=70 N=70  
Source : Table 14.2.1.7 of Clinical Study  Report  for V59P l 3El; 'Data represented  as (difference in %)(95% 
CI of  difference ). 
 
 
8.2.2 Success C1iteria  for Secondar y Obje ctive(s)  
 
8.2.2.1  Success C1ite1ia for Secondar y Safety Objective(s)  
 
There are no success criteria associated with the secondary safety objectives . 
 
8.2.2.2  S uccess C1ite1ia for Seco ndar y Efficacy Objecti ve(s) 
There are no secondary efficacy objectives in this study . 
 
 
 
 
 
 
00 
.... PR0-01 TEMP 06 / Atlas No.293620  
VersionNo.4 / Vers ion Date: January 29,20 15 
Protocol V59_77 
Page 66 of86  GSK 
03FEB16  Confident ial 
Regula tory Review Protoco l Version 2 
VersionNo.4 / Version Date: January 29, 2015 00 
" 
::, z u 
8  
  
8.2.2.3  Success C1ite1ia for Secondar y Immunoge nicity Objective(s)  
 
There are no success criteria associated withthe  secondary  immunogenicity object ives in 
this study . 
 
8.3 Anal ysis Sets  
8.3.l AllEnroll ed Set 
 
All screened subjects who provide informed consent and provide demographic and/or 
baseline screening assessments, regardless of the subject 's randomization and treatment 
status in the study, and received a Sub ject ID . 
8.3.2 All E xposed  Set 
 
All subjects in the enro lied se t who rece ive a study vaccinat ion. 
 
8.3.3 Safety  Set 
 
Solicited Safety S et (solicited local an d sys temic adver se ev ents and other solicited 
adve rse events) 
 
All subjects in the Exposed  Set with any solicited  adverse event data. 
Unsolicited Safety Set (unsolicited a dverse events) 
All subjects in the Exposed  Set with unso licited  adverse event  data. 
Overall Safety  Set 
All subjects who are in the So licited Safety Set and/or Unsolicited Safety Set. 
 
Subjects  will be analyzed  as "treated " (i.e., according  to the vaccine a subject received, 
rather  than the vaccine to which  the subject  may have  been randomized).  
 
8.3.4 Full Anal ysisSet (FAS)Effica cy/l mmun ogenicity Set 
Full Anal ysis Set Immunoge nicity 
FAS <Day 1) 
All subjects in the All Enroll ed Set who:  
• are randomized;  
 
 
PR0--0 1 TEMP 06 / Atlas No . 293620  
Protocol V59_77 
Page 67 of86  GSK 
03FEB16  Confident ial 
Regula tory Review Protoco l Version 2 
VersionNo.4 / Version Date: January 29, 2015 00 
" 
::, z u 
8  
  
• provide  evaluab le serum  samples at Day 1 whose  result  is available for at least  one 
serogroup.  
FAS (Day4)  
All subjects in the All Enrolled Set who:  
• are randomized;  
• receive  the study  vaccination;  
• provide evaluab le serum samples at Day 1 whose result is available for at least one 
serogroup (except for hSBA titer 8 , GMTs and between -group GMRs calculated at 
specific timepoints); and 
• provide evaluab le serum samples  at Day 4 whose  result  is available  for at least one 
serogroup.  
FAS (Day6)  
 
All subjects in the All Enrolled Set who:  
• are randomized;  
• receive  the study  vaccination;  
• provide evaluab le serum samples at Day 1 whose result is available for at least one 
serogroup (except for hSBA titer 8 , GMTs and between -group GMRs calculated at 
specific  timepoints);  
• provide  evaluab le serum samples at Day 6 whose result  is available for at least one 
serogroup.  
FAS (Day29)  
All subjects in the All Enrolled Set who:  
• are randomized;  
• receive  the study  vaccination;  
• provide evaluab le serum samples at Day 1 whose result is available for at least one 
serogroup (except for hSBA titer 8 , GMTs and between- group GMRs calculated at 
specific  timepoints);  
• provide  evaluab le serum  samples at Day 29 whose result  is available  for at least one 
serogroup.  
In case of vaccination  error, subjects  in the FAS  sets will be analyzed " as randomized " 
(i.e., according  to the vaccine a subject was designated to receive, which  may be different 
fromthe  vaccine the subject  actually  received).  
 
PR0-01 TEMP 06 / Atlas No.293620  
Protocol V59_77 
Page 68of86  GSK 
03FEB16  Confident ial 
Regula tory Review Protoco l Version 2  
  
8.3.S Per Protocol (PP) Set Efficacy/l mmunoge nicity Set 
 
A PPS will be defined for each FAS  described in the previous  Section  with additional 
criteria  specified  below: _All subjects  in the FAS  Immunogenicitywho:  
• Correctly  receive the study  vaccine (i.e., receive the vaccine  to which  the subjects  is 
randomized and at the scheduled time points).  
• Have no protocol deviations l eadingto exclusion (see section 8.3.8, Protocol  
Deviations ) as defined prior to unblinding / analysis . 
• Are not excluded  due to other  reasons defmed prior to unblinding  or analysis  (see 
section 8.3.8,  Protocol  Devia tions) 
 
Examples for subjects excluded  due to other reasons than protocol  deviations  are: 
Subjects  who withdrew  informed  consent.  
8.3.6 Other Anal ysis Sets 
 
There are no other analysis sets used in this study . 
 
8.3.7 Subgroups 
 
Using  the FAS (Day 29), the analyses of the primary  objectives will be replicatedby: age 
group; center; gender; and race. 
8.3.8 Protocol Deviation s 
 
A protocol deviation is any change , divergence, or departure from the study design or 
procedures of a study  protocol.  A protocol  deviation  may be a reason to remove  data from 
an analysis set at the time of analysis . CSR-reportab le protocol  deviations  will be defined 
as exclusionary  fromthe  analysis according  to protocol objectives  and endpoints , which 
will be specified  in the statistical analysis  plan. In some cases exclusion of data may be 
due to a reason  other  than a protocol  deviation,  e.g. earlytermination . 
 
8.4 Statistical Anal ysis Plan  
 
8.4.l An alysis of Demogr aphic  an d Baseline C hara cteris tics 
 
Descriptive statistics (mean, standard deviation, median , minimum and maximum) for 
age, height and weight at enrolment will be calculated overall and by study group . 
 
Distributions  of subjects by sex and ethnic  origin  will be summarized  overall  and by 
study  group . 
 
PR0--0 1 TEMP 06 / Atlas No. 293620  
VersionNo.4 / Vers ion Date: January 29, 2015 

Protocol V59_77 
Page 69 of86  GSK 
03FEB16  Confidentia l 
Regulatory Review Protoco l Version 2  
 ....  
8.4.2 Anal ysis of Primary Objective(s)  
 
8.4.2.1  Analysis of Primary Safety Objective(s) 
There are no primary safety o bjectives in this study.  
8.4.2.2  Anal ysis of Primar y Effi cacy Objective(s) 
There are no primary  efficacy objectives  in this study.  
8.4.2.3  Anal ysis of Pr imar y Immun  ogenicity Objective(s)  
 
8.4.2.3.1  Sta tistical Hypotheses 
Null  hypothesis:  P, :::; 0 ,8 0 
Al terna tive hypothesis: P, > 0 .80 
 
Where: P, is the popula tion seroresponse rate for the pooled Menveo -Menveo and 
Menactra -Menveo group; i =,1 2, 3 4 refer to serogrou p A, C, Wand Y respecti vely. The 
level of significance is fixed at one -sided 0. 025. 
 
8.4.2.3.2  Anal ysis Sets 
 
The analysis population  to be used for the primary objectives  is the FAS  (Month  l) Set. 
Analyses of primary objectives willberepeated on the PPS (Month 1) to assess 
robustness of  results . 
 
8.4.2.3.3  Statis tical Methods 
 
General 
 
Missing  immunogenicity values are assumed MCAR  (Miss ing Comple tely At Random ) 
and therefore  may not contain information that impact  the result  of the analysis (i.e., not 
informative).  Imputation  methods  willtherefore  not be used.  
 
Overall si gnifi cance level for all hypothesis tests is one-sided a = 2.5%. 
 
 
 
 
 
"6'; 
00 
.... 
 
::, z 
u 
8  
PR0-01 TEMP 06 / Atlas No. 293620  
VersionNo.4 / Vers ion Date: January 29 , 2015 

Protocol V59_77 
Page 70 of86  GSK 
03FEB16  Confidentia l 
Regulatory Review Protoco l Version 2 
PR0-01 TEMP  06 / Atlas  No. 293620  
VersionNo.4 / Version Date: January 29, 2015  
  
Seroresponse (Day 29)  
Seroresponse is defined  as: a) post-vaccinat ion hSBA titer 8 forsubjects with a pre- 
vacci
nation  hSBA t iter <4; b) forsubjects  with a pre-vaccinationhSBA  titer 4, an 
increase of at least four times  the pre-vaccination  hSBA . 
For 
each ACWY serogroup , the percentage of subjects withseroresponse will be 
computed, along with associated two -sided 95%Clopper -Pearson Cls. 
Further details of the statist ical methods will be provided in the SAP . 
8.4.3 Analysis of Seconda  ry Obje ctive(s)  
8.4.3.1 Analysis of Seco nda ry Safety Ob jective(s) 
8.4.3.1.1 Anal ysis of Extent of Exposure 
Subjects will be analyzed  to the extent that they were exposed  to study  vaccines and 
according to the availab le safety  data for the subject  during any study period . Subjects 
who withdraw  early or who are lost to follow-upwill  be removed  from  the summary  table 
denominator for the time period in which  they have  no availa ble safety  data collected . 
8.4.3.1.2 Analysis of Solicited Local, Systemic an d Oth er Adve rse Events 
 
All solicited  adverse  events  will be summarized according to defined  severity  grading 
scales . 
Frequencies and percentages of subjects experiencing each adverse event will be 
presented  for each symptom severity . Summary  tables showing the occUITence of any 
localor systemic adverse  event  overall  and at each time point will also be presented . 
Post-vaccination solicited adverse events reported from Day 1 to Day 7 willbe 
summarized  for the intervals  Day 1 (6 hours) - Day 3, Days  4-7, Day 1 (6 hours)  - Day 7 
by maximal severity and by study group. Separate analyses will be performed for 
solicited AEs reported 30 minutes after vaccination. The severity of solicited local 
adverse events , including injection-site erythema and induration,  will be categorized 
based  on linear measurement: None  (0-24 mm), Mild  (25-50 mm), Moderate (51-100 
mm), Severe ( > 100mm) . 
Injection site pain and systemic reactions , including fat igue, headache, myalgia , 
arthralgia, chills , nausea , lossof appetite , occurring up to 7 days after each vaccination 
will be summarized according to "mild", "moderate" or "severe" . 
Protocol V59_77 
Page 71 of86  GSK 
03FEB16  Confidentia l 
Regulatory Review Protoco l Version 2 
PR0--01 TEMP  06 / Atlas  No. 293620  
VersionNo.4  / Version Date:  January  29, 2015   
  
Each solicited  local and systemic  adverse event will also be further  summarized as "none" 
versus  ''anY'. 
Use of antipyret ics and analgesics will be summarized by frequency, by type of use 
(prophylactic  versus  treatment)  and percentage of subjects  reporting  use. 
Body teJl1)erature will be summarized separately according to the 3 schemes described 
below and will be broken down according to route of measurement:  
• by O.S °C increments from 36 .0°Cup to ,::40°C; 
• by 1°C increments: <36.0, 36.0-36.9, 37.0-37.9, 38.0-38.9, 39.0-39.9, ,::40°C; 
• According to different cut-offs (< versus ::::): 38 . 0 , 38 .S , 39 . 0 , 39 . S , 40 .0 ° C . 
 
8 .4 .3 .1. 3 An al ys i s o f U n so li cited Advene Even ts 
 
1bis analysis  applies  to all adverse events  occurring  during  the study, judged either  as 
probably related , possibly related , or not related to vaccination by the investigator, 
recorded  in AE CRF , with a start date on or after the dateof first vaccination. AE starting 
prior to the first vaccination willonly be listed . The original verbatim terms used by 
investigators  to identify  adverse events  in the CRFs  will be mapped to preferred terms 
using the MedDRA dictionary . The adverse events will then be grouped by MedDRA 
preferred terms into frequency tables  according  to system  organ  class  (SOC) . 
 
All reported adverse events , as well as adverse events judged by the investigator as at 
least possibly related to study vaccine, will be summarized according to SOC and 
preferred term within  SOC . These summaries will be presented by study  group  and by 
interval  of study observation. When an adverse  event occurs  more than once  for a subject, 
the maximal  severity and strongest  relationship to the vaccine  will be counted.  
 
Separate summaries  will be produced for the following categories:  
• Adverse  events  that are possibly or probably  related to vaccine  
• Unsolicited  AEs reported within  30 minutes  after  vaccination  
• Unsolicited  AEs reported within  30 days  after vaccination  
• Adverse  events  leading  to withdrawal  
• Adverse  events  leading  to a medically attended visit  
• Serious adverse events  
Data listings  of all adverse  events will be provided  by subject. In addition , adverse events 
in the categories above  will be provided  as listed  data.  
Protocol V59_77 
Page 72 of86  GSK 
03FEB16  Confidentia l 
Regulatory Review Protoco l Version 2 
::, z u 
8  
 ....  
8.4.3.1.4 Statistical Hypothe ses 
 
There are no statistical hypotheses associated with the secondary safety o bjectives . 
 
8.4.3.1.S Anal ysis Sets  
 
Analyses  of solicited  adverse events - and other  solicited  reactions  - and unsolicited 
adverse events  will be performed  on the relevant safety  sets. 
 
8.4.3.1.6 StatisticalM ethods 
 
For unsolicited adverse events, the entirestudy period will be divided into the following 
intervals : onset within 30 minutes after vaccination , onset within 28 days after 
vaccination; and from Day 1 through Day 181. For solicited adverse events , the so licited 
study period will be divided  into intervals: from 6 hours through day 3; from day 4 
through day 7; and from 6 hours through day 7. 
 
No imputation methods will be used to address missing safety data. 
 
Snmmarif>s  of safety will be presented using  frequencies  and percentages  within  each 
study  group . No statist ical comparisons  among  the studygroups  with respect to any of the 
safety  parameters will be performed.  
 
8.4.3.2  Anal ysis of Secondary Effi cacy Objective(s) 
 
There are no secondary efficacy objectives associated with this study.  
 
8.4.3.3  Analys is of Seconda  ry Immun ogenicity Objective(s)  
 
8.4.3.3.1  Sta tistical Hypothe ses 
 
Analyses  related to the secondary immunogenicityobject ives will be descriptive ; no 
formal  statistical  tests will be performed.  
8.4.3.3.2  Anal ysis Sets 
 
Analyses of secondary imm1mogenicity  will be based on the F AS and repeated on the 
PPS. 
 
 
 
 
 
 
"6'; 
00 
....  
PR0-01 TEMP 06 / Atlas No . 293620  
VersionNo.4 / Vers ion Date: January 29, 2015 
Protocol V59_77 
Page 73 of86  GSK 
03FEB16  Confidentia l 
Regulatory Review Protoco l Version 2 
::, z u 
8  
 ....  
8.4.3.3.3  Statistica l Methods  
 
Genera l 
The hSBA titers at each visit will be logarithmicallytransformed (basel O) to obtain 
approximately nonnally distributed data . 
 
For comparison  of percentages  and GMT  ratios,  unadjusted  estimates will be obtained 
along with adjusted estimates from regression models to account for potential baselin e 
imbalance between study  groups . 
For eachN. meningitidis serogroup A, C, Wand Y , unadjusted GMTs will be calculated, 
withtheir associated two -sided 95% Cls, by e xponentiating the corresponding log - 
tra
nsformed means and their 95% Cls. Adjusted GMR.s will be obtained from Analysis of 
Covariance (ANCOVA) models.  
 
See section 8.4.2.3.3 for other relevant details . 
 
Seroresponse (Day 29) 
 
The percentage of subjects with seroresponse and associated two- sided 95% Clopper - 
Pe
arson  Cls will be computed by group (Menveo -Menveo , Menactra -Menveo , and Naive) 
and N. meningitidis serogroups  A, C, W and Y test strains . Differences  in percentages and 
associated 95% Cls between study groups will be calculated using the Miettinen & 
Nurminen score method . 
 
In a descriptive fushion - using the difference in percentages and 95% Cls - each of the 
previously vaccinated groups will be compared to the nai:ve group . Also the two 
previously vaccinated study groups will be compared to each other.  
 
As sensitivity  analyses , the difference  in percentages will also be obtained  from  a log- 
lin
ear model adjusting for center , pre-vaccinationtiter and age-group.  Please see SAP  for 
technical details.  
 
 
 
 
 
 
 
 
"6'; 
00 
.... Percentage of Subjects \ Vith h SBA titere::8 (Da y I, Da y 4, Da y 6, and Da y 29 ) 
For each study  group and in the pooled group, the percentage  of subjects  with hSBA  titer 
8 andassoc iated two-sided 95% Clopper-P earson Cls will be computed by the N. 
meningitidis  serogroups  A, C, W and Y teststrains on Day 1, Day 4, Day 6 and Day 29 
(as applicable, depending on blood  draw  schedule).  
Differences in percentages and associated 95% Cls between study groups will be 
calculated using the Miettinen & Nurminen score method.  
 
PR0-01 TEMP 06 / Atlas No. 293620  
VersionNo.4 / Vers ionDate: January 29 , 2015 
Protocol V59_77 
Page 74of86  GSK 
03FEB 16 Confident ial 
Regula tory Review Protoco l Version 2  
  
In a descriptive fashion - using the difference in percentages and 95% Cls - the previously 
vaccinated groups (individually and pooled) will be compared to the naive group . Also 
the two previously  vaccinated  groups  will be compared  to each  other . 
 
As sensitivity  analyses , the difference  in percentages will also be obtained  from  a log- 
lin
ear model  adjusting  for center, pre-vaccinationtiter and age-group. Please see SAP  for 
technical details . 
 
Between-gro up Ratios of Gl\lll T s (A d jus ted and U nad ju sted)  
 
The between  -group ratio  ofhSBA  GMTs  and corresponding 95%  CI, at each of Visit Day 
1 (Persistence), Day 4, Day 6 and Day 29 against  each N. meningiti.dis  serogroups  A, C, 
W and Y test strains will be obtained by exponentiatingthe mean between- group 
differences in log -transformed titers and the corresponding 95% Cls at each of the 
timepo ints specified . 
Additionally , adjusted ratio  of GMTs  will be obtained  fromANCOVA models  including 
center , pre-vaccination  titer and age-group  as factors  in the model.  
 
The previous ly vaccinated  groups  (individually  and pooled)  will be compared to the naive 
group  at each  timepoint  - descriptively - using  the ratios  of GMTs . 
The two previously vaccinated groups will be compared at each timepoint using GMT 
ratios . 
\Vithin-gro up Ratios of Gl\lll T s (Ad jus ted an d U na d ju sted)  
 
Within  each study  group  and for each  antigen/serotype , ratios  of GMT will be calculated, 
as applicable , at: 
• Visit Day 4 versus  at Visit Day 1 ; 
• Visit Day 6 versus  at Visit Day 1 ; and 
• Visit Day 29 versus  at Visit Day 1. 
 
The unadj usted  GMRs  and 95%  Cis will be constructed  by exponentiating  the mean 
within -groupdifferences  in log-transformed titers  and the corresponding  95%  Cls. 
Adjusted GMRs will be obtained from Analysis of Covariance (ANCOVA) models 
including center and age -group as factors in the model.  
 
 
Further details  of the statistical  methods  will be provided  in the Statistical  Analysis  Plan 
(SAP). 
 
PR0-01 TEMP 06 / Atlas No . 293620  
VersionNo.4 / Vers ion Date: January 29 , 2015 

Protocol V59_77 
Page 75of86  GSK 
03FEB 16 Confident ial 
Regula tory Review Protoco l Version 2 
::, z u 
8  
 ....  
8.4.4 Analys is of Explora tor y Obje ctives  
 
8.4.4.1  Anal ysis of Explora tor y Safety Objective(s) 
There are no exploratory safety  object ivesin this study.  
8.4.4.2  Anal ysis of Explora tor y Effica cy Objective(s)  
There are no exploratory efficacy objectives in this study.  
8.4.4.3  Anal ysis of Explora tor y Immuno geoicity  Objective(s) 
There are no exploratory immunogenicityobjectives  in this study . 
8.5 Sam ple Size an d Power Considera  tions of Pti mar y Objectives 
Statist ical power was estimated based on observed  data from  study  V59Pl3El , where 
seroresponse rates at one- monthpost booster dose of MenACWY -CRM ranged from 
97%  (90% -100%) to 100%  (95% -100%) for serogroup A, 93%  (85% -98%)  for serotype  
C; 91%  (82%- 97%) to 93%  (84%- 98%)  for serogroup W ; and 90%  (80% -96%)  to 93% 
(84% -98%)  for serogroup Y among  subjects  printed  with MenACWY -CRM  or Menactra 
in the three  years  preceding  the study . 
Assuming the true seroresponse rates in the pooled group range from 90% to 97% 
(alternative hypothes is) for each serotype , a sample  size of n=540will  have  at least 96% 
power to show  sufficienc y of immune response  to a booster  dose  of MenACWY- CRM  in 
the pooled group, compared with a pre-specified reference seroresponse of 80% (null 
hypothesis) using  an exact test with 0.025 one-sided  significance level. When taking  a 
10%  dropout  rate into account , N=600  previousl y vaccinated subjects  have  to be enrolled 
in the study.  Calculat ions have  been done with nQuery  Advisor  (Version 7 .0). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
"6'; 
00 
....  
PR0-01 TEMP 06 / Atlas No. 293620  
VersionNo.4 / Vers ionDate: January 29 , 2015 
Protocol V59_77 GSK  Confidential  
VersionNo.4  / Version Date:  January  29, 2015  00 
" 
::, z u 
8  
 03FEB16  Regulatory Review  Protocol Version 2 Page 76 of86  
 
 
Table 8.5-1: Statistical Power to Test for Suffici ency of Immun e Response 
Given a Range of True Sero  respo nse Rates for Evaluabl e Samp le 
Size of 540 subjects 
 
Ser ot}11e  T111e Seroresponse Rate  Pow er 
A 0.97  0.99 
C 0.93  0.99 
w 0.91  0.99 
y 0.90  0.99 
Total Power   0.96 
 
8.6 Interim Analysis 
No interim analysis of data from this study is planned.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PR0- 01 TEMP 06 / Atlas No. 293620  
Protocol V59_77 GSK  Confidential  
VersionNo.4  / Version Date:  January  29, 2015  00 
" 
::, z u 
8  
 03FEB 16 Regulatory  Review  Protoco l Version  2 Page n of86  
 
9. SOURCE DOCUMENTATION , STUDY MONITORING AND AUDITING  
In order to ensure consistency across sites, study monitoring and auditing will be 
standardized and performed in accordance with the Sponsor's or delegated contract 
research organization ' s (CRO) standard operating procedures and applicable regulatory 
requirements (e.g., FDA, EMA, and ICH guidelines).  
Prior to enrolment of the first study subject, GSK or delegate willtrain investigators 
and/or their study staff on the study protoco allapplicable studyprocedures, 
documentation  practices and all electronic  systems . CRFs  supplied  by the Sponsor  must 
be completed for each randomized subject (see section 8.3.1, All Enrolled Set for 
definition  of enrolled  subject) . Documentation  of screened but not enrolled  subjects  must 
be maintained  at the site and made available  for review  by the site monitor.  Data  and 
documents  willbechecked by the Sponsor and/or  monitor . 
9.1 Source  Documentation  
 
Prior to the start of the study , the site staff participating in the study conduct will be 
instructed  on what  documents  willberequired  for review  as source  documents.  The kinds 
of documents that willserve as source documents willbe agreed between Sponsor or 
delegate and investigator and designees and specified in the SDA prior to subject 
enrolment.  
 
In addition , source documentation must include all of the following: subject identification 
(on each page) , eligibility and participation, proper informed consent procedures, dates of 
visits , adherence to protocol procedures , adequate reporting and follow -up of adverse 
events ,: documentation of prior /concomit ant medication/vaccines , study vaccine 
receipt/dispensing/return records , study vaccine administration information, any data 
collected by a telephone conversation with the subject and/or parent(s)/legal guardian(s) 
and date of complet ion and reason . 
 
 
 
 
 
 
 
 
 
 
"6'; The subject and/or parent(s)/legal guardian(s) must also allow access to the subject's 
medical records . Each subject and/or the parent(s)/legal guardian(s) must be informed of 
this prior to the start of the study and consent for access to medical records may be 
required in accordance with local regulations . 
All safetydata reported by subjects  must  be written  down in source documents  prior  to 
entry  of the data into CRFs . If there  are multiple  sources of information  (e.g., Subject 
Diary , verbal  report  of the subject , telephone contact details , medical chart)  supporting 
the diagnosis of an adverse event , thesesources must be identified in the source 
documents , discrepancies between sources clarified, the ultimate diagnosis must be 
justified  and written  in the source  documents , and this diagnosis  must be captured  in the 
 
PR0--01 TEMP 06 / Atlas No. 293620  
Protocol V59_77 
Page 78of86  GSK 
03FEB 16 Confident ial 
Regula tory Review Protoco l Version 2 
::, z u 
8  
 ....  
Adverse Event CRF (AE CRF) . The AE CRF must also capture which source(s) of 
infonnation were  used to detennine the adverse event (e.g., subject  recall , medical  chart , 
Subject  Diary) . 
9.2 Study Moni t01ing, A uditin g a nd So urce Data Verific ation 
Prior to enrolment of the first study subject, GSK or its designee (e.g., a CRO) will 
develop a Clinical Monitoring Plan to specify  how centralized and/or on- site monitoring , 
including clinical specimens reconciliation, will be perfonned for the study. Study 
progress will be monitored byGSK or its designee as frequently  as necessary to ensure:  
• that the rights and well-beingof human  subjects are protected,  
• the reported  study data are accurate, complete, and verifiable  from  the source  
documents and 
• the conduct of the study is in compliance  with the cUITent  approved 
protocol/am ednment(s ), GCP and applicabl e regulatory  requirements.  
Contact  details  for the GSK teamor its designee involved in study monitoring w ill be 
provided to the investigator . Study data recorded  on CRFs will be verified by checking 
the CRFentries against source documents in order to ensure data completeness and 
accuracy  as required  by study protocol . . 
Data verification may also be performed through a centralized review of data (e.g., 
checking for outliers  or other anomalies) . Additional documents  such as the investigator 
site file, phannacy records , and infonned consent documentation must  also be available 
for review if requested . Arrangements  for monitoring visits  will bemade  in advance  in 
accordanc e with the monitorin g plan, excep t in case of emergency . 
The investigator  a nd/or site staff must  make  source documents of subjects enrolled  in this 
study  available  for inspection  by GSK or its representative at the time of each  monitoring 
visit and Sponsor  audits , when  applicable. These documents  must  also be available  for 
inspection, verification and copying, as required by regulation, sbyofficials of the 
regulatory health authorities (e.g., FDA, EMA and others) and/or ECs/IRBs. The 
investigator and  study site staffmust comply  with applicable  privacy , data protection  and 
medical  confidentiality laws for use and disclosure of infonnation related  to the study and 
enrolled  subjects.  
 
 
 
 
 
 
 
"6'; 
00 
....  
PR0-01 TEMP 06 / Atlas No. 293620  
VersionNo.4 / Vers ion Date: January 29, 2015 
Protocol V59_77 
Page 79of86  GSK 
03FEB 16 Confident ial 
Regula tory Review Protoco l Version 2 
::, z u 
8  
 ....  
10. DATA MANAG EME1''T  
 
10.1 Data Entry and Management 
 
In this study , all clinical data (including , but not limited to , AF/SAEs , concomitant 
medications , medical history, and physical  assessments), safety  data, and immllllogenicity 
data will be entered onto case report  forms  (CRFs) in a timely  fashion  by the invest igator 
and/or the investigator 's dedicated site staff. Data entered onto CRFs are stored on a 
secure website . The data collected on this secure website are assimilated into an 
electronic data capture  (EDC)  system,  which  is compliant with Title  21 Part 11 policies  of 
the Code of Federal Regulations (FDA 1997). The data system includes password 
protection  and internal  quality  checks . The EDC  system  will be designed and validated  by 
the Sponsor prior to activation for data entry by sites. The investigator or designated 
delegate nrust review data entered and electronicallysign the CRFs to verifytheir 
accuracy . 
 
Access to the EDC system for data entryor review will require training and distinct 
individual access code assignments  to those site staff members  who willbe entering  study 
data and those  involved  in study  oversight  who may review  study  data. Data  are collected 
within  the EDC  system,  to which  the Sponsor  and site monitors  have  exclusively  "read 
only" access . 
 
10.2 Data Cla1ifi cation  
 
As part of the conduct  of the trial, the Sponsor  may havequestions about  the data entered 
by the site, referred  to as queries . The monitors  and the Sponsor are the only parties  that 
can generate a query . All corrections and clarifications will be entered into the EDC 
system  and will be identified  by the person entering  the information,  the reason for the 
change, as well as the time of the changes made . If changes are made to a previously  and 
electronically signed  CRF , the investigator  must  confirm  and endorse  the changes . 
 
10.3 Data Protectio n 
 
GSK  respects  the subjects ' rights  to privacy  and willensure the confidentiality  of their 
medical information in accordance  with all applicablelaws  and regulations . 
 
 
 
 
 
 
 
 
 
"6'; 
00 
....  
PR0-01 TEMP 06 / Atlas No. 293620  
VersionNo.4 / Vers ion Date: January 29, 2015 
Protocol V59_77 
Page 80of86  GSK 
03FEB 16 Confident ial 
Regula tory Review Protoco l Version 2 
::, z u 
8  
 ....  
11. RECORD  RETENTI ON 
 
Investigators must retain all study records required by GSK and by the applicable 
regulations in a secure and safe facility. The investigator must consult a GSK 
representativebefore disposal of any studyrecords , andmust notify the Sponsor of any 
change in the location, disposition, or custody of the study files. Essential documents 
must be retained for 1S years. "Essential documents " are defined as documents that 
individually  and collect ively pennit  evaluation of the conduct  of a study  and the quality 
of the data produced. These documents  should be retained  for a longer period,  however , if 
required by the applicable  national  regulatory or institutional requirements . 
 
These principles of record  retention  will also be applied to the storage  of immtmogenicity 
samples , provided that the integrity  of the stored sample  pennits  testing.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
"6'; 
00 
....  
PR0-01 TEMP 06 / Atlas No. 293620  
VersionNo.4 / Vers ion Date: January 29, 2015 
Protocol V59_77 
Page 81 of86  GSK 
03FEB16  Confidentia l 
Regulatory Review Protoco l Version 2  
  
12. USE  OF Jll,'FORMATION AND  PUB LICATION  
 
GSK assures that the key design elements of this protocol willbe posted in a publicly 
accessible  database such as clinicaltrials .gov, and in compliance  with ct11Tent  regulations.  
 
GSK  also assures that key results  of this clinical  study  will be posted  in a publicly 
accessible database within  the required time-frame from  theend  of study  as defined in 
section  3.9, End of Study . 
In accordance withstandard editorial, ethical  practices and ct11Tent guidelines  of Good 
Publication  Practice (Graf 2009) , GSK  will generally support  publication  ofmulticenter 
studies  only in their  entirety  and not as individual  center data. In this case, a coordinating 
investigator  will be designated by mutual  agreement  prior  to the start of the study . The 
coordinating investigator  will also sign the clinical study report  on behalf of the principal 
investigators  (CPMP/EWP /2747 /00). Authorship  willbe determined by mutual agreement 
and in line with International Committee of Medical Journal Editors authorship 
requirements . Any fonnal publication of the studyin which contribution of GSK 
personnel exceeded that of convent ional monitoring will be considered as a joint 
publication  by the investigator  and the appropriate  GSK  personnel.  
 
Novartis  must be notified  of any intent  to publish  data collected from  the study  and prior 
approval  from  GSK must be obtained  prior  to submission  for publication . 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PR0-01 TEMP 06 / Atlas No. 293620  
VersionNo.4 / Vers ion Date: January 29, 2015 

Protocol V59_77 
Page 82 of86  GSK 
03FEB16  Confidentia l 
Regulatory Review Protoco l Version 2 
::, z u 
8  
 ....  
13. ETID CAL CONSIDERATIO NS 
 
13.1 Regulato ry and Ethical Compliance 
The study will beconducted in compliance  with the protocol, GCP and applicable 
regulatory  requirement (s). 
This clinical study was designed and shall be implemented and reported in accordance 
withthe ICH HarmonizedTripartite Guidelines for Good Clinical Practice , with 
applicable local regulations including European Directive 2001/ 20/EC , US Code of  
Federal  Regulations  Title  21, and Japanese Ministry  ofHealth,  Labor , and Welfare , GSK 
codes on protection of human rights , and with the ethical princip les laid down in the 
Declaration of Helsinki (EuropeanCouncil 2001, US Code of Federal Regulations, ICH 
1997) . 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
"6'; 
00 
.... 13.2 Informed Consent Procedur es 
 
Eligiblesubjects may only be included in the study after providing written informed 
consent or assent , as described in section 5.1.1, Informed Consent/Assent. Before  the start 
of the study , the invest igator will have  the informed  consent  and any other  materials  that 
will be provided  to the subjects reviewed  and approved bythe IRB/EC. This review  and 
approval  will be documented  and stored  with other studydocuments.  The investigator  or 
designee must fully  inform thesub ject or legalguardian  of all pertinent  aspects of the 
study. A copy of the written  informed  consent  will be given  to the subject  or the designee. 
The subject/designee  must be allowed  ample  time to ask about thedetails  of the study  and 
to make a decision  as to whether  or not to participate  in the study . The subjectand/or  
legal guardian(s)  mu st sign the consent  form  indicating  their  agreement to participate in 
the studybefore anystudy -related procedures are conducted . The informed consent 
process may be conducted up to 5 days prior to vaccination on Day I. If the subject 
and/or  legal guardian(s)  is unable  to read and write , a witness must  be present  during the 
informed  consent  discussion  and at the time of informed  consent  signature.  
Prior to the start of the study, GSK will provide to investigators a proposed informed 
consent form  that complies  with the ICH GCP  guideline and regulatory requirements and 
is considered appropriate for this study . Any changes to the proposed consent form 
suggested by the investigator must  be agreed  to byGSK  before  submission to the IRB/EC 
and a copy  of the approved  version  must be provided to the GSK monitor after IRB/EC 
approval  
Women  of childbearing potential should be in formed that taking the study medication 
may involve unknown risks to the fetus  if pregnancy were  to occur during the study and 
agree  that in order to participate  in the study they must adhere  to the contraception  
 
PR0-01 TEMP 06 / Atlas No. 293620 
VersionNo.4 / Vers ion Date: January 29 , 2015 
Protocol V59_77 
Page 83 of86  GSK 
03FEB16  Confidentia l 
Regulatory Review Protoco l Version 2 
"6'; 
00 
" PR0-01 TEMP  06 / Atlas  No. 293620  
VersionNo.4  / Version Date:  January  29, 2015  
::, z u 
8  
  
requirements  indicated in the protocol  for the duration of the study . If case of doubts  on 
the ability  of a subject to adhere  to these requirements , that subject should  not be allowed 
in the  study  
 
Before  the start of the study , the investigator  will have the informed assent,  the informed 
consent, and any other materials that will be provided  to the subject and/or parent(s)/legal 
guardian(s) reviewed and approved by the IRB /EC. This review and approval will be 
documented and stored  with other  study  documents . The investigator or designee  must 
fully  inform  the subject and/or  parent (s)/legal  guardian(s) of all pertinent  aspects of the 
study . A copy of the written  informed consent  and informed assent  will be given  to the 
subject  and/or  parent(s)/legal  guardian(s) . 
In addition , the investigator  or designee  should explain pertinent  aspects of the study  in an 
age appropriate manner to pediatric subjects who are eligible for informed assent in 
accordance with local policies . The subject and parent(s)/legal guardian(s) must be 
allowed amp le time to ask about the details of the study and to make a decision as t o 
whether  or not to participate in the study. The subject and parent(s)/legal  guardian(s) must 
sign the consent/assentforms indicating  their  agreement  to participate  in the study  before 
any study- related procedures are conducted . If the subject and/or parent(s)/legal 
guardian(s)  are unable  to read and write , a witness  must  be present  during the informed 
consent/assentdiscussion and at the time of informed consent/assentsignature . 
13.3 Respons ibilitie s of the Investiga tor a nd IRB/EC 
 
The protocol  and the proposed  informed  consent  form  must  be reviewed  and approved by 
a properly  constituted  IRB/EC  before  study start. Proper ly constituted  IRB/EC  is defined 
in ICH Guideline for Good Clinical Practice  E6 (RI), Section  3 (ICH 1997 ). A signed  and 
dated statement that the protocol and informed consent have been approved by the 
IRB/EC must be given to GSK before  study  initiation . Prior  to study  start and at any time 
the protocol is amended during studyconduct , the investigator is required to sign a 
protocol signature  page  confirming his/her  agreement  to conduct the study  in accordance 
with these  documents  and all of the instructions  and procedures  found  in this protoco l and 
to give access to all relevant data and records to GSK monitors , auditors , GSK Clinical 
Quality Assurance representatives , designated agents of Novartis , IRBs/ECs , and 
regulatory authorities as required . If an inspection of the clinical site is requested by a 
regulatory  authority , the investigator  must  inform  GSK  immediately that this request has 
been made . 
 
The investigator also responsib le for the following:  
• Maintaining a list of appropriate ly qualified persons to whom the investigator has 
delegated significant study- related  duties . 
Protocol V59_77 
Page 84 of86  GSK 
03FEB16  Confidentia l 
Regulatory Review Protoco l Version 2 
"6'; 
00 
" PR0-01 TEMP  06 / Atlas  No. 293620  
VersionNo.4  / Version Date:  January  29, 2015  
::, z u 
8  
  
• Demonstrating the capability  of recruiting  the required  number of suitable  subjects 
within  the recruitment  period.  
• Demonstrating sufficient  time and staffing  to properly conduct and complete  the study 
within  the agreed study period.  
• Ensuring that all persons assisting with the study are adequately  informed about the 
protoco the  investigationalproduct(s,)and  their study- related  duties and functions  
• Ensuring that appropriately trained  health  care professionals  are responsible for all 
study- related  medical  decisions and for ensuring appropriate  medical  care of subjects  
experiencing  any adverse  event related  to the study.  
• If permission to do so is given by the subject and/or parent(s)/legal guardian(s) , 
ensuring that the subject' s primary healthcare  provider is informed of the subject' s 
participation  in the study.  
The investigator should not implement any deviation from, or changes of the protocol 
without agreement  by the Sponsor and prior review and documented  approval/favourable 
opinion from theIRB/IEC of an amendment, except where necessary to eliminate an 
immediate  hazard(s) to study subjects, or when  thechange(s)  involves only logistical  or 
administrative aspects of the study (e. g., change in monitor(s) , change of telephone 
nwnber(s )). In addition, the investigato ,ror person designated by the investigato ,rshould 
document and explain  any deviation  from  the approved  protocol.  
 
The investigator may implement a deviation from, or a change of, the protocol to 
eliminate an immediate hazard(s) to study subjects without prior IRB/IEC 
approval/favourable opinion.  As soon as possible , the implemented  deviation  or change , 
the reasons  for it, and, if appropria te, the proposed  protocol  amendment (s) shoul d be 
submitted:  
(a) to theIRB/IEC for review and approval/favourable  opinion,  
(b) to the Sponsor for agreement  and, if required,  
(c) to the regulatory authority(ies).  
13.4 Protocol Ame ndments 
An amendment  is a written  description  of change(s)  to or formal clarification  of a study 
protocolwhich  may impact  on the conduct of the clinical  study, potential benefit  of the 
clinical  study, or may affect subject safety , including  changes  of study  objectives , study 
design, subject  population, samplesizes, studyprocedures , or significant administrative 
aspects. An administrative change of a study protocol is a minor correction or 
clarification  that has no significant impact on the waythe  clinical study  is to be conducted  
Protocol V59_77 
Page 85 of86  GSK 
03FEB16  Confidentia l 
Regulatory Review Protoco l Version 2 
PR0-01 TEMP  06 / Atlas  No. 293620  
VersionNo.4  / Version Date:  January  29, 2015   
  
and no effect  on subject  safety  (e.g., change  of telephone number(s) , logistical changes. ) 
Protocol amendments  nrust be approved  by GSK,  health  authorities  where  required,  and 
the IRB/EC. In cases when the amendment is required in order to protect the subject 
safety , the amendment can be implemented  prior to IRB/EC  approval . Notwithstanding , 
the need  for formal approval  of a protocol  amendmen ,tthe investigator  is expected  to take 
any inunediate  action  required  for the safety  of anysubject  included  in this study , evenif 
this action  represents  a deviation from the protocol. In such cases, GSK should be notified 
of this action, the IRB/EC at the study site, and, if required bylocal regulations, the 
relevant  health  authority)  should be informed  within  10 working days. 
Protocol V59_77 
Page 86 of86  GSK 
03FEB16  Confidentia l 
Regulatory Review Protoco l Version 2 
PR0-01 TEMP  06 / Atlas  No. 293620  
VersionNo.4  / Version Date:  January  29, 2015   
  
14. REFE RENCE LIST 
 
Code  of Federal  Regulations  (1997) : Food and Drug  Administration,  U.S. Depar1ment  of 
Health and Human Services: Title 21, Part 11: Electronic Records Electronic Signatures. 
Federal Register 62: 13464 
European Parliament (1995) : Directive 95 /46/EC of the European Parliament and of the 
Counc il of 4 April 2001. Official Journal of the European Communities . L 281/31-39 
European Parliament (2001) : Directive  2001/ 20/EC  of the European Parliament and of 
the Council  of 4 April  2001.  Official Journal  of the European  Communities . L 121/34-44 
Graf C, Battisti WP, Bridges  D (2009). Good  publica tion practice for communicating 
company Sponsored medical research: the GPP2  guideline s. BMJ ; 339: b4330 
ICH (1997)  ICH Harmoni sed Tripartite  ICH Guideline  for Good Clinical Practices E6 
(RI). Federal Register , 62 (90): 25691 -25709  
ICH (1998)  ICH Harmoni sed Tripartite  ICH Guideline  for Statistical Principles  for 
Clinical  Trials E9. Federal Register , 63 (179) : 49583  
Levine RJ . (1988) Ethics and Regulations of Clinical Research. New Haven: Yale 
University Press.  
U.S. Depar1ment of Health and Human Services , Food and Drug Administration, CBER 
(2009 ): Guidance for Industry Patient- Reported Outcome Measures : Use in Medical 
Product Development to Support Labeling Claims  
 
59th World Medical Association General Assembly (October 2008) Declaration of 
Helsinki - Ethical Principles for Medical Research Involving Human Subjects. Seoul , 
Korea  
 
 ---- 
.... Novarti s 
 
 
 
PPo• -    - -' Document A !J!ro val Ce rtificate / 
PPD /    
1.,;..  _  
 
 
 
Theindivi:lual s listed have appl'()ved this docume nt for ii!Jplementatio n using an electronic si turein the 
Atlas EDM S. JPPD 
 
 
 
U serName: pp-o• -   -   - .. PP D 
Ti tl e : C l u ster  Phys ician -Meningi  t is an d Sepsis  Franch ise 
Date: Friday, 12 February 20 16 , 09:32 GMT  
Meani ng: As an approver, I agree with the content and format of this document  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
00 
.... 
 
::, z 
u 
8 

Protocol V59_77 
Page I of85  GSK 
24FEB16  Confidentia l 
Regulatory Review Protoco l Version 3 
PR0--01 TEMP  06 / Atlas  No. 293620  
VersionNo.4 / Version Date: January 29,20 15  
  
 
 
CLINICAL STUDY PROT OCO L VS9 77 Vers ion 3 
 
 
 
A Phase 3b, Controlled, Open -Label , Multi- Center Study to Evaluate Safety and 
Inumnogenicit y of a Single  Dose of GlaxoSm iht Kline's Meningococca l ACWY 
Conjugate Vaccine  (Menveo), Administered  to Healthy  Individuals 15 through 55 years 
of age, approximate ly 4-6 years  after primary ACWY  vaccinat ion. 
 
 
Safety  and Immunogenicity Study of a Single  Dose  of Menveo,  Administered  to Subjects 
15 through  55 years  of age, approximately  4-6 years  after primary ACWY vaccination  
 
 
 
 
Property o f GlaxoS mithKline Vaccines (her eafter referred to as GSK) 
Confidential 
May not be u sed, divulged, published  or otherwise  disclose d  without  \VIi tt .e n 
co n se n t o f GS K 
Protocol V59_77 
Page 2of85  GSK 
24FEB16  Confidentia l 
Regulatory Review Protoco l Version 3 
PR0-01 TEMP  06 / Atlas  No. 293620  
VersionNo.4  / Version Date:  January  29, 2015   
  
TABLE OF CONTE NTS 
TABLE  OF CONTENTS  ..................................................................................................... 2 
PROTOCOL SYNOPS IS VS9 77 ................................................................................... 7  
LIST OF ABBREVIATIONS  ............................................................................................. 20 
1. BACKGROUND AND RATIONALE  ..................................................................... 21  
1.1 Background .......................................................................................................... 21 
1.2 Rationale  .............................................................................................................. 22 
2. OBJECTIVES  ........................................................................................................... 23 
2.1 Primary  Object ive(s)  ........................................................................................... 23 
2.2 Secondary Objective(s)  ........................................................................................ 23 
2.3 Exploratory  Objective(s)  ...................................................................................... 24 
3. STUDYDESIGN ................................................................................................. 2S 
3.1 OverviewofStudyDesign. ..............................................................................        2S 
3.2 StudyPeriod ..................................................................................................... 27  
3.3 Blinding Procedures  ............................................................................................. 27 
3.4 Data  Collect ion ............................................................................................................. 27  
3.4.1 Data Collected  from Subjects  .................................................................... 27  
3.4.2 Tools Used  for Data  Collecti on ........................................................................... 28  
3.S Collection of Clinical  Specimens  ..................................................................... 29  
3.6 Stopping/Pausing Guidelines  ........................................................................... 30  
3.7 Data  Monitoring Committee  ............................................................................ 30  
3.8 Premature Withdrawal  from Study .................................................................. 30  
3.9 EndofStudy ............................................................................................... 32  
4. SELECTION  OFSTUDY POPULATION  ................................................................ 34 
4.1 Inclusion Criteria  .................................................................................................. 34 
4.2 Exclusion Criteria ......... ................................................................................... 3S 
4.3 Criteria  for Delay of Vaccination  and/or Blood Sampling  ................................ 36  
S. STUDYPROCEDURES  ...................................................................................... 37  
S.1 Pre-vaccination  Clinic  Visit(s ) .................................................................................. 37  
Protocol V59_77 
Page 3of85  GSK 
24FEB16  Confidentia l 
Regulatory Review Protoco l Version 3 
PR0-01 TEMP  06 / Atlas  No. 293620  
VersionNo.4  / Version Date:  January  29, 2015   
 5.1.1 Informed Consent/Assent ......................................................................... 37  
5.1.2 Screening  ....................................................................................................... 38 
5.1.3 Enrolment ................................................................................................. 39  
5.1.4 Randomization .............................................................................................. 40 
5.2 Vaccination  Clinic  Visit.  ................................................................................. 41  
5.2.1 Post-vaccinationProcedures  ........................................................................... 41  
5.2.2 Post-vaccination Reminders  ......................................................................... 42 
5.3 Post-vaccinat ion Visit(s) ........................................................................................ 42  
5.3.1 Follow -up Clinic  Visit(s)  ........................................................................... 43  
5.3.2 Safety Follow-up Calls  .................................................................................. 44 
5.4 Unscheduled Visits .............................................................................................. 44 
5.5 Study Terminati on Visit. ........................................................................................ 44  
5.5.1 Early  Termination  Visit.  ........................................................................... 45  
6. TREATMENT  OF SUBJECTS ................................................................................ 46 
6.1 StudyVaccine(s)  ..................................................................................................... 46  
6.2 Non-Study Vaccines  ......................................................................................... 47  
6.3 Vaccine Preparationand Administration  .......................................................... 47  
6.4 Vaccine Administration  Error or Overdose ofVaccine .................................... 48  
6.5 Prior and Concomitant Medications  and Vaccines  .......................................... 49  
6.6 Vaccine Supply, Labeling , Storage and Tracking  ................................................. 50  
7. ASSESSMENTS  .................................................................................................. 52  
7.1 SafetyAssessment ............................................................................................ 52  
7.1.1 Solicited  Adverse Events  .......................................................................... 52  
7.1.2 Unsolic ited Adverse Events  ........................................................................ 54  
7.1.3 Evaluation of Adverse Events  ........................................................................ 54 
7.1.4 Serious Adverse Events ............................................................................. 56  
7.1.4.1  Adverse Events  of Special  Interest  ..................................................... 57  
7.1.5 Methods for Recording Adverse Events  and Serious Adverse Events  ....... 58  
7.1.5.1  Post-Study Events  .............................................................................. 58  
Protocol V59_77 
Page 4of85  GSK 
24FEB16  Confidentia l 
Regulatory Review Protoco l Version 3 
PR0-01 TEMP  06 / Atlas  No. 293620  
VersionNo.4  / Version Date:  January  29, 2015   
  
7.1.6 Pregnancies. ..............................................................................................    S9 
7.1.7 Safety  LaboratoryMeasurements  .............................................................. S9 
7.2 Efficacy  Assessment ........................................................................................ S9 
7.3 Immunogenicity  Assessment ............ ................................................................  S9 
8. STATISTICAL  CONSIDERATIONS  .................................................................. 6 1 
8.1 Endpoints ......................................................................................................... 6 1 
8.1.1 Primary  Endpoint(s) ........................................................................................... 6 1 
8.1.1.1  Primary  SafetyEndpoint(s) ................................................................ 6 1 
8.1.1.2  Primary  EfficacyEndpoint(s) ............................................................. 6 1 
8.1.1.3  Primary  Immunogenicity Endpoint(s) ................................................... 6 1 
8.1.2 Secondary Endpoint(s)  .................................................................................. 6 1 
8.1.2.1  Secondary Safety Endpoint(s)  ................................................................ .. 61 
8.1.2.2  Secondary Efficacy Endpoint(s)  .............................................................. 62  
8.1.2.3  Secondary Immunogenici ty Endpoint(s)  .................................................. 62  
8.1.3 ExploratoryEndpoint(s) ............................................................................ 62  
8.1.3.1  Exploratory Safety Endpoint(s) .......................................................... 62  
8.1.3.2  Exploratory Efficacy  Endpoint(s)  ................................................................ .. 62 
8.1.3.3  Exploratory Immunogenicity  Endpoint(s) .......................................... 62  
8.2 Success  Criteria  ................................................................................................ 63  
8.2.1 Success  Criteria for Primary O bjective(s)  .................................................. 63  
8.2.1.1  Success  Criteria for Primary Safety Objective(s)  ....................................  63 
8.2.1.2  Success  Criteria for Primary Efficacy Objective(s)  ................................ 63  
8.2.1.3  Success  Criteria for Primary Immunogenicity  Objec tive(s)  ................. 63  
8.2.1.3.l Rationalefor Combining the Menveo -Menveoand Menactra- Menveo  
groups  ....................................................................................... 63 
8.2.2 Success  Criteria for Secondary Objective(s)  ................................................... 64  
8.2.2.1  Success  Criteria  for Secondary Safety Object ive(s)  ............................... 64  
8.2.2.2  Success  Criteria  for Secondary  Efficacy  Objective(s)  ......................... 64  
8.2.2.3  Success  Criteria  for Secondary  Immunogenicity Object ive(s). ............ 6S 
Protocol V59_77 
Page 5of85  GSK 
24FEB16  Confidentia l 
Regulatory Review Protoco l Version 3 
PR0-01 TEMP  06 / Atlas  No. 293620  
VersionNo.4  / Version Date:  January  29, 2015   
  
8.3 Analysis  Sets .................................................................................................... 65  
8.3.1 All Enrolled Set ......................................................................................... 65  
8.3.2 All Exposed Set ......................................................................................... 65  
8.3.3 Safety Set. ................................................................................................. 65  
8.3.4 Full Analysis Set (FAS) Efficacy/Immunogenic ity Set. .............................. 65  
8.3.5 Per Protocol (PP) Set Efficacy/Immunogenicity Set ................................... 67  
8.3.6 Other  Analysis  Sets ................................................................................... 67  
8.3.7 Subgroups ................................................................................................. 67  
8.3.8 Protocol Deviations  .................................................................................. 67  
8.4 Statistical Analys is Plan ................................................................................... 67  
8.4.1 Analysis  of Demographic and Baseline Characteristics  ............................ 67  
8.4.2 Analysis of Primary Objective(s)  ................................................................. 68 
8.4.2.1  1   Analysis of Primary SafetyObjective(s)  ................................... 68  
8.4.2.2  Analys is of Primary Efficacy  Objective(s)  .......................................... 68  
8.4.2.3  Analys is of Primary Immunogenicity Objective(s)  ................................ 68 
8.4.2.3.1  Statisti cal Hypotheses ..................................................................... 68 
8.4.2.3.2  2 ................................................................................. Analysis  Sets
 68 
8.4.2.3.3  Statist ical Methods ...................................................................... 68  
8.4.3 Analysis of  Secondary Objective(s) ......................................................... 69  
8.4.3.1  Analys is of Secondary Safety Objective(s) ...................................... 69  
8.4.3.1.1  Analysis  of Extent  of Exposure ................................................... 69  
8.4.3.1.2  Analysis  of Solicited  Local, Systemic  and Other  Adverse Events  69 
8.4.3.1.3  Analysis of Unsolicited  Adverse Events  ..................................... 70  
8.4.3.1.4  Statist ical Hypotheses ...................................................................... 71 
8.4.3.1.5  5 ................................................................................. Analysis  Sets
 71 
8.4.3.1.6  Statist ical Methods  ...................................................................... 71  
8.4.3.2  Analys is of Secondary Efficacy  Objective(s) .................................. 71  
8.4.3.3  Analys is of Secondary ImmunogenicityObject ive(s) ......................... 71  
Protocol V59_77 
Page 6of85  GSK 
24FEB16  Confidentia l 
Regulatory Review Protoco l Version 3 
PR0-01 TEMP  06 / Atlas  No. 293620  
VersionNo.4  / Version Date:  January  29, 2015   
 8.4.3.3.1  Statist ical Hypotheses ...................................................................... 71 
Protocol V59_77 
Page 7of85  GSK 
24FEB16  Confidentia l 
Regulatory Review Protoco l Version 3 
PR0-01 TEMP  06 / Atlas  No. 293620  
VersionNo.4  / Version Date:  January  29, 2015   
 8.4.3.3.2  Analysis Sets ................................................................................ 71  
8.4.3.3.3  Statistical Methods  ...................................................................... 72  
8.4.4 Analysis of Exploratory Objectives ............................................................... 74  
8.4.4.1  Anal ysis of ExploratorySafety  Objective(s)  .................................................. 74  
8.4.4.2  Analysis of ExploratoryEfficacy O bjective(s)  ...........................................74  
8.4.4.3  Analysis of Exploratory lmmunogeni city Objective(s)  ........................ 74 
8.5 Samp le Size and Power  Cons iderations of Primary  Object ives .............................. 74  
8.6 Interim Analys is............................................................................................................ 75  
9. SOURCE  DOCUMENTATION , STUDY  MONITORING  AND AUDITING  ... 76  
9.1 Source Documentat ion ..................................................................................................76  
9.2 Study  Monitoring , Auditing  and Sourc e Data Verification  .................................. 77 
10. DATA MANAGEMENT  .......................................................................................... 78 
10.1 Data  Entry and Manage ment ....................................................................................... 78  
10.2 Data  Clarificat ion ........................................................................ .............................. 78  
10.3 Data  Protec tion .............................................................................................................. 78  
11. RECORD RETENTION  ...................................................................................... 79  
12. USE OF INFORMATION  AND  PUBLICATION  ..................................................... 80  
13. ETHICAL  CONSIDERATIONS  ............................................................................. 81 
13.1 Regulatory and Ethical Compliance  ..................................................................... 81 
13.2 Informed Consent Procedures  .............................................................................. 81 
13.3 Respons ibilities of the Invest igatorand  IRB/EC ................................................. 82  
13.4 Protocol Amendmen ts ............................................................................................... 83  
14. REFERENCE LIST ................................................................................................... 85 
Protocol V59_77 
Page 8of85  GSK 
24FEB16  Confidentia l 
Regulatory Review Protoco l Version 3 
PR0-01 TEMP  06 / Atlas  No. 293620  
VersionNo.4  / Version Date:  January  29, 2015   
 PR OTO COL SYNOP SIS V59 77 
 
Name of Sponsor: 
GlaxoSmithKline 
Vaccines  Proto col numb er: 
 
V59 77 Gene1ic nam e of study vaccine(s):  
 
Meningococcal (groups A, C, W, and Y) 
oligosaccharide diphtheria CRM- 197 
conjugate vaccine  
Title of Stud y: A Phase 3b, Controlled,  Open -Label,Multi -Center  Study  to Evaluate 
Safet y and Immunogenicity  of a Single  Dose  of GlaxoSm iht Kline ' s Meningococcal 
ACWY Con jugate Vaccine (Menveo) , Administered  to Healthy  Individuals 15 througll 
55 years of age, approximate ly 4-6 years after primary  ACWY vaccination . 
Study Pe1i od : Approximately  180 days 
(six months). Clinical Pha se: 3b 
Background and Rati onale: 
 
Neisseria meningitidis  is a leading  cause of bacterial  meningitis  and sepsis worldwide, 
capab le of causing outbreaks and epidemics  of invasive diseas e. Meningococcal  disease 
is associated  with higll morbidity  and mortality  even  among  patients  who receive  early 
antibiotic  treatment.  Most cases  of invasive disease worldwide are caused  byserogroups 
A, B, C, W and  Y. 
The quadrivalent meningococcal oligosaccharide diphtheria CRM -197 conjugate 
vaccine (MenACWY -CRM; Menveo, GSK Vaccines) is approved for active 
immunization of individuals from 2 months througll 55 years of age in the United 
States. As of February 2015 , more than 30,000of subj ectshave been exposed to 
MenACWY -CRM vaccine in completed  clinical studies and more  than 24million  doses 
of the vaccine  have  been distributed  globally . 
The US Advisory Committee  on Immunization  Practices  (ACIP) recommends  routine 
vaccination with a quadrivalent conjugated meningococcal vaccine for adolescents at 
11-12 years of age with a booster dose administered 5 years later. While a substantial 
body of data exists showing a robust immune response and good antibody persistence 
after a single dose ofMenACWY- CRM in adolescents , the response to a booster dose of 
MenACWY- CRM in this agegroup has only been evaluated in 2 clinical studies with 
limited  number of subjects.  
A robust anamoestic  immune response to a booster doseofMenveo vaccine 
administered  at approximately  5 years  after previous  vaccination with thesame  vaccine 
or a licensed  meningococcal oolysaccharide vaccine (Menomune®) was demonstrated in 
Protocol V59_77 
Page 9of85  GSK 
24FEB16  Confidentia l 
Regulatory Review Protoco l Version 3 
PR0-01 TEMP  06 / Atlas  No. 293620  
VersionNo.4  / Version Date:  January  29, 2015   
  
Name of Sponsor:  
 
GlaxoSmithKline 
Vaccines  Protocol number : 
V59 77  Gene1i c name of study vaccine(s): 
 
Meningococcal (groups A, C , W, and Y) 
oligosaccharide diphtheria CRM -197 
conjugate vaccine  
the phase  2 clinical  study  V59P6El  . High  titers  of bactericidal  antibodies  against  the 
vaccine  serogroups  were achieved at 7 and 30 days  after booster  dose  in MenACWY - 
prim
ed subjects . However , the number of subjects  included in this studywas  relatively 
small (N=101, including 50 subjects who received a booster dose after the primary 
MenACWY -CRM  vaccination).  
 
In the phase 3b clinical study V59Pl3 El , a booster dose of MenACWY -CRM was 
given 3 years after primary vaccination with either MenACWY -CRM or Menactra®(a 
meningococcal diphtheria toxoid- conjugated MenACWY vaccine , MenACWY -D) in 
adolescents.A booster dose was able to substantially increase antibody titers against all 
4 serogroups  irrespective  of the priming  vaccine.  Again, only a small  number  of 
subjects (N=160) received the MenACWY- CRM booster, (83 who received primary  
MenACWY -CRM and 77 who received MenACWY -D). 
 
In the light of thecurrent ACIP recommendation for a booster dose of MenACWY - 
CRM ,
 there  exists  a need  to evaluate the response  to a MenACWY- CRM  booster  given 
at -5  years  after primary  vaccination  in meningococca -lvaccin eprimed  adolescent s. 
Generation of this data would  also be of relevance in outbreak management  and 
vaccination  of travelers  to endemic areas . 
 
The purpose/aim of this study is to assess the safety and ant ibodyresponse to 
vaccination with a booster  dose  of Menveo  given  4-6 years  after primary vaccination 
and the response  to a single  dose  given to vaccine -naive subjects , and to describe  the 
immune response over time after a single dose of Menveo , administered to subjects 
previous ly vaccinated with Menveo or Menactra or to vaccine- naive subjects. The 
inclusion of vaccine -naive subjects in a separate study arm is to enable comparison of 
the rapidity and magnitude of an aoarooestic  response to a booster dose (in primed 
individuals) or the primary response to a first dose (in naive individua ls) of 
MenACWY -CRM . 
Study Objectives:  
 
P1i mary Objective(s): Immun ogenicity ob jective:  
 
L To demonstrate a sufficient immune response following a single dose of 
MenACWY -CRM  (Menveo)  vaccine , !riven  to sub jects who previously  received  
Protocol V59_77 
Page 10of85  GSK 
24FEB16  Confidentia l 
Regulatory Review Protoco l Version 3 
PR0-01 TEMP  06 / Atlas  No. 293620  
VersionNo.4  / Version Date:  January  29, 2015   
  
Name of Spo nsor: 
 
GlaxoSmithKline 
Vaccines  Protoco l number:  
V59 77  Gene1i c name of s tudy vaccine(s): 
 
Meningococcal (groups A, C, W, and Y) 
oligosaccharide diphtheria CRM -197 
conjugate vaccine  
Menveo or Menactra, as measured by the percentage of subjects with hSBA 
seroresponse against N. meningitidis serogroups  A, C, W and  Y at Day 29 after 
vaccination  
Criteria to demonstrate  immune  response  sufficiency:  The immune  response  will be 
considered  as sufficien t if thelowerlimi t of theone- sided  97.5% CI for percentage 
of subjects wi th hSBA seroresponse agains t serogroups A, C, Wand Y is greater 
than 80% (z n pooled group of subjects who received primary vaccination w ith 
Menveo  or Menactra).  
Seco ndary O bjec tive(s) : 
Immun ogenicity objectives : 
1. To compare the immunogenicityofa single dose ofMenACWY -CRM vaccine , 
between subjects who previously received Menveo , subjects who previously 
received  Menactra  and vaccine -naive  individuals , as measured  by the percentage  of 
subjects with hSBA titer 8 , with hSBA seroresponse, and hSBA GMTs against N. 
meningitidis serogroups  A, C, W and Y at Day 29 after  vaccination  
2. To compare the immune responses over time following a single dose of 
MenACWY -CRM  vaccine, between  subjects  who previously  received Menveo , 
subjects  who previously  received Menactra and vaccine -naive individuals , as 
measured  by the percentage of subjects  with hSBA  titer ,::8 and hSBA GMTs  against  
N. meningitidis serogroups A, C, Wand Y at Day I, Day 4, Day 6 , and Day 29 after 
vaccination  
3. To assess persistence  of bactericidal antibodies  against  serogroups  A, C, Wand Y at 
approximately 4-6 years after the primary  vaccination with Menveo and after the 
primary  vaccinat ion with Menactra in comparison  with naturally -acquired  level in 
vaccine -naive individuals , as measured by the percentage of subjects with hSBA 
titer ,::8 and hSBA  GMTs  at Day 1. 
Safety objectives : 
1. To assess reactogenicity  and safety  of MenACWY -CRM  vaccine when  administered 
to subjects who previously received Menveo or Menactra and vaccine- naive 
individuals  
Protocol V59_77 
Page 11of85  GSK 
24FEB16  Confidentia l 
Regulatory Review Protoco l Version 3 
PR0-01 TEMP  06 / Atlas  No. 293620  
VersionNo.4  / Version Date:  January  29, 2015   
  
Name of Spo nsor: 
 
GlaxoSmithKline 
Vaccines  Protoco l number : 
 
V59 77 Gene1i c name of s tudy vaccine(s):  
 
Meningococcal (groups A, C, W, and Y) 
oligosaccharide  diphth eriaCRM-197 
conjugate vaccine  
Study Design: 
This is a phas e 3b, controlled , open- label, multi -center studyto evaluate safety and 
immunogenicity of MenACWY -CRM  after a single vaccinat ion in healthy individual s 
who were  vaccinated  with Menveo  or Menactra  4 to 6 years  ago and in vaccine-naive 
individuals.  
Study population: Approximately  700 healthy  subjects  15 througll 55 years  of age will 
be enrolled in the study. 
Duration  of the study: The duration  of this study is approximately 6 months per subject. 
Writte n informe d consen t and, as applicabl e accordin g to local  guidelin es, written 
assent will be obtained  before conduct ing any study -specificprocedures . 
Vaccination  schedule: All subjects will receive  a single dose ofMenACWY -CRM at 
Day I. 
Stud y groups:  
• Group  Menveo-Menveo: approximately  300 subjects, who were  vaccinated  with a 
single dose of Menveo 4 to 6 years  ago, will receive  one dose of MenACWY-CRM.  
• Group Menactra- Menveo:approximately 300 subjects , who were vaccinated with a  
single dose ofMenactra 4 to 6 years ago, will receive onedose of MenACWY - 
CRM. 
• Group Naive: approximately 100 subjects , ofsimilar age to subjects enrolled in 
other primed  groups, equally  enrolled  across  allclinical sites, who have not received 
any meningococcal vaccination,  will receive  one dose of MenACWY- CRM.  
Randomization/ Stratification:  
Within  each  study  group, subjects  will be randomized  into one of two different blood 
draw schedules according  to a 1:1 ratio, described as follows:  
• Subjects  getting  blood draws  at Day1 , Day4  and Day 29. 
• Subjects  getting blood draws  at Day1 , Day 6 and Day 29. 
Protocol V59_77 
Page 12of85  GSK 
24FEB16  Confidentia l 
Regulatory Review Protoco l Version 3 
PR0-01 TEMP  06 / Atlas  No. 293620  
VersionNo.4  / Version Date:  January  29, 2015   
  
Name of Sponsor: 
 
GlaxoSmithKline 
Vaccines  Protoco l number:  
V59 77  Gene1i c name of study vaccine(s):  
 
Meningococcal (groups A, C, W, and Y) 
oligosaccharide diphtheria CRM -197 
conjugate vaccine  
For a schematic overview , see Table 1. 
 
Ta ble I: Sch ema tic diagra m of the VS9_77 stu dy gro ups 
Vacc.ine History Vacc.ination in current 
study Blood draw schedule   
M enveo 
N=300 Menveo Blood draw Day 1 , 4, 29 (N =l50) 
Blood draw Day 1, 6, 29 (N =l50) 
Menactra  
N=300 Menveo Blood draw Day 1 , 4, 29 (N =l50) 
Blood draw Day 1, 6, 29 (N =l50) 
Vaccine -Naive 
N=IOO Menveo Blood draw Day I, 4, 29(N =50) 
Blood draw Day I, 6, 29(N =50) 
 
Blinding:  open-label study . 
Blood samn!P.s : Three (3) blood samples of approximately 10 mL each will be collected 
according to the blood draw schedule in Table I . 
Data collection: Electronic Case Reporting Form (eCRF) . 
 
Study  clinic visits: Three  (3) clinic  visits  at Day 1, Day 4 or Day 6 and Day 29 are 
piaruied for each  subject.  
Reminder  Phone  calls: Two  (2) reminder  phone  calls  will beconducted at Day 3 and 
Day 5 after the study  vaccination to remind the subject/  legal  guardian  to complete the 
diary  card.  
 
Safety phone  calls: Three (3) safety phone  calls  (at Day 15, Day91 and Day181)  will 
be conducted to collect  any medically -attended  AEs, AEs leading  to withdrawal,  SAEs , 
related medications and any vaccinations.  In addition , all unsolicited  AEs and related 
medications  occurring  after  the vaccination  willbe collected during  the safety  call at 
Day15.The  Day 181 Safety Phone  call will also serve as the termination  visit.  
 
Solicited Adverse Events (injection site pain, erythema, induration, fatigue , headache , 
myalgia, arthralgia, loss of appetite , nausea, chills and fever) occurring on the day of  
vaccination and the following six davs ffiav I throu h Dav 7) will be recorded daily  
Protocol V59_77 
Page 13of85  GSK 
24FEB16  Confidentia l 
Regulatory Review Protoco l Version 3 
PR0-01 TEMP  06 / Atlas  No. 293620  
VersionNo.4  / Version Date:  January  29, 2015   
  
Name of Sponsor: 
 
GlaxoSmithKline 
Vaccines  Protoco l number : 
V59- 77 Gene1ic name of study vaccine(s):  
 
Meningococcal (groups A, C , W, and Y) 
oligosaccharide diphtheria CRM -197 
conjugate vaccine  
using a Diary Card for all subjects . 
 
Unsolicited AEs occurring within 28 days after studyvaccination willbecollecte. d 
Qualified site staff willinterview the subject by phone approximately 14 days after 
vaccination  and in person  at the study  site approximately 28 days after study  vaccination 
to assess the occurrence of any unsolicited  AEs . 
Medicall}'. -attended  AEs AEs leading  to stud}'.withdrawal  and SAEs will be collected 
during the entire study period . These data will becaptured by interviewing the subject  
and/or subjects ' parents / guardian (as applicable) during the site visits and phone calls 
and by review of available medical records. Subjects and/or parents / guardian willbe 
encouraged to call the site in the event of any medically -attended AEs or any AEs which 
theyperceive as being of concern during the entire studyperiod . 
 
Table 2: Schematic diagram of the VS9_77 study desig n. 
Day l Day 4 Day 6  Day15 Day 29  Day 91 Day 181 
Blood draw 
(all sub jects)  Blood draw 
(50% of Blood draw 
(50% o f Safety 
Phone call Blood draw 
(allsubjects)  Safety 
Phone  Safety 
Phone call  
Menveo  subjects)  subjects )   call Study  
      tennination  
Number of Subjects planned: Approximately 700 subjects are planned for enrollment 
into this study, approximately 300 subjects who previously received Menveo (Menveo- 
Menveo group) , 300 subjects who previously received Menactra (Menactra- Menveo 
group) and 100 meningococcal vaccine -naive subjects (Naive group) . Assuming a 10% 
drop- out rate that should provide approximately 630 eval uable subjects.  
Study Populati o n and Su bject Char acte1istics : The list of inclusion and exclusion 
criteria is included in protocol section 4, Selection of Study Population.  
Study  Procedures : The study  includes  three  clinic  visits , one vaccination , three  blood 
draws,  and threesafety  phone  calls  for each  subject.  All studyprocedures  associated 
with the pre -vaccination, vaccination , post-vaccination, unscheduled and study 
termination  visit are described in section  5.0. 
Study Vacci nes: 
Protocol V59_77 
Page 14of85  GSK 
24FEB16  Confidentia l 
Regulatory Review Protoco l Version 3 
PR0-01 TEMP  06 / Atlas  No. 293620  
VersionNo.4  / Version Date:  January  29, 2015   
  
Name of Spo nsor:  
 
GlaxoSmithKline 
Vaccines  Protoco l number : 
V59 77  Gene1i c name of s tudy vaccine(s):  
 
Meningococcal (groups A, C , W, and Y) 
oligosaccharide diphtheria CRM -197 
conjugate vaccine  
GlaxoS mithKlin e Me ningococca l MenAC\1VY - CRl "\1 vacc in e (M e n veo): 
Meningococcal (groups A, C, Wand Y)oligosaccharide diphtheria CRM- 197 con jugate 
vaccine is supplied as a vial contain 10 µg of serogroup A oligosaccharides and 5 µg of 
serogroups C, W and Y oligosaccharides, conjugated to Corynebacterium diphtheriae 
CRM 191 protein. Overall injection volume of 0.5 mL. 
 
The vaccine will be adm inistered  intramuscularly , preferably in the deltoid area of the 
non-dominant arm.  
P1i mary Endpoint(s): 
Immun ogenicity Endpoi nts: 
The following measures will be summarized for the pooled (Menveo- Menveo and  
Menactra- Menveo) group.  
1. Percentage of subjects  with hSBA  seroresponse1 against N. meningitidis  serogroups 
A, C, Wand Y at Day29. 
 
Secondary Endpoints: 
Immun ogenicity endpoints: 
The following measures will be summarized for Menveo -Menveo, Menactra -Menveo , 
Naive and the pooled (Menveo -Menveo and Menactra -Menveo) groups unless 
otherwise noted:  
 
1. Percentage  of subjects  with hSBA  titer 8 against  N. meningitidis  serogroups  A, C, 
Wand Y at Day 1 , Day 4 , Day 6 and Day 29; 
2. Percentage s of subjects with hSBA seroresoonse  against  N. meninf!itidis  sero!!I'ouos  
 
 
1 Seroresponse is defined as : a) post -vaccination hSBA 8 for subjectswitha pre -vaccination hSBA <4; b) 
for subjects with a pre -vaccinationhSBA ' an increase of at least four timesthe pre- vaccinationhSBA.  
Protocol V59_77 
Page 15of85  GSK 
24FEB16  Confidentia l 
Regulatory Review Protoco l Version 3 
PR0-01 TEMP  06 / Atlas  No.293620  
VersionNo.4  / VersionDate: January 29,2015   
  
Name of Spo nsor:  
 
GlaxoSmithKline 
Vaccines  Protoco l number : 
 
V59 77 Gene1i c name of s tudy vaccine(s):  
 
Meningococcal (groups A, C , W, and Y) 
oligosaccharide diphtheria CRM -197 
conjugate vaccine  
A, C, Wand Y at Day4 , Day 6 and Day 29 (Day 29  Except the pooled group) ; 
3. hSBAGMfs  againstN.  meningitidis  serogroupA, C, Wand  YatDay 1, Day4, Day 
6 andDay29;  
4. Ratios  ofhSBA  GMTs  at Day 1, Day 4, Day 6 and Day29 (between study  groups).  
5. Ratios  ofhSBA  GMfs  at Day 4 , Day 6, and Day 29 compared to Day 1 (within  
study  groups).  
 
Safety endpoi nts: 
 
Safety of the study vaccine will be assessed in the pooled vaccine group (Menveo - 
Men
veo and Menactra- Menveo)  and the vaccine- naive group  in terms of the frequency 
(percentage) of reported adverse  events including:  
1. Any unsolicited  AEs reported  within  30 minutes after vaccination;  
2. Solicited  local and systemic  AEs reported from  Day 1 (6 hours)  through  Day 7 after  
vaccination ; 
3. Other  indicators  of reactogenicity (e.g. use of analgesics / antipyretics , body 
temperature) within  7 days  after  vaccination ; 
4. All unsolicited  AEs reported from  Day 1 through Day 29 after  vaccination;  
5. Medically -attended AEs, AEs leading  to withdrawal  and SAEs reported from  Day 1 
through Day 181 (during  the entire  studyperiod).  
Statistical Anal yses: 
P1i mary Immun ogenicity Objective  
The primary population  for the analysis  of sufficient immune response  is the Full 
Analysis  Set (FAS) , and will consist  of pooled  data from  the Menveo -Menveoand 
Menactra- Menveo  group  (n=540 evaluable).  
 
To demonstrate immune response sufficiency after MenACWY -CRM booster vaccine 
administration, the lower limit of the one- sided 97.5% Confidence Interval (CI) for 
percentage of subjects with hSBA seroresponse against eaciI of serogroups A, C , W and  Y must  be !!reater  than 80%  (in the pooled  !!l'OUP  of subjects  who received  , 
Protocol V59_77 
Page 16of85  GSK 
24FEB16  Confidentia l 
Regulatory Review Protoco l Version 3 
PR0-01 TEMP  06 / Atlas  No.293620  
VersionNo.4  / Version Date:  January  29, 2015  
  
Name of Sponsor: 
 
GlaxoSmithKline 
Vaccines  Proto col numb er: 
V59- 77 Gene1ic nam e of study vaccine(s):  
 
Meningococcal (groups A, C, W, and Y) 
oligosaccharide diphtheria CRM- 197 
conjugate vaccine  
vaccination with Menveo or Menactra)  
Hypothesis:  
Null hypothesis Alternative  hypothesis  
P, s 0.80 P, > 0.80 
Where: P., is the population seroresponse rate for the pooled Menveo -Menveoand 
Menactra- Menveo  group;  i = 1,2,3,4 refer  to serotypes A, C, Wand  Y respectively . 
Samp le Size: 
Statistical power  was estimated  based  onobserved data from  study V59Pl3El , where 
seroresponse rates  at one-month post booster dose of MenACWY -CRM  ranged from: 
97% (90% -100%) to 100% (95%- 100%)  for serogroupA; 93% (85%- 98%)for 
serogroup C; 91% (82% -97%)to 93% (84%- 98%) forserogroup W; and 90% (80% - 
96%) to 93% (84%- 98%) forserogroup  Y among  subjects primed  with MenACWY- 
CRM or Menactra  in the three  years  preceding  the study.  
Assuming the true seroresponse rates in the pooled group range from 90% to 97% 
(alternative hypothesis) for each serotype , a sample  size of n =540 will have at least 96% 
power to show sufficiency of immune  response to a booster dose of MenACWY -CRM 
in the pooled group , compared  with a pre-specified reference  seroresponse  of 80% (null 
hypothesis) using an exact test with 0.025 one-sided significance level When taking a 
10% dropout rate into account , N=600 previously vaccinated subjects have to be 
enrolled  in the study. Calculations  have  been  done  with nQuery  Advisor (Version  7.0). 
Tab le 3:  Stati stical Power  to Tes t for Sufficiency of Immune  Response 
Given a Range of True Seroreponse Rates for Evaluabl e 
Sample S ize of 540 subjects 
Serotype T111e Serores po nse Rate Powel'  
A 0.97  0.99 
C 0.93  0.99 
w 0.91  0.99 
Protocol V59_77 
Page 17of85  GSK 
24FEB16  Confidentia l 
Regulatory Review Protoco l Version 3 
PR0-01 TEMP  06 / Atlas  No.293620  
VersionNo.4  / Version Date:  January  29, 2015  
  
Name of Sponsor: 
 
GlaxoSmithKline 
Vaccines  Protoco l number:  
V59- 77 Gene1i c name of study vaccine(s): 
 
Meningococcal (groups A, C, W, and Y) 
oligosaccharide diphtheria CRM- 197 
conjugate vaccine  
y 0.90 0.99 
Total Power   0.96 
Interim Analysis: No interim analysis is planned for this study . 
Data Mo nito1i ng Committee: No DMC will be utilized for the study . 
GSK 
24FEB  16 Confidential  
Regulatory Review Protoco l Version 3  Protocol  V59_77 
Page  17 of85  
§ 
r"a 
" PR0--01 TEMP  06 / Atlas  No. 293620  
Version No.4 / Version Date : January  29, 2015  N 
::, z u 
8  
  
Table 4 Time and Events Table  
 
Visit Type 
Study period  
Study Day 
 
Visit Window (Days)  
 
 
Visit Number  Clinic Visit  Clinic Visit  Phone Call  Clinic Visit  Phone Call Clinic Visit Phone Call Phone Call  
Screening  Treatment  Tre.itment  Treatment  Treatment  Treatment  Follow -up Follo w-up 
 1 3, 5 4/6• 15 29 91 181 
 
-5 
to 1  
0 2 days (- 
1/+l ), 4 
da ys (0/ +2) 
after vacc  3/5 days 
(-1/+l ) 
after vacc  14 days  
(-2/+2) 
after vacc  28days 
(- 7/+14) 
after vacc  90days 
(-14/+14) 
aftel' vacc  180 days 
(-14/+14)  
after vacc  
Pre- 
vacc.ina tion 1 N/A 2 3 4 5 6 
Study Event  References   
Study Treatment    
Vaccination (vacc) Section 5.2  X       
Screening and 
Safety    
Informed Consent"  Section 5.1.1  X        
Medical History  Section 5.1.2 X        
Physical Exam  Sections 5.1.2 
and 5 .3.1 X x<  
X  
X   
Pregnancy Test Sections 3 .5 and 
5 .1.2 X x<       
Exclusion/Inclusi on 
Criteria  Section4  X        
Randomization  Section 5. 1.4  x<       
30 Minutes Post 
Injection Assessment  Section 5.2.1  X       
GSK 
24FEB  16 Confidential  
Regulatory Review Protoco l Version 3  Protocol  V59_77 
Page  18 of85  
§ 
r"a 
" PR0--01 TEMP  06 / Atlas  No. 293620  
Version No.4 / Version Date : January  29, 2015  N 
::, z u 
8  
  
Visit Type 
Study period  
Study Day 
 
Visit Window (Days)  
 
Visit Number  Clinic Visit  Clinic Visit  PhoneCall  Clinic Visit  Phone Call Clinic Visit Phone Call Phone Call 
Screening  Treatment  Tre.itment  Treatment  Treatment  Treatment  Follow-up Follo w-up 
 1 3, 5 4/6• 15 29 91 181 
 
-5 
to 1  
0 2 days (- 
1/+l ), 4 
days(0/+2) 
after vacc  3/5 da)'S 
(-1/+l ) 
after vacc 14 days  
(-2/+2) 
after vacc  28days  
(-7/+14) 
after vacc  90days 
(-14/+14) 
aftel' vacc  180 days  
(-14/+14)  
after vacc  
Pre- 
vacc.ina tion 1 NIA 2 3 4 5 6 
Study Event References   
SubjectDiary 
Dispensed with 
Training   
Section 5.2.1   
X       
SubjectDiary  
Reminder Call Section 5.2.2   xi xi     
Subject Diary 
Reviewed  and 
Collected   
Section 5.3.1        
X   
Assess Unso licited  
AEs Secti on 7. 1  X  X X X   
Assess SAEs  Section 7. 1.4  X  X X X X X 
Assess fo r medically 
attended AEs and 
AEs leading to 
withdrawal   
Sections 7. I.4.I 
and7.1.3   
X   
X  
X  
X  
X  
X 
Assess relevant 
medications/ 
vaccina tions Secti ons5.1.2 
and 6.5  
X  
X   
X  
X  
X  
X  
X 
GSK 
24FEB  16 Confidential  
Regulatory Review Protoco l Version 3  Protocol  V59_77 
Page  19 of85  
§ 
r"a 
" PR0--01 TEMP  06 / Atlas  No. 293620  
Version No.4 / Version Date : January  29, 2015  N 
::, z u 
8  
  
Visit Type 
Study period  
Study Da y 
 
Visit Window (Days)  
 
 
Visit Number  Clinic Visit  Clinic Visit  PhoneCall  Clinic Visit  Phone Call  Clinic Visit Phone Call  Phone Call  
Screening  Treatment  Tre.itment  Treatment  Treatment  Treatment  Follow - up Follow - up 
 1 3, 5 4/6• 15 29 91 181 
 
-5 
to 1  
0 2 days (- 
1/+l ), 4 
da ys (0 /+2) 
after vacc  3/5 da)'S 
(-1/+l ) 
after vacc  14 days  
(-2/+2) 
after vacc  28days 
(-7/+14) 
after vacc  90days 
(-14/+14) 
aftel' vacc  180 days 
(-14/+14)  
after vacc  
Pre- 
vacc.ina tion 1 NIA 2 3 4 5 6 
Study  Event I References   
Imm unogenicity    
Serology blood draw  I Section 3.5  X"  X  X   
Study C-0mp lerion 
Pt·ocedure  
StudyTennination' I Section 5.5        X 
 Notes : 
• Subject  will berandomized  into a blood draw  schedul e in a I:I ratio. Thesecond  clinic  visit will occur  at Day 4 OR Day 6. 
b Confirm consent fonn( s) signed prior to any procedures . 
' Procedure to be performed prior to vaccination  
d  If the clinic visit at Day 4 is overlapping with thespecified window of the Day 3 reminder call. the Day  3 reminder call may be omitted.  
If the clinic visit at Day 6 is overlapping w ith the specified window of the Day 5 reminder call, the Day 5 reminder call may beomitted.  
• Subject s who tenninat e thestudy  early  are recommended  to complet e certai nstudy-relatedprocedures . See section 5.5 for  further  detail s. 
Protocol V59_77 
Page 20of85  GSK 
24FEB16  Confident ial 
Regula tory Review  Protoco l Version 3 
PR0-01 TEMP  06 / Atlas  No. 293620  
VersionNo.4 / Version Date: January 29 , 2015  
  
LIST OF ABBRE VIATIO NS 
 
ACIP 
AE 
CI 
CBE R 
CRM 
CRO 
EC 
eCRF  
EDC 
FAS 
FDA 
GCP 
GMR 
GMT  
GSK 
hSBA 
IB ICF 
ICH
 
 
IM 
IRB 
LSLV  
MedDRA  
pp 
Ref. 
SAE  
soc 
SOP  Advisory Committee on Imm1mz iation  Practices 
Adverse Event  
Confidence Inteival  
Center for Biologics Evaluation and Research 
Cross Reactive material  
Contract Research Organization 
Ethics Committee  
Electronic  Case Report  Form 
ElectronicData Capture  
Full Analysis Set  
Food and Drug Administration 
Good Clinical Practices 
Geometric Mean Ratio Geometric  
Mean Titer GlaxoSmithKline 
Vaccines Human Serum 
Bactericidal Assay  Invest igator ' s 
Brochure  
Informed Consent Form  
International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Intramuscular
 
Institutional Review Board  
Last Subject Last Visit  
Medical Dictionary for Regulatory Act ivities 
Per Protocol  
Reference  
Serio us Adverse Event 
System Organ Class  
Standard Operating Procedure  
Protocol V59_77 
Page 21of85  GSK 
24FEB16  Confident ial 
Regula tory Review  Protoco l Version 3 
PR0-01 TEMP  06 / Atlas  No. 293620  
VersionNo.4 / Version Date: January 29 , 2015  
  
l. BACKG ROUl''-D M 'D RATIO NALE  
 
1.1 Backgro und 
 
Neisseria meningitidis is a leading cause of bacterial meningitis and sepsis worldwide , 
capable of causing outbreaks and epidemics of invasive disease. Meningococcal disease is 
associated with high morb idity and mortality even among patients who receive early 
antibiotic treatment. Most cases of invasive disease worldwide are caused by serogro ups 
A, B , C, W and Y . 
 
The quadrivalent meningococcal oligosaccharide diphtheria CRM- 197 conjugate vaccine 
(MenACWY -CRM; Menveo, GSK Vaccines) is approved for active immunization of 
individuals  from  2 months  through  55 years of age in the United  States . As of February 
2015, more than 30,000 of subjects  have  been exposed to MenACWY- CRMvaccine in 
completed clinical studies and more than 24 million doses of the vaccine have been 
distributed  globally . 
 
The US Advisory Committee on Immunizat ion Practices (ACIP) recommends routine 
vaccination  with a quadrivalent  conjugated  meningococcal vaccine for adolescents  at 11- 
12 years of age with a booster dose  administered  5 years later. While  a substantial body of 
data exists showing a robust immune response and good antibody persistence after a 
single dose of MenACWY- CRM in adolescents , the response to a booster dose of 
MenACWY -CRM in this age group has only been evaluated in 2 clinical studies with 
limited  number of subjects. 
 
A robust anamnest ic immune response to a booster dose of Menveo vaccine administered 
at approximately 5 years after previous vaccination with the same vaccine or a licensed 
meningococcal polysaccharide vaccine (Menomune®) was demonstrated in the phase 2 
clinical study V59P6El . High titers of bactericidal antibodies against the vaccine 
serogroups were achieved at 7 and 30 days after booster dose in MenACWY -CRM - 
pri
med subj ects. However , the number of subj ects inc luded in this study was relatively 
small (N =101, including 50 subjects who received a booster dose after the primary 
MenACWY -CRM vaccination) . 
 
In the phase 3b clinical study V59Pl3 El , a booster dose of MenACWY -CRM was given 
3 years after primary vaccina tion with either MenACWY- CRM or Menactra® (a 
meningococcal diphtheria toxoid- conjugated MenACWY vaccine , MenACWY- D) in 
adolescents . A booster dose was able to substantially increase antibody titers against all 4 
serogroups irrespective of the priming vaccine . Again, only small number of subjects 
(N=160) received the MenACWY- CRM booster , (83 who received primary MenACWY - 
CRM 
and 77 who received MenACWY- D). 
Protocol V59_77 
Page 22of85  GSK 
24FEB16  Confident ial 
Regula tory Review  Protoco l Version 3 
PR0-01 TEMP  06 / Atlas  No. 293620  
VersionNo.4 / Version Date: January 29 , 2015  
  
In the light of the current ACIP recommendation  for a booster  dose  of MenACWY -CRM, 
there exists a need to evaluate the response to a MenACWY -CRM booster given at - 5 
years after primary vaccination in meningococcal -vaccineprimed adolescents. Generation 
of this data would also be of relevance in outbreak management and vaccination of 
travelers  to endemic areas . 
 
1.2 Rational e 
 
The purpose/aim of this study is to assess the safety and anti body response to vaccination 
with a booster  dose  ofMenveo  given 4-6 years  after  primary  vaccination  and the response 
to a single dosegiven to vaccine -naive subjects , and to describe the immune response 
over time after a single dose of Menveo , dministi>red  to su b j ects previous ly vaccinated 
with Menveo or Menactra or to vaccine- naive  subjects.  The inclusion  of vaccine -naive  
subjects  in a separate study  arm is to enable comparison  of the rapidity  and magnitude  of 
an anamnestic response  to a booster  dose  (in primed individuals)  or the primary  response 
to a first dose(in  naive individuals)  of MenACWY -CRM.  
Protocol V59_77 
Page 23of85  GSK 
24FEB16  Confident ial 
Regula tory Review  Protoco l Version 3 
PR0--01 TEMP  06 / Atlas  No. 293620  
VersionNo.4 / Version Date: January 29 , 2015  
  
2. OBJE CTIVES 
 
2.1 Plima ry Objective(s)  
 
Plima ry Immun ogeoicity Objective(s)  
 
1. To demonstrate a sufficient immune response following a single dose of MenACWY - 
CRM
 (Menveo) vaccine , given to subjects who previously received Menveo or 
Menactra , as measured by the percentage of subjects with hSBA seroresponse against  
N. m.eningitidis serogroups A , C, W and Y at Day 29 after vaccination  
Criteria  to demonstrate immune  response sufficiency: The immune  response will be 
considered  as sufficient  if the lower  limit of the one-sided  97.5% CI for percentage of 
subjects with hSBA  seroresponse against serogroups  A, C, Wand  Y is greater  than 
80% (in pooled  group  of subjects who received  primary vaccination  with Menveo  or 
Menactra).  
 
2.2 Seco  nd a r y O bjec ti ve(s) 
 
Seco nd a r y I m m un oge ni city O bjec ti ve(s) 
 
1. To compare the immunogenicityof a single dose of MenACWY -CRM vaccine , 
between  subjects  who previously  received  Menveo , subjects  who previous ly received 
Menactra and vaccine- naive  individuals , as measured by the percentage of subjects  
withhSBA titer ;,:8, with hSBA seroresponse, and hSBA GMTs against N. 
meningitidis  serogroups  A, C, W and Y at Day 29 after vaccinat  ion 
2. To compare the immune responses over time following a single dose of MenACWY - 
CRM v
accine, between subjects who previously received Menveo, subjects who 
previously received Menactra and vaccine -naive individuals , as measured by the 
percentage of subjects with hSBA titer 8 and hSBA GMTs against N. meningitidis 
serogroups  A, C, Wand  Y at Day 1, Day 4, Day 6, and Day 29 after vaccination  . 
3. To assess persistence of bactericidal antibodies against serogroups A, C , Wand Y at 
approximately 4- 6 years after the primary vaccinat ion with Menveo and after the 
primary vaccination with Menactra in compar ison with naturally -acquired level in  
vaccine -naive individuals , as measured by the percentage of subjects with hSBA titer 
8 and hSBA GMTs a t Day 1. 
4. 
 
Seco ndary Safety Objective(s)  
Protocol V59_77 
Page 24of85  GSK 
24FEB16  Confident ial 
Regula tory Review  Protoco l Version 3 
::, z u 
8  
 N  
1. To assess reactogenicity andsafety of MenACWY -CRMvaccine when administered  
to subjects who previously received Menveo or Menactra and vaccine -naive  
individuals.  
2.3 Explor atory Objecti ve(s) 
There are no  exploratoryobjectives . 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
§ 
r"a 
"  
PR0-01 TEMP 06 / Atlas No.293620  
VersionNo.4 / Vers ion Date: January 29,20 15 
Protocol V59_77 
Page 25of85  GSK 
24FEB16  Confident ial 
Regula tory Review  Protoco l Version 3 
::, z u 
8  
  
3. STUD Y DESIGN 
 
3.1 Overview o f Study Design 
This is a phase 3b, controlled, open -labe multi-center studyto evaluate safety and 
immunogenicityof  MenACWY -CRM  after a single  vaccination  in healthy  individuals 
who were vaccinated with Menveo or Menactra 4 to 6 years  ago and in vaccine- naive 
individuals  
Study populat ion: Approximately 700 healthy subjects 15 through 55 years of age willbe 
enrolled in the study.  
Duration of the study : The duration of this study is approximately 6 months per subject.  
 
Written informed consent  and, as applicable according to local guidelines, written assent  
willbeobtained before conducting anystudy- specificprocedures.  
 
Vaccination schedule:  All subjects will receive a single dose of MenACWY -CRM at Day  
1. 
 
Study groups : 
 
Group  Menveo -Menveo : approximately  300 subjects , who were vaccinated with a single 
dose  ofMenveo  4 to 6 years ago, will receive  one dose of MenACWY -CRM.  
 
Group Menactra -Menveo approximately 300 subjects , who were vaccinated with a single 
dose  of Menactra  4 to 6 years  ago, willreceive one doseof MenACWY- CRM.  
 
Group Naive : approximately 100 subjects equally enrolled across all clinical sites, who 
have not received any meningococcal vaccination, willreceive one dose of MenACWY - 
CRM.  
 
Randomization / Stratification : 
Within  each study group , subjects  willberandomized into one of two different  blood 
draw  schedules according to a 1:1 ratio , described as follows:  
• Subjects  getting  blood draws  at Day 1 , Day 4 and Day 29. 
• Subjects  getting blood  draws  at Day 1, Day 6 and Day 29. 
 
For a schematic overview , see Table 1  
 
 
 
§ 
.N... 
r..a..  
PR0-01 TEMP 06 / Atlas No. 293620  
VersionNo.4 / Vers ion Date: January 29, 2015 
Protocol V59_77 
Page 26of85  GSK 
24FEB16  Confident ial 
Regula tory Review  Protoco l Version 3 
::, z u 
8  
  
Table 3.1-1: Schemati c diag ram of the VS9 _77 study gro up s 
 
Vacd ne Histor y Vaccination in cwTent 
study  Blood draw schedule  
Menveo  
N=300 Menveo  Blood draw Day I, 4, 29 (N =150)  
Blood draw Day I, 6, 29 (N = l 50)  
Menactra  
N=300 Menveo  Blood draw Day I, 4, 29 (N =150) 
Blood draw Day I, 6, 29 (N = l 50)  
Vaccine -Naive  
N=IOO Menveo  Blood draw Day 1, 4, 29 (N =50) 
Blood draw Day 1 , 6, 29 (N =50) 
 
Blinding· open- label study.  
 
Blood sanmles: Three (3) blood samp les of approximately 10 mL each will be collected 
according to the blood draw schedule in Table 3.1.1. 
Data collection: Electronic Case Reporting Form (eCRF) . 
 
Study  clinic  visits:  Three (3) clinic  visits  at Day I, Day 4 or Day 6 and Day 29 are 
planned for eachsubject.  
 
Reminder  Phone  calls : Two  (2) reminder  phone  calls  willbe conducted at Day 3 and Day 
S after the study  vaccination  to remind the subject/  legal  guardian  to comp lete the diary 
card. 
 
Safety phone calls: Three (3) safety  phone  calls  (at Day IS, Day 91 and Day 181)  will be 
conducted to collect any medically -attendedAEs , AEs leading to withdrawal , SAEs, 
related medications and any vaccinations . In addition, all unsolicited AEs and related 
medications  occurring  after  the vaccination  will be collected during  the safety  call at Day 
IS. The Day 181 Safety Phonecall  will also serve as the termination  visit.  
 
Solicited  Adverse  Events (injection  site pain,  erythema , induration, fatigue, headache, 
myalgia, arthralgia , loss of appet ite, nausea, chills  and fever) occurring  on the day of 
vaccination  and the following  six days (Day  1 through  Day 7) willbe recorded daily 
using  a Diary  Card for all subjects.  
 
Unsolicited AEs occurring within 28 days after studyvaccinat ion will be co llected . 
Qualified site staff willinterview the subject by phone approximately 14 days after 
vaccination  and in person at the studysite  approximately  28 days  after studyvaccinat ion 
to assess  the occurrence  of any unsolicited  AEs. 
 
 
§ 
.N... 
r..a..  
PR0- 01 TEMP 06 / Atlas No.293620  
VersionNo.4 / Vers ion Date: January 29, 201 5 
Protocol V59_77 
Page 27of85  GSK 
24FEB16  Confident ial 
Regula tory Review  Protoco l Version 3 
::, z u 
8  
  
Medically -attended AEs AEs leading  to stuqy  withdrawal  and SAEs will be collected 
during  the entire  study  period . These data will be captured by interviewing  the subject 
and/or  subjects ' parents  / guardian (as applicable)  during  the sitevisits  and phone  calls 
and by review  of available medical records . Subjects and/or  parents / guardian  will be 
encouraged to call the site in the event of any medically -attended AEs or any AEs which 
theyperceive  as being  of concern during  the entire  study  period.  
 
Table 3.1-2: Schematic di agram of the V59_ 77 study design 
 
Day l Da y 4 Da y 6 Da y 15 Da y 29  Da y 9 1 Da y 181 
Blood draw 
(all subjects ) Blood draw 
(50¾ of  Blood draw 
(50% of Safety 
Phone call  Blood draw 
(all subjects)  Safety 
Phone  Safety Phone  
call 
Men veo subjects)  subjects)   call Study  
      termination  
 
3.2 Study Period 
 
Each subject should  expect to participate  in the study  for 6 months , from  the time of 
enrolment through  the last study  visit.  
 
3.3 Blind ing Prncedur es 
 
The trial is designed as an open -label study . 
 
3.4 Data Collection 
3.4.l D ata Collected from  Subjects 
 
The following  data will be collected from each subject over the duration of their  study 
participation:  
• Demographic  Information.  
• Adverse  Events . 
• Medical  History . 
• Concomitant  Medications/Vaccination. s 
• Information on the blood  samples . 
 
All data collected  must only be identified  using  the Subject  ID, as described in section  
S.1.4, Randomization.  
 
 
§ 
,N.._ 
r,.a._  
PR0-01 TEMP 06 / Atlas No. 293620  
VersionNo.4 / Vers ion Date: January 29, 2015  
Protocol V59_77 
Page 28of85  GSK 
24FEB16  Confident ial 
Regula tory Review  Protoco l Version 3 
::, z u 
8  
 N  
3.4.2 Tools Used for Da ta Collec tion 
 
Data will be recorded in the Sub ject Diary and collected on electronic Case Report Forms 
(eCRFs).  
 
Subj ect Diar y 
 
Paper Diaries  (pDiaries) , hereafter referred to as Subject Diaries  will be the onlysource 
document allowed for solicited localand systemic adverse events (including body 
temperature measurements) , starting  after  the initial,  30minute  post-vaccination period at 
the clinic . The following  additional  rules  apply to documentation of safety  information 
collected  in the Subject Diary.  
 
The Investigator  or delegated staff should  monitor the Subject's  Diary  status throughout 
the study  for compliance and any solicited  local and systemic  adverse events  that were of 
concern to the sub ject. 
 
• No corrections or additions to the information recorded by the subject or 
parent(s)/legalguardian(s) within the Sub ject Diary will be allowed after it is 
delivered to the  site. 
• Any blank  or illegible  fields  on the Subject  Diary  must  be described as missing  in the 
eCRF.  
 
Case R ep01t F or m s 
This study  utilizes  electronic Case Report  Forms (eCRFs)  to collect study -related data 
from each  subject.  A qualified  site staff member(s) is required to enter  subject data in the 
eCRFs in English  based on the medical information  available in each subject ' s source 
record.  
 
Data should  be entered into the eCRF  in a timely  fashion following  each subject ' s clinic 
visit, study  procedure , or phone  call. Each subject's eCRF casebook will be compared 
withthe  subject's  source records  by a GSK- approved study  monitor  (or designee) over 
the duration  of the study  in order to ensure data collection  accuracy.  
 
 
 
 
 
 
 
§ 
r"a 
" The following additional rules apply to documentation of Sub ject Diary information 
collected in the eCRFs:  
• The site must enter all readable  entries  in the Subject Diary  into the eCRF , including 
those  values  that may be biologically  implausible (e.g. bodytemperature:  400°C) . 
• Any illegible or implausible data should be reviewed with the subj ect and/or 
parent(s)/legal  guardian(s). If an underlying  solicited  or unsolicited  adverse  event is 
 
PR0-01 TEMP 06 / Atlas No.293620  
VersionNo.4 / Vers ion Date: January 29,2015 
Protocol V59_77 
Page 29of85  GSK 
24FEB16  Confident ial 
Regula tory Review  Protoco l Version 3 
::, z u 
8  
  
described  on review with the subject, this should be described  in the source document 
and reported  as an unsolicited adverse  event  in the Adverse Event eCRF  (e.g., if the 
subject above confinns body temperature of 40°C on the day in which body 
temperature:  400°C was written  into his/her Subject  Diary , this fever of 40°C  should 
be recorded  in the Adverse Event eCRF) . 
• Any newly  described  safety  infonnation (including a solicited  adverse event) nrust not 
be written  into the Subject Diary  andnrust  be described  in the study  file as a verbally 
reported  adverse  event. Any adverse  event  reported  in this fashion  must  be described  
as an unsolicited  adverse  event  and therefore  entered on the Adverse  Event eCRF.  
3.5 Collection of Clinical Specimens 
The following clinical  specimens  are required to be collected  from  each subject in this 
study:  
• Blood. 
• Urine for  pregnancy  testing  (As per routine practice, specimens willbetested  at each 
site). 
Processing of a specimen should be completed bya qualified site member and in 
accordance with the study -specificClinical Specimen Laboratory Manual. Testing of 
serum  specimens willbe performed  by a GSK or a designated  laboratory. Refer to the 
study -specific  Clinical Specimen  Laboratory  Manual  for additional details . 
 
Blood Speci mens 
Approximately  10 mL sample of blood willbedrawn from  all subjects at visit Day 1 
before vaccination , and at visit Day 4 or Day 6 and Day 29. The blood volume  willnot 
exceed 10mL at each time point in order to provide the necessary serum volume 
(approximate ly half of the blood  draw  volume)  for the serology assays.  
The blood will be used for immunological assays. See section  7, Assessments  for 
additional details . 
The total amount of blood collected  over the study period  per subject will be 
approximately  30mL. 
 
 
 
 
 
§ 
.N... 
r..a.. U1in e S p eci m e ns 
Urine  willbe collected  for pregnancy  testing  in females of child  bearing  potential. Urine 
will becollected  at visit Day 1 before  vaccination  and the results  recorded  in the source 
document and  eCRF.  
 
PR0-01 TEMP 06 / Atlas No.293620  
VersionNo.4 / Vers ion Date: January 29,20 15 
Protocol V59_77 
Page 30of85  GSK 
24FEB16  Confident ial 
Regula tory Review  Protoco l Version 3 
::, z u 
8  
  
3.6 Stopping/Pausing Guideline s 
There are no predetermined stopping rules  in this study. Subjects  may be withdrawn  from 
the study according to investigator discretion as described in section 3 .8, Premature  
Withdrawal from  Study . 
 
3.7 Data Monit01ing Co mmittee 
No DMC will be utilized for the study . 
3.8 Premature \Vithdrawal from  Study 
 
Subjects may withdraw at any time , or be dropped from the study at the discretion of the 
investigator should any untoward effects occur and/or for safety reasons . In addition, a 
subject may be withdrawn by the investigator or the Sponsor if he/she violates the study 
plan or for administrative reasons . The investigator or study coordinator nrust notify the 
Sponsor immediately when a subject has been withdrawn due to an adverse event.  
 
The circumstances  above  are referred to as premature  withdrawal  from  the study , and the 
reason for premature  withdrawal should  be clearly documented and detailed  in the source 
documentation. The invest igator should make every attempt to evaluate the subject 's 
safety , including resolution of ongoing AEs, at the time of premature withdrawal . If a 
subject  wants  to withdraw  from  the study  before  or prior  to the last planned study  visit, 
the subject  will be asked to be followed  for safety  for the duration of the study. When  a 
subject  withdraws , or is withdrawn,  from the study , the procedures  described in section  
S.5.1,  Early Termination  Visit  should be completed if possible.  
 
The reasons  for premature  withdrawal from  the study  include : Adverse  event , death, 
withdrawal of consent, lost to follow -up, administrative  reason, and protocol  deviation . 
These reasons  are described in greater detail  below . 
AdverseE vent 
 
For anysub ject withdrawn from study participation prior to the planned Study 
Termination  Visit,  it is important to determine  if an AE was associated  with the reason for 
discontinuing  the study . This AE nrust  be identified on the AE eCRF  page  by indicating 
"Withdrawn from study due to AE". Any ongoing AEs at the time of studywithdrawal 
must be followed  until resol ution  or stabilization  
 
 
 
 
 
 
§ 
.N... 
r..a..  
PR0-01 TEMP 06 / Atlas No. 293620 
VersionNo.4 / Vers ion Date: January 29, 2015 
Protocol V59_77 
Page 31 of85  GSK 
24FEB16  Confident ial 
Regula tory Review  Protoco l Version 3  
  
Death  
For anysubj ect withdrawn  from  study participation  due to death , this shoul d be noted  on 
the StudyTennination eCRF page and the associated SAE that led to the death must be 
reported . 
\ Vith drawal of consent 
 
The subject and/o r parent(s)/legal guardian(s) can withdraw consent for participation in 
the study at any time without penalty or loss of benefit to which the sub ject is otherwise 
entitled . Reason for early termination should b e deemed as " withdrawal of consent' ' if the 
subject withdraws from participation due to a non-medical reason (i.e., reason other than 
AE). If the subject and/or parent(s)/legal guardian(s) intends to withdraw consent from 
the study, the invest igatorshould clarify if the subject will withdrawcompletely from the 
study or if the subject willcontinue study participation forsafety , or a subset of other 
study procedures . If the subj ectrequests complete withdrawal from the study, no further 
study interventions will be perfor med with the subject.  
If a subject and/or parent(s)/legalguardian(s)  withdraws  consent but does not revoke the 
HIPAA authorization,  the Sponsor will have fullaccess  to the subject ' s medical  records , 
including tennination visit information. If a subject and/or parent(s)/legal guardian(s) 
revokes only the HIP AA authorization, the Sponsor will have fullaccess to all of the 
subject' s medical  records  prior to the date and time of written  revocation.  
 
Lo st to Follow -Up 
For subjects who fail to show up for final visits  (clinic  or telephone contacts) , or for three 
consecutive visits, study staff are encouraged to make  at least three  documented  attempts 
to contact  the subject by telephone and at least one documented  written  attempt  to contact 
the subject and/or parent (s)/legal guardian(s) to encourage the completion of study 
termination procedures . These efforts to contact the subject should be recorded in the 
source document. The termination date for the subject to be captured on the Study 
Tennination eCRF  page  is the date of the last successful contact  (clinic  visit or telephone ) 
withthe  subject. 
 
Administrative R eason 
 
Examples for subjects withdrawn  from  the study due to administrativereason  can include: 
Sponsor decision to terminate the study, subject discontinuation for insurance i ssues, 
moving , no time , etc. This reason should be noted in the StudyTennination eCRF page 
and any ongoing AEs at the time of studywithdrawal should be followed until 
resolution/stabilization, if possible. 
 
PR0-01 TEMP 06 / Atlas No.293620  
VersionNo.4 / Vers ion Date: January 29,2015 

Protocol V59_77 
Page 32of85  GSK 
24FEB16  Confident ial 
Regula tory Review  Protoco l Version 3  
  
If the clinical study is prematurely tenninated by the Sponsor, the investigator is to 
promptly inform the study subjects and local EC/IRB and should assure appropriate 
therapy  and follow  up for the subjects . All procedures  and requirements  pertaining  to the 
archiving of study documents should be followed . All other study materials (study 
medication/vaccines , etc.) must be returned to the Sponsor . 
 
For sub jects who are withdrawn from the study due to receipt of an excluded 
medication/vaccination or due to significant protocol non -compliance , this reason should 
be noted in the StudyTermination eCRF page . 
 
Prot ocol D eviation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
§ 
.N... 
r..a.. 
 
::, z 
u 
8 A protocol deviation is any change , divergence, or departure from the study design or 
procedures of a study  protocol . In general, subjects  associated with protocol  deviations 
may remain  in the study  unless  continuation  in the study  jeopardizes the subject' s health, 
safety , or rights . 
 
Investigators will apply due diligence to avoid protocol deviations . Under no 
circumstances should  the investigator  contact  GSK or its agents , if any, monitoring  the 
study to request approval of a protocol deviation, as no authorized deviations are 
permitted. If the investigator  feels  a change to the protoco l would  improve  the conduct  of 
the studythis  must be considered a protocol  amendment , and unless  such an amendment 
is agreed upon  by GSK and approved  by the IRB/EC  and health  authorities  it cannot  be 
implemented . 
 
Any subject who becomes pregnant during the  study, despite the protocol requirement for 
adequate contraception should be encouraged to continue participating in the study for 
safety follow -up only. The site must complete a Pregnancy Report CRF (initial report) as 
soon as possible after learning of pregnancy occurrence (see section 7 .1.6, Pregnancies  
for further details). If the subject withdraws fromthe study for any of  the above 
categories except death, the site will obtain permission from the subject to continue to 
remain in contact with her until the outcome of the pregnancy is known, evenif the 
outcome  is not known until  after  the subject reaches the end of follow -up period . 
 
3.9 End of Study 
 
Most clinica l trials intende d to support  the efficacy/imm unogenc i  ityand safet y of an 
Investigational  Product  proceed to fullcomp letion  of planned sample size accrual.  
Evaluation  of the primary  and/or  secondary immunogenicity/ efficacyobjectives requires 
the testing  of biological  samples from  the study  subjects , which  can only be compl eted 
after all samp les are collected . The last samples  for the analysis of the primary and/or  
 
PR0-01 TEMP 06 / Atlas No. 293620 
VersionNo.4 / Vers ion Date: January 29, 2015 
Protocol V59_77 
Page  33 of85  GSK 
24FEB16  Confidentia l 
Regulatory Review Protoco l Version 3  
  
secondary objectives will be taken at the last clinic  visit, Day 29. For the purpose  of this 
protocol, end of study is defined as the completion of the testing of such biological 
samples , to be achieved no later than 8 months after collection of the last biological 
sample  at Day 29 visit.  
 
If the compl etion of testing  occurs  prior  the completion  of the Last Subject Last Visit 
(LSLV)  the latter  date defines the end of study  visit.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PR0-01 TEMP 06 / Atlas No . 29362 0 
VersionNo.4 / Vers ion Date: January 29 , 2015 

Protocol V59_77 
Page  34 of85  GSK 
24FEB16  Confidentia l 
Regulatory Review Protoco l Version 3 
::, z u 
8  
  
4. SELECTION  OF STUDY POPULA TION 
 
4.1 Inclusio n C1iteria  
 
In order  to participate in this study, all subjects must  meet  ALL  of the inclusion criteria 
described . 
 
1. Individuals  of IS through SS years of age on the day of informed  consent  or assent.  
2. Individuals  who received Menveo  4 to 6 years prior  to enrollment at an age  of 11 
years  or older  (Menveo -Menveo group) 
OR 
Individuals who received Menactra 4 to 6 years prior to enrollment at an age of 11 
years  or older  (Menactra -Menveo group) 
OR 
Individuals who have not received any previous meningococcal vaccine (Naive 
group) . 
3. Individuals who have  voluntarily given written  informed  consent  or assent after the 
nature  of the study has been  explained according  to local  regulatory  requirements , 
prior to study entry . If the subject is under age 18 at the tinie of enrollment , the 
parent (s)l1egal guardian( s) of the subject should have voluntarily given written  
informed consent.  
 
4. Individuals who can comp ly with  study procedures  including follow -up2 
S. Males  
Or 
Fema les of non- ciiildbearingpotential3 
Or 
 
 
2 A subject  and/or  parent(s )/Jegal guardian(s)  is/are considered  to be compliant  if the Investigator  judges 
thatthe subjectwill comp letetheSubject  Diary  and return for all thefollow -up visitsscheduled  in the 
study.  
3 A female is considered to be of non-childbearingpotential  prior  to menarcheand  after natural or induced 
menopause . Natural  menopause  is recognized  to have  occuned  after 12 consecutive months  of amenorrhea 
for which thereis  nootherobvious  pathological or physiol ogicalcause.  Induced menopause  is recognized 
tohave occurred after hysterectomy , after bilateral oophorecotmy , or iatrogenic ablation of ovarian 
ftmction.  
 
§ 
,N.._ 
r,.a._  
PR0- 01 TEMP 06 / Atlas No. 293620  
VersionNo.4 / Vers ionDate: January 29 , 2015 . 
Protocol V59_77 
Page  35 of85  GSK 
24FEB16  Confidentia l 
Regulatory Review Protoco l Version 3 
::, z u 
8  
 N  
Females of childbearing  potential who are using aneffect ive birth  contro l method4 
which  they intendto  use for at least 30 days  after the last study  vaccination.  
4.2 Exclusion Crite1i a 
 
Each sub ject must not have:  
1. History  of any meningococcal  vaccine administration  other thanthe single 
vaccination  given at 4 to 6 years ago (Menveo -Menveoan d Menactra- Menveo 
groups)  
OR 
History of any meningococcal vaccine administration (Naive group)  
2. Current  or previous, confirmed  or suspected disease caused  by N. meningitidis . 
3. Househol d contact with and/or intimate exposure to an in dividual with any l aboratory 
confirmed  N. meningitidis  infection  within  60 days prior to study vaccination. 
4. Progressive , unstabl e or uncontrolled clinical conditions . 
S. Hypersensitivity, including allergy , to any component of vaccines , medicinal products 
or medical equipment whose use is foreseen in this study.  
6. Clinical conditions representing a contraindication  to intramiscular vaccination  (IM) 
and blood draws.  
7. Abnormal functi on of the immune  system resulting from:  
a. Clinical  conditions . 
b. Systemic administration  of corticosteroids (PO/IV/IM) for more  than 14 
consecutive days within  90 days prior to study vaccination.  
c. Administration  of antineoplastic and immunomodulating agents or radiotherapy 
within  90 days prior to study vaccination. 
 
 
 
 
 
 
 
 
 
 
§ 
r"a 
" 4 The following birth control methods areconsidered effective: 
Abstinence  
Hormonal contracept ive(such asoral,injection, transdennal patch, implant) if used for at least 30  
days prior to informed consent  
Diaphragm preferably with spermicide, tubal occlusion device 
Intrauterine device (IUD)  
Tubal ligation 
Male par1ner using condom preferab ly with spermicide  
Male par1ner having been vasectomized at least six months prior toinformed consent  
 
 
PR0--0 1 TEMP 06 / Atlas No . 293620  
VersionNo.4 / Vers ion Date: January 29 , 2015 
Protocol V59_77 
Page 36of85  GSK 
24FEB16  Confidentia l 
Regulatory Review Protoco l Version 3  
  
8. Received immunoglobulins  or any blood products  within  180 days  prior  to informed 
consent.  
9. Received systemic antibiotic  treatment within  3 days  prior  to study vaccination or 
blood  draw.  
10. Received an investigational  or non- registeredmedicinal  product  within  30 days prior 
to study  vaccination  . 
11. Study  personnel  as an immediate  family  or household member.  
12. Individual s who have received any other vaccines within 7 days (for inactivated 
vaccines) or 14 days (for live vaccines) prior to vaccination in this study or who are  
planning to receive  any vaccine within  28 days  from  the study vaccination.  
13. Individual s who have experienced a moderate or severe acute infection and/or fever 
defined as a temperature 38°C (100.4°F) within 3 days prior to study vaccination.  
14. Any other clinical  condition  that, in the opinion of the investigator, might  pose 
additional  risk to the subject  due to participation  in the study . 
 
 
4.3 C1ite1ia for De.la y of Vacc ina tion and/or Blood Sam pling 
 
There may be instances when individuals meet all eligibility criteria for vaccination yet 
have a transient clinical circumstance which may warrant delay of vaccination: body 
temperature eleva tion [ 38.0° C 100 .4° F) within 3 days prior to intended study 
vaccination ], systemic antibiotic treatment within 3 days prior to study vaccination or 
blood  draw.  Unde r such  circumstanc es, a subjec t may be considere d eligible  for study 
enrolment after the appropriate window for delay has passed and inclusion/exclusion 
criteria  have  been rechecked,  and if the subject is confirmed  to be eligible.  
 
There is a clinical circumstance that warrants delay of blood collection for 
immunogenicityassessments in this study.  This situation  is listed  below . In the event  that 
a subject  meets  this criterion for delay of blood collection,  blood  collection  may proceed 
once  the window  for delay  has passed. 
 
Subject  has received  a dose  of systemic antibiotics  less than 3 days before the intended 
blood collection . 
 
 
 
 
 
 
PR0-01 TEMP 06 / Atlas No. 293620  
VersionNo.4 / Vers ion Date: January 29, 2015 

Protocol V59_77 
Page 37of85  GSK  
24FEB16  Confidential  
Regulatory Review Protoco l Version 3  
 N  
5. STUDY  PROCEDURE S 
 
The sections  that follow provide  an overview  of the procedures  that are to be followed  in 
enrolling,  evaluating , and following  subjects  who participate  in this clinical  study . Visits 
can be either  clinic  visits  or safety follow -up telephone calls , as specified  in the Table 
below  and in the Time and Events  Table4 . 
 
Tabl e 5-1 Study Proced ures 
 
Visit Category  Procedu res 
Pre-vaccinationClinic Visit(s)  Section 5.1 describes ptocedures to befollowed 
prior  to study vaccinat ion: informed consent/assent,  
screening , enrolment , andrandomization  
Vaccinat iooClinic Visit(s) Section 5.2 describes ptocedures to befollowed 
during each clinic visit invo lvingvaccination: 
vaccination,  post-vaccination ptocedures,  and post- 
vaccination reminders  
Post-vaccination Visit(s)  Section 5.3 describes follow -up clinic  visits and 
safety  follow-up calls  
Unschedu led Visit(s)  Section  5.4 describes  possib le procedures  to be 
followed  at unscheduled clinic v isit 
Study Termination Visit  Section  5.5 describes  ptocedures  to befollowed  at 
the last study visit for a subject  (may  include early  
termination visit)  
 
5.1 Pre-vacci nation Clinic Visit(s)  
 
This section  describes the procedures  that must be performed  for each potential subject 
prior  to vaccination,  including  obtaining informed  consent/assent,  screening , enrolment 
and randomization.  
5.1.l Infor med Consent/Assent 
 
"Informed consent" is the voluntary agreement of an individual or his/her legal 
guardian(s) to participate in research. Consent must be given with free will of choi ce, and 
without undue inducement. The individual must have sufficient knowledge and 
understanding of the nature of the proposed research, the anticipated risks and potential 
benefits , and the requirements of the research to be ab le to make an informed decision . 
 
 
 
 
§ 
r"a 
" 
::, z 
u 
8 "Assent" is a term used to express willingness to participate in research by persons who 
are by definition too young to give informed consent but who are old enough to 
understand the proposed research in general , its expected risks and possible benefits , and 
 
PR0--01 TEMP 06 / Atlas No.293620 
VersionNo.4  / Vers ionDate: January 29,2015 
Protocol V59_77 
Page 38 of85  GSK  
24FEB16  Confidentia l 
Regulatory Review Protocol Version 3  
  
theactivities expected of them as subjects. Assent by itself is not sufficien t, however. If 
assent is given, informed consent must still be obtained from the subject's parent(s) or 
legal guardian(s).  Local laws  define  who constitutes  a "child,"  and such definitions  dictate 
whether  or not a person can legall y consent  to participate in a protocol  (Levine  1988) . 
 
Infonned consent of the parent(s)/legal guardian(s) and assent of subject following local  
!RB/EC guidance must be obtained before conducting any study- specific procedures (i.e., 
all of the procedures described in the protocol). The process of obtaining informed 
consent and assent should be documented in the sub ject source document in addition to 
maintaining a copy of the signed and dated informed consent. Additional specifics 
regarding the informed consen t and assent processes are located in section 13.2, Infonned 
Consent Procedures . 
If a subject and/or paren t(s)/legalguardian(s) is unable to read, an impartial witness 
should  be present  during  the entire  informed consent and assent discussion.  An impartial 
witness is defined as a person who is independent from study conduct, who cannot be 
unfairly  influenced by those  involved  with the study , who attends  the informed consent 
process if the subject or the subject' s legall y acceptable representative cannot  read,  and 
who reads  the informed consent form  and any other  written  information  supplied  to the 
subject.  After the written  informed consent form  and any other  written  information to be 
provided to subjects, is read and explained to the subject and/or parent(s)/legal 
guardian(s)  and after the subject  and/or  parent(s)/legal  guardian(s)  has verbally  consented 
to the subject's participation in the study and, if capable of doing so, has signed and 
personally  dated the informed  consent  form,  the witness  should  sign and personally date 
the consent  form.  By signing  the consent form,  the witness  attests that the information  in 
the consent form and any other written information was accurately explained to , and 
apparently understood  by, the subject and/or  parent(s)/legal  guardian(s)  and that informed 
consent was freely given by the subject and/or  parent(s)/ legal  guardian(s).  
 
5.1.2 Screening 
 
After  an individual  has consented  to participate  in the study  and infonned  consent/assent 
is signed, that individual  will be given a unique  Screening Number manually created by 
the investigator. The subject ' s unique Screening Number will be documented in the 
Screening and Enrolment  log. The eligibility  of the subject  will be determined based on 
the inclusion  and exclusion  criterialisted  in section  4, Selection  of Study  Population  and 
evaluated during  this screening  procedure.  
 
Prior  to study  enrolment , demographic  data will be collected  from  the subject,  including: 
date of birth,  gender, race, ethnicity , prior  vaccination against meningitis.  
 
 
 
PR0-01 TEMP 06 / Atlas No.293620  
VersionNo.4 / Vers ion Date: January 29,2015 

Protocol V59_77 
Page 39 of85  GSK  
24FEB16  Confidentia l 
Regulatory Review Protocol Version 3 
N 
r"a VersionNo.4 / Version Date: January 29 , 2015 
" 
::, z u 
8  
  
Medical history  willalso be collected,  including but not limited  to any medical  history 
that may be relevant to subject eligibility for study participation such as prior 
vaccinations , concomitant  medications , and previous  and ongoing  illnesses  or injuries . 
Relevant  medical history can also include  any medical history  that contributes  to the 
understanding  of an adverse event that occurs  during  study  participation,  if it represents 
an exacerbation of an underlying  disease /pre-existingproblem.  
 
Review of systems is a structured interview that queries the subject and/or parent(s)/legal 
guardian(s) as to any complaints the subject has experienced across each organ system 
This will be performed before enrolment and used to guide physical examination . 
 
If applicable, prior and concomitant  medications  or vaccinations taken  prior  to start of 
study  should  be collected (refer to section  6.5, Prior  and Concomitant  Medications  and 
Vaccines for further  details) . 
 
Collect  vital signs  (heart rate , blood  pressure , and temperature (preferably  taken  orally) . 
Measure height  and weight.  
Perform pregnancy testing in women of childbearing potential (refer to section 3.5, 
Collection of Clinical Specimens for additional information ) 
A general physical  examination  is to be performed  by a qualified health  care practitioner . 
"Qualified  health  care practitioner " refers  to any licensed  health  care professional  who is 
permitted  by institutional  policy  to perform  physical  examinations  and who is identified 
within  the Study  Staff Signature  Log. 
 
The data collected through study  assessments listed  above  willbewritten  in the source 
document  (see section  9.1, Source  Documentation ). Should the physical  assessment 
reveal any abnormal  values  or events , these  must be documented in the CRF  Adverse 
Events  Form  
 
Prior to vaccination, approximately 10 mL of bl ood will bedrawn from all subjects for 
the immunological testing see section 3.5, Collection of Clinical Specimens . 
 
In the even t that the individua l is determined  ineligibl e for studyparticipation , he/she  is 
considered a screen failure . The reason for screen failure must be documented in the 
Screening and Enrolment  log. If the individual  is determined to be eligible for the study, 
he/she  willbeenrolled into the study . 
5.1.3 Em·olment 
 
After  signing  the informed  consent/assent fonn,  if an individual  is determined to be 
eligible  for study  participation,  the investigator  will emoll the subject.  
§ PR0-01 TEMP  06 / Atlas  No. 293620  
Protocol V59_77 
Page 40 of85  GSK  
24FEB16  Confidentia l 
Regulatory Review Protocol Version 3 
N 
r"a VersionNo.4 / Version Date: January 29 , 2015 
" 
::, z u 
8  
  
5.1.4 Randomization  
 
Upon entering subject demographic data in IRT , the system will assign a 7 digit subject 
ID number consisting of the 3 digit site number and 4 digit order of randomization at the 
site. Access to IRT can be obtained by the site staff either via web or telephone (as back 
up). The Subject ID will be the subject ' s unique identification number for all CRFs and 
associated study documentation that will be used for duration of the study. After 
randomization, the Screening Number ceases to be  used and remains in the Screening and 
Enrolment Log only. : During the randomization transaction in IRT Subjects will be 
assigned a kit number for Menveo vaccination and will be randomized to a blood draw 
schedule (1:1 according to previous vaccination status). The list of randomization 
assignments is produced by the IRT service provider and approved by GSK 
Randomization  Office  according to applicable GSK Standard  Operating Procedure  (SOP) . 
 
IRT will also be used to ensure adequate and appropriate distribution of enrolment of 
naivesubjects  across all sites. Further details may be found  in study -specific  plans , for eg, 
the IRT User  Manual and the Randomization  Configuration Document . 
 
If for any reason, after signing the infonned consent form (ICF) , the subject who is 
eligible  and enrolled  fails to be randomized, this is called a randomization  failure  and the 
early terminat ion studyprocedures nrust be applied. The reason for all randomization 
failures should be recorded in the Screening and Enrolment Log and in the source 
document  as specified  in the Source  Data Agreement  (SDA) . The information on subjects 
who are randomization failures should be kept distinct from subjects who are screen 
failures , as described in section  5.1.2, Screening.  
 
If for any reason, after randomization the subject fails to undergo treatment , this is an 
Early Termination and the reason should  be recorded in source  document  as specified  in 
the SDA.  The information on these  Early Termination  subjects  should be kept distinct  in 
the source  documentation from  randomization  failures.  
 
Within each study group, subjects will be randomized into one of two different blood 
draw schedules according to a 1:1 ratio , described as follows:  
• Subjects  getting blood  draws  at Day 1, Day 4 and Day 29. 
• Subjects  getting blood  draws  at Day 1, Day 6 and Day 29. 
 
If for any reason, after enrolment the subject  fails to undergo  treatment/study  procedures 
this is an Early  Termination  and the reason should be recorded in source document  as 
specified in the Source Data Agreement (SDA) . The information on these Early 
Termination  subjects  should  be kept distinct in the source  documentation  from subjects 
who are screen  failures, as described in sectio n 5.1.2 , Screening . 
§ PR0--01 TEMP  06 / Atlas  No. 293620  
Protocol V59_77 
Page 41 of85  GSK  
24FEB16  Confidentia l 
Regulatory Review Protocol Version 3 
N 
r"a VersionNo.4 / Version Date: January 29 , 2015 
" 
::, z u 
8  
  
5.2 Vaccination Clinic Visit 
 
The first vaccination will be performed on Day 1. 
 
For studies  which  have  visits  for concomitant  vaccinations  or treatments , see section  6.5, 
Prior  and Concomitant  Medications  and Vaccines for those  visit procedures.  
 
Ensure all blood samples are taken p 1ior to the vaccination . 
 
After completing the pre -vaccination procedures on day 1, administer the vaccine to the 
subject according to the procedures described in section 6.3, Vaccine Preparation and  
Administration. Observe the blinding procedures described in section 3.3, Blinding  
Procedures . 
 
Prior  to administrationof  study  vaccinat ion, confirm  that the subject does  not meet  any 
criteria for delaying additional  study vaccinat ions as described in section  4, Selection  of 
Study  Populat ion. 
5.2.1 Post-vaccination Proced ures 
 
The following post -vaccination procedures will be performed on day 1. 
 
• After vaccination, the subject will be observed for at least 30 minutes including 
observation for unsolicited adverse events , solicited adverse events , and body  
temperature measurement. Record all safety data collected during this time in the 
subject 's source  document.  
• A Subject Diary  will be used in this study to document  solicited  adverse events . The 
Subject  Diary  is the only source  for collection  of these data; therefore , it is critical that 
the subject completes the Subject Diary correctly . The subject should be trained on 
how and when to complete eaclJ field  of the Subject  Diary.  
• The subject and/or parent(s)/legal guardian(s) should be trained on how to self- 
measu
re localsolicited  adverse  events . The measurement of solicited  local  adverse 
events is to be performed using  the ruler provided  by the site. 
• The subject and/or  parent(s)/legal  guardian(s)  should  be instructed  how to perform 
bodytemperature measurement using the thermometer provided by the site. If the 
subject  feels unusually hot or cold during  the day, the subject and/or  parent(s)/legal 
guardian(s) should  check  body  temperature. If the subject  has fever , the highest  body 
temperature observed  that dayshould  be recorded in the Subject  Diary.  
Subject  Diary  training  should  be directed  at the individual(s)  who will perform the 
measurements  of adverse  events and who will enter the information  into the Subject  
§ PR0-01 TEMP  06 / Atlas No.293620  
Protocol V59_77 
Page 42 of85  GSK  
24FEB16  Confidentia l 
Regulatory Review Protocol Version 3 
::, z u 
8  
  
Diary. This individual may not be the subject and/or parent(s)/legal guardian(s) , but if a 
person other than the subject and/or parent(s)/legal guardian(s) enters infonnation into the 
Subject Diary , this person's identity must be documented in the Subject Diary or subject ' s 
source record. Any individual that makes entries into the Subject Diary must receive 
training on completion of the Subject Diary at the time of the visit. Tilis training must be documented in the subject 's source record .
 
 
The same indiv idual should complete the Subject Diary throughout the course of the  
study.  
 
• The site should schedule the next study activity clinic visit on Day 4 or Day 6 
depending to which blood draw schedule subject was randomized to with the subject  
and/or  parent(s)/legalguardian(s).  
 
The subject  and/or  parent(s)/legal  guardian(s) will be reminded  to comp lete the Subject 
Diary  and to contact the site if there  are any questions , and to contact the siteimmediately 
(or as soon  as the subject  is medically  stable) if the subject has a medical  condition  that 
leads  to a hospitalization  or an emergency room  visit or to a visit to/by  a doctor  or is of 
concern.  
5.2.2 Post-vaccination Reminde rs 
 
Reminder  calls  or alerts are not intended  to be an interview  for collection  of safety data. If 
the subject  and/or  parent(s)/legal  guardian(s)  wishes  to describe safety infonnation,  this 
information should only be collected by a healthcare professional at the site , and the 
safety  data described must be written  down in the subject 's medical chart . 
 
Subject Diary Reminder Calls 
 
Subject Diary reminder calls will be performed on day 3 and day S. The purpose of this 
callis to remind the subject and/or parent(s)/legal guardian(s) about completion of the 
Subject Diary. The call follows the Subject Diary Reminder Telephone Call Script 
provided to the site. The subject and/or parent(s)/legalguardian(s) should be reminded to 
contact the site via the telephone number provided in the informed consent to discuss 
medical questions. If the clinic visit at Day 4 or Day 6 overlaps with the specified window 
of the Day 3 or Day S reminder call , the Day 3/Day S reminder call may be omitted . 
5.3 Post-vaccination Visit(s) 
 
Post-vaccinationvisits  will be performed  on Day 4 or Day 6according  to the blood  draw 
schedule to which  subject was randomized and Day 29. 
 
 
§ 
.N... 
r..a..  
PR0-01 TEMP 06 / Atlas No.293620  
VersionNo.4  / Vers ionDate: January 29,2015 
Protocol V59_77 
Page 43 of85  GSK  
24FEB16  Confidentia l 
Regulatory Review Protocol Version 3  
  
5.3.l Follow-up Clinic Visit.(s)  
 
Fo llow -up clinic  visits  willbeperformed on Day 4 or Day 6 according  to the blood  draw 
schedule to which subject was randomized and on Day 29.During the follow-up clinic 
visit:  
 
• Subject  Diary  will be reviewed  at Day 29. No changes to the infonnation recorded 
within  the Subject  Diary  are permissible . For details  on the Subj ect Diary  see sections  
3.4.2, Tools Used for Data Collection and 5.2.1, Post-vaccination Procedures . The 
subject and/or parent (s)/legal guardian(s) willbeinterviewed to determine if any 
unsolicited  adverse events  occurred an d if any concomitant  medications  or vaccines 
were taken/received  in the  time since  the last clinic  visit.  This interview  willfollowa 
script which willfacilitate the co llection of relevant safety information. The 
healthcare profess ional reviewing these data willdiscuss the symptoms (if any) 
reported  by the subject  and willdetermine if any ad ditional  diagnoses  and/or adverse 
events are present. Adverse events reported by the subject and/or parent(s)/legal 
guardian( s) at this follow-up clinic visit must be recorded in the subject's source  
documentan d on an Adverse Events CRF , as speci fied in section 7.1, Safety  
Assessment, and not written  on the script  used for the interview . 
• Performa brief symptom -directed physical examination if necessary according to 
symptoms  the subjec t has reported.  This is a physical  examinat ion that willinclude  an 
examinat ion of organ  systems  that are relevant  to the investigator  based on review  of 
the subject's reported adverse events , concomitant medication use. This assessment 
may include: measurement of vital signs , body temperature and a check of general 
appearance . The physical assessment must be performed by the investigator or 
designee of the investigator , who is qualified to perform a phys ical assessment in 
accordance  with their  institutional  policy . Corresponding information  is documented 
in the subject ' s source  document  and CRF (s). 
• Collect a blood sample (see section 3.5, Collection of Clinical Specimens for 
additional information ). 
 
The site should  schedule the next study activity  safety  call withthe  subject and/or 
parent (s)/legal  guardian(s).  
 
The subjec t and/or  parent (s)/legal  guardian(s)] willreceive  a written  remin der of the next 
planned study  activity . The subject and/or  parent(s)/l egal guardian(s)  will bereminded to 
contact the site if there  are any questions  and to contact  the siteimmediately  (or as soon 
as the subject is medically stable) if the subject has a medical condi tion that leads to a 
hospitalizationor an emergency  roomvis it. 
 
 
PR0--01 TEMP 06 / Atlas No.2936 20 
VersionNo.4 / Vers ion Date: January 29,20 15 

Protocol V59_77 
Page 44 of85  GSK  
24FEB16  Confidentia l 
Regulatory Review Protocol Version 3 
::, z u 
8  
  
5.3.2 S afety Follow-upCalls 
 
Safety follow -up call will be performed on Day 1S , Day 91 and Day 181.  
 
Safety follow -up calls are calls made to the subject by a healthcare  professional 
designated on the site log. These calls will follow a script which will facilitate the 
collection of relevant safety information . The subject and/or parent(s)/legalguardia n(s) 
will be inteIViewed  according to the script, and information  related  to unsolicited  adverse 
events (only at Day 1S), serious adverse events (SAEs),  medically attended adverse 
events , AEs leading to withdrawal and concomitant medications or vaccinations 
associated with those events will be reviewed . All safety information described by the 
subject must be written down in a designated location within the source document and not 
written  on the script  used for the telephone  call. 
 
Thesite  should schedule the next study  activity  with the subject and/or  parent(s)/legal 
guardian(s).  
 
The subject and/or  parent(s)/legal  guardian(s) will be reminded  to contact  the site if there 
are any questions and to contact the site immediately (or as soon as the subject is 
medically  stable) if the subject has a medical condition that leads to a hospitalizationor 
an emergency room  visit.  
5.4 Unsch eduled Visits 
 
Unscheduled visits are not expected within this protocol.  
 
5.5 Study T erminati on Visit 
 
The study termination visit willoccur on Day 181. The termination visit will be a 
telephone call . The date of termination is the date of the last contact ( clinic visit or 
telephonecall) in which  the subject 's health  status  was assessed or, in cases where  the 
subject  does not agree to any further  safety  follow- up, it is the date consent  is withdrawn. 
This date should  be recorded on the termination  CRF  page . For visit procedures  to be 
performed  for a subject whos e planned  study participation  ends  prematurel y, please  see 
section S.S.1 , Early Termination Visit.  
During the telephone call, the following procedures will be performed: inteIView of 
subject  and/or parent(s)/legal  guardian(s)  to collect medically  attended adverse  events , 
AEs leading  to withdrawal , SAEs , as well as inteIView of subject and/or  parent(s)/legal 
guardian(s)  to collect concomitant  medications/ vaccinat ions associated  with those  events . 
All safety information  described by the subject nrust  be written  down  in a designated  
 
 
§ 
.N... 
r..a..  
PR0--01 TEMP 06 / Atlas No.293620 
VersionNo.4 / Vers ion Date: January 29,2015 
Protocol V59_77 
Page 45 of85  GSK  
24FEB16  Confidentia l 
Regulatory Review Protocol Version 3 
::, z u 
8  
  
location  within  the source  document  and not written  on the script  used for the telephone 
call. 
The site will review  with the subject and/or parent(s)/legal  guardian(s) the plan of when 
infonnation relating to the subject's participation in the study may be available (e.g., 
study  results , treatment assignments).  It will also be discussed how infonnation relating to 
the subject ' s participation  in the study will be shared  with the subject's  healthcare  
provider , if the subject and/or parent(s)/legalguardian(s) chooses to share this  
infonnation.  
 
The site willcomplete the tennination  CRF  page  and this will mark the completion of the 
subject 's participation in the  study.  
5.5.1 E ar ly T ermin ati on Visit  
 
When a subject is withdrawn  from  treatment or withdraws  from  the study , the investigator 
will notifythe  Sponsor  and, when  possible, will perform  the procedures listed  below.  The 
reason(s)  for the early  tennination  will be included in the subject' s source documentation. 
If the EarlyTermination  Visit  is a telephone call, collect  as much infonnation as possible . 
Early Termination Visits  include  subjects  who were randomized but not treated.  
 
At the clinic visit or during the telephone call, the following procedures will be 
performed: interview of subject and/or parent(s)/legal guardian(s) to collect adverse 
events , medically attended adverse events, AEs leading to withdrawal , SAEs , interview of 
subject and/or parent(s)/legalguardian(s) to collect concomitant medications/ 
vaccinations.  
The site will review with the subject and/or parent(s)/legal guardian(s) the plan o f when 
infonnation relating to the subject's participation in the study may be available  (e.g., 
study results , treatment assignments). It will also be discussed how information relating to 
the subject ' s participation in the study will be shared with the subject's healthcare 
provider , if the subject and/or parent(s)/legalguardian(s)  chooses to  share this 
infonnation.  
 
The sitewillcomplete  the termination  CRF  page  and this will mark the completion of the 
subject 's participation in the  study.  
 
 
 
 
 
 
 
 
§ 
.N... 
r..a..  
PR0-01 TEMP 06 / Atlas No.293620  
VersionNo.4  / Vers ionDate: January 29,2015 
Protocol V59_77 
Page 46 of85  GSK  
24FEB16  Confidentia l 
Regulatory Review Protocol Version 3 
PR0--01 TEMP  06 / Atlas  No.293620  
VersionNo.4 / Version Date: January 29,20 15  
  
6. TREATME1''T OF SUBJECTS  
 
All vaccines associated with this study  are to be stored  separately  from  other  vaccines and 
medications  in a secure location  under appropriate  storage  condi tions with temperature 
monitoring . All vaccine s associated w ith this study must be checked for expiration 
date  p1i or to use . Expired  vacc ines must  not be administered  to subject s. 
 
6.1 Study Vaccine(s)  
 
The term  'study  vaccine  ' refers  to those  vaccines  provided by the  Sponsor , which  will be 
evaluated as part of the study objectives . The study vaccines specific to this study are 
described below . The study vaccines specific to this study is the MenACWY -CRM 
vaccine  (Menve o® , GSK)  . 
 
The Meningococcal ACWY conjugate vaccine is obtained by extemporaneous mixing 
just before  injection  of the lyophilized  MenA -CRM  component with the MenCWY -CRM 
fullliquid vaccine . The pharmaceutical form is Powder and solution for solution for 
injection. Menveo® is provided as vial/vial presentation . MenA lyophilised conjugate 
component (glass vial) and MenCWY liquid conjugate component (glass vial). After 
reconstitution, MenACWY -CRM will have the following c omposition per O.S mL of 
injectable  solution  (SeeTable 6 .1-1): 
 
Tabl e 6.1-1: MenAC\VY -CR"l\1 Composition  
 
Nameof Ingr edient  Unit and/ol' Percenta ge Fol'mula 
(Dose 0.5 mL) 
D1111gSubstances  
CRM 191-MenA conjug;ite  10 µg MenA,16.7 - 33.3µgCRM 191 
CRM 191-MenCconjug;ite  5 µgMenC, 7. 1 - 12.5 µg CRM197  
CRM 191-MenWconjugate  5 µg Men W, 3.3-  8.3µgCRM191 
CRM 191-MenYconjug;ite  5 µg MenY , 5.6- 10 µgCRM197  
Sodium chloride  4.5mg  
Excipients  
Sucrose  12.5 mg  
Sodium phosphate buffer 
Sodium dihydrogen phosphate  
Disodium hydrogen phosphate dehydrate  !OmM 
2.5mM  
7.5mM  
Potassium dihydrogen phosphate  5mM  
Water for Injection  q.s 0.5 mL  
VolumeofFormulation  0.6mL  
Protocol V59_77 
Page 47 of85  GSK  
24FEB16  Confidentia l 
Regulatory Review Protocol Version 3 
PR0-01 TEMP  06 / Atlas No. 293620 
VersionNo.4 / Version Date: January29 , 2015   
  
Name of Ingredient Unit and/ol' Percentage Fol'mula 
(Dose 0.5 mL) 
Appearance  Colotless to light yellow 
Vaccine Presenta tion Asingle do se of two vials 
One 0.5 mL dose ofMenACWY will be administered by intranruscular (IM) injection  in 
the deltoid  area of non-dominant arm (preferably .) 
 
For more  detailed  information,  refer to the latest  version of Investigator Brochure  and 
SPC for Menveo ® , which  are included in the investigator site file. 
6.2 Non-Study Vaccines 
Not applicable.  
6.3 Vaccine Pr epa rntion and Adminis tra tion 
The investigator or designee will beresponsible  for oversi ghtof  the administration  of 
vaccine to subjects enrolled  in the study  according  to the procedures stipulated  in this 
study  protocol  All vaccines will be administered  onlyby  personnel  who are qualified  to 
perform that function  under  applicable  local  laws and regulat ionsfor  the specific study 
site. 
All studyvaccines to be administered  to the subjects must be stored in a safe and locked 
place  with no access  by unauthorized  personnel.  
The study  vaccines will be stored  at the defined  temperature  range  (i.e. +2 to +8 C). The 
storage  temperature  of the vaccines  will bemonitored daily  with temperature  monitoring 
devices and  willberecorded . 
Any temperature deviation, i.e. temperature outside the range (+2 to +8°C), must be 
reported  to the sponsor as soon as detected . Following  the exposure  to such  a temperature 
deviat ion, vaccines will not be used  until  written  approval  has been  given by the sponsor . 
The study vaccine  should be allowed  to reach room temperature  before  administration, 
according  to local  vaccinat ion practice.  
MenACWY- CRM (Menveo) vaccine is prepared by aseptically withdrawing all fluid 
fromthe  vial containing the MenCWY -CRM  liquid  conjugate component and injecting 
the liquid  into the vial containing the MenA- CRM lyophilized portion. Invert  and shake 
the vial well until the vaccine is dissolved. The finalmixed vaccine is then ready for 
administrationof the MenACWY  formulation  (0.5 mLJdose of injectable  solution) . 
Protocol V59_77 
Page 48 of85  GSK  
24FEB16  Confidentia l 
Regulatory Review Protocol Version 3  
  
Detailed vaccine preparation and administration instructions will be provided to 
investigators in the Protocol Ancillary Document prior to study start.  
PRE CAU TIO NS TO BE OBS ERVED IN ADMINISTERING STUDY VACCI NE: 
 
Prior  to vaccination,  subjects  must be determined  to be eligible  for study vaccination and 
it must  be clinically  appropriate  in the judgment  of the investigator  to vaccinate.  
Eligibilityfor vaccination prior to first study vaccine dministration  is detennined by 
evaluating the entry  criteria  outlined  in protocol  sections  4.1, Inclusion  Criteria  and 4.2, 
Exclusion Criteria . 
 
Eligibility  for non- study vaccines should  be determined by the investigator, pending  the 
review  of the package  insert of the relevant vaccine.  
Study vaccines should not be  dministered  to individuals with known hypersensitivity to 
any component of the vaccines . 
 
Standard immunization practices are to be observed and care should be taken to 
administer the in jection : intramuscularl y. Before administering vaccine, the vaccination 
site is to be disinfected with a skin disinfectant (e.g., 70% alcohol) . Allow the skin to dry. 
DO NOT in ject in travasc ularly. 
 
As with all injectable vaccines, trained medical personnel and appropriate medical 
treatment  should be readily  available in case of anaphylactic reactions following  vaccine 
administration . For example, epinephrine 1:1000, diphenhydramine , and/or other 
medications  for treating  anaphylaxis should be available . 
6.4 Vaccine Adminish· ation En or or Overdose of Vaccine 
 
Vaccine administration  error  is defined as receiving  a dose of studyvaccine  that was not 
reconstituted  as instructed  or administered by a different  route  from  the intended route  of 
administration. An overdose of studyvaccine (whether accidental or intentional) is 
defined when a dosage  higher than the recommended dosag e is administered in one dose 
of study  vaccine . 
 
Any vaccine administrationerror  or overdose  of study vaccine  detailed  in this protocol 
must be reported as an adverse  event,  and if the vaccine  dministration  error  or overdose 
is associated  with a serious  adverse  event, it must be reported as such  within  24 hours  to 
the Sponsor . 
 
 
 
 
§ 
.N... 
r..a.. 
 
::, z 
u 
8  
PR0--01 TEMP 06 / Atlas No. 293620  
VersionNo.4 / Vers ion Date: January 29, 2015 
Protocol V59_77 
Page 49 of85  GSK  
24FEB16  Confidentia l 
Regulatory Review Protocol Version 3 
PR0-01 TEMP  06 / Atlas  No. 293620  
VersionNo.4 / Version Date: January 29 , 2015  
  
6.5 Plior and Concomitant M edications and Vaccines 
All medicatoi ns, vaccines  and blood  products  taken or received  by the subject within  30 
days prior to the start of the study are to berecorded on the Prior and Concomitant 
Medications CRF. 
In addition, the following are considered prior medications for this protocol: all 
medication/vaccines  described in theinclusion and exclusion criteria  of this protocol 
including:  
 
• Systemic administration  of corticosteroids  (PO/IV/IM) for more  than 14 consecutive 
days within  90 days prior to study vaccination ; 
• Administration of antineoplastic anrl  iroro1momodulating  agents or radiotherapy 
within  90 days prior to study vaccination;  
• Tmmnnnglobulins or anyblood products within  180 days prior to informed consent ; 
• Systemic antibiotic  treatment  within  3 days prior  to study vaccinat ion or blood draw; 
• Any investigationalor non-registered  medicinal  product within  30 days prior to study  
vaccination ; 
• Administration  of vaccines  within  7 days (for inactivated  vaccines)  or 14 days (for 
live vaccines ) prior  to vaccination  in this study  or who are planning to receive any 
vaccine  within  28 days from the studyvaccination . 
Use of analgesics/antipyreticsto prevent or treat so licitedAEs will be captured in the 
Subject Diary from day 1-7 following each vaccination. Medications taken for 
prophylaxis arethose  intended to prevent  the onset of symptoms. Medications taken for 
treatment  are intended to reduce  or eliminate  the presence  of symptoms that are present. 
Concomitant medications  include  all prescription and non-prescription  medications 
(including  vaccines)  taken  by/administeredto  the subject  during the 30 days  after study 
vaccination  andmust  be documented on the Concomitant  Medications CRF. Mineral 
supplementsand  vitamins  are not considered  concomitant  medications.  
When recording concomitant medications/vaccine, sthey should be checked against the 
study entry  and continuation criteria  in section  4, Selection  of Study Population to ensure 
that the subject should be enrolled/continue in the study.  
Concomitant medication  dministered  for treatment of AEs with medically -attended 
visits, AEs leading  to study withdrawal  andSAEs must be documented during the entire 
study period.  
Protocol V59_77 
Page 50 of85  GSK  
24FEB16  Confidentia l 
Regulatory Review Protocol Version 3 
PR0-01 TEMP  06 / Atlas  No. 293620  
VersionNo.4 / Version Date: January 29 , 2015  
  
Any vaccine not foreseen in the studyprotocol in the period  starting  at Day1 and ending 
at Day 181 must be recorded  in the eCRF. 
6.6 Vaccine Supply, Labeling, Storage and Tracki ng 
The Sponsor willensure the following 
• Supply the study vaccine(s).  
• Appropriate  labeling  of allstudyvaccines provided that complies  with the legal 
requirements of each country where  the study is to be performed.  
The investigator must ensure the following:  
 
• Acknowledge  receipt of the study  vaccines bya designated staff member  at the site, 
including:  
Confirmation that the vaccines were received in good condition 
Confirmation  to the Sponsor of the temperature  range during shipment from  the 
Sponsor  to the investigator 's designate dstorag e location  
Confirmation by the Sponsor that the vaccines are authorized for use.  
• Proper  storage of the study vaccines , including: 
Storage in a secure , locked, temperature -controlled location.  
Proper storage according to the instructions specified on the labels.  
Appropriate  record keeping and inventory of the study vaccines , including regular 
documentation of adequate storage temperature.  
• Appropriate  use of the study  vaccines, including : 
Not use of vaccines  prior to receipt  of authorization for use fromthe  Sponsor . 
Use only in accordance  with the approved  protocol  
Proper  handling , including confirmat ion that the vaccine  has not expired  prior to 
administration. 
• Appropriate  documentation of administrationof  vaccines  to study subjects including:  
- Date, dosag e, batch/lot numbers , expiration dates , unique identifying numbers 
assigned to subjects  and study vaccines , and time of vaccine  administration.  This 
information will bemaintained in an accountability log that will be reviewed by 
the site monitor . 
Protocol V59_77 
Page 51 of85  GSK  
24FEB16  Confidentia l 
Regulatory Review Protocol Version 3 
PR0-01 TEMP  06 / Atlas  No. 293620  
VersionNo.4 / Version Date: January 29 , 2015  
  
- Reconciliation of all vaccines received from the Sponsor . Reconciliation is 
defined as mairitaioiog  records of which and how many vaccines were received , 
which  vaccines  were administered  to subjects , which  vaccines  were destroyed  at 
the site, and which  vaccines  were  returned  to the Sponsor , as applicable.  
- Proper  adherence  to the local  institutional policy  with respect  to destruction  of 
study vaccines.  
• Complete record keeping of vaccine use , wastage , return or destruction, including  
documentation  of 
Copy of the site's procedure for destruction of hazardous material . 
Number of doses  destroyed,  date of destruction,  destruction  code (if available) , 
method  of destruction,  and name of individual  performing destruction.  
Vaccines that have  been stored  differently  from  the manufacturer's  indications  must not 
be used unless  the Sponsor  provides  written  authorization  for use. In the event that the use 
cannot  be authorized,  the Sponsor  will make every effort  to replace the vaccine supply.  
All vaccines used in conjunction  with this protocol  must be stored separately from  normal 
hospital/practicestocks to prevent unintentional use of study vaccines outside of the 
clinical  study setting.  
 
Monitoring  of vaccine accountability will be performed by the study  monitor  during site 
visits  and at the completion  of the study.  
 
At the conclusion of the study , and as appropriate during the course of the study , the 
investigator must ensure that all unused studyvaccines , packaging and supplementary 
labels  are destroyed  locally  (upon  approval  fromSponsor)  or returned  to the Sponsor  or to 
the Depot for  destruction.  
Protocol V59_77 
Page 52of85  GSK 
24FEB16  Confident ial 
Regula tory Review  Protoco l Version 3  
 N  
7. ASSESSMENTS  
 
7.1 Safety Assess ment 
The measures  of safety  used in this study areroutine  clinical procedures. They include a 
close vigilance for, and stringent reporting of, selected  local  and systemic adverse  events 
routinely monitored in vaccine  clinical  studies as indicators of reactogenicity.  
An adverse event (AE) is defined as anyuntoward medical occurrence in a subject or 
clinical  investigation  subject administered a pharmaceutical  product at any dose that does 
not necessarily have to have a causal relationship withthis treatment. Therefore, an AE 
can be any unfavorable and unintended sign (including an abnonnal labora tory finding, 
for example), symptom, or disease temporally associated with the use of an 
investigational product, whether or not considered related  to the investigational product. 
This definition includes intercurrent  illnesses or injuries  and exacerbation of pre-existing 
conditions . 
The period  of observation  for AEs extends  fromthe  time the subject  signs informed 
consent  until  he or she completes  the specified  safety  follow -up period  of 180 days  or 
terminates  the study early  (whichever  comes  first). AEs occurring after  the informed 
consent  form is signed  but prior  to receiving  study vaccine/product will be documented  as 
an adverse event and recorded  within  source  document.  Howe ver, any AEs occurring  
prior to receipt of anystudyvaccine  will be analyzed separately from " treatment 
emergent' ' AEs (AEs occurring after dministration  of the first study vaccine).  
Adverse events  are collected as either  solicited  or unsolicited adverse events. Solicited 
events arederived from organized data collection systems, such as Subject Diaries or 
interview.  
7.1.1 Solicited Adv erse E vents 
 
The term"reactogenicity'' refers to solicited signs and symptoms ("solicited adverse 
events ") occurring in the hours and days following a vaccination , to be collected by the 
subject and/or parent(s)/legalguardian(s) for 7 consecutive days, using a pre- defmed 
Subject Diary.  
The following solicited  adverse events are included  in the Subject  Diary . Each  adverse 
event  is to be assessed using the scoring system reported  in parentheses  below:  
 
 
 
 
 
§ 
r"a 
" 
::, z 
u 
8  
PR0--0 1 TEMP 06 / Atlas No. 293620  
VersionNo.4 / Vers ion Date: January 29, 2015 
Protocol  V59_77 
Page 53 of85  GSK  
24FEB  16 Confident ial 
Regulatory  Review  Protoco l Vers ion 3  
  
Solicited Loca l Advers e Events 
Injectionsite  pain, erythema,  induration , Solicited  Systemic  Adverse Events 
Fatigue, headache, myalgia, arthralgia , loss of appetite, nausea , chills  and fever . 
Table  7.1.1 -1 Severity grading  for solicitedlocal  and systemic AEs 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fever is defined  and measured  by a body temperature 38.0°C(100.4F).  Route  of 
temperature measurement is preferably  oral.  
 
Other Indicators of Reactogenici ty: 
• Use of analgesics  / antipyretics  for prophylaxis (Days  1-7) 
• Use of analgesics  / antipyretics  for treatment  (Days  1-7) 
• Body temperature , described  in degrees  Celsius  and summarized  by route  of 
measurement and in 05°C increments from 36.·o c . 
The study staff must review the data entered  into the Subject Diary  as described  in section 
3.4.2, Tools Used  for Data  Collection  and section  S.3.1 , Follow-up Clinic  Visit( s). 
 
PR0-01 TEMP 06 / Atlas No . 293620  
VersionNo.4 / Vers ion Date: January 29, 2015 
 ]',fild  Moderate Se.vel'e 
Pain  No inteiference with 
dailyactivity  Inteiferes with daily 
activity  Prevents daily activity  
Erythema  25-50mm  51- IOOmm  > l OOmm  
lnduration  25-50 mm  51- IOOmm  > l OOmm  
Fatigue  No inteiference with 
dailyactivity  Inteifereswith daily 
activity  Prevents daily activity  
Headache  No inteiference with 
activity  Inteifereswith daily 
activity  Prevents daily activities  
Myalgia  No inteiference with 
activity  Inteifereswith daily 
activity  Prevents daily activities  
Arthralgja  No inteiference with 
activity  Interferes with daily 
activity  Prevents daily activities  
Loss ofappetite  Eating less than usual 
with no effect  on normal  
activity  Eating less than usua l / 
inteifer ed with normal  
activity  Not eating at all 
Nausea  No inteiference with 
dailyactivity  Inteiferes with daily 
activity  Prevents daily activity  
Chills  No inteiference with 
activity  Inteiferes with daily  
activity  prevents dai ly activit ies 
 
Protocol V59_77 
Page 54of85  GSK 
24FEB16  Confidential  
Regulatory Review Protoco l Version 3  
  
Note:  Anysolicited  adverse  event  that meets  any of the following  criteria  must be entered 
into subjects' source document (see section 9. 1, Source Documentation) and also as an 
adverse event  on the Adverse Event  CRF: 
 
• Solicited  local  or systemic adverse  event  that continues beyond day7 after 
vaccination.  
• Solicited  local  or systemic adverse  event  that leads  to a visit to a healthcare  provider  
(medically  attended  adverse  event,  see section 7.1.3, Evaluation of Adverse Events ). 
• Solicited  local  or systemic adverse event  leading  to thesubject withdrawing  fromthe 
study or the subject being  withdrawn  from  the study by the investigator  (adverse  event  
leadin g to withdrawal,  see section  7.1.3, Evaluation of Adverse Events) . 
• Solicited  local  or systemic adverse event  that otherwise meets  the definition  of a 
serious adverse  event  (see section 7.1.4, Serious Adverse Events ). 
7.1.2 Unsolicited Adverse  Events 
An unsolicited adverse event is an adverse  event that was not solicited  using a Subject 
Diary and that was spontaneously communicated bya subject and/or parent(s)/legal 
guardian(s) who has signed the informed consent. 
Potential unsolicited  AEs may be medically  attended  (defined  as symptoms  or illnesses 
requiring hospitalization,  or emergency room  visit, or visit to/by a health  care provider), 
or were of concern to the subject and/or parent(s)/legal guardian(s) . In case of such 
events , subjects and/or parent(s)/legal  guardian(s) will be instructed  to contact  the site as 
soon as possible to report the event(s) . The detailed information about the reported 
unsolicited AEs willbe collected  by the qualified  site personnel  during the interview  and 
will be documented in the subject's records.  
 
Unsolicited AEs that arenot  medically attended nor perceived as a concern by subjects 
and/or parent(s )/legal guardian(s) will be collected during interview with the subject 
[and/or parent (s)/legal guardian(s) and by review of available medical records at the next 
visit (see section 5.3 , Post- vaccination Visit(s )). 
7.1.3 Evaluation of Adverse Events 
Every effort  should be made  by the investigator  to evaluate  safety information reported  by 
a subject  for an underlying diagnosis  and to capture  this diagnosis  as the event  in the AE 
page. In other words , the practice of reporting only symptoms (e.g., " cough" or "ear 
pain") are better reported  according to the underlying  cause (e.g., "asthma exacerbation " 
or "otitismedia "). 
 
§ 
.N... 
r..a.. 
 
::, z 
u 
8  
PR0-01 TEMP 06 / Atlas No. 293620  
VersionNo.4 / Vers ionDate: January 29 , 2015 
Protocol V59_77 
Page  55 of85  GSK 
24FEB16  Confidential  
Regulatory Review Protoco l Version 3  
  
The severity of events  reported  on the Adverse  Events  CRF  willbe determined  by the 
investigator  as: 
 
Mild: 
Moderate: 
Severe:  transient  with no limitation  in normal  daily  activity. 
some limitation  in normal  daily  activity.  
unable to perform normal daily activity.  
 
The relationship of the studytreatment to an AE will be determined by the investigator 
based  on the following definitions:  
 
1. Not Related  
The AE is not related to an investigational vaccine if there is evidence that clearly 
indicates  an alternat ive explanation.  If the subject  has not received  the vaccine , the timing 
of the exposure  to the vaccine  and the onset  of the AE are not reasonably related in time, 
or other facts, evidence or arguments exist that reasonably suggest an alternative 
explanation,  then the AE is not related . 
2. Possibly  Related  
 
The administrationof the investigational vaccine and AE are considered reasonably 
related  in time and the AE could  be explained  by exposure to the investigational  vaccine 
or by other  causes.  
 
3. Probably  Related  
 
Exposure to the investigational vaccine and AE are reasonably related in time and no 
alternati ve explanation has been identified . 
 
The relationship of the studytreatment to an unsolicited AE will be determined by the 
investigator . 
 
Note : solicited  AEs will not be evaluated for relati onship to study treatment.  Grading for 
severity of solicited local and systemic AEs is described in section 7.1.1, Solicited  
Adverse  Events . 
 
Adverse events will also be evaluated by the investigator for the co -existence of any of 
the other following conditions :  
 
• "Medically  attended adverse event ": an adverse event that leads  to a visit to a 
healthcare provider.  
• AEs leading  to withdrawal:  adverse  events  leadin g to study or vaccine  withdrawal.  
 
PR0-01 TEMP 06 / Atlas No. 293620  
VersionNo.4 / Vers ionDate: January 29, 2015 

Protocol V59_77 
Page  56 of85  GSK 
24FEB16  Confidential  
Regulatory Review Protoco l Version 3 
§ PR0-01 TEMP  06 / Atlas  No. 293620  
VersionNo.4  / Version Date:  January  29, 2015  N 
r"a 
" 
::, z u 
8  
  
If solicited or unsolicited adverse events have been reported and the subject and/or 
parent(s)/legalguardian(s)]  indicated that the symptoms  required  medical  attendance or 
were of concern, the subject and/or parent(s)/legalguardian(s) must be contacted for 
further information.  
When  the subject and/or parent(s)/legal  guardian(s) is contacted  for any of these reasons , 
the contact  must be documented in thesubject's source documentation.  
All AEs, regardless  of severity , willbe monitored until resolution or until the investigator 
assesses them as chronic or stable . All subjects experiencing AEs - whether considered 
associated with the use of the study vaccine or not - must bemonitored until symptoms 
subside and any abnormal  laborator y values  have  returned  to baselin e, or until there  is a 
satisfactory explanation for the changes observed , or until death, in which case a full 
pathol ogist's report  shoul d be supplie d, if possibl e. The investigator' sassessmen t of 
ongoing Adverse Events at the time of each subject's  last visit should be documented  in 
the subject ' s medical  chart.  
7.1.4 Serio us Adverse  Events 
A serious adverse event  (SAE) is defined  as any untoward medical  occurrence  that at any 
dose results  in one or more  of the following:  
• Death.  
• Is life-threatening (i.e ., the subject was , in theopinion of the investigator , at 
immediate  risk of death  from  the event as it occUITed); it does not refer  to anevent 
which  hypothetically might have  caused  death  if it were  more  severe.  
• Required or prolonged hospitalization. 
• Persisten t or significan t disability /incapacity (i.e., the even t causes a substantial 
disruption of a person 's ability  to conduct normal life functions).  
• Congenital anomaly /or birth  defect.  
• An important and significant medical event that may not be immediately life 
threatening or resulting in death or hospitalization but, based upon appropriate 
medical  judgment, may jeopardize  the subject or may require  intervention  to prevent 
one of the other outcomes listed  above . 
Adverse events which do not fall into these categories are defined as non -serious.  
It should be noted that a severe adverse event  need  not be serious in nature  and that a 
serious adverse event  need  not, bydefinii ton,be severe . 
Protocol V59_77 
Page  57 of85  GSK 
24FEB16  Confidential  
Regulatory Review Protoco l Version 3 
§ PR0-01 TEMP  06 / Atlas  No. 293620  
VersionNo.4  / Version Date:  January  29, 2015  N 
r"a 
" 
::, z u 
8  
  
Serious  adverse events  will be captured both on the Vaccines  Serious  Adverse  Event 
(VSAE)  form  as well as on the AE CRF.  All SAEs will be evaluated by the investigator 
for relationship of the event to studyvaccine. SAEs that are judged to be possib ly or 
probably related to the study vaccine should be reported to the Sponsor as 
related/suspected  events.  
 
The relationship of the studytreatment to an SAE will be determined by the investigator 
based on the following definitions:  
 
1. Related/suspected  
 
The SAE  is judged  by the investigator to be possibly  or probably related to the study 
vaccine on the AE CRF  page (see section7.1.3, Evaluation of Adverse Events). 
 
2. Not Related  
 
The SAE is not related if exposure to the study vaccine has not occurred, or the 
occurrence of the SAE  is not reasonably related in time, or the SAE  is considered 
unlikely to be related to use of the study  vaccine, i.e., there  are no facts  (evidence)  or 
arguments to suggest  a causal  relationship.  
 
The relationship of the studyvaccine to an SAE will be determined by the invest igator.  
 
In addition , SAEs  will be evaluated by the Sponsor or designee  for "expectedness. " An 
unexpected  AE is one that is not listed  in the cUITent  Summary  of Product  Characteristics 
or the Invest igator's  Brochure  or an event that is by nature  more  specific  or more severe 
than a listed  event  
 
In addition , a pre -existing event or condition that results in hospitalization should be 
recorded  on the Medical  History  CRF. If the onset  of an event  occUITed  before  the subject 
entered the study (e.g., any pre -planned hospitalization for conditions like cosmetic 
treatments or for non -emergency routine visits for a pre -existing condition) , the 
hospitalizationwould not lead to an AE being classified as serious unless , in the view of 
the investigator , hospitalization was prolonged as a result of participation in the clinical 
study or was necessary  due to a worsening  of the pre-existing  condition . 
7.1.4.1 Adverse Events of Special Interest 
Adverse Events of Special Interest (AESis) will not be assessed during the study . 
Protocol V59_77 
Page  58 of85  GSK 
24FEB16  Confidential  
Regulatory Review Protoco l Version 3 
::, z u 
8  
  
7.1.S Methods for R ecording Adverse Ev ents and Se1ious Adverse Events 
 
Findings regarding Adverse Events must be reported on an Adverse Events CRF , as 
specified in section  7.1.1, Solicited  Adverse  Events , and on the VSAE  form,  if applicab le, 
which  is part of the Investigator  Site File. All findings  in subjects experiencing AEs nrust 
be reported also in the subject's  source  document.  
 
All SAEs which  occur during  the course  of the study, whether  considered to be associated 
withthe  study  vaccination or not, must  be reported w i thin 24 hours o f the site becomin g 
awar e of the event to GSK  or its designee . Specific  instructions  and contact details  for 
collecting  and reporting  SAEs to GSK willbeprovided  to the investigator . 
 
All SAEs are also to be documented on the Adverse Events CRF. Any medication or 
other therapeutic measures used to treat the AE will berecorded on the appropriate 
CRF(s) in addition to the outcome of the AE.  
 
After receipt of the init ial report, representatives of GSK or its designee willcontact the 
investigator if it is necessary to obtain further information for assessment of the event.  
 
All SAEs must be reported by the invest igator to his/her corresponding EC / IRB 
applicab le regulatory authoriti es in accordance with inst itutional policy /regulatory 
requirements and ad equate documentation of this notification must be provided to the 
Sponsor . 
 
GSK or its designee must also comply with the applicable regulatory requirement(s) 
related to the reporting  of suspected  unexpected  serious  adverse vaccine reactions (also 
known  as SUSARs) to the regulatory  authority(ies)  and the IRB/EC . If a SUSAR or other 
safety signal relating to use of one of the study vaccines is reported to GS K or its 
designee, the Sponsor willcommunicate the information to the investigator and the 
investigato r will beresponsi lb e forsubmittin g this informatio n to the EC/IR B and other 
relevant authorities . 
 
7.1.S. l Post-S tudy Even ts 
 
Any SAE  that occurs  outside  of the protocol -specifiedfo llow-up period  and considered to 
be caused by the study vaccine  nrust  be reported  to GSK or its designee . These SAEs will 
be processed by GSK or its designee  as during  the course  of the study, until  1 month  after 
Last Subject Last Visit (LSLV) . Instructions and contact details for collecting and 
reporting these  suspected  SAEs will beprovided  to the investigato .r 
 
 
 
 
§ 
.N... 
r..a..  
PR0--0 1 TEMP 06 / Atlas No.293620 
VersionNo.4 / Vers ion Date: January 29,2015 
Protocol V59_77 
Page  59 of85  GSK 
24FEB16  Confidential  
Regulatory Review Protoco l Version 3 
::, z u 
8  
  
7.1.6 Pregnan cies 
 
To ensuresub jects' safety , each  pregnancy in a subject after study  vaccination must be 
reported  to GSK or delegate within  72 hours  of the site learning  of its occurrence . If the 
subject  agrees to submit  this information,  the pregnancy must be followed  to determine 
outcome , including  spontaneous  or voluntary  termination,  details of the birth,  and the 
presence or absence of any birth  defects , congenital  abnormalit ies, or maternal and/or 
newborn  complications . This follow -up should occur even  if intended duration  of safety 
follow -up for the study  has ended . 
 
Pregnancy data must be recorded on a Pregnancy Report CRF (initial report) and 
Pregnancy Follow- Up CRF (outcome report) and reported to GSK or de legate.  
Instructions and contact details for submitting the Pregnancy CRFs will be provided to the 
investigator . 
Any pregnancy outcome meeting the definition of a SAE (see section 7.1.4, Serious  
Adverse Events ) must also be reported on the VSAE Report Form.  
 
7.1.7 Safety La bora  tory l\lll eas ur em e n ts 
No safety laboratory measurements will be done in this study.  
 
7.2 Efficacy Assessment  
This section is not applicable . This study has no efficacy measurements . 
 
7.3 Immunoge nicity Assess ment 
 
The functional measure of immunogenicity used in this study, Serum Bactericidal Assay 
(SBA) , is a measure of the ability of antibodies , in concert with human complement, to 
kill meningococci, and is widely used and generally recognized as the serological 
correlate of protection The key measures of irom1mogenicity willbe the percentages of 
subject s with  serorespon se[ I J  , percentages  of subjects  who achiev e hSBA  titers  8  and, 
and the hSBA GMfs against serogroups A, C , W and Y reference strains  
 
These measurements  willbe assessed  in serology samples collected at Visit Day 1 , 4 or 8 
and Day 29. The measures of immunogenicity  used in this study  are standard,  i.e., widely  
 
 
[ I J S eroresponse to N. mening itidis serogroup s A, C, W and Y is defined a s: for subject s with a pre - 
vaccin
ation hSBA titer < 4, a post-vaccinationhSBA titer 2:8; for subjectswith a pre-vaccina tion hSBAti ter 
24: , an increas e in hSBA  titer of at least four times the pre-vaccinatio ntiter. 
 
§ 
.N... 
r..a..  
PR0- 01TEMP 06 / Atlas No . 29362 0 
VersionNo.4 / Vers ion Date: January 29 , 2015 
Protocol V59_77 
Page  60 of85  GSK 
24FEB16  Confidential  
Regulatory Review Protoco l Version 3 
PR0-01 TEMP  06 / Atlas  No. 293620  
VersionNo.4 / Version Date: January 29 , 2015  
  
used and generally recognized as reliable , accurate , and relevant (able to describe the  
quality and extent of the immune response).  
All subjects  will have  a blood draw  at Day I , before  vaccination.  Subsequent  blood  draws  
willbe at either Day 4 or Day 6 post vaccination, and at Day 29 po st vaccination . 
Primary:  
Collected  samples may be used  in other assays , for test improvement  or development of 
analytical methods  related to the study  vaccines or the disease under evaluation  to allow a 
more reliable measurement of the vaccine response . Under these circumstances , 
additional testing on the samples may be performed by GSK outside the scope of the 
protocol Any sample testing willbe done in line with the co nsent of the individual 
subject 's parent/  guardian.  
 
Testing willbe conducted by qualified and certified laboratories. All assays will be 
performed in GSK, Clinical Laboratory Sciences , or a delegate laboratory.  
Protocol V59_77 
Page  61 of85  GSK 
24FEB16  Confidential  
Regulatory Review Protoco l Version 3 
PR0--01TEMP  06 / Atlas  No. 293620 
VersionNo.4 / Version Date: January 29 , 2015  
  
8. STATISTICAL CONSIDERATI ONS 
 
8.1 Endpoint s 
8.1.1 Plimai-y En dpoint(s) 
 
8.1.1.1  P1im ary Safety Endpoint(s) 
 
There are no primary safety endpoints in this study.  
8.1.1.2  P1imar y Effica cy Endpoint(s)  
 
There are no primary efficacy endpoints in this study.  
 
8.1.1.3  P1imary Immunog enicity Endpoint(s)  
 
Thefo llowing measure will be summarized for the pooled (Menveo- Menveo and 
Menactra- Menveo) group  
 
1. Percentage  of subjects  with hSBA  seroresponse5 against N. meningitidis  
serogroups A, C, W and Y at Day 29.  
8.1.2 Secondary Endpoin t(s) 
 
8.1.2.1  Secondar y Safety Endpoint(s)  
 
Safety of the study vaccine will be assessed in the pooled vaccine group (Menveo - 
Men
veo and Menactra- Menveo ) and the vaccine -naivegroup in teims of the frequency 
(percentage ) of reported  adverse  events including  
 
1. Any unsolicited  AEs reported  within  30 minutes  after vaccination;  
2. Solicited  local  and systemic  AEs reported  from  Day 1 (6 hours ) through  Day 7 
after vaccination;  
3. Other  indicators  of reactogenicity  (e.g. use of analgesics / antipyret ics, body 
temperature) within  7 days  after vaccinat ion; 
4. All unsolicited  AEs reported  from  Day 1 through  Day 29 after vaccination;  
 
 
 
 
5 Seroresponse is defined as: a) post-vaccinati on hSBA ?:8 for subjectsw ith a pre-vaccinati on hSBA <4; b) 
for subjects  with a pre-vaccinationhSBA  ?:4, an increase of at least four timesthe pre-vaccinationhSBA.  
Protocol V59_77 
Page  62 of85  GSK 
24FEB16  Confidential  
Regulatory Review Protoco l Version 3 
PR0-01 TEMP  06 / Atlas  No. 293620 
Version No.4/ Version Date:  January  29, 2015   
  
5. Medically-attended AEs, AEs leading  to withdrawal and SAEs  reported from Day 
1 through Day 181 (entire  study period) . 
Adverse events will be coded using MedDRA preferred terms as applicabl e. 
 
8.1.2.2  Secondar y Effica cy Endp oint(s)  
There are no secondary efficacy endpoints in this study.  
 
8.1.2.3  Secondar y Immun ogenicity Endp oint(s) 
The following measures will be nmmari:i:ed  for Menveo -Menveo , Menactra -Menveo, 
Naive and the pooled (Menveo-M enveoand Menactra-M enveo)groups unless otherwise 
noted:  
 
1. Percentage  of subjects  with hSBA titer 8 against  N. meningitidis  serogroups A , C, 
Wand  Y at Day 1, Day 4, Day6  and Day 29; 
2. Percentagesof  subjectswith  hSBA  seroresponse against  N. meningitidis 
serogroups A, C, Wand  Y at Day 4, Day 6 and Day 29 (Day  29: Except  the 
pooled group);  
3. hSBA GMfs  againstN.  meningitidis  serogroup A , C, Wand  Y at Day 1, Day 4, 
Day 6 and Day 29; 
4. Ratios  of hSBA GMfs  atDay 1 , Day 4, Day 6 and Day 29 (between  study 
groups).  
5. Ratios of hS BA GMfs  atDay  4, Day6, and Day 29 compared  to Day 1 (within 
study groups).  
8.1.3 Explora  tory En dpoin t(s) 
 
8.1.3.1  Explorat ory Safety Endpoint(s)  
There are no exploratory safety endpoints in this study.  
 
8.1.3.2  Explorat ory Effica cy Endpoint(s)  
There are no exploratory efficacy endpoints in this study . 
 
8.1.3.3  Explora tory Immun ogenicity Endpoint(s) 
 
There are no exploratory immunogenicity endpoints in this study.  
Protocol V59_77 
Page  63 of85  GSK 
24FEB16  Confidential  
Regulatory Review Protoco l Version 3  
  
8.2 Success C1iteria  
 
8.2.1 Success C1iteria for P1imary Objective(s) 
 
8.2.1.1 Success C1ite1ia for P1imary S afety  Obje ctive(s)  
There are no primary  safety  objectives in this study.  
8.2.1.2 S uccess C1ite1ia for P1ima r y Effica cy O bjective(s)  
There  are no primary  efficacy  objectives in this study.  
8.2.1.3 Success C1ite1ia for P1imary Immun ogenicity Objective(s)  
To demonstrate  immune response  sufficiency  after  MenACWY -CRM  booster  vaccine 
administration, the lower limit of the one -sided 97.S% Confidence Interval (CI) for 
percentage of subjects with hSBA  seroresponse  against each  of serogroups  A, C, Wand  
Y must be greater than 80% (in the poo led group of subjects who received primary  
vaccination with Menveo or Menactra) . The threshold of80% was previously agreed for 
demonstration of immune response adequacy in other age groups (e.g. in infants , study 
VS9_36). 
 
8.2.1.3.1  Rationale for C ombining the Menveo-Menveo and Menach ·a-Menveo 
groups 
Table 8 .2.1.3.1-1 shows  excerpt of data from  a previous  study  (VS9P l3El) assessing the 
immunogenicityof  a booster dose of Menveo among  subjects  who had previously been 
vaccinated with either Menveo or Menactra 3 years  prior  in another study  (VS9P13)  while 
subjects were 11- 18 years old. The table shows almost identical seroreponse rates and 
95%  Cls at one-month post-booster  dose  of Menveo for subjects  previous  vaccinated with 
Menveo and Menactra. This suggests that data from the two groups can be pooled or 
combined for analysis  of seroresponse  following  a booster  doseof Menveo as planned in 
the current  studyVS9_ 77. 
 
 
 
 
 
 
 
 
 
 
 
 
§ 
.N... 
r..a.. 
 
::, z 
u 
8  
PR0--0 1 TEMP 06 / Atlas No. 293620  
VersionNo.4 / Vers ion Date: January 29, 2015 
Protocol V59_77 
Page  64 of85  GSK 
24FEB16  Confidential  
Regulatory Review Protoco l Version 3 
PR0-01 TEMP  06 / Atlas No. 2936 20 
VersionNo.4  / Version Date: January29 , 2015   
  
Table8.2.l.3.l -1:  hSBA Sero response at On e Mo nth F ollowing the Booster at 3 
Years  After Vaccina tion, by Serogro up - Booster- P P Population 
 
Vaccina tion ACWY /ACWY  
Gt·o up IV Menact J"a/ A 
GroupV  Y Difference'  
G1·onp IV - G 1·onp V 
<I'. 
Q. :, eco  Overal l Seroresponse  
e  
 
68 (97%) 
(90-100)  
 
70(100°/o) 
(95-100)   
 
(-3%) 
(-10-2) 
N=70 N=70  
u 
Q. :, eco  Overal l Seroresponse  
e  
 
66 (93%)  
 
65 (93%)   
 
(0%) 
(84-98) (84-98) (-9-10) 
N=71 N=70  
 
 
 
Q. :, 
ee  Overal l Seroresponse   
 
63 (91%) 
(82-97)  
 
64 (93%)  
(84-98)   
 
(-! %) 
(-11-8) 
N=69  N=69   
> 
Q. :, 
.ec.o  Overal l Seroresponse  e "'  
 
63 (90%)  
(80-96)  
 
65 (93%) 
(84-98)   
 
(-3%) 
(-13-7) 
N=70 N=70  
Source : Table 14.2.1.7 of Clinical Study  Report  for V59Pl3El ; 'Data represented  as (difference in %)( 95% 
CI of  difference ). 
 
 
8.2.2 Success C1i teria for Secondar y Objective(s)  
 
8.2.2.1 SuccessC 1i te1i a for Seco ndary Safety Objective(s)  
 
There are no success criteria associated with the secondary safety objectives . 
 
8.2.2.2 S uccess  C1i te1i a for Seco ndary Efficacy Objective(s)  
There are no secondary efficacy objectives in this study . 
Protocol V59_77 
Page  65 of85  GSK 
24FEB16  Confidential  
Regulatory Review Protoco l Version 3 
PR0--01 TEMP  06 / Atlas  No. 293620  
VersionNo.4  / Version Date:  January  29, 2015   
  
8.2.2.3 Success C 1i te1i a for Seco ndary Immun ogenicity Objective(s)  
 
There are no success criteria associated withthe secondary  immunogenicity object ives in 
this study . 
 
8.3 Anal ysis Sets  
8.3.l AllEn rolled Set 
 
All screened subjects who provide informed consent and provide demographic and/or 
baseline screening assessments, regardless of the subject 's randomization and treatment 
status in the study, and received a Subject ID . 
8.3.2  All Exposed Set 
 
All subjects in the enro lied set who receive a study vaccination.  
 
8.3.3  Safety Set 
 
Solicite d Safety Set (solicited  local and systemic adverse events and other solicited 
adverse events) 
 
All subjects  in the Exposed  Set with any solicited  adverse  event data. 
Unso licited Safety Set ( unso licited adve rse events) 
All subjects  in the Exposed  Set with unsolicited  adverse  event  data. 
Overa ll Safety Set 
All subjects who are in the Solicited Safety Set and/or Unsolicited SafetySet.  
 
Subjects  will be analyzed as "treated " (i.e., according to the vaccine a subject  received, 
rather  than the vaccine to which  the subject  may have  been randomized).  
 
8.3.4  Full AnalysisSet  (FAS) Efficacy/l mmunoge nicity Set 
Full Anal ysisSet  Immun ogenicity 
FAS <Day 1) 
All subjects in the All Enrolled Set who : 
• are randomized;  
Protocol V59_77 
Page  66 of85  GSK 
24FEB16  Confidential  
Regulatory Review Protoco l Version 3 
PR0-01 TEMP  06 / Atlas  No.293620  
VersionNo.4 / Version Date: January 29,2015   
  
• provide  evalua ble serum  samples  at Day 1 whose  result  is available  for at least one 
serogroup . 
FAS (Day4)  
All subjects in the All Enrolled Set who:  
• are randomized;  
• receive  the study  vaccinat ion; 
• provide  evaluab le serum samples at Day 1 whose result  is available for at least one 
serogroup  (excep t for hSBA  titer 8, GMTs  and between- group GMRs  calculated at 
specific timepoints); and 
• provide  evaluab le serum samples at Day 4 whose result  is available for at least one 
serogroup . 
FAS (Day6)  
 
All subjects in the All Enrolled Set who:  
• are randomized;  
• receive  the study  vaccinat ion; 
• provide evaluab le serum samples at Day 1 whose result is available for at least one 
serogroup (except for hSBA titer 8, GMTs and between- group GMRs calculated at 
specific  timepoints);  
• provide  evaluab le serum samples at Day 6 whose result  is available for at least one 
serogroup.  
FAS (Day29)  
All subjects in the All Enrolled Set who:  
• are randomized;  
• receive  the study  vaccinat ion; 
• provide evalua ble serum samples at Day 1 whose result is available for at least one 
serogroup (except for hSBA titer 8, GMTs and between- group GMRs calculated at 
specific  timepoints);  
• provide  evaluab le serum  samples at Day 29 whose result  is available  for at least one 
serogroup.  
In case of vaccination  error, subjects  in the FAS  sets will be analyzed " as randomized " 
(i.e., according  to the vaccine a subject was designated  to receive, which  may be different 
fromthe  vaccine the subject  actually  received).  
Protocol V59_77 
Page  67 of85  GSK 
24FEB16  Confidential  
Regulatory Review Protoco l Version 3 
PR0--01 TEMP  06 / Atlas  No. 293620  
VersionNo.4 / Version Date: January 29 , 2015  
  
8.3.S Per Protocol (PP) Set Efficacy/l mmunoge nicity Set 
A PPS willbedefined for each FAS  described in the previous  Section  with additional 
criteria specified  below . 
All sub jects in the FAS Immunogenicitywho  
• Correctly  receive the study  vaccine  (i.e., receive the vaccine to which  the subjects  is 
randomized and at the scheduled time points).  
• Have no protocol deviations leadingto exclusion (see section 8.3.8, Protocol  
Deviations ) as defined prior to unblinding / analysis . 
• Are not excluded due to other  reasons  defmed prior to unblinding or analysis (see 
section  8.3.8 , Protocol Devia tions) 
 
Examples for subjects excluded  due to other reasons  than protocol  deviations  are: 
Subjects  who withdrew  informed  consent.  
8.3.6 Other Anal ysis Sets 
 
There are no other analysis sets used in this study . 
 
8.3.7 Subgroups 
Using  the FAS  (Day 29), the analyses of the primary  objectives  willbereplicated by 
center; gender;  and race.  
8.3.8 Protocol D eviations 
 
A protocol deviation is any change , divergence , or departure from the study design or 
procedures of a study protocol . A protocol deviation may be a reason to remove data from 
an analysis set at the time of analysis. CSR -reportable protocol deviations will bedefined 
as exclusionary fromthe analysis accor ding to protocol objectives and endpoints, which 
will bespecified in the statistical analysis plan . In some cases exclusion of data may be 
due to a reason  other  than a protocol  deviation,  e.g. early  termination . 
 
8.4 Statistical Anal ysis Plan  
 
8.4.1 Anal ysis of Demographic and Baseline Charac teristics 
 
Descriptive  statistics  (mean,  standard  deviation,  median , minimum and maximum) for 
age, height  and weight at enrolment willbecalculated overall  and by study  group.  
Protocol V59_77 
Page  68 of85  GSK 
24FEB16  Confidential  
Regulatory Review Protoco l Version 3 
::, z u 
8  
 N  
Distributions  of subjects by sex and ethnic  origin  will be summarized  overall  and by 
study  group . 
 
8.4.2 Anal ysis of Primar y Objective(s)  
 
8.4.2.1  Anal ysis of Primar y Safety Objective (s) 
There are no primary safety ob jectivesin this study . 
8.4.2.2  Anal ysis of Primar y Efficacy Objective(s) 
There are no primary efficacy objectives in this study.  
8.4.2.3  Anal ysis of Primar y Immunog enicity  Obje ctive(s) 
 
8.4.2.3.1  Statistical Hypotheses 
Null hypothesis: P, :;; 0,8 0 
 
Alternative  hypothesis:  P, > 0 .80 
Where: P, is the population seroresponse rate for the pooled Menveo -Menveo and 
Menactra- Menveo group ; i =,1 2, 3 4 refer to serogroup A, C, Wand Y respectively . The 
level of significance is fixed at one- sided 0.02S. 
 
8.4.2.3.2  Anal ysis Sets 
 
The analysis population to be used for the primary objectives is the FAS (Day 29) Set. 
Analyses of primary objectives willbe repeated on the P PS (Day 29) to assess robustness 
of results . 
 
8.4.2.3.3  Statistical Methods 
General 
Missing immunogenicityvalues are assumed MCAR (Missing Completely At Random ) 
and therefore  may not  contain  information  that impact  the result  of the analysis  (i.e., not 
informative). Imputation methods  will therefore  not be used . 
 
Overall significance level for all hypothesis tests is one-sided a = 2.5% . 
 
 
§ 
r"a 
"  
PR0-01 TEMP 06 / Atlas No. 293620  
VersionNo.4 / Vers ion Date: January 29, 2015 

Protocol V59_77 
Page  69 of85  GSK 
24FEB16  Confidential  
Regulatory Review Protoco l Version 3 
::, z u 
8  
  
Seroresponse (Day 29)  
Seroresponse is defined  as: a) post-vaccinat ion hSBA  titer 8forsubjects with a pre- 
vacci
nation  hSBA  titer <4; b) forsubjects with a pre-vaccination  hSBA  titer 4, an 
increase of at least four times  the pre-vaccination  hSBA.  
For 
each ACWY serogroup , the percentage of subjects withseroresponse will be 
computed, along with associated two -sided 95%Clopper -Pearson Cls. 
Further details of the statistical methods will be provided in the SAP . 
8.4.3 Anal ysis of Seco ndary Obje ctive(s)  
8.4.3.1 Anal ysis of Seco ndary Safety Objective(s) 
8.4.3.1.1  Analysis of Extent of Exposur e 
Subjects will be analyzed to the extent that they were exposed to study vaccines and 
according to the available safety data for the subject during any study period. Subjects 
who withdraw early or who  are lost to follow -up will be removed  from  the summary  table 
denominator  for the time period  in which  they have no available safety  data collected.  
8.4.3.1.2  Anal ysis of Solicited Local,Syst emic and Other Adve rse Events 
 
All solicited  adverse  events  will be summarized according to defined  severity  grading 
scales . 
Frequencies and percentages of subjects experiencing each adverse event will be 
presented  for each symptom severity . Summary  tables showing theoccurrence  of any 
local or systemic adverse  event  overall  and at each time point will also be presented . 
Post-vaccination solicited adverse events reported from Day 1 to Day 7 willbe 
summarized  for the intervals  Day 1 (6 hours) - Day 3, Days  4-7, Day 1 (6 hours)  - Day 7 
by maximal severity and by study group. Separate analyses will be performed for 
solicited AEs reported 30 minutes after vaccination. The severity of solicited local 
adverse events , including  injection -site erythema  and induration,  will be categorized 
based  on linear measurement: None (0-24 mm), Mild  (25-50 mm), Moderate (51-100 
mm), Severe ( > 100mm ). 
Injection site pain and systemic reactions , including fatigue , headache, myalgia , 
arthralgia, chills , nausea , loss of appetite, occurring up to 7 days after each vaccination 
will be summarize d according to "mild", "moderate" or "severe" . 
 
§ 
.N... 
r..a..  
PR0-01 TEMP 06 / Atlas No. 293620  
VersionNo.4 / Vers ion Date: January 29, 2015 
Protocol V59_77 
Page 70of85  GSK 
24FEB16  Confidentia l 
Regulatory Review Protoco l Version 3  
  
Each solicited  local and systemic  adverse event will also be further  summarized as "none" 
versus  ''anY'. 
Use of antipyreticsand  analges ics will be summarized by frequency, by type of use 
(prophylactic  versus  treatment)  and percentage of subjects  reporting  use. 
Body teJl1)erature  will be summarized  separately  according  to the 3 schemes described 
below  and will be broken down according  to route  of measurement:  
• by O.S °C increments from  36.0°Cup to ,::40°C; 
• by 1°C increments: <36.0 , 36.0-36.9, 37.0-37.9, 38.0-38.9, 39.0- 39.9, ,::40°C; 
• According to different cut-offs ( < versus ::::): 38 . 0 , 38 .S , 39 . 0 , 39.S , 40 .0 ° C . 
 
8 .4 .3 .1. 3 An al ys i s o f U n so li cited Advene Even ts 
 
This analysis applies to all adverse  events  occurring  during the study, judged either as 
probably relate d, possibly related , or not related to vaccination by the investigator, 
recorded in AE CRF , with a start date on or after the dateof  first vaccination.  AE starting 
prior to the first vaccination willonly be listed . The original verbatim terms used by 
investigators  to identify adverse events  in the CRFs  will be mapped to preferred terms 
using the MedDRA dictionary . The adverse events will thenbe grouped by MedDRA 
preferred terms into frequency tables  according  to system  organ  class (SOC) . 
 
All reported adverse events , as well as adverse events judged by the invest igator as at 
least possibly relate d to study vaccine, willbe summarized according to SOC and 
preferred term  within  SOC . These summaries will be presented by study  group  and by 
interval  of study  observation . When  an adverse event occurs  more than once  for a subject, 
the maxima l severity  and strongest  relationship to the  vaccine  willbe counted.  
 
Separate summaries will be producedfor the foll owing categories:  
• Adverse  events  that are possibly  or probably relate d to vaccine  
• Unsolicited  AEs reported within  30 minutes  after  vaccination  
• Unsolicited  AEs reported  within  30 days  after vaccinat ion 
• Adverse  events  leading  to withdrawal 
• Adverse  events  leading  to a medically  attended  visit 
• Serious adverse events  
Data  listings  of all adverse events will be provided  by subject.  In addition, adverse  events 
in the categories above  will be provided  as listed  data.  
 
PR0--01 TEMP 06 / Atlas No . 293620  
VersionNo.4 / VersionDate: January 29, 2015 

Protocol V59_77 
Page 71of85  GSK 
24FEB16  Confidentia l 
Regulatory Review Protoco l Version 3 
::, z u 
8  
  
8.4.3.1.4 Statis tical Hypotheses 
 
There are no statistical hypotheses associated with the secondary safety object ives. 
 
8.4.3.1.S Anal ysis Sets  
 
Analyses  of solicited  adverse events - and other solicited  reacti ons - and unsolicited 
adverse events  will be performed  on the relevant safety sets. 
 
8.4.3.1.6 Statis tical Methods 
 
For unsolicited adverse events , the entirestudy period will be divided into the fo llowing 
intervals : onset within 30 minu tes after vaccination , onse t within 28 days after 
vaccination; and from Day 1 through Day 181. For solicited adverse events , the solicited 
study period will be divided into intervals : from 6 hours through day 3; from day 4 
throughday 7; and from 6 hours through day 7.  
 
No imputation methods will be used to address missing safety data. 
 
SnmmariPS of safety  will be presented using  frequencies and percentages within  each 
study  group. No statisti cal comparisons  among the studygroups  with respect to any of the 
safety  parameters will be performed.  
 
8.4.3.2  Anal ysis of Seco nda ry Efficacy O bjective(s)  
 
There are no secondary efficacy objectives associated with this study . 
 
8.4.3.3  Anal ysis of Seco nda ry I mmun ogenicity Objective(s)  
 
8.4.3.3.1  Sta tistical Hypotheses 
 
Analyses  related to the secondary  immunogenic ity objectives  will be descriptive; no 
forma l statistical  tests will be performed.  
8.4.3.3.2  Anal ysis Sets 
 
Analyses of secondary imm1mogenicity  will be based on the FAS  and repeated on the 
PPS.  
 
 
 
 
 
 
§ 
.N... 
r..a..  
PR0-01 TEMP 06 / Atlas No. 293620 
VersionNo.4 / Vers ion Date: January 29, 2015 
Protocol V59_77 
Page 72of85  GSK 
24FEB16  Confidentia l 
Regulatory Review Protoco l Version 3 
::, z u 
8  
  
8.4.3.3.3  StatisticalMeth ods 
 
General 
The hSBA titers at each visit will be logarithmicallytransformed (basel O) to obtain 
approximately nonnally distributed data . 
 
For comparison of percentages and GMT ratios , unadjusted estimates will be obtained 
along with adjusted estimates from regression models to account for potential baseline 
imbalance between study groups . 
For each N. meningitidis serogroup A, C, Wand Y , unad justedGMTs will be calculated , 
withtheir associated two -sided 95% Cls , by exponentiating the corresponding log - 
tr
ansformed means and their 95% C ls. Adjusted GMR.s will be obtained from Analysis of 
Covariance (ANCOVA) models.  
 
See section 8.4.2.3.3 for other relevant details . 
 
Seroresponse (Day 29) 
 
The percentage of sub jects with seroresponse and associated two- sided 95% Clopper - 
Pears
on Cls will be computed by group  (Menveo -Menveo , Menactra- Menveo , and Naive) 
and N. meningitidis  serogroups  A, C, W and Y test strains . Differences  in percentages and 
associated 95% Cls between study groups will be calculated using the Miettinen & 
Nurminen score method . 
 
In a descriptive fushion - using the difference in percentages and 95% Cls - each of the 
previously vaccinated groups will be compared to the nai:Ve group . Also the two 
previously vaccinated study groups will be compared to each other . 
 
As sensitivity  analyses , the difference in percentages will also be obtained  from  a log- 
lin
ear model adjusting for center and pre-vaccination titer. Please see SAP  for technical 
details . 
 
 
 
 
 
 
 
 
 
§ 
.N... 
r..a.. Percent age o f Su bjects \Vith hSBA titere::8 (Da y I , Da y 4, Da y 6, and D ay 29) 
 
For each  study  group  and in the pooled  group, the percentage  of subjects with hSBA titer 8 
andassoc iatedtwo -sided 95% Clopper -Pearson Cls will be computed by the N. 
meningitidis serogroups A, C , W and Y test strains on Day 1, Day 4 , Day 6 and Day 29 
(as applicable, depending on blood  draw  schedule) . 
Differences  in percentages and associated  95%  Cls between study  groups  will be 
calculated using  the Miettinen  & Nurminen score method.  
 
PR0-01 TEMP 06 / Atlas No. 293620  
VersionNo.4 / Vers ion Date: January 29, 2015 
Protocol V59_77 
Page 73of85  GSK 
24FEB16  Confidentia l 
Regulatory Review Protoco l Version 3  
  
In a descriptive  fashion  - using  the difference in percentages  and 95%  Cls - the previously 
vaccinated groups  (indivi duall y and pooled) will be compared to the naive  group . Also 
the two previously  vaccinated  groups  will be compared to each  other . 
 
As sensitivity  analyses , the difference  in percentages will also be obtained from  a log- 
lin
ear model adjusting  for center and pre-vaccinationtiter.  Please see SAP  for technical 
details.  
 
Between-gr oup Rati os of Gl\lll T s (Ad ju s ted an d U na d ju sted)  
 
The between  -group ratio  ofhSBA  GMTs  and corresponding 95%  CI, at each of Visit Day 
1 (Persistence), Day 4, Day 6 and Day 29 against  each N. meningiti.dis  serogroups  A, C, 
W and Y test strains will be obtained by exponentiatingthe mean between- group 
differenc es in log-transformedtiters and the corresponding 95% Cls at each of the 
timepoints  specified.  
Additionally , adjusted ratio  of GMTs  will be obtained  fromAN COVA models  including 
center and pre-vaccination titer as factors  in the model.  
 
The previously vaccinated groups (individually and pooled) will be compared to the naive 
group at each timepoint - descriptively - using the ratios of GMTs . 
The two previously vaccinated groups will be compared at each timepoint using GMT 
ratios.  
\Vithin-gro up Rati os of Gl\lll T s (Ad jus ted an d U na d ju sted)  
Within  each study  group  and for each  antigen/serotype , ratios  of GMT will be calculated, 
as applicable , at: 
• Visit Day 4 versus  at Visit Day 1 ; 
• Visit Day 6 versus  at Visit Day 1 ; and 
• Visit Day 29 versus  at Visit Day 1. 
 
The unadj usted  GMRs  and 95%  Cis will be constructed by exponentiating the mean 
within -groupdifferences  in log-transformed titers  and the corresponding  95%  Cls. 
Adjusted GMRs will be obtained from Analysis of Covariance (ANCOVA) models 
including center as factor in the model. Further details of the statistical methods will be 
provided in the Statistical Analysis Plan (SAP) . 
 
 
 
 
PR0-01 TEMP 06 / Atlas No.293620  
VersionNo.4 / Vers ion Date: January 29,2015 

Protocol V59_77 
Page 74 of85  GSK  
24 FEB  16 Confidential  
Regulat ory Revie w Protoco l Version 3  
  
8.4.4 Analys is of Explora  tor y Objectiv es 
 
8.4.4.1 Anal ysis of Explora tor y Safety Objective(s)  
There are no exploratory safety  object ivesin this study.  
8.4.4.2 Anal ysis of Explorator  y Efficac y Objecti ve(s) 
There are no exploratory efficacy objectives in this study . 
8.4.4.3 Anal ysis of Explora  tor y Immunogeoicity  Objective( s) 
There are no exploratory  immunogenicityobject ives in this study.  
8.5 Sam ple Size and Power Considera  tions  of P1imary  Objecti ves 
Statisti cal power was estimated based on observed  data from  study  V59Pl3El  , where 
seroresponse rates  at one-month  post booster  dose  ofMenACWY -CRM  ranged  from 
97%  (90% -100%) to 100%  (95% -100%)for  serogroup  A, 93%  (85%- 98%) for serotype  
C; 91%  (82% -97%) to 93%  (84%- 98%) for serogroup W ; and 90%  (80%- 96%) to 93% 
(84% -98%)  for serogroup Y among  subjects  printed with MenACWY -CRM  or Mena ctra 
in the three  years  preceding  the study . 
Assuming the true seroresponse rates in the pooled group range from 90% to 97% 
(alternative hypothes is) for each  serotype , a samp le size of n=540will have  at least 96% 
power to show  sufficiency  of immune response  to a booster  dose of MenACWY -CRM  in 
the pooled group, compared with a pre-specified reference seroresponse of 80% (null 
hypothesis) using  an exact test with 0.025 one-sided  significance level. When taking  a 
10%  dropout  rate into account , N=600  previousl y vaccinated subjects  have  to be enrolled 
in the study.  Calculations  have  been done  with nQuery  Advisor  (Version 7 .0). 
 
Table 8.5-1: Sta tistical Power to Test for Sufficie ncy of Immune Response 
Given a Range of True Seroresponse Rates for Evaluab le Samp le 
Size of 540 subjec ts 
 
Serot}11e T111e Sero r es ponseRate  Power  
A 0.97  0.99 
C 0.93  0.99 
w 0.91 0.99 
y 0.90 0.99 
Total Power   0.96 
 
§ 
.N... 
r..a.. 
 
::, z 
u 
8  
PR0- 01 TEMP 06 / Atlas No.293620  
VersionNo.4 / Vers ion Date: January 29, 2015  
Protocol V59_77 
Page 75 of85  GSK 
24FEB16  Confident ial 
Regulatory Review Protoco l Version 3  
  
8.6 Interim  Anal ysis 
No interim analysis of data from this study is planned.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PR0--01 TEMP 06 / Atlas No.293620 
VersionNo.4 / Vers ion Date: January 29,20 15 

Protocol V59_77 GSK  Confident ial 
::, z u 
8  
 N 24FEB16  Regula tory Review  Protocol Version 3 Page 76 of85  
 
 
9. SOUR CE DOCUMENTA TION, S TUDY MONITORING AND AUDITING  
In order to ensure consistency across sites, study monitoring and auditing will be 
standardized and performed in accordance with the Sponsor's or delegated contract 
research organization ' s (CRO) standard operating procedures and applicable regulatory 
requirements (e.g., FDA, EMA, and ICH guidelines).  
 
Prior to enrolment of the first study subject, GSK or delegate will train invest igators 
and/or their study staff on the study protoco allapplicable studyprocedures , 
documentation practices and all electronic systems . CRFs supplied by the Sponsor must 
be completed for each randomized sub ject (see section 8.3.1, All Enrolled Set for 
definition of enrolled subject) . Documentation of screened but not enrolled subjects must 
be maintained at the site and made available for review by the site monitor. Data and 
documents  will be checked  by the Sponsor  and/or  monitor . 
9.1 Source Documentatio n 
 
Prior to the start of the study , the site staff participating in the study conduct will be 
instructed  on what  documents  will be required for review as source  documents . The kinds 
of documents that will serve as source documents will be agreed between Sponsor or 
delegate and investigator and designees and specified in the SDA prior to subject  
enrolment.  
 
In addition , source  documentation  must include  all of the following:  subject  identification 
(on each  page), eligibility  and participation,  proper  informed  consent procedures , dates of 
visits , adherence to protocol procedures , adequate reporting and follow -up of adverse 
events ,: documentation of prior /concomitant medication/vaccines , study vaccine 
receipt/dispensing/ return records , study vaccine administration information, any data 
collected  by a telephone  conversation  with the subject and/or  parent(s)/legal  guardian(s) 
and date of completion  and reason.  
 
 
 
 
 
 
 
 
 
 
§ 
r"a 
" The subject and/or parent(s)/legal guardian(s) must also allow access to the subject 's 
medical records . Each  subject and/or  the parent(s)/legal  guardian(s)  must be informed  of 
this prior to the start of the study and consent for access to medical records may be 
required in accordance  with local  regulations . 
All safetydata reported by subjects  must  be written  down in source documents  prior  to 
entry  of the data into CRFs.  If there  are multiple  sources of information  (e.g., Subject 
Diary , verbal  report  of the subject,  telephone contact details , medical chart)  supporting 
the diagnosis of an adverse event , thesesources must be identified in the source 
documents , discrepancies between sources clarified, the ultimate diagnosis must be 
justified  and written  in the source  documents , and this diagnosis  must be captured  in the 
 
PR0--01 TEMP 06 / Atlas No.293620 
VersionNo.4 / Vers ion Date: January 29,2015 
Protocol V59_77 GSK  Confident ial 
::, z u 
8  
 24FEB16  Regula tory Review  Protocol Version 3 Page n of85  
 
Adverse Event CRF (AE CRF) . The AE CRF must also capture which source(s) of 
infonnation were  used to detennine the adverse event (e.g., subject  recall , medical  chart, 
Subject  Diary) . 
9.2 Study Monitorin  g, Auditin g and Sow·ce Data Verific ation 
Prior to enrolment of the first study subjec t, GSK or its designee (e.g., a CRO) will 
develop a Clinical Monitoring Plan to specify how centralized and/or on -site monitoring, 
including clinical specimens reconciliation, will be performed for the study. Study 
progress will be monitored byGSK or its designee as frequently  as necessary to ensure:  
• that the rights and well-beingof human  subjects are protected,  
• the reported  study data are  accurate , comp lete, and verifiable  from  the source  
documents and 
• the conduct of the study is in comp liance with the cUITent  approved 
protocol/am ednment(s ), GCP and applicabl e regulatory  requirements.  
Contact  details  for the GSK teamor its designee involved in study monitoring w ill be 
provided to the investigator . Study data recorded on CRFs will be verified by checking 
the CRFentries against source documents in order to ensure data completeness and 
accuracy  as required  by study protoc ol. . 
Data verification may also be performed through a centralized review of data (e. g., 
checking for outliers  or other anomalies) . Additional documents  such as the investigator 
site file, pharmac y records , and infonned consent documentation must also be availab le 
for review  if requested. Arrangements  for monitoring visits  will be made  in advance  in 
accordance  with the monitorin g plan, excep t in case of emergency . 
The investigator and/or site staff must  make  source documents of subjects  enrolled  in this 
study  available  for inspection  by GSK  or its representative at the time of each  monitoring 
visit and Sponsor  audits , when  applicable. These documents  must  also be available  for 
inspection, verification and copying, as required by regulation, sbyofficials of the 
regulatory health authorities (e .g., FDA, EMA and others) and/or ECs/IRBs. The 
investigator and study site staff must comply  with applicable privacy , data protection and 
medical  confidentiality laws for use and disclosure of infonnation related  to the study and 
enrolled  subjects.  
 
 
 
 
 
 
 
§ 
,N.._ 
r,.a._  
PR0-01 TEMP 06 / Atlas No.293620  
VersionNo.4 / Vers ion Date: January 29,20 15 
::, z u 
8 Protocol V59_77 
Page 78of85  GSK 
24FEB16  Confident ial 
Regula tory Review Protoco l Version 3  
  
10. DATA MANAG EME1''T  
10.1 Data Enh·y and Management 
 
In this study , all clinical data (including , but not limited to, AE/SAEs , concomitant 
medications , medical  history , and phys ical assessments) , safety  data, and immunogenicity 
data will be entered onto case report  fonns  (CRFs)  in a timely  fashion  by the investi gator 
and/or the investigator 's dedicated site staff. Data entered onto CRFs are stored on a 
secure website . The data collected on this secure website are assimilated into an 
electronic data capture  (EDC)  system,  which  is compliant with Title  21 Part 11 policies of 
the Code of Federal Regulations (FDA 1997). The data system includes password 
protection  and internal  quality  checks . The EDC  system  will be designed  and validated  by 
the Sponsor prior to activation for data entry by sites. The investigator or designated 
delegate nrust review data entered and electronicallysign the CRFs to verifytheir 
accuracy . 
 
Access to the EDC system for data entryor review will require training and distinct 
individual access code  assignments  to those  site staff members who willbe entering  study 
data and those  involved  in study  oversight  who may review  study  data. Data  are collected 
within the EDC system, to which the Sponsor and site monitors have exclusive ly "read 
only" access . 
 
10.2 Data Cla1ifi cation  
 
As part of the conduct  of the trial, the Sponsor  may havequestions about  the data entered 
by the site, referred  to as queries . The monitors  and the Sponsor are the only parties that 
can generate a query . All corrections and clarifications will be entered into the EDC 
system  and will be identified  by the person  entering  the information,  the reason for the 
change, as well as the time of the changes made . If changes are made to a previously  and 
electronically signed  CRF , the investigator  must  confirm  and endorse the changes . 
 
10.3 Data Protectio n 
 
GSK  respects  the subjects ' rights  to privacy  and willensure the confidentiality  of their 
medical information in accordance  with all appli cable laws and regulations . 
 
 
 
 
 
 
 
 
 
§ 
.N... 
r..a..  
PR0-01 TEMP 06 / Atlas No. 293620  
VersionNo.4 / Vers ion Date: January 29, 2015 
::, z u 
8 Protocol V59_77 
Page 79of85  GSK 
24FEB16  Confident ial 
Regula tory Review Protoco l Version 3  
  
11. RECORD  RETEN TION  
 
Investigators must retain all study records required by GSK and by the applicable 
regulations in a secure and safe facility. The investigator must consult a GSK 
representativebefore disposal of any studyrecords , andmust notify the Sponsor of any 
change in the location, disposition, or custody of the study files. Essential documents 
must be retained for 1S years . "Essential documents" are defined as documents that 
individually  and collectiv ely permit evaluation of the conduct  of a study  and the quality 
of the data produced. These documents  should be retained  for a longer  period,  however , if 
required by the applicable  national  regulatory or institutional requirements . 
 
These principles  of record  retention  will also be applied to the storage  of immnoogenicity 
samples , provided that the integrity  of the stored  sample  permits  testing.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
§ 
.N... 
r..a..  
PR0-01 TEMP 06 / Atlas No. 293620  
VersionNo.4 / Vers ion Date: January 29, 2015 
::, z u 
8 Protocol V59_77 
Page 80of85  GSK 
24FEB16  Confident ial 
Regula tory Review Protoco l Version 3  
  
12. USE  OF Jll,'FORMATION AND  PUBLICATION  
 
GSK  assures that the key design  elements of this protocol  willbe posted  in a publicly 
accessible database such  as clinicaltrials .gov, and in compliance with cUITent  regulations.  
 
GSK  also assures that key results  of this clinical  study  will be posted  in a publicly 
accessible database within  the required time-frame from  theend  of study  as defined in 
section  3.9, End of Study.  
In accordance with standard editorial, ethical practices and cUITent  guidelines  of Good 
Publication  Practice  (Graf 2009) , GSK will generally  support  publication  of mult icenter 
studies  only in their  entirety and not as individual  center data . In this case, a coordinating 
inves tigator  will be designated by mutual  agreement  prior  to the start of the study . The 
coordinating investigator  will also sign the clinical study report  on behalf of the principal 
inves tigators  (CPMP/EWP /2747 /00). Authorship  willbe determined by mutual agreement 
and in line with International Committee of Medical Journal Editors authorship 
requirements . Any fonnal publication of the study in which contribution ofGSK 
personnel exceeded that of conventional monitoring will be considered as a joint 
publication  by the inves tigator  and the appropriate  GSK  personnel.  
 
Novartis  must be notified  of any intent  to publish  data collected from  the study  and prior 
approval from  GSK must be obtained  prior  to submission  for publication . 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
§ 
.N... 
r..a..  
PR0-01 TEMP 06 / Atlas No. 293620  
VersionNo.4 / Vers ion Date: January 29 , 2015 
::, z u 
8 Protocol V59_77 
Page 81of85  GSK 
24FEB16  Confident ial 
Regula tory Review Protoco l Version 3  
  
13. ETID CAL CONSIDERATIO NS 
 
13.1 Regulato ry and Ethical Compliance 
The study will be conducted in compliance with the protocol,  GCP and applicable 
regulatory  requirement (s). 
 
This clinical study  was designed and shall  be implemented  and reported in accordance 
withthe ICH HarmonizedTripartite Guidelines for Good Clinical Practice , with 
applicable local regulations including European Directive 2001/ 20/EC , US Code of 
Federal Regula tions Title  21, and Japanese Ministry  ofHealth,  Labor , and Welfare , GSK 
codes on protection of human rights , and with the ethical princip les laid down in the 
Declaration  of Helsinki  (European Council  2001,  US Code  of Federal Regulations , ICH 
1997 ). 
 
13.2 Inform ed Consent Procedures 
 
Eligible subjects may only be included in the study after providing written informed 
consent or assent , as described in section  5.1.1, Informed  Consent/Assent.  Before  the start 
of the study , the invest igator  will have  the informed  consent  and any other  materials  that 
will be provided to the subjects  reviewed  and approved  by the IRB/EC. This review  and 
approval  will be documented  and stored with other  studydocuments.  The investigator  or 
designee must fully inform the subj ect or legal guardian of all pertinent aspects of the 
study . A copy of the written  informed consent  will be given to the subject or the designee. 
The subject/designee  must  be allowed ample  time to ask about  the details  of the study and 
to make a decision  as to whether  or not to participate  in the study. The subject and/or  legal  
guardian(s ) must sign the consent form indicating their agreement to participate in the 
study before  anystudy- related  procedures  are conducted . The informed consent process 
may be conducted up to 5 days prior  to vaccination  on Day I. If the subject  and/or  legal 
guardian(s) is unable to read and write , a witness must be present during the infonned 
consent discussion  and at the time of informed  consent signature . 
 
Prior to the start of the study, GSK will provide to investigators a proposed informed 
consent form that complies with the ICH GCP guideline and regulatory requirements and 
is considered appropriate for this study . Any changes to the proposed consent form 
suggested by the investigator must be agreed to by GSK before submission to the IRB/EC 
and a copy of the approved version must be provided to the GSK monitor after IRB/EC 
approval  
 
 
 
 
§ 
.N... 
r..a.. Women of childbearing potential should be informed that taking the study medication 
may involve unknown risks to the fetus if pregnancy were to occur during the study and 
agree tha t in order to participate in the study they must adhere to the contraception  
 
PR0-01 TEMP 06 / Atlas No. 293620  
VersionNo.4 / Vers ion Date: January 29, 2015 
Protocol V59_77 
Page 82of85  GSK 
24FEB16  Confident ial 
Regula tory Review Protoco l Version 3 
§ PR0-01 TEMP  06 / Atlas  No.293620  
VersionNo.4 / Version Date: January 29,20 15 N 
r"a 
" 
::, z u 
8  
  
requirements  indicated in the protocol  for the duration of the study . If case of doubts  on 
the ability  of a subject  to adhere to these  requirements,  that subject should not be allowed 
in the study  
Before the start of the study, the investigator willhave the informed assent, the informed 
consent, and any other materials that will be provided to the subject and/or parent(s)/legal 
guardian(s) reviewed and approved by the IRB/EC. This review and approval willbe 
documented and stored with other study documents . The investigator or designee must 
fully inform the subject and/or parent(s)/legalguardian(s) of all pertinent aspects of the 
study. A copy of the written informed consent and informed assent willbegiven to the 
subject and/or parent(s)/legalguardian( s). 
 
In addition , the investigator  or designee  should explain pertinent  aspects of the study  in an 
age appropriate manner to pediatric subjects who are eligible for informed assent in 
accordance with local policies. The subject and parent(s)/legalguardian(s) must be 
allowed amp le time to ask about the details of the study and to make a decision as to 
whether  or not to participate in the study. The subject and parent(s)/legal  guardian(s) must 
sign the consent/assent forms  indicating  their  agreement to participate  in the study  before 
any study- related procedures are conducted. If the subject and/or parent(s)/legal 
guardian(s)  are unable  to read and write , a witness  must  be present  during the informed 
consent/assentdiscussion and at the time of informed  consent/assentsignature.  
13.3 Responsibilitie s of the In vestiga tor a nd IRB/EC 
 
The protocol  and the proposed  informed  consent  form  must  be reviewed  and approved by 
a properly  constituted  IRB/EC  before study start. Proper ly constituted  IRB/EC is defined 
in ICH Guideline  for Good  Clinical  Practice E6 (RI), Section  3 (ICH 1997 ). A signed and 
dated statement that the protocol and informed consent have been approved by the 
IRB/EC must be given to GSK  before  study  initiation.  Prior  to study start and at any time 
the protocol is amended during studyconduct , the investigator is required to sign a 
protocol signature  page  confirming his/her  agreement  to conduct the study  in accordance 
withthese  documents  and all of the instructions  and procedures  found  in this protocol and 
to give access  to all relevant  data and records  to GSK monitors,  auditors, GSK  Clinical 
Quality Assurance representatives , designated agents of Novartis , IRBs/ECs , and 
regulatory authorities as required. If an inspection of the clinical site is requested by a 
regulatory  authority , the investigator  must  inform  GSK  immediately that thisrequest  has 
been made.  
 
The investigator also responsibl e for the following:  
• Maintaining a list of appropriate ly qualified persons to whom the investigator has 
delegated significant study- related  duties . 
Protocol V59_77 
Page 83of85  GSK 
24FEB16  Confident ial 
Regula tory Review Protoco l Version 3 
§ PR0-01 TEMP  06 / Atlas  No.293620  
VersionNo.4 / Version Date: January 29,20 15 N 
r"a 
" 
::, z u 
8  
  
• Demonstrating the capability  of recruiting  the required  number of suitable  subjects 
within  the recruitment  period.  
• Demonstrating sufficient  time and staffing  to properly conduct and complete  the study 
within  the agreed study period.  
• Ensuring that all persons  assisting with the study are adequately  informed about the 
protoco the investigationalproduct(s ,)and their  study- relatedduties  and functions  
• Ensuring that appropriately trained  health  care professionals  are responsible for all 
study- related  medical  decisions and for ensuring appropriate  medical  care of subjects  
experiencing  any adverse  event related  to the study.  
• If permission  to do so is given  by the subjec t and/o r parent( s)/lega lguardian(s) , 
ensuring that the subject' s primary healthcare  provider is informed of the subject' s 
participation  in the study.  
The investigator should not implement any deviation from, or changes of the protocol 
without agreement  by the Sponsor and prior review and documented  approval/favourabl e 
opinion from theIRB/IEC of an amendment, except where necessary to eliminate an 
immediate  hazard(s) to study subjects , or when  thechange(s) involves only logistical  or 
administrative aspects of the study (e.g., change in monitor(s), change of telephone 
nwnber(s)). In addition, the investigato, ror person designated by the investigato ,rshould 
document  and explain  any deviation  from  the approved  protocol.  
 
The investigator may implement a deviation from, or a change of, the protocol to 
eliminate an immediate hazard(s) to study subjects without prior IRB/IEC 
approval/fav ourable opinion.  As soon  as possibl e, the implemented  deviation  or change , 
the reasons  for it, and, if appropria te, the proposed  protocol  amendment (s) shoul d be 
submitted:  
(a) to theIRB/IEC  for review  and approval/fa vourable opinion,  
(b) to the Sponsor for agreement  and, if required,  
(c) to the regulatory authority(ies).  
13.4 Prot ocol Amen dments 
An amendment is a written description of change(s) to or formal clarification of a study 
protocol which may impact on the conductof the clinical study, potential benefit of the 
clinical study, or may affect subject safety , including changes of study objectives , study 
design, subject population, samp le sizes, studyprocedures , or significant administrative 
aspects . An administrative change of a studyprotocol is a minor correction or 
clarificat ionthat has no significant  impact  on the waythe clinical study is to be conducted  
Protocol V59_77 
Page 84 of85  GSK 
24FEB16  Confidentia l 
Regulatory Review Protoco l Version 3  
  
and no effect  on subject  safety  (e.g., change  of telephone number(s) , logistical changes. ) 
Protocol amendments  nrust be approved  by GSK,  health  authorities  where  required , and 
the IRB/EC . In cases when  the amendment  is required  in order to protect  the subject 
safety , the amendment can be implemented  prior  to IRB/EC  approval.  Notwithstanding , 
the need  for formal approval  of a protocol  amendmen ,tthe investigator is expected  to take 
any inunediate  action  required  for the safety  of anysubject  included  in this study , evenif 
this action  represents  a deviation from the protocol. In such cases, GSK should be notified 
of this action, the IRB/EC at the study site, and, if required bylocal regulations, the 
relevant  health  authority) should be informed  within  10 working days.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PR0-01 TEMP 06 / Atlas No.29362 0 
VersionNo.4 / Vers ion Date: January 29,2015 

Protocol V59_77 
Page 85 of85  GSK 
24FEB16  Confidentia l 
Regulatory Review Protoco l Version 3 
::, z u 
8  
  
14. REFE RENCE LIST 
Code  of Federal  Regulations  (1997):  Food and Drug  Administration,  U.S. Depar1ment  of 
Health and Human Services: Title 21, Part 11: Electronic Records Electronic Signatures . 
Federal Register 62: 13464  
European Parliament (1995):  Directive  95/46/EC  of the European  Parliament and of the 
Council  of 4 April  2001.  Official Journal  of the European  Communities . L 281/31-39 
European Parliament (200 1): Directive 2001/ 20/EC of the European Parliament and of 
the Council of 4 April 2001. Official Journal of the European Communities . L 121/34-44 
Graf C, Battisti WP, Bridges D (2009) . Good publication practice for communicating 
company Sponsored medical research: the GPP2 guidelines . BMJ ; 339: b4330  
ICH (1997)  ICH Harmonised  Tripartite  ICH Guideline  for Good Clinical Practices E6 
(RI). Federal Register , 62 (90):  25691 -25709  
 
ICH (1998)  ICH Harmonised Tripartite  ICH Guideline for Statistical  Principles  for 
Clinical  Trials E9. Federal Register , 63 (179) : 49583  
Levine  RJ. (1988)  Ethics  and Regulations  of Clinical Research . New Haven: Yale 
University  Press . 
 
U.S. Depar1ment of Health and Human Services , Food and Drug Administration, CBER 
(2009 ): Guidance for Industry Patient- Reported Outcome Measures : Use in Medical 
Product Development to Support Labeling Claims  
 
59th World Medical Association General Assembly (October 2008) Declaration of 
Helsinki - Ethical Principles for Medical Research Involving Human Subjects . Seoul, 
Korea  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
§ 
.N... 
r..a..  
PR0- 01 TEMP 06 / Atlas No. 293620  
VersionNo.4 / Versi onDate: January29 , 2015 
::, z u 
8  
 I 
N UserName :PPD PO 
Ti tle: Cluster Phys ician -Meningi tis an d Sepsis Franch ise Novarti s 
 
 
 
PPo• -    - -' Document A !J!roval Certificate  / 
PPD /    
1.,;..  _  
 
 
 
Theindivi:luals listed have appl'()ved this docume nt for ii!Jplementatio n using an electronic signature in the 
Atlas EDMS . tFPO  
I S 
-----------  
Date: Wednesday, 24 February 20 1,6 1 3:16 GMT  
Meani ng: As an approver, I agree with the content and format of this document  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
§ 
r"a 
" 
